| Orlistat Capsules USP | Each hard gelatin capsule contains | |
| Orlistat USP 120 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Diazepam Capsules IP | Each hard gelatin capsule contains | |
| Diazepam IP 5 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Diazepam Capsules IP | Each hard gelatin capsule contains | |
| Diazepam IP 10 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Tapentadol Capsules | Each hard gelatin capsule : | |
| Tapentadol Hydrochloride IP 75 mg | |
| | |
| Tapentadol Capsules | Each hard gelatin capsule : | |
| Tapentadol Hydrochloride IP 50 mg | |
| | |
| Rosuvastatin & Aspirin Capsules | Each hard gelatin capsule : | |
| Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 5 mg | |
| Aspirin IP 75 mg | |
| | |
| Rosuvastatin & Aspirin Capsules | Each hard gelatin capsule : | |
| Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 10 mg | |
| Aspirin IP 75 mg | |
| | |
| Rosuvastatin & Aspirin Capsules | Each hard gelatin capsule : | |
| Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 10 mg | |
| Aspirin IP 150 mg | |
| | |
| Atorvastatin & Aspirin Capsules | Each hard gelatin capsule: | |
| Atorvastatin Calcium IP | |
| eq. to Atorvastatin 10 mg | |
| Aspirin IP 75 mg | |
| | |
| Alpha Lipoic Acid, | Each hard gelatin capsule : | |
| Mecobalamine, | Alpha Lipoic Acid USP 100 mg | |
| Pyridoxine, Foilc Acid, | Mecobalamine IP 1500 mcg | |
| Benfotiamine, Biotin | Pyridoxine Hydrochloride IP 3 mg | |
| With Chromuim Capsules | Foilc Acid IP 2 mg | |
| Benfotiamine 50 mg | |
| Biotin USP 5 mg | |
| Chromuim Picolinate USP | |
| Chromuim 200 mcg | |
| Excipients q.s. | |
| Permitted Color Used | |
| | |
| Atorvastatin, Clopidogrel and | Each hard gelatin capsule contains | |
| Aspirin Capsules | Atorvastatin Calcium IP | |
| Eq. to Atorvastatin (As pellets) 10 mg | |
| Clopidogrel Bisulphate IP | |
| Eq. Clopidogrel (As pellets) 75 mg | |
| Aspirin IP 75 mg | |
| (As Enteric coated pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Atorvastatin, Clopidogrel and | Each hard gelatin capsule contains | |
| Aspirin Capsules | Atorvastatin Calcium IP | |
| Eq. to Atorvastatin (As pellets) 20 mg | |
| Clopidogrel Bisulphate IP | |
| Eq. Clopidogrel (As pellets) 75 mg | |
| Aspirin IP 75 mg | |
| (As Enteric coated pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Atorvastatin, Clopidogrel and | Each hard gelatin capsule contains | |
| Aspirin Capsules | Atorvastatin Calcium IP | |
| Eq. to Atorvastatin (As pellets) 20 mg | |
| Clopidogrel Bisulphate IP | |
| Eq. Clopidogrel (As pellets) 75 mg | |
| Aspirin IP 150 mg | |
| (As Enteric coated pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Esomeprazole and Domperidone | Each hard gelatin capsule contains | |
| Capsules | Esomeprazole Magnesium Trihydrate IP | |
| Eq.to Esomeprazole 40 mg | |
| (As enteric coated pellets) | |
| Domperidone IP 30 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Tapentadol Hydrochloride | Each hard gelatin capsule contains | |
| Capsules | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 25 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Tapentadol Hydrochloride | Each hard gelatin capsule contains | |
| Capsules | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 100 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Dexrabeprazole Sodium and | Each hard gelatin capsule contains | |
| Domperidone Capsules | Dexrabeprazole Sodium 10 mg | |
| (As entric coated pellets) | |
| Domperidone IP 30 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Esomeprazole (EC) and | Each hard gelatin capsule contains | |
| Levosulpiride (SR) Capsules | Esomeprazole Magnesium Trihydrate IP | |
| Eq.to Esomeprazole 40 mg | |
| (As enteric coated pellets) | |
| Levosulpiride 75 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Esomeprazole Gastro resistant | Each hard gelatin capsule contains | |
| Capsules IP | Esomeprazole Magnesium Trihydrate IP | |
| Eq.to Esomeprazole 40 mg | |
| (As enteric coated pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Esomeprazole Gastro resistant | Each hard gelatin capsule contains | |
| Capsules IP | Esomeprazole Magnesium Trihydrate IP | |
| Eq.to Esomeprazole 20 mg | |
| (As enteric coated pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Ubiquinol Capsules | Each hard gelatin capsule contains | |
| Ubiquinol 100 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Thiamine, Riboflavin, Pyridoxine | Each hard gelatin capsule contains | |
| Niacinamide, Calcium Pantothenate | Thiamine Mononitrate IP 10 mg | |
| and Cyanocobalamin Capsules | Riboflavin IP 5 mg | |
| For Therapeutic Use | Pyridoxine Hydrochloride IP 1.5 mg | |
| Niacinamide IP 45 mg | |
| Calcium Pantothenate IP 5 mg | |
| Cyanocobalamin IP 5 mcg | |
| Approved colour use in empty capsule shell | |
| | |
| Mecobalamin,Alpha Lipoic Acid, | Each hard gelatin capsule contains | |
| Thiamine, Pyridoxine HCI, | Mecobalamin IP 1500 mcg | |
| Calcium Pantothenate and | Alpha Lipoic Acid USP 100 mg | |
| Folic Acid Capsules | Thiamine IP 10 mg | |
| For Therapeutic Use | Pyridoxine Hydrochloride IP 3 mg | |
| Calcium Pantothenate IP 5 mg | |
| Folic acid IP 1.5 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Rosuvastatin & Clopidogrel | Each hard gelatin capsule : | |
| Aspirin Capsules | Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 10 mg | |
| Clopidogrel Bisulphate IP | |
| eq. to Clopidogrel 75 mg | |
| Aspirin IP 75 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Rosuvastatin & Clopidogrel | Each hard gelatin capsule : | |
| Aspirin Capsules | Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 20 mg | |
| Clopidogrel Bisulphate IP | |
| eq. to Clopidogrel 75 mg | |
| Aspirin IP 75 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Rosuvastatin & Clopidogrel | Each hard gelatin capsule : | |
| Aspirin Capsules | Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 20 mg | |
| Clopidogrel Bisulphate IP | |
| eq. to Clopidogrel 75 mg | |
| Aspirin IP 150 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Acebrophylline | Each hard gelatin capsule : | |
| Capsules | Acebrophylline 200 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Orlistat | Each hard gelatin capsule : | |
| Capsules USP | Orlistat (As Pellets) USP 60 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Colostrum | Each hard gelatin capsule : | |
| Capsules | Colostrum 500 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Caroverine Hydrochloride | Each hard gelatin capsule: | |
| Capsules | Caroverine Hydrochloride eq. to Caroverine 20 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalamin, Nortriptyline | Each hard gelatin capsule : | |
| Pregabalin Capsules | Methylcobalamin IP 1500 mcg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Pregabalin IP 75 mg | |
| Approved colour used in empty capsule shell | |
| | |
| llaprazole & | Each hard gelatin capsule contains | |
| Domperidone (SR) | llprazole IP 10 mg | |
| Capsules | (As per enteric coated pellets) | |
| Domperidone 30 mg | |
| (As per sustain Release pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Rabeprazole Sodium & | Each hard gelatin capsule contains | |
| Levosulpiride | Rabeprazole Sodium IP 20 mg | |
| Capsules | (As per enteric coated pellets) | |
| Levosulpiride 75 mg | |
| (As per sustain Release pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Acebrophylline | Each hard gelatin capsule contains | K |
| Capsules | Acebrophylline 100 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Itraconazole | Each hard gelatin capsule contains | |
| Capsules | Itraconazole (As pellets) BP 100 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Itraconazole | Each hard gelatin capsule contains | |
| Capsules | Itraconazole (As pellets) BP 200 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Indomethacin (SR) & | Each hard gelatin capsule contains | |
| Omeprazole Capsules | Indomethacin IP 75 mg | |
| (As per sustain Release pellets) | |
| Omeprazole IP 20 mg | |
| (As per enteric coated pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Indomethacin (SR) | Each hard gelatin capsule contains | |
| Capsules | Indomethacin IP 75 mg | |
| (As per sustain Release pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Propranolol Hydrochloride & | Each hard gelatine capsule contains | |
| Flunarizine Di hydrochloride | Propranolol Hydrochloride IP 40 mg | |
| Capsules | Flunarizine Di hydrochloride 10 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Rabeprazole Sodium & | Each hard gelatin capsule contains | |
| Levosulpiride | Rabeprazole Sodium IP 20 mg | |
| Capsules | (As per enteric coated pellets) | |
| Levosulpiride 20 mg | |
| (As per sustain Release pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Clindamycin | Each hard gelatin capsule contains | |
| Hydrochloride | Clindamycin Hydrochloride BP | |
| Capsules IP | Eq. to Clindamycin 150 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Clindamycin | Each hard gelatin capsule contains | |
| Hydrochloride | Clindamycin Hydrochloride BP | |
| Capsules IP | Eq. to Clindamycin 300 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Dicyclomine HCI , | Each hard gelatin capsule contains | |
| Tramadol HCI, | Dicyclomine Hydrochloride IP 10 mg | |
| & Paracetamol Capsules | Tramadol Hydrochloride IP 50 mg | |
| Paracetamol IP 325 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Doxycycline Hydrochloride | Each hard gelatin capsule contains | |
| & Sarratiopeptidase | Doxycycline Hydrochloride IP 100 mg | |
| Capsules | Sarratiopeptidase IP 10 mg | |
| (As enteric coated granules) | |
| Approved colour used in empty capsule shell | |
| | |
| Vitamin B-Complex | Each hard gelatin capsule contains | |
| Capsules | Thiamine Mononitrate IP 1 mg | |
| Riboflavin IP 1 mg | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| Niacinamide IP 15 mg | |
| Lactic Acid Bacillus IP 1000 mill.spor | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalmin , | Each hard gelatin capsule contains | |
| Pyridoxine Hcl With | Methylcobalmin 1500 mcg | |
| Alpha Lipoic Acid | Pyridoxine Hydrochloride IP 1.5 mg | |
| Capsules | Alpha Lipoic Acid IP 100 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalmin, | Each hard gelatin capsule contains | |
| Alpha Lipoic Acid, | Methylcobalmin 500 mcg | |
| Glucosamine Sulphate | Alpha Lipoic Acid 100 mg | |
| & Chondrotine Sulphate | Glucosamine Sulphate IP 500 mg | |
| Capsules | Chondrotine Sulphate 400 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalmin, | Each hard gelatin capsule contains | |
| Alpha Lipoic Acid, | Methylcobalmin 1500 mcg | |
| & Pregabalin with | Alpha Lipoic Acid 200 mg | |
| Folic Acid Capsules | Pregabalin IP 75 mg | |
| Folic Acid IP 1500 mcg | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalmin, | Each hard gelatin capsule contains | |
| & Pregabalin | Methylcobalmin 1500 mcg | |
| Capsules | Pregabalin IP 75 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalmin, | Each hard gelatin capsule contains | |
| & Pregabalin | Methylcobalmin 750 mcg | |
| Capsules | Pregabalin IP 75 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Lactic Acid Bacillus | Each hard gelatin capsule contains | |
| Capsules | Lactic Acid Bacillus IP 1000 mill.Spor | |
| Approved colour used in empty capsule shell | |
| | |
| Calcium Citrate, | Each hard gelatin capsule contains | |
| Calcitriol with Zinc | Calcium Citrate Malate 500 mg | |
| Capsules | Calcitriol IP 0.25 mcg | |
| Zinc Sulphate IP 7.5 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Prebiotic & Probiotic | Each hard gelatin capsule contains | |
| Capsules | Streptococcus faecalis 30 million | |
| Clostridium Butyricum 2 million | |
| Bacillus Mesentericus IP 1 million | |
| Lactic Acid Bacillus IP 50 million | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Ponceau 4R or Titanium Dioxide IP / Sunset Yellow | |
| | |
| DIPHENHYDRAMINE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULE IP | Diphenhydramine Hydrochloride IP 25 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| INDOMETHACIN CAPSULE IP | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Indomethacin IP 25 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| LOPERAMIDE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULE IP | Loperamide Hydrochloride IP 2 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| OMEPRAZOLE CAPSULES IP | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Omeprazole (As enteric coated pellets) IP 20 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| PIROXICAM CAPSULE IP 10 mg. | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Piroxicam IP 10 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| PIROXICAM CAPSULE IP 20 mg. | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Piroxicam IP 20 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| LANSOPRAZOLE CAPSULES IP | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Lansoprazole (As enteric coated pellets) IP 30 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| LANSOPRAZOLE & | Each hard gelatin capsule contains | |
| DOMPERIDONE CAPSULES | Lansoprazole (As enteric coated pellets) IP 30 mg | |
| Approved Date : 19/04/2007 | Domperidon (As coated pellets) IP 10 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| PANTOPRAZOLE SODIUM & | Each hard gelatin capsule contains | |
| DOMPERIDONE (SR) CAPSULES | Pantoprazole Sodium Sesquihydrate IP | |
| Approved Date : 19/04/2007 | Eq. to Pantoprazole (As enteric coated pellets) 20 mg | |
| Domperidon (As sustained release pellets) IP 10 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| PANTOPRAZOLE SODIUM & | Each hard gelatin capsule contains | |
| DOMPERIDONE (SR) CAPSULES | Pantoprazole Sodium Sesquihydrate IP | |
| Approved Date : 11/10/2007 | Eq. to Pantoprazole (As enteric coated pellets) 40 mg | |
| Domperidon (As sustained release pellets) IP 30 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| MEFENAMIC ACID & DICYCLOMINE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULES | Dicyclomine Hydrochloride IP 10 mg | |
| Approved Date : 05/09/2008 | Mefenamic Acid IP 250 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| OMEPRAZOLE & | Each hard gelatin capsule contains | |
| DOMPERIDONE CAPSULES | Omeprazole (As enteric coated pellets) IP 20 mg | |
| Approved Date: 05/09/2008 | Domperidon (As coated pellets) IP 10 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| DICYCLOMINE HYDROCHLORIDE & | Each hard gelatin capsule contains | |
| PARACETAMOL CAPSULES | Dicyclomine Hydrochloride IP 10 mg | |
| Approved Date : 25/03/2010 | Paracetamol IP 325 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| TRAMADOL | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULES IP | Tramadol Hydrochloride IP 50 mg | |
| Approved Date : 25/03/2010 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| RABEPRAZOLE SODIUM CAPSULES | Each hard gelatin capsule contains | |
| Approved Date : 25/03/2010 | Rabeprazole Sodium (As enteric coated pellets) IP 20 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| RABEPRAZOLE SODIUM & | Each hard gelatin capsule contains | |
| DOMPERIDONE (SR) CAPSULES | Rabeprazole Sodium (As enteric coated pellets) IP 20 mg | |
| Approved Date : 25/03/2010 | Domperidon (As sustained release pellets) IP 10 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| CHLORPHENIRAMINE | Each hard gelatin capsule contains | |
| MALEATE CAPSULES IP | Chlorpheniramine Maleate IP 8 mg | |
| Approved Date : 15/01/2011 | Approved colour used in empty capsule shell | |
| | |
| DICYCLOMINE HYDROCHLORIDE & | Each hard gelatin capsule contains | |
| DICLOFENAC SODIUM CAPSULES | Dicyclomine Hydrochloride IP 20 mg | |
| Approved Date : 08/01/2014 | Diclofenac Sodium IP 50 mg | |
| Approved colour used in empty capsule shell | |
| | |
| PHENYLEPHRINE HYDROCHLORIDE & | Each hard gelatin capsule contains | |
| CHLORPHENIRAMINE MALEATE CAPSULES | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date : 08/01/2014 | Chlorpheniramine Maleate IP 4 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| RABEPRAZOLE SODIUM (EC) & | Each hard gelatin capsule contains | |
| DOMPERIDONE (SR) CAPSULES | Rabeprazole Sodium (As enteric coated pellets) IP 20 mg | |
| Approved Date : 17/04/2014 | Domperidon (As sustained release pellets) IP 30 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| RABEPRAZOLE SODIUM (EC) & ITOPRIDE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE (SR) CAPSULES | Rabeprazole Sodium (As enteric coated pellets) IP 20 mg | |
| Approved Date : 21/11/2014 | Itopride Hydrochloride (As sustained release pellets) IP 150 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| OMEPRAZOLE CAPSULES | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Omeprazole (As enteric coated pellets IP 40 mg | |
| Approved colour used in empty capsule shell | |
| | |
| PANTOPRAZOLE SODIUM & | Each hard gelatin capsule contains | |
| DOMPERIDONE (SR) CAPSULES | Pantoprazole Sodium eq. to IP | |
| Approved Date : 11/10/2007 | Pantoprazole 40 mg | |
| Domperidone IP 10 mg | |
| Approved colour used in emply capsule shell | |
| | |
| FLUCONAZOLE CAPSULES IP | Each hard gelatin capsule contains | |
| Approved Date : 27/03/2012 | Fluconazole IP 150 mg | |
| Approved colour used in empty capsule shell | |
| | |
| CHLORAMPHENICOL CAPSULES IP | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Chloramphenicol IP 250 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| CHLORAMPHENICOL CAPSULES IP | Each hard gelatin capsule contains | |
| Approved Date : 19/04/2007 | Chloramphenicol IP 500 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| DOXYCYCLINE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULES IP | Doxycycline Hydrochloride IP | |
| Approved Date : 19/04/2007 | Equivalent to Doxycycline 100 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| OXYTETRACYCLINE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULES IP | Oxytetracycline Hydrochloride IP 250 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| TETRACYCLINE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULES IP | Tetracycline Hydrochloride IP 250 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| TETRACYCLINE | Each hard gelatin capsule contains | |
| HYDROCHLORIDE CAPSULES IP | Tetracycline Hydrochloride IP 500 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| VITAMIN B-COMPLEX CAPSULES | Each hard gelatin capsule contains | |
| For Prophylactic Use | Thiamine Mononitrate IP 1 mg | |
| Approved Date : 19/04/2007 | Riboflavine IP 1 mg | |
| Cyanocobalamin IP 0.5 mcg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| DOXYCYCLINE WITH | Each hard gelatin capsule contains | |
| LACTIC ACID BACILLUS CAPSULES | Doxycycline Hyclate IP | |
| Approved Date : 19/04/2007 | Equivalent to Doxycycline 100 mg | |
| (Coated Pellets) | |
| Lactic Acid Bacillus 90 mill.Spor | |
| (As Enteric Coated Pellets) | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| ELEMENTAL IRON, ZINC SULPHATE | Each hard gelatin capsule contains | |
| WITH FOLIC ACID CAPSULES | Elemental Iron 50 mg | |
| For Therapeutic Use | (In the form of Carbonyl Iron) | |
| Approved Date : 19/04/2007 | Zinc Sulphate Monohydrate USP 61.8 mg | |
| (Equivalent to 22.5 Mg of Elemental Zinc) | |
| Folic Acid IP 0.5 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| MULTIVITAMIN CAPSULES | Each hard gelatin capsule contains | |
| For Prophylactic Use | Thiamine Mononitrate IP 1 mg | |
| Approved Date : 19/04/2007 | Riboflavine IP 1 mg | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| Vitamin A Concentrate ( As Palmitate) | |
| Eq. to Vitamin A IP 2000 IU | |
| Vitamin D, (As Cholecalciferol) IP 100 IU | |
| Niacinamide IP 15 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| MULTIVITAMIN WITH L-LYSINE, | Each Capsule Contains | |
| ZINC SULPHATE CAPSULES | Vitamin A Acetate IP 5000 IU | |
| For Therapeutic Use | Vitamin D3 (As Cholecalciferol) IP 500 IU | |
| Approved Date : 19/04/2007 | Vitamin E Acetate IP 15 mg | |
| Vitamin B1 Mono IP 10 mg | |
| Vitamin B2 IP 10 mg | |
| Vitamin B6 HCI IP 3 mg | |
| L-Lysine Mono HCI IP 50 mg | |
| Vitamin B12 IP 10 mcg | |
| Calcium Panthothenate IP 25 mg | |
| Vitamin C (Coated) IP 75 mg | |
| Zinc Sulphate IP 20 mg | |
| Equivalent to elemental zinc 4.50 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| MULTIVITAMIN CAPSULES | Each hard gelatin capsule contains | |
| For Prophylactic Use | Thiamine Mononitrate IP 1 mg | |
| Approved Date : 15/01/2011 | Riboflavine IP 1 mg | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Niacinamide IP 15 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| FERROUS FUMERATE WITH | Each hard gelatin capsule contains | |
| FOLIC ACID CAPSULES | Ferrous Fumerate IP 200 mg | |
| For Therapeutic Use | Folic Acid IP 1500 mcg | |
| Approved Date : 15/10/2011 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| MULTIVITAMIN, FOLIC ACID WITH | Each hard gelatin capsule contains | |
| CALCIUM PANTHOTHENATE CAPSULES | Thiamine Mononitrate IP 1 mg | |
| For Prophylactic Use | Riboflavine IP 1 mg | |
| Approved Date : 08/01/2014 | Pyridoxine Hydrochloride IP 0.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Calcium Panthothenate IP 1 mg | |
| Folic Acid IP 100 mcg | |
| Niacinamide IP 20 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| MULTIVITAMIN, | Each hard gelatin capsule contains | |
| FOLIC ACID, ZINC SULPHATE | Thiamine Mononitrate IP 5 mg | |
| CALCIUM PANTHOTHENATE CAPSULES | Riboflavine IP 5 mg | |
| For Prophylactic Use | Pyridoxine Hydrochloride IP 1.5 mg | |
| Approved Date : 08/01/2014 | Cyanocobalamin IP 5 mcg | |
| Calcium Panthothenate IP 5 mg | |
| Folic Acid IP 1000 mcg | |
| Niacinamide IP 45 mg | |
| Zinc Sulphate IP 20 mg | |
| Eq. to elemental Zinc 4.5 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| CHOLECALCIFEROL | Each hard gelatin capsule contains | |
| (Vitamin D3) CAPSULES | Vitamin D3 (As Cholecalciferol) IP 10000 IU | |
| Approved Date : 20/07/2016 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| CHOLECALCIFEROL | Each hard gelatin capsule contains | |
| (Vitamin D3 ) CAPSULES | Vitamin D3 (As Cholecalciferol) IP 60000 IU | |
| Approved Date : 20/07/2016 | Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| ANTIOXIDANT, MULTIVITAMINS & | Each hard gelatin capsule contains | |
| MULTIMINERALS CAPSULES | Pyridoxine Hydrochloride IP 3 mg | |
| For Prophylactic Use | Niacinamide IP 50 mg | |
| Approved Date : 20/07/2016 | Cyanocobalamin IP 5 mcg | |
| Folic Acid IP 1 mcg | |
| Copper Sulphate USP 2.5 mg | |
| Calcium Panthothenate IP 12.5 mg | |
| Zinc Sulphate Monohydrate IP 15 mg | |
| Chromium Chloride Hexahydrate USP 65 mcg | |
| Manganese Chloride IP 1 mcg | |
| Lactic Acid Bacillus 60 mill. spor | |
| Selenium Dioxide Monohydrate USP 60 mcg | |
| Calcium Ascorbate BP 25 mg | |
| Di Basic Calcium Phosphate IP 200 mg | |
| Containing: | |
| Calcium 45.0 mg | |
| Phosphorous 36.2 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| ANTIOXIDANT, MULTIVITAMINS & | Each hard gelatin capsule contains | |
| MULTIMINERALS CAPSULES | Calcium Ascorbate BP 50 mg | |
| For Prophylactic Use | Lycopene 6% USP 5000 mcg | |
| Approved Date : 20/07/2016 | Mix Carotene 10% 10.33 mg | |
| Wheat Germ Oil BP 25 mg | |
| Zinc Sulphate Monohydrate IP 24.5 mg | |
| Selenium Dioxide Monohydrate USP 75 mcg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| ANTIOXIDANT, MULTIVITAMINS & | Each hard gelatin capsule contains | |
| MULTIMINERALS CAPSULES | Calcium Ascorbate BP 50 mg | |
| For Prophylactic Use | Lycopene 6 % USP 5000 mcg | |
| Approved Date : 20/07/2016 | Mix Carotene 10% 10.33 mg | |
| Wheat Germ Oil BP 25 mg | |
| Zinc Sulphate Monohydrate IP 24.5 mg | |
| Selenium Dioxide Monohydrate USP 75 mcg | |
| L-Cartnitine L-Tartrate USP 125 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| THIAMINE (MONO), RIBOFLAVINE, | Each hard gelatin capsule contains | |
| NICOTINAMIDE, PYRIDOXINE HCL, | Thiamine Monoitrale IP 10 mg | |
| CALCIUM PANTOTHENATE, | Riboflavine IP 10 mg | |
| CYANOCOBALAMIN WITH FOLIC ACID | Nicotinamide IP 50 mg | |
| & VITAMIN C CAPSULES | Pyridoxine Hydrochloride IP 3 mg | |
| Calcium Pantothenate IP 12.5 mg | |
| For Therapeutic Use | Cyanocobalamin IP 5 mcg | |
| Approved Date : 27/03/2012 | Folic Acid IP 1 mg | |
| Vitamin C IP 100 mg | |
| Approved colour used in empty capsule shell | |
| | |
| LACTIC ACID, THIAMINE (MONO), | Each hard gelatin capsule contains | |
| RIBOFLAVINE, NICOTINAMIDE, | Lactic Acid Bacillus 40 mill.Sp | |
| PYRIDOXINE HCL, D-PANTHENOL | Thiamine Monoitrate IP 2 mg | |
| WITH FOLIC ACID CAPSULES | Riboflavine IP 2.5 mg | |
| For Prophylactic Use | Nicotinamide IP 22.5 mg | |
| Approved Date : 27/03/2012 | Pyridoxine Hydrochloride IP 0.75 mg | |
| D-Panthenol IP 2.5 mg | |
| Folic Acid IP 300 mcg | |
| Approved colour used in empty capsule shell | |
| | |
| FERROUS FUMARATE, L-LYSINE, | Each hard gelatin capsule contains | |
| FOLIC ACID, CYANOCOBALAMIN | Ferrous Fumarate IP 350 mg | |
| WITH ZINC, COPPER & MANGANESE | L-Lysine Hydrochloride IP 150 mg | |
| CAPSULES | Folic Acid IP 1.5 mg | |
| Cyanocobalamin IP 15 mcg | |
| For Prophylactic Use | Zinc Sulphate IP | |
| Approved Date : 27/03/2012 | Eq. to Elemental Zinc 66 mg | |
| Copper Sulphate IP | |
| Eq. to Elemental Copper 80 mcg | |
| Manganese Sulphate USP 250 mg | |
| Approved colour used in empty capsule shell | |
| | |
| THIAMINE (MONO), RIBOFLAVINE, | Each hard gelatin capsule contains | |
| CYANOCOBALAMIN, | Thiamine Mononitrate IP 1 mg | |
| PYRIDOXINE HCL CAPSULES | Riboflavine IP 1 mg | |
| For Prophylactic Use | Cyanocobalamin IP 0.5 mcg | |
| Approved Date : 21/11/2014 | Pyridoxine Hydrochloride IP 0.5 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Esomeprazole (EC) and | Each hard gelatin capsule contains | |
| Itopride HCl (SR) Capsules | Esomeprazole Magnesium Trihydrate IP | |
| Eq.to Esomeprazole 40 mg | |
| (As enteric coated pellets) | |
| Itopride Hydrochloride IP 150 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Dabigatran Etexilate | Each hard gelatin capsule contains | |
| Capsules 110 mg | Dabigatran Etexilate Mesilate | |
| Eq.to Dabigatran Etexilate 110 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Dabigatran Etexilate | Each hard gelatin capsule contains | |
| Capsules 150 mg | Dabigatran Etexilate Mesilate | |
| Eq.to Dabigatran Etexilate 150 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Fluoxetine Capsules IP 10 mg | Each hard gelatin capsule contains | |
| Fluoxetine Hydrochloride IP | |
| Eq.to Fluxetine 10 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Fluoxetine Capsules IP 20 mg | Each hard gelatin capsule contains | |
| Fluoxetine Hydrochloride IP | |
| Eq.to Fluxetine 20 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Diacerein Capsules IP 50 mg | Each hard gelatin capsule contains | |
| Diacerein IP 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Celecoxib Capsules 200 mg | Each hard gelatin capsule contains | |
| Celecoxib IP 200 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Celecoxib Capsules 100 mg | Each hard gelatin capsule contains | |
| Celecoxib IP 100 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Celecoxib and Diacerein Capsules | Each hard gelatin capsule contains | |
| Celecoxib IP 100 mg | |
| Diacerein IP 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Celecoxib and Diacerein Capsules | Each hard gelatin capsule contains | |
| Celecoxib IP 200 mg | |
| Diacerein IP 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 25 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 25 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 50 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 75 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 75 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 100 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 100 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 150 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 150 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 225 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 225 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pregabalin Capsules IP 300 mg | Each hard gelatin capsule contains | |
| Pregabalin IP 300 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Sulpiride Capsules | Each hard gelatin capsule contains | |
| Sulpiride IP 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Sulpiride Capsules | Each hard gelatin capsule contains | |
| Sulpiride IP 200 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Tapentadol and Carisoprodol | Each hard gelatin capsule contains | |
| Capsules | Tapentadol HCI IP | |
| Eq. to Tapentadol 70 mg | |
| Carisoprodol IP 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pantoprazole (EC) and | Each hard gelatin capsule contains | |
| Levosulpiride (SR) Capsules | Pamotprazole Sodium IP | |
| Eq.to Pantoprazole 40 mg | |
| (As enteric coated pellets) | |
| Levosulpiride 75 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Sildenafil Citrate Capsules | Each hard gelatin capsule contains : | |
| Sildenafil Citrate IP | |
| Eq. to Sildenafil 25 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Sildenafil Citrate Capsules | Each hard gelatin capsule contains : | |
| Sildenafil Citrate IP | |
| Eq. to Sildenafil 50 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Sildenafil Citrate Capsules | Each hard gelatin capsule contains : | |
| Sildenafil Citrate IP | |
| Eq. to Sildenafil 100 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Pantoprazole Sodium (EC) and | Each hard gelatin capsule contains | |
| Itopride HCI (SR) Capsules | Pantoprazole Sodium IP | |
| Eq.to Pantoprazole 40 mg | |
| (As enteric coated pellets) | |
| Itopride Hydrochloride IP 150 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Itopride HCI (SR) Capsules | Each hard gelatin capsule contains | |
| Itopride Hydrochloride IP 150 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Cyproheptadine Hydrochloride | Each hard gelatin capsule contains | |
| Capsules | Cyproheptadine Hydrochloride IP 4 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Omeprazole (EC) and | Each hard gelatin capsule contains | |
| Cinitapride (ER) Capsules | Omeprazole IP 20 mg | |
| (As Gastro-resistant pellets) | |
| Cinitapride Hydrogen Tartrate | |
| Eq. to Cinitapride 3 mg | |
| (As extended release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Pantoprazole Sodium (EC) and | Each hard gelatin capsule contains | |
| Cinitapride (SR) Capsules | Pantoprazole Sodium IP | |
| Eq.to Pantoprazole 40 mg | |
| (As Gastro-resistant pellets) | |
| Cinitapride Hydrogen Tartrate | |
| Eq. to Cinitapride 3 mg | |
| (As extended release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Nebivolol and Valsartan | Each hard gelatin capsule contains | |
| Capsules | Valsartan IP 80 mg | |
| Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 5 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Loxapine Capsules USP | Each hard gelatin capsule contains | |
| Loxapine Succinate USP | |
| Eq. to Loxapine 5 mg | |
| Approved colour to used | |
| | |
| Loxapine Capsules USP | Each hard gelatin capsule contains | |
| Loxapine Succinate USP | |
| Eq. to Loxapine 10 mg | |
| Approved colour to used | |
| | |
| Loxapine Capsules USP | Each hard gelatin capsule contains | |
| Loxapine Succinate USP | |
| Eq. to Loxapine 20 mg | |
| Approved colour to used | |
| | |
| Loxapine Capsules USP | Each hard gelatin capsule contains | |
| Loxapine Succinate USP | |
| Eq. to Loxapine 50 mg | |
| Approved colour to used | |
| | |
| Riboflavin, Pyridoxine HCI | Each hard gelatine capsule contains: | |
| Nicotinamide, Cyanocobalamin, | Riboflavin IP 5 mg | |
| Calcium Pantothenate and | Pyridoxine Hydrochloride IP 1.5 mg | |
| Folic Acid Capsules | Cyanocobalamin IP 10 mcg | |
| Nicotinamide IP 15 mg | |
| Calcium Pantothenate IP 5 mg | |
| Folic Acid IP 100 mcg | |
| Approved colour use | |
| | |
| Riboflavin, Pyridoxine HCI | Each hard gelatine capsule contains: | |
| Nicotinamide, Cyanocobalamin, | Riboflavin IP 2 mg | |
| Calcium Pantothenate and | Pyridoxine Hydrochloride IP 0.5 mg | |
| Folic Acid Capsules | Cyanocobalamin IP 10 mcg | |
| Nicotinamide IP 15 mg | |
| Calcium Pantothenate IP 5 mg | |
| Folic Acid IP 100 mcg | |
| Approved colour use | |
| | |
| Mycophenolate Mofetil | Each hard gelatin capsule contains | |
| Capsules IP 250 mg | Mycophenolate Mofetil IP 250 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Mycophenolate Mofetil | Each hard gelatin capsule contains | |
| Capsules IP 500 mg | Mycophenolate Mofetil IP 500 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Dabigatran Etexilate Mesyalte | Each hard gelatin capsule contains | |
| Capsules | Dabigatran Etexilate Mesyalte IP 110 mg | |
| Eq. to Dabigatran Etexilate | |
| Approved colour used in empty capsule shell | |
| | |
| Propranolol Hydrochloride | Each hard gelatin capsule contains | |
| Sustained release Capsules | Propranolol Hydrochloride IP 80 mg | |
| (As Sustained release Pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Propranolol Hydrochloride and | Each hard gelatin capsule contains | |
| Benodrofluazide Capsules | Propranolol Hydrochloride IP 80 mg | |
| Benodrofluazide IP 2.5 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Cyproheptadine Hydrochloride | Each hard gelatin capsule contains | |
| Capsules | Cyproheptadine Hydrochloride IP 4 mg | |
| Colour: Brilliant Blue / Tartrazine / Ponceau 4R | |
| Approved colour used in empty capsule shell | |
| | |
| Atorvastatin, Clopidogrel and | Each hard gelatin capsule contains | |
| Aspirin Capsules | Atorvastatin Calcium IP | |
| Eq. to Atorvastatin (As pellets) 40 mg | |
| Clopidogrel Bisulphate IP | |
| Eq. Clopidogrel (As pellets) 75 mg | |
| Aspirin IP 75 mg | |
| (As Enteric coated pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Lithium Carbonate Capsules | Each hard gelatin capsule contains | |
| Lithium Carbonate IP 250 mg | |
| Approved colour used in empty capsule shell q.s. | |
| | |
| Lithium Carbonate Capsules | Each hard gelatin capsule contains | |
| Lithium Carbonate IP 300 mg | |
| Approved colour used in empty capsule shell q.s. | |
| | |
| Rececadotril Dispersible Capsule | Each uncoated dispersible Capsule contains : | |
| Rececadotril IP 100 mg | |
| Excipients q.s. | |
| | |
| Elemental Iron, Zinc Sulphate, | Each hard gelatin capsule contains | |
| Folic Acid, Vitamin B12 and | Elemental Iron 100 mg | |
| Vitamin C Capsules | (In the form of Carbonyl Iron) | |
| Zinc Sulphate Monohydrate USP 61.8 mg | |
| For Therapeutic Use | (Equivalent to 22.5 Mg of Elemental Zinc) | |
| 19.06.2023 | Folic Acid IP 1.5 mg | |
| Vitamin B12 IP 15 mcg | |
| Vitamin C (Coated) IP 75 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Sildenafil, Dapoxetine Hcl, | Each hard gelatin capsule contains : | |
| Diclofenac sodium and | Sildenafil Citrate IP | |
| Pyridoxine Hydrochloride | Eq. to Sildenafil 100 mg | |
| Capsules | Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 30 mg | |
| FOR Export only | Diclofenac sodium IP 50 mg | |
| 19.06.2023 | Pyridoxine Hydrochloride IP 10 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Mecobalamin, Benfotiamine and | Each hard gelatin capsule contains | |
| Pyridoxine HCI Capsules | Mecobalamin IP 0.5 mg | |
| 02.09.2023 | Benfotiamine 100 mg | |
| Pyridoxine HCI IP 50 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalamin, Pregabalin, | Each hard gelatin capsule contains | |
| Alpha Lipoic Acid, Pyridoxine HCI | Methylcobalamin IP 1500 mcg | |
| and Folic Acid Capsules | Alpha Lipoic acid IP 200 mg | |
| 02.09.2023 | Pregabalin IP 75 mg | |
| Pyridoxine HCI IP 5 mg | |
| Folic Acid IP 2.5 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Methylcobalamin, Alpha Lipoic Acid, | Each hard gelatin capsule contains | |
| Pyridoxine HCl and Folic Acid | Methylcobalamin IP 1500 mcg | |
| Capsules | Alpha Lipoic acid IP 100 mg | |
| 02.09.2023 | Pyridoxine HCI IP 3 mg | |
| Folic Acid IP 1.5 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Cefdinir Capsules IP 300 mg | Each hard gelatin capsule contains | |
| 02.09.2023 | Cefdinir IP 300 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Diclofenac Sodium (SR) and | Each hard gelatin capsule contains | |
| Eperisone HCI (SR) | Diclofenac Sodium IP 100 mg | |
| Capsules | As sustained release pellets) | |
| 02.09.2023 | Eperisone Hydrochloride JP 150 mg | |
| (As sustained release pellets) | |
| Approved colour used in empty capsule shell | |
| | |
| Flunarizine Dihydrochloride | Each hard gelatin capsule contains | |
| Capsules | Flunarizine Dihydrochloride IP | |
| 02.09.2023 | Eq. to Flunarizine 5 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Flunarizine Dihydrochloride | Each hard gelatin capsule contains | |
| Capsules | Flunarizine Dihydrochloride IP 10 mg | |
| 02.09.2023 | Eq. to Flunarizine | |
| Approved colour use in empty capsule shell | |
| | |
| Eperisone Hydrochloride | Each hard gelatin capsule contains | |
| Sustained Release Capsules | Eperisone Hydrochloride JP 75 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Eperisone Hydrochloride | Each hard gelatin capsule contains | |
| Sustained Release Capsules | Eperisone Hydrochloride JP 150 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Zaleplon Capsules IP | Each hard gelatin capsule contains | |
| Zaleplon IP 5 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Zaleplon Capsules IP | Each hard gelatin capsule contains | |
| Zaleplon IP 10 mg | |
| Approved colour use in empty capsule shell | |
| | |
| Phentermine Hydrochloride | Each hard gelatin capsule contains | |
| Capsules USP | Phentermine Hydrochloride USP 37.5 mg | |
| Approved colour used in empty capsule shell | |
| | |
| Ginseng with Multi Vitamin, | Each hard gelatin capsule contains : | |
| Calcium Panthothenate, | Ginseng Extract IP 45 mg | |
| Folic Acid & Zinc Capsules | Vitamin A Palmetate IP 2500 IU | |
| For Prophylactic Use | Vitamin D3 (As Cholecalciferol) IP 200 IU | |
| Vitamin E Acetate IP 10 mg | |
| Vitamin B1 Mono IP 2 mg | |
| Vitamin B2 IP 3 mg | |
| Vitamin B6 HCI IP 1 mg | |
| Vitamin B12 IP 1 mcg | |
| Calcium Panthothenate IP 5 mg | |
| Vitamin C (Coated) IP 50 mg | |
| Zinc Sulphate IP | |
| Equivalent to elemental zinc 1mg | |
| Niacinamide IP 25 mg | |
| Ferrous Fumarate IP 200 mg | |
| Folic Acid IP 300 mcg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Alpha Lipoic Acid, Mecobalamin, | Each hard gelatin capsule : | |
| Pyridoxine, Foilc Acid, | Alpha Lipoic Acid USP 10 mg | |
| Vitamin B1 Capsules | Mecobalamin IP 1500 mcg | |
| For Therapautic Use | Pyridoxine Hydrochloride IP 3 mg | |
| Foilc Acid IP 1.5 mg | |
| Vitamin B1 (Mono) IP 10 mg | |
| Excipients q.s. | |
| Approved colour used in empty capsule shell | |
| | |
| Valsartan Capsules | Each hard gelatin capsule contains | |
| Valsartan IP 80 mg | |
| Approved coloured used in empty capsule shell | |
| | |
| Valsartan Capsules | Each hard gelatin capsule contains | |
| Valsartan IP 160 mg | |
| Approved coloured used in empty capsule shell | |
| | |
| Rosuvastatin and Clopidogrel | Each hard gelatin capsule contains | |
| Capsules | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin (As pellets) 20 mg | |
| Clopidogrel Bisulphate IP | |
| Eq. Clopidogrel (As pellets) 75 mg | |
| Excipients q.s. | |
| Approved coloured used in empty capsule shell | |
| | |
| Rosuvastatin and Aspirin | Each hard gelatin capsule contains | |
| Capsules | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin (As pellets) 20 mg | |
| Aspirin IP 75 mg | |
| (As Enteric coated pellets) | |
| Approved coloured used in empty capsule shell | |
| | |
| Rosuvastatin and Aspirin | Each hard gelatin capsule contains | |
| Capsules | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin (As pellets) 20 mg | |
| Aspirin IP 150 mg | |
| (As Enteric coated pellets) | |
| Approved coloured used in empty capsule shell | |
| | |
| Diosmin Capsules | Each hard gelatin capsule contains | |
| Diosmin (Micronised) BP 150 mg | |
| Approved coloured used in empty capsule shell | |
| | |
| Atorvastatin & | Each hard gelatin capsule: | |
| Aspirin Capsules | Atorvastatin Calcium IP | |
| eq. to Atorvastatin (As pellets) 10 mg | |
| Aspirin (As Enteric coated pellets) IP 150 mg. | |
| Approved coloured used in empty capsule shell | |
| | |
| Atorvastatin & | Each hard gelatin capsule: | |
| Aspirin Capsules | Atorvastatin Calcium IP | |
| eq. to Atorvastatin (As pellets) 20 mg | |
| Aspirin (As Enteric coated pellets) IP 150 mg. | |
| Approved coloured used in empty capsule shell | |
| | |
| Levodopa Capsules IP | Each hard gelatin capsule contains | |
| Levodopa IP 125 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Levodopa Capsules IP | Each hard gelatin capsule contains | |
| Levodopa IP 250 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Levodopa Capsules IP | Each hard gelatin capsule contains | |
| Levodopa IP 500 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Oseltamivir Phosphate | Each hard gelatin capsule contains | |
| Capsules IP | Oseltamivir Phosphate IP 75 mg | |
| Eq. to Oseltamivir | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Oseltamivir Phosphate | Each hard gelatin capsule contains | |
| Capsules IP | Oseltamivir Phosphate IP 45 mg | |
| Eq. to Oseltamivir | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Oseltamivir Phosphate | Each hard gelatin capsule contains | |
| Capsules IP | Oseltamivir Phosphate IP 30 mg | |
| Eq. to Oseltamivir | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Methylcobalamin, Pregabalin, | Each hard gelatin capsule contains | |
| Pyridoxine HCI, Benfotiamine | Methylcobalamin IP 750 mcg | |
| and Folic Acid Capsules | Pregabalin IP 75 mg | |
| For Therapeutic Use | Pyridoxine HCI IP 2 mg | |
| Benfotiamine 7.5 mg | |
| Folic Acid IP 0.75 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shell | |
| | |
| Carisoprodol Capsules | Each hard gelatin capsule contains : | |
| Carisoprodol IP 350 mg | |
| Excipients q.s. | |
| Approved colour to be use in empty capsule shall | |
| | |
| Carisoprodol Capsules | Each hard gelatin capsule contains : | |
| Carisoprodol IP 500 mg | |
| Excipients q.s. | |
| Approved colour to be use in empty capsule shall | |
| | |
| Flurazepam HCI Capsules | Each hard gelatin capsules contains : | |
| Flurazepam HCI IP | |
| Eq. to Flurazepam 15.0 mg | |
| Excipients q.s. | |
| | |
| Isotretinoin Capsules IP | Each hard gelatin capsule contains: | |
| Isotretinoin IP 5 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Isotretinoin Capsules IP | Each hard gelatin capsule contains: | |
| Isotretinoin IP 10 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Isotretinoin Capsules IP | Each hard gelatin capsule contains: | |
| Isotretinoin IP 20 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Isotretinoin Capsules IP | Each hard gelatin capsule contains: | |
| Isotretinoin IP 30 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Isotretinoin Capsules IP | Each hard gelatin capsule contains: | |
| Isotretinoin IP 40 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenvatinib Capsules IP | Each hard gelatin capsule contains: | |
| Lenvatinib Mesylate IP | |
| Eq. to Lenvatinib 4 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenvatinib Capsules IP | Each hard gelatin capsule contains: | |
| Lenvatinib Mesylate IP | |
| Eq. to Lenvatinib 8 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenvatinib Capsules IP | Each hard gelatin capsule contains: | |
| Lenvatinib Mesylate IP | |
| Eq. to Lenvatinib 10 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenalidomide Capsules IP | Each hard gelatin capsule contains: | |
| Lenalidomide IP 5 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenalidomide Capsules IP | Each hard gelatin capsule contains: | |
| Lenalidomide IP 10 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenalidomide Capsules IP | Each hard gelatin capsule contains: | |
| Lenalidomide IP 15 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Lenalidomide Capsules IP | Each hard gelatin capsule contains: | |
| Lenalidomide IP 25 mg | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Topotecan Hydrochloride IP | Each hard gelatin capsule contains: | |
| Capsules | Topotecan Hydrochloride IP 1 mg | |
| Eq. to Topotecan | |
| Excipients q.s. | |
| Approved colour use in empty capsule shells | |
| | |
| Dexrabeprazole Sodium And | Each hard gelatin capsule contains | |
| Domperidone Capsules | Dexrabeprazole Sodium 60 mg | |
| (As modified release pellets) | |
| Domperidone IP 30 mg | |
| (As sustained release pellets) | |
| Approved colour use in empty capsule shell | |
| | |
| Ramipiril and Amlodipine tablet | Each uncoated tablet contains : | |
| Ramipril IP 2.5mg | |
| Amlodipine Besylate IP | |
| Eq. to Amlodipine 5 mg | |
| Approved colour to be use | |
| | |
| Ramipiril and Amlodipine tablet | Each uncoated tablet contains : | |
| Ramipril IP 5mg | |
| Amlodipine Besylate IP | |
| Eq. to Amlodipine 5 mg | |
| Approved colour to be use | |
| | |
| Ramipiril and Amlodipine tablet | Each uncoated tablet contains : | |
| Ramipril IP 10mg | |
| Amlodipine Besylate IP | |
| Eq. to Amlodipine 5 mg | |
| Approved colour to be use | |
| | |
| Betahistine Hydrochloride tablet IP | Each uncoated tablet contains : | |
| Betahistine Hydrochloride IP 8 mg | |
| | |
| Acebrophylline (SR) and montelukast Tablets | Each uncoated billayer tablet contains : | |
| Acebrophylline 200mg | |
| Montelukast Sodium IP | |
| Eq. to Montelukast 10mg | |
| Approved colour to be use | |
| | |
| Acebrophylline and N-Acetylcysteine Tablets | Each film coated tablet contains : | |
| Acebrophylline 100mg | |
| N-Acetylcysteine BP 600mg | |
| Approved colour to used | |
| Piroxicam and Betacyclodextrin Dispersible Tablets | Each uncoated dispersible tablet contains: | |
| Piroxicam IP 20mg | |
| Betacyclodextrin IP 50mg | |
| Approved colour to used | |
| | |
| Piroxicam | Each uncoated dispersible tablet contains: | |
| Dispersible Tablets | Piroxicam IP 20mg | |
| Approved colour to used | |
| | |
| Allylestrenol Tablets | Each film coated tablet contains: | |
| Allylestrenol IP 5mg | |
| Approved colour to used | |
| | |
| Bilastine Tablets | Each uncoated tablet contains: | |
| Bilastine 20mg | |
| Approved colour to used | |
| | |
| Paracetamol, Phenylephrine, | Each uncoated tablet contains: | |
| Bromhexine, Gualphenesin and | Paracetamol IP 500 mg | |
| Chlorpheniramine Maleate | Phenylephrine HCI IP 5 mg | |
| Tablets | Bromhexine Hydrochloride IP 4 mg | |
| Gualphenesin IP 50 mg | |
| Chlorpheniramine maleate IP 4 mg | |
| Approved colour to used | |
| | |
| Telmisartan and Ramipiril | Each uncoated tablet contains : | |
| Tablets | Telmisartan IP 40 mg | |
| Ramipril IP 5 mg | |
| Approved colour to used | |
| | |
| Telmisartan and Ramipiril | Each uncoated tablet contains : | |
| Tablets | Telmisartan IP 40 mg | |
| Ramipril IP 2.5 mg | |
| Approved colour to used | |
| | |
| Voglibose Tablets IP | Each uncoated tablet contains : | |
| Voglibose IP 0.2 mg | |
| | |
| Voglibose Tablets IP | Each uncoated tablet contains : | |
| Voglibose IP 0.3 mg | |
| | |
| Metformin Hydrochloride Tablets | Each uncoated tablet contains | |
| Metformin Hydrochloride IP 750 mg | |
| | |
| Metformin HCl and Glimepiride | Each uncoated tablet contains | |
| Tablets | Metformin Hydrochloride IP 750 mg | |
| Glimepiride IP 0.5 mg | |
| | |
| Metformin HCl and Glimepiride | Each uncoated tablet contains | |
| Tablets | Metformin Hydrochloride IP 750 mg | |
| Glimepiride IP 1 mg | |
| | |
| Metformin HCl and Glimepiride | Each uncoated tablet contains | |
| Tablets | Metformin Hydrochloride IP 750 mg | |
| Glimepiride IP 2 mg | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayered tablet contains : | |
| and Glimepiride tablets | Metformin Hydrochloride IP 750 mg | |
| (As sustained release) | |
| Glimepiride IP 0.5 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayered tablet contains : | |
| and Glimepiride tablets | Metformin Hydrochloride IP 750 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayered tablet contains : | |
| and Glimepiride tablets | Metformin Hydrochloride IP 750 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride Tablets | Each uncoated tablet contains | |
| Metformin Hydrochloride IP 850 mg | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 850 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 850 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 850 mg | |
| (As sustained release) | |
| Glimepiride IP 3 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayred tablet contains : | |
| tablets | Metformin Hydrochloride IP 850 mg | |
| (As sustained release) | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayred tablet contains : | |
| tablets | Metformin Hydrochloride IP 750 mg | |
| (As sustained release) | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 7.5 mg | |
| Approved coloured used | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| Glimepiride IP 1 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 7.5 mg | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 7.5 mg | |
| Approved coloured used | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| Glimepiride IP 2 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 7.5 mg | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Approved coloured used | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated bilayred tablet contains : | |
| and Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Approved coloured used | |
| | |
| Fexofenadine Hydrochloride | Each uncoated tablet contains : | |
| Tablets | Fexofenadine Hydrochloride IP 30 mg | |
| | |
| Itraconazole Sustained Release | Each film coated (SR) tablet contains : | |
| Tablets | Itraconazole USP 200 mg | |
| Approved coloured used | |
| | |
| Etodolac Tablets IP | Each film coated tablet contains : | |
| Etodolac IP 150 mg | |
| Approved coloured used | |
| | |
| Etodolac Tablets IP | Each film coated tablet contains : | |
| Etodolac IP 200 mg | |
| Approved coloured used | |
| | |
| Etodolac Tablets IP | Each film coated tablet contains : | |
| Etodolac IP 300 mg | |
| Approved coloured used | |
| | |
| Etodolac Tablets IP | Each film coated tablet contains : | |
| Etodolac IP 400 mg | |
| Approved coloured used | |
| | |
| Etodolac & Paracetamol Tablets | Each film coated tablet contains : | |
| Etodolac IP 400 mg | |
| Paracetamol IP 325 mg | |
| Approved coloured used | |
| | |
| Etodolac Prolonged Relesed | Each film coated (PR) tablet contains : | |
| Tablets IP | Etodolac IP 200 mg | |
| Approved coloured used | |
| | |
| Etodolac Prolonged Relesed | Each film coated (PR) tablet contains : | |
| Tablets IP | Etodolac IP 600 mg | |
| Approved coloured used | |
| | |
| Gabapentin Tablets IP | Each film coated tablet contains : | |
| Gabapentin IP 100 mg | |
| Approved coloured used | |
| | |
| Gabapentin Tablets IP | Each film coated tablet contains : | |
| Gabapentin IP 300 mg | |
| Approved coloured used | |
| | |
| Gabapentin and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Gabapentin IP 400 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| | Approved coloured used | |
| | |
| Pregabalin and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Pregabalin IP 75 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| | Approved coloured used | |
| | |
| Faropenem Sodium Tablets JP | Each film coated tablet contains : | |
| Faropenem Sodium JP | |
| Eq. to Faropenem 200 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Ezetimibe | Each film coated tablet contains : | |
| Tablets IP | Ezetimibe IP 10 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 5 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Ezetimibe | Each film coated tablet contains : | |
| Tablets IP | Ezetimibe IP 10 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Ezetimibe | Each film coated tablet contains : | |
| Tablets IP | Ezetimibe IP 10 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 40 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets IP | Fenofibrate IP 160 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 5 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets IP | Fenofibrate IP 80 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 10 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets IP | Fenofibrate IP 145 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 10 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets IP | Fenofibrate IP 145 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets IP | Fenofibrate IP 67.5 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 10 mg | |
| Approved coloured used | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets IP | Fenofibrate IP 67.5 mg | |
| Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Approved coloured used | |
| | |
| Memantine HCI Tablets IP | Each film coated tablet contains : | |
| Memantine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Memantine HCI Tablets IP | Each film coated tablet contains : | |
| Memantine Hydrochloride IP 5 mg | |
| Approved coloured used | |
| | |
| Montelukast Tablets IP | Each film coated tablet contains : | |
| Montelukast Sodium IP | |
| Eq. Montelukast 10 mg | |
| Approved coloured used | |
| | |
| Montelukast Tablets IP | Each film coated tablet contains : | |
| Montelukast Sodium IP | |
| Eq. Montelukast 5 mg | |
| Approved coloured used | |
| | |
| Drotaverine Tablets IP | Each film coated tablet contains : | |
| Drotaverine Hydrochloride IP 80 mg | |
| Approved coloured used | |
| | |
| Drotaverine Tablets IP | Each film coated tablet contains : | |
| Drotaverine Hydrochloride IP 40 mg | |
| Approved coloured used | |
| | |
| Azilsartan Medoxomil Tablets | Each film coated tablet contains : | |
| Azilsartan Kamedoxomil | |
| Eq. Azilsartan Medoxomil 10 mg | |
| Approved coloured used | |
| | |
| Azilsartan Medoxomil Tablets | Each film coated tablet contains : | |
| Azilsartan Kamedoxomil | |
| Eq. Azilsartan Medoxomil 20 mg | |
| Approved coloured used | |
| | |
| Paracetamol Effervescent | Each uncoated Effervescent tablet contains : | |
| Tablets | Paracetamol IP 500 mg | |
| Approved coloured used | |
| | |
| Paracetamol Effervescent | Each uncoated Effervescent tablet contains : | |
| Tablets | Paracetamol IP 1000 mg | |
| Approved coloured used | |
| | |
| Torsemide tablets IP | Each uncoated tablet contains : | |
| Torsemide IP 5 mg | |
| | |
| Torsemide tablets IP | Each uncoated tablet contains : | |
| Torsemide IP 10 mg | |
| | |
| Torsemide tablets IP | Each uncoated tablet contains : | |
| Torsemide IP 20 mg | |
| | |
| Torsemide tablets IP | Each uncoated tablet contains : | |
| Torsemide IP 100 mg | |
| | |
| Diltiazem Modified Release | Each modified release film coated tablet contains : | |
| Tablets IP | Diltiazem Hydrochloride IP 30 mg | |
| Approved coloured used | |
| | |
| Diltiazem Modified Release | Each modified release film coated tablet contains : | |
| Tablets IP | Diltiazem Hydrochloride IP 60 mg | |
| Approved coloured used | |
| | |
| Diltiazem Modified Release | Each modified release film coated tablet contains : | |
| Tablets IP | Diltiazem Hydrochloride IP 90 mg | |
| Approved coloured used | |
| | |
| Loratadine Tablets IP | Each uncoated tablet contains : | |
| Loratadine IP 5 mg | |
| | |
| Loratadine Tablets IP | Each uncoated tablet contains : | |
| Loratadine IP 10 mg | |
| | |
| Loratadine and Ambroxol HCI | Each film coated tablet contains : | |
| Tablets | Loratadine IP 5 mg | |
| Ambroxol Hydrochloride IP 60 mg | |
| Approved coloured used | |
| | |
| Telmisartan and Amlodioine | Each uncoated tablet contains : | |
| Tablets IP | Telmisartan IP 80 mg | |
| Amlodipine Besylate IP | |
| Eq. to Amlodipine 10 mg | |
| | |
| Avanafil Tablets | Each film coated tablet contains : | |
| Avanafil 50 mg | |
| Approved colour to used | |
| | |
| Avanafil Tablets | Each filmcoated tablet contains : | |
| Avanafil 100 mg | |
| Approved colour to used | |
| | |
| Avanafil Tablets | Each filmcoated tablet contains : | |
| Avanafil 200 mg | |
| Approved colour to used | |
| | |
| Sildenafil Citrate & Dapoxetine Hcl | Each film coated tablet contains : | |
| Tablets | Sildenafil Citrate IP | |
| Eq. to Sildenafil 50 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 30 mg | |
| Approved colour to used | |
| | |
| Glimepiride, Metformin HCI (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Voglibose IP 0.2 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HCI (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Voglibose IP 0.2 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HCI (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Voglibose IP 0.3 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HC (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Voglibose IP 0.3 mg | |
| Approved coloured used | |
| | |
| Levocetirizine, Montelukast and | Each uncoated bilayered tablet contains | |
| Ambroxol HCI (SR) tablets | Levocetirizine Hydrochloride IP 5 mg | |
| Montelukast sodium IP | |
| Eq. to Montelukast 10 mg | |
| Ambroxol Hydrochloride 75 mg | |
| (As Sustained Release form) | |
| Approved coloured used | |
| | |
| Saxagliptin and Metformin HCI | Each film coated tablet contains | |
| Extended Release Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As extended release) | |
| Saxagliptin Hydrochloride | |
| Eq. to Saxagliptin 5 mg | |
| Approved coloured used | |
| | |
| Tapentadol Hydrochloride | Each film coated contains | |
| Tablets | Tapentadol Hydrochloride IP | |
| Eq. to Tapentado 25 mg | |
| Approved coloured used | |
| | |
| Phenytoin Sodium Tablets IP | Each film coated contains | |
| Phenytoin Sodium IP 50 mg | |
| Approved coloured used | |
| | |
| Phenytoin Sodium Tablets IP | Each film coated contains | |
| Phenytoin Sodium IP 100 mg | |
| Approved coloured used | |
| | |
| Flunarizine Tablets IP | Flunarizine Tablets IP | |
| Each uncoated tablet contains : | |
| Flunarizine Dihydrochloride IP | |
| Eq. to Flunarizine 5 mg | |
| | |
| Paracetamol, Phenylephrine, | Each uncoated tablet contains: | |
| Caffeine and Chlorpheniramine | Paracetamol IP 325 mg | |
| Tablets | Phenylephrine HCI IP 10 mg | |
| Caffeine (Anhydrous) IP 30 mg | |
| Chlorpheniramine maleate IP 4 mg | |
| Approved colour to used | |
| | |
| Propranolol HCl and Flunarizine | Each uncoated tablet contains : | |
| Tablets | Propranolol HCI IP 40 mg | |
| Flunarizine Dlhydrochloride IP | |
| Eq. to Flunarizine 10 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Glimepiride | Each flim coated tablet contains : | |
| Tablets | Glimepiride IP 1 mg | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCI | Each uncoated tablet contains: | |
| Tablets | Metformin HCI IP 500 mg | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCI | Each uncoated tablet contains: | |
| Tablets | Metformin HCI IP 500 mg | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 4 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCI | Each uncoated tablet contains: | |
| Tablets | Metformin HCI IP 1000 mg | |
| (As Sustained Release) | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCI | Each uncoated tablet contains: | |
| Tablets | Metformin HCI IP 1000 mg | |
| (As Sustained Release) | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 4 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCI | Each uncoated tablet contains: | |
| Tablets | Metformin HCI IP 500 mg | |
| (As Sustained Release) | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 4 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCI | Each uncoated tablet contains: | |
| Tablets | Metformin HCI IP 500 mg | |
| (As Sustained Release) | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone Maleate Tablets | Each uncoated tablet contains : | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 1 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone Maleate Tablets | Each uncoated tablet contains : | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone Maleate Tablets | Each uncoated tablet contains : | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 4 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone Maleate Tablets | Each uncoated tablet contains : | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 8 mg | |
| Approved colour to used | |
| | |
| Guaiphenesin, Bromhexine Hcl, | Each uncoated tablet contains : | |
| and Chlorpheniramine | Guaiphenesin IP 50 mg | |
| Tablets | Bromhexine HCl IP 4 mg | |
| Chlorpheniramine maleate IP 2 mg | |
| Approved colour to used | |
| | |
| Paracetamol, Guaiphenesin, | Each uncoated tablet contains : | |
| Chlorpheniramine maleate and | Paracetamol IP 325 mg | |
| Bromhexine HCI Tablets | Guaiphenesin IP 100 mg | |
| Bromhexine Hydrochloride IP 8 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Approved colour to used | |
| | |
| Montelukast, Acebrophylline | Each uncoated tablet contains : | |
| and Levocetirizine HCI Tablets | Montelukast Sodium IP | |
| Eq. to Montelukast 10 mg | |
| Acebrophylline 200 mg | |
| (As prolonged release) | |
| Levocetirizine Hydrochloride IP 5 mg | |
| Approved colour to used | |
| | |
| Paracetamol, Phenylephrine, | Each uncoated tablet contains : | |
| Cetirizine and Ambroxol Tablets | Paracetamol IP 325 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Cetirizine Hydrochloride IP 5 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Approved colour to used | |
| | |
| Camylofen Dihydrochloride and | Each film coated tablet contains : | |
| Paracetamol Tablets | Camylofen Dihydrochloride 50 mg | |
| Paracetamol IP 325 mg | |
| Approved colour to used | |
| | |
| Tofisolam Tablets | Each uncoated tablet contains : | |
| Tofisoalm JP 100 mg | |
| | |
| Tofisolam Tablets | Each uncoated tablet contains : | |
| Tofisoalm JP 50 mg | |
| | |
| Tianeptine Sodium Tablets | Each sugar coated tablet contains : | |
| Tianeptine sodium BP 12.5 mg | |
| Approved colour to used | |
| | |
| Diphenhydramine HCI Tablets | Each uncoated tablet contains : | |
| Diphenhydramine Hydrochloride IP 25 mg | |
| Approved colour to used | |
| | |
| Acetaminophen, Phenylephrine, | Each uncoated tablet contains : | |
| Caffeine and Dexchlorpheniramine | Acetaminophen IP 500 mg | |
| Maleate Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Caffeine (Anhydrous) IP 30 mg | |
| Dexchlorpheniramine maleate IP 2 mg | |
| Approved colour to used | |
| | |
| Ebastine and Montelukast Sodium | Each film coated tablet contains : | |
| Tablets | Ebastine IP 10 mg | |
| Montelukast Sodium IP | |
| Eq. to Montelukast 10mg | |
| Approved colour to used | |
| | |
| Norfloxacin and Tinidazole | Each film coated tablet contains : | |
| Tablets | Norfloxacin IP 200 mg | |
| Tinidazole IP 300 mg | |
| Approved colour to used | |
| | |
| Ebastine Tablets IP 10 mg | Each film coated tablet contains : | |
| Ebastine IP 10 mg | |
| Approved colour to used | |
| | |
| Ebastine Tablets IP 20 mg | Each film coated tablet contains : | |
| Ebastine IP 20 mg | |
| Approved colour to used | |
| | |
| Levosulpiride Tablets | Each uncoated tablet contains : | |
| Levosulpiride 25 mg | |
| | |
| Losartan Potassium and | Each film coated tablet contains : | |
| Amlodipine Tablets IP | Losartan Potassium IP 50 mg | |
| Amlodipine besylate IP | |
| Eq. to Amlodipine 5 mg | |
| Approved colour to used | |
| | |
| Losartan Potassium and | Each uncoated tablet contains : | |
| Hydrochlorothiazide Tablets IP | Losartan Potassium IP 25 mg | |
| Hydrochlorothiazide IP 5 mg | |
| | |
| Losartan Potassium and | Each film coated tablet contains : | |
| Hydrochlorothiazide Tablets IP | Losartan Potassium IP 25 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Approved colour to used | |
| | |
| Faropenem Sodium (ER) Tablets | Each film coated Extended Release tablet contains : | |
| Faropenem Sodium JP | |
| Eq. to Faropenem 300 mg | |
| Approved coloured used | |
| | |
| Methyldopa Tablets IP | Each film coated tablet contains : | |
| Methyldopa IP | |
| Eq. to Anhydrous Methyldopa 125 mg | |
| Approved coloured used | |
| | |
| Methyldopa Tablets IP | Each film coated tablet contains : | |
| Methyldopa IP | |
| Eq. to Anhydrous Methyldopa 250 mg | |
| Approved coloured used | |
| | |
| Nicoumalone Tablets IP 2 mg. | Each Uncoated tablet contains : | |
| Nicoumalone BP 2 mg | |
| | |
| Temazepam Tablets | Each Uncoated tablet contains : | |
| Temazepam IP 10 mg | |
| | |
| Temazepam Tablets | Each Uncoated tablet contains : | |
| Temazepam BP 20 mg | |
| Excipients q.s. | |
| | |
| Triazolam Tablets | Each Uncoated tablet contains : | |
| Triazolam USP 0.25 mg | |
| Excipients q.s. | |
| | |
| Clonazepam and Propranolol HCI | Each uncoated tablet contains : | |
| Tablets | Clonazepam IP 0.25 mg | |
| Propranolol Hydrochloride IP 10 mg | |
| Approved coloured used q.s. | |
| | |
| Clonazepam and Propranolol HCI | Each uncoated tablet contains : | |
| Tablets | Clonazepam IP 0.5 mg | |
| Propranolol Hydrochloride IP 20 mg | |
| Approved coloured used q.s. | |
| | |
| Cinnarizine and Dimenhydrinate | Each orally disintegrating tablets contains | |
| Mouth dissolving Tablets | Cinnarizine IP 20 mg | |
| Dimenhydrinate IP 40 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Cetirizine HCI, Paracetamol | Each uncoated tablet contains: | |
| With Nimesulide Tablets | Cetirizine Hydrochloride IP 5 mg | |
| Paracetamol IP 325 mg | |
| Nimesulide IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Camylofin Dihydrchloride | Each film coated tablet contains: | |
| and Paracetamol Tablets | Camylofin Dihydrchloride IP 50 mg | |
| Paracetamol IP 325 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Ursodeoxycholic Acid Tablet IP 150 mg | Each film coated tablet contains | |
| Ursodeoxycholic Acid IP 150 mg | |
| Approved coloured used | |
| | |
| Ursodeoxycholic Acid Tablet IP 300 mg | Each film coated tablet contains | |
| Ursodeoxycholic Acid IP 300 mg | |
| Approved coloured used | |
| | |
| Methylcobalamin, Folic acid and | Each film cooted tablet contains : | |
| L-Carnitine Tartrate Tablets | Methylcobalamin IP 1500 mcg | |
| Folic Acid IP 1.5 mg | |
| For Therapeutic Use | L-Carnitine L-Tartrate IP | |
| Eq. L-Carnitine 500 mg | |
| Approved colour to be use | |
| | |
| Doxycycline and Ambroxol Tablete | Each filin coated tablet contains: | |
| Doxycycline Hydrochloride IP | |
| Equivalent to Doxycycline 100 mg | |
| Ambroxol Hydrochloride IP 75 mg | |
| Approved colour to be use | |
| | |
| Dexamethasone Tablets | Each uncoated tablet contains: | |
| Dexomethasone IP 2 mg | |
| | |
| Pregabaline & | Each film coated tablet contains : | |
| Nortriptyline Tablets | Pregabaline IP 75 mg | |
| For Therapeutic Use | Nortriptyline HCI IP | |
| Eq. to Nortriptyline 10 mg | |
| Approved colour to be use q.s. | |
| | |
| Roxithromycin, Ambroxol Mcl and | Each film coated tablet contains : | |
| Lactic Acid Basillus Tablets | Roxithromycin IP 150 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Lactic Acid Basillus IP 30 mil.Sp. | |
| Approved colour to be use | |
| | |
| Roxithromycin and Ambroxol Hel | Each film coated tablet contains : | |
| Tablets | Roxithromycin IP 150 mg | |
| Ambroxol Hydrochloride IP 60 mg | |
| Approved colour to be us | |
| | |
| Methylcobalamin Tablets | Each film coated tablet contains : | |
| Methylcobalamin IP 1500 mcg | |
| Approved colour to be use | |
| | |
| Methylcobalamin Tablets | Each film coated tablet contains : | |
| Methylcobalamin IP 500 mcg | |
| Approved colour to be use | |
| | |
| Ferrous Sulphate and Folic Acid | Each film coated tablet contains : | |
| Tablets IP | Ferrous Sulphate IP 300 mg | |
| Eq. to elemental Iron 60 mg | |
| Folic acid IP 0 .25 mg | |
| Approved colour to be use | |
| | |
| Ferrous Sulphate Tablets | Each film coated tablet contains : | |
| Ferrous Sulphate IP 300 mg | |
| Eq. to elemental Iron 60 mg | |
| Approved colour to be use | |
| | |
| Deflazacort Tablets | Each uncoated tablet contains : | |
| Deflazacort 12 mg | |
| Excipients q.s. | |
| | |
| Deflazacort Tablets | Each uncoated tablet contains : | |
| Deflazacort 18 mg | |
| Excipients q.s. | |
| | |
| Deflazacort Tablets | Each uncoated tablet contains : | |
| Deflazacort 24 mg | |
| Excipients q.s. | |
| | |
| Ferrous Sulphate, Folic Acid | Each film coated tablet contains : | |
| and Zinc Tablets | Ferrous Sulphate IP 300 mg | |
| Eq. to elemental Iron 60 mg | |
| Folic acid IP 1.5 mg | |
| Zinc Sulphate Monohydrate IP | |
| Eq. to Zinc 22.5 mg | |
| Approved colour to be use | |
| | |
| Ferrous Ascorbate, Folic Acid | Each film coated tablet contains : | |
| and Zinc Tablets | Ferrous Ascorbate | |
| Eq. to elemental Iron 100 mg | |
| Folic acid IP 1.5 mg | |
| Zinc Sulphate Monohydrate IP | |
| Eq. to Zinc 22.5 mg | |
| Approved colour to be use | |
| | |
| Ferrous Ascorbate, Folic Acid, Zinc | Each film coated tablet contains: | |
| and Methylcobalamin Tablets | Ferrous Ascorbate | |
| Eq. to elemental Iron 100 mg | |
| Folic acid IP 1 mg | |
| Zinc Sulphate Monohydrate IP | |
| Eq. to Zinc 10 mg | |
| Methylcobalamin IP 500 mcg | |
| Approved colour to be use | |
| | |
| Calcium Citrate Maleate, Folic Acid | Each film coated tablet contains : | |
| and Vitamin D3 Tablets | Calcium Citrate Maleate | |
| Eq. to Calcium 250 mg | |
| Folic acid IP 50 mcg | |
| Vitamin D3 IP 250 IU | |
| Approved colour to be use | |
| | |
| Doxycycline, Ambroxol and | Each film coated tablet contains : | |
| Bromhexine HCI Tablets | Doxycycline Hydrochloride IP | |
| Equivalent to Doxycycline 100 mg | |
| Ambroxol Hydrochloride IP 8 mg | |
| Bromhexine HCI IP 4 mg | |
| Approved colour to be use | |
| | |
| Doxylamine, Pyridoxine HCL | Each enteric coated tablet contains : | |
| and Folic Acid Tablets | Doxylamine Succinate BP 20 mg | |
| Pyridoxine HCI IP 20 mg | |
| Folic acid IP 5 mg | |
| Approved colour to be use | |
| | |
| Mecobalamin, Folic Acid, Benfotiamine, | Each film coated tablet contains : | |
| Alpha Lipoic Acid and Chromium | Mecobalamin IP 1500 mcg | |
| Myo Inositol with Pyridoxine HCL Tablets | Folic acid IP 1.5 mg | |
| Benfotiamine IP 200 mg | |
| Alpha Lipoic Acid IP 100 mg | |
| Chromium Polynicotinate 200 mcg | |
| Myo Inositol 10 mg | |
| Pyridoxine HCl IP 20 mg | |
| Approved colour to be use | |
| | |
| Glutathione Tablets | Each uncoated tablet contains : | |
| Glutathione 600 mg | |
| Exciplents q.s. | |
| | |
| Paracetamol and Caffeine | Each uncoated tablet contains : | |
| Tablets IP | Paracetamol IP 500 mg | |
| Caffeine (Anhydrosu) IP 25 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Paracetamol and Caffeine | Each uncoated tablet contains : | |
| Tablets IP | Paracetamol IP 650 mg | |
| Caffeine (Anhydrosu) IP 50 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Levofloxacin and Ornidazole | Each film coated tablet contains : | |
| Tablets | Levofloxacin Hemihydrate IP | |
| Eq. to Levofloxacin 250 mg | |
| Ornidazole IP 500 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Fexofenadine, Montelukast and | Each film coated tablet contains : | |
| Acebrophylline Tablets | Fexofenadine Hydrochloride IP 120 mg | |
| Montelukast sodium IP | |
| Eq. to Montelukast 10 mg | |
| Acebrophylline 200 mg | |
| Approved coloured used | |
| | |
| Sildenafil Citrate & Dapoxetine HCl | Each film coated tablet contains : | |
| Tablets | Sildenafil Citrate IP | |
| Eq. to Sildenafil 100 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 60 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Sildenafil Citrate & Dapoxetine HCl | Each film coated tablet contains : | |
| Tablets | Sildenafil Citrate IP | |
| Eq. to Sildenafil 100 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 30 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Mefenamic Acid and | Each uncoated tablet contains : | |
| Dicyclomine HCI Tablets | Mefenamic acid IP 125 mg | |
| Dicyclomine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin (SR), Gliclazide Tablets | Each uncoated tablet contains | |
| Metformin Hydrochloride IP 500 mg | |
| (As sustained release ) | |
| Gliclazide IP 80 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Furazolidone and Metronidazole | Each uncoated tablet contains | |
| Tablets | Furazolidone IP 50 mg | |
| Metronidazole IP 100 mg | |
| Excipients q.s. | |
| | |
| Dexchlorpheniramine Maleate, | Each uncoated tablet contains : | |
| Paracetamol, Caffeine & | Paracetamol IP 325 mg | |
| Phenylephrine Hydrochloride | Dexchlorpheniramine Maleate IP 2 mg | |
| Tablets | Caffeine (Anhydrous) IP 25 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Metformin (sustained released) and | Each uncoated tablet contains | |
| Voglibose Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Voglibose IP 0.2 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin (sustained released) and | Each uncoated tablet contains | |
| Voglibose Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Voglibose IP 0.3 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCl and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| Glimepiride IP 3 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCl and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| Glimepiride IP 4 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCI (SR) and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 4 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCI (SR) and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 3 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCI (SR) and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Glimepiride IP 3 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Metformin HCI (SR) and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Glimepiride IP 4 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCl and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 1000 mg | |
| Glimepiride IP 3 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Metformin HCl and | Each uncoated tablet contains | |
| Glimepiride Tablets | Metformin Hydrochloride IP 1000 mg | |
| Glimepiride IP 4 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Pioglitazone, Metformin HCI | Each uncoated tablet contains | |
| and Gliclazide Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 60 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Pioglitazone, Metformin HCI | Each uncoated tablet contains | |
| and Gliclazide Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 30 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated tablet contains | |
| and Gliclazide (SR) Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Gliclazide (As sustained release) IP 60 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Pioglitazone, Metformin HCI (SR) | Each uncoated tablet contains | |
| and Gliclazide (SR) Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Gliclazide (As sustained release) IP 30 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Clomipramine Hydrochloride | Each uncoated tablet contains | |
| (sustained relesed) Tablets | Clomipramine Hydrochloride IP 75 mg | |
| (As sustained release) | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Vardenafil Tablets 10 mg | Each film coated tablet contains : | |
| Vardenafil Hydrochloride | |
| Eq. to Vardenafil 10 mg | |
| Approved colour to be used | |
| | |
| Vardenafil Tablets 20 mg | Each film coated tablet contains : | |
| Vardenafil Hydrochloride | |
| Eq. to Vardenafil 20 mg | |
| Approved colour to be used | |
| | |
| Vardenafil Tablets 40 mg | Each film coated tablet contains : | |
| Vardenafil Hydrochloride | |
| Eq. to Vardenafil 40 mg | |
| Approved colour to be used | |
| | |
| Vardenafil Chewable Tablets | Each uncoated chewable tablet contains : | |
| Vardenafil Hydrochloride | |
| Eq. to Vardenafil 20 mg | |
| Approved colour to be used | |
| | |
| Pirfenidone Tablets IP 400 mg | Each film coated tablet contains : | |
| Pirfenidone IP 400 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Flibanserin Tablets 100 mg | Each film coated tablet contains | |
| Flibanserin 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Dextromethorphan Hydrobromide, | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride & | Dextromethorphan HBO IP 10 mg | |
| Chlorpheniramine Maleate | Phenylephrine Hydrochloride IP 5 mg | |
| Tablets | Chlorpheniramine Maleate IP 2 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Fluconazole Tablets IP 200 mg. | Each uncoated tablet contains | |
| Fluconazole IP 200 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Cetrizine Hydrochloride Tablets IP | Each uncoated tablet contains | |
| Cetirizine Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| | |
| Rebamipide Tablets | Each film coated tablet contains | |
| Rebamipide IP 100 mg | |
| Excipients q.s. | |
| | |
| Nitazoxanide Tablets | Each film coated tablet contains | |
| Nitazoxanide 500 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol, Ambroxol HCI, | Each uncoated tablet contains: | |
| Guaiphenesin, Cetirizine Hcl & | Paracetamol IP 325 mg | |
| Phenylephrine Hydrochloride | Ambroxol Hydrochloride IP 15 mg | |
| Tablets | Guaiphenesin IP 50 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Cetirizine Hydrochloride IP 5mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol and Zaltoprofen | Each film coated tablet contains: | |
| Tablets | Paracetamol IP 325 mg | |
| Zaltoprofen JP 80 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tranexamic acid and Etamsylate | Each film coated tablet contains: | |
| Tablets | Tranexamic Acid IP 250 mg | |
| Etamsylate BP 250 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Prochlorperazine Maleate | Each orally disintegrating tablet contains : | |
| Orally Disintegrating Tablets | Prochlorperazine Maleate IP 5 mg | |
| Excipients q.s. | |
| | |
| Prochlorperazine Maleate | Each orally disintegrating tablet contains : | |
| Orally Disintegrating Tablets | Prochlorperazine Maleate IP 10 mg | |
| Excipients q.s. | |
| | |
| Naproxen and Domperidone | Each uncoated tablet contains : | |
| Tablet | Naproxen IP 250 mg | |
| Domperidone IP 10 mg | |
| Excipients q.s. | |
| | |
| Naproxen Tablets IP | Each uncoated tablet contains : | |
| Naproxen IP 250 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Naproxen Tablets IP | Each uncoated tablet contains : | |
| Naproxen IP 500 mg | |
| Excipients q.s. | |
| Approved coloured to be used | |
| | |
| Amlodipine Besylate and | Each uncoated bilayred tablet contains : | |
| Metoprolol Succinate | Amlodipine Besylate | |
| Prologned-release Tablets | Eq. to Amlodipine IP 5 mg | |
| Metoprolol Succinate IP 47.5 mg | |
| Eq. to Metoprolol Tartrate 50.0 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Amlodipine Besylate and | Each uncoated bilayred tablet contains : | |
| Metoprolol Succinate | Amlodipine Besylate | |
| Prologned-release Tablets | Eq. to Amlodipine IP 5 mg | |
| Metoprolol Succinate IP 23.75 mg | |
| Eq. to Metoprolol Tartrate 25.0 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Atorvastatin and Aspirin tablets | Each Film coated tablet contains | |
| Atorvastatin Calcium | |
| Eq. to Atorvastatin IP 10 mg | |
| Aspirin IP 75 mg | |
| Excipients q.s. | |
| Approved coloured be used | |
| | |
| Amlodipine Besylate and | Each uncoated tablet contains | |
| Hydrochlorothizide tablets | Amlodipine Besylate | |
| Eq. to Amlodipine IP 5 mg | |
| Hydrochlorothizide IP 12.5 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Paracetamol and Domperidone | Each uncoated tablet contains | |
| Tablets | Paracetamol IP 325 mg | |
| Domperidone IP 10 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Paracetamol and Domperidone | Each uncoated tablet contains | |
| Tablets | Paracetamol IP 500 mg | |
| Domperidone IP 20 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Orinidazole Tablets | Each Film coated tablet contains : | |
| Orinidazole IP 500 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| N-Acetylsteine Tablet | Each Film coated tablet contains : | |
| N-Acetylsteine USP 600 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Rifaximin Tablets | Each Film coated tablet contains : | |
| Rifaximin Eur. 200 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Rifaximin Tablets | Each Film coated tablet contains : | |
| Rifaximin Eur. 400 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Rifaximin Tablets | Each Film coated tablet contains : | |
| Rifaximin Eur. 550 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Vildagliptin tablets IP | Each uncoated tablet contains : | |
| Vildagliptin IP 50 mg | |
| Excipients q.s. | |
| | |
| Vildagliptin tablets IP | Each uncoated tablet contains : | |
| Vildagliptin IP 100 mg | |
| Excipients q.s. | |
| | |
| Sildenafil Citrate tablets | Each film coated tablet contains : | |
| Sildenafil Citrate IP | |
| Eq. to Sildenafil 150 mg | |
| Approved coloured used | |
| | |
| Sildenafil Citrate tablets | Each film coated tablet contains : | |
| Sildenafil Citrate IP | |
| Eq. to Sildenafil 200 mg | |
| Approved coloured used | |
| | |
| Metformin (SR) & | Each film coated tablet contains | |
| Glimepride Tablets IP | Metformin Hydrochloride (as sustain release) IP 500 Mg | |
| Glimepride IP 1 mg | |
| Permitted Color Used | |
| | |
| Telmisartan with | Each film coated tablet contains | |
| Chlorthalidone Tablets | Telmisartan IP 40 mg | |
| Chlorthalidone IP 6.25 mg | |
| Permitted Color Used | |
| | |
| Telmisartan with | Each film coated tablet contains | |
| Chlorthalidone Tablets | Telmisartan IP 40 mg | |
| Chlorthalidone IP 12.5 mg | |
| Permitted Color Used | |
| | |
| Telmisartan with | Each film coated tablet contains | |
| Chlorthalidone Tablets | Telmisartan IP 80 mg | |
| Chlorthalidone IP 6.25 mg | |
| Permitted Color Used | |
| | |
| Telmisartan with | Each film coated tablet contains | |
| Hydrochlorothazide | Telmisartan IP 40 mg | |
| Tablet IP | Hydrochlorothazide IP 12.5 mg | |
| Permitted Color Used | |
| | |
| Chlorthalidone Tablets IP | Each uncoated tablet contains : | |
| Chlorthalidone IP 50 mg | |
| Permitted Color Used | |
| | |
| Olmesartan, Cilnidipine | Each film coated tablet contains | |
| with Chlorthalidone Tablets | Olmisartan Medoxomil IP 40 mg | |
| Cilnidipine IP 10 mg | |
| Chlorthalidone IP 12.5 mg | |
| Permitted Color Used | |
| | |
| Ezetimibe Tablets IP | Each flimcoated tablet contains | |
| Ezetimibe 10 mg | |
| Permitted Color Used | |
| | |
| Diclofenac Potassium Tablets | Each film coated tablet contains : | |
| Diclofenac Potassium BP 50 mg | |
| Permitted Color Used | |
| | |
| Diclofenac Potassium Tablets | Each uncoated tablet contains : | |
| Diclofenac Potassium BP 50 mg | |
| Permitted Color Used | |
| | |
| Diclofenac Potassium Tablets | Each sustained release tablet contains : | |
| Sustained Release Tablets | Diclofenac Potassium IP 100 mg | |
| Permitted Color Used | |
| | |
| Metformin Sustain Release | Each film coated sustain release tablet contains | |
| Tablets IP | Metformin Hydrochloride IP 500 mg | |
| Permitted Color Used | |
| | |
| Metformin Sustain Release | Each film coated sustain release tablet contains | |
| Tablets IP | Metformin Hydrochloride IP 1000 mg | |
| Permitted Color Used | |
| | |
| Metformin (SR) & | Each film coated tablet contains | |
| Glimepride Tablets IP | Metformin Hydrochloride (as sustain release) IP 500 mg | |
| Glimepride IP 2 mg | |
| Permitted Color Used | |
| | |
| Clonazepam Tablets IP | Each Uncoated tablet contains : | |
| Clonazepam IP 0.5 mg | |
| Excipients q.s. | |
| | |
| Clonazepam Tablets IP | Each Uncoated tablet contains : | |
| Clonazepam IP 1 mg | |
| Excipients q.s. | |
| | |
| Clonazepam Tablets IP | Each Uncoated tablet contains : | |
| Clonazepam IP 2 mg | |
| Excipients q.s. | |
| | |
| Clonazepam and Escitalopram Oxelate | Each uncoated tablet contains: | |
| Tablets IP | Clonazepam IP 0.25 mg | |
| Escitalopram Oxelate IP | |
| Eq. to Escitalopram 10 mg | |
| Excipients q.s. | |
| | |
| Zolpidem Tartrate Prolonged release | Each Uncoated prolonged release tablet contains : | |
| Tablets IP | Zolpidem Tartrate IP 6.25 mg | |
| Excipients q.s. | |
| | |
| Zolpidem Tartrate Prolonged release | Each Uncoated prolonged release tablet contains : | |
| Tablets IP | Zolpidem Tartrate IP 12.50 mg | |
| Excipients q.s. | |
| | |
| Zolpidem Tartrate Tablets IP | Each Uncoated prolonged release tablet contains : | |
| Zolpidem Tartrate IP 5.0 mg | |
| Excipients q.s. | |
| | |
| Zolpidem Tartrate Tablets IP | Each Uncoated prolonged release tablet contains : | |
| Zolpidem Tartrate IP 10.0 mg | |
| Excipients q.s. | |
| | |
| Lorazepam Tablets IP | Each Uncoated tablet contains : | |
| Lorazepam IP 1 mg | |
| Excipients q.s. | |
| | |
| Lorazepam Tablets IP | Each Uncoated tablet contains : | |
| Lorazepam IP 2.0 mg | |
| Excipients q.s. | |
| | |
| Nimetazepam Tablets | Each Uncoated tablet contains : | |
| Nimetazepam 5.0 mg | |
| Excipients q.s. | |
| | |
| Oxazepam Tablets IP | Each Uncoated tablet contains : | |
| Oxezepam IP 10.0 mg | |
| Excipients q.s. | |
| | |
| Oxazepam Tablets IP | Each Uncoated tablet contains : | |
| Oxezepam IP 15.0 mg | |
| Excipients q.s. | |
| | |
| Oxazepam Tablets IP | Each Uncoated tablet contains : | |
| Oxezepam IP 30.0 mg | |
| Excipients q.s. | |
| | |
| Bromazepam Tablets | Each Uncoated tablet contains : | |
| Bromazepam BP 1.5 mg | |
| Excipients q.s. | |
| | |
| Bromazepam Tablets | Each Uncoated tablet contains : | |
| Bromazepam BP 3 mg | |
| Excipients q.s. | |
| | |
| Bromazepam Tablets | Each Uncoated tablet contains : | |
| Bromazepam BP 6 mg | |
| Excipients q.s. | |
| | |
| Temazepam Tablets | Each Uncoated tablet contains : | |
| Temazepam BP 10 mg | |
| Excipients q.s. | |
| | |
| Temazepam Tablets | Each Uncoated tablet contains : | |
| Temazepam BP 20 mg | |
| Excipients q.s. | |
| | |
| Trizolam Tablets | Each Uncoated tablet contains : | |
| Triazolam USP 0.25 mg | |
| Excipients q.s. | |
| | |
| Alprazolam Tablets IP 1 mg | Each uncoated tablet contains : | |
| Alprazolam IP 1 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Alprazolam and Propranolol | Each uncoated tablet contains : | |
| Hydrochloride Tablets | Alprazolam IP 0.25 mg | |
| Propranolo Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Alprazolam and Propranolol | Each uncoated tablet contains : | |
| Hydrochloride Tablets | Alprazolam IP 0.25 mg | |
| Propranolo Hydrochloride IP 20 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Dapagliflozin tablets | Each film coated tablet contains: | |
| Dapagliflozin Propanediol monohydrate | |
| Eq. to Dapagliflozin 5 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Dapagliflozin tablets | Each film coated tablet contains: | |
| Dapagliflozin Propanediol monohydrate | |
| Eq. to Dapagliflozin 10 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Flurazepam HCI Capsules | Each hard gelatin capsules contains : | |
| Flurazepam HCI IP | |
| Eq. to Flurazepam 5 mg | |
| Excipients q.s. | |
| | |
| Flurazepam HCI Capsules | Each hard gelatin capsules contains : | |
| Flurazepam HCI IP | |
| Eq. to Flurazepam 10 mg | |
| Excipients q.s. | |
| | |
| Flurazepam HCI Capsules | Each hard gelatin capsules contains : | |
| Flurazepam HCI IP | |
| Eq. to Flurazepam 15 mg | |
| Excipients q.s. | |
| | |
| Zolpidem Tartrate orally | Each uncoated orally Disintegrating tablet contains : | |
| Disintegrating Tablets | Zolpidem Tartrate IP 5 mg | |
| Excipients q.s. | |
| | |
| Zolpidem Tartrate orally | Each uncoated orally Disintegrating tablet contains : | |
| Disintegrating Tablets | Zolpidem Tartrate IP 10 mg | |
| Excipients q.s. | |
| | |
| Zinc Sulphate Tablets | Each uncoated bless contains | |
| Zinc Sulphate Monohydrate IP | |
| eq. to Elemental Zinc 5 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (SR), | Each uncoated bilayered tablet contains | |
| Glimepride Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release form) | |
| Glimepride IP 0.5 mg | |
| Approved colour to used | |
| | |
| Oral Rehydration Salts IP | Each sachet 21g contains | |
| Sodium chloride IP 2.60 g | |
| Dextrose anhydrose IP 13.5 g | |
| Potassium Chloride IP 1.50 g | |
| Sodium Carate IP 2.90 g | |
| Excipients q.s. | |
| | |
| Metformin Hydrochloride (ER). | Each uncoated tablet contains | |
| Teneligliptin Tablets | Metformin Hydrochloride IP 500 mg | |
| (as extaned release form) | |
| Tenengliptin Hydrobromide Hydrate IP | |
| eq. to Teneligliptin 20 mg | |
| Approved colour to used | |
| | |
| Metformin Hydrochloride (ER). | Each uncoated tablet contains | |
| Teneligliptin Tablets | Metformin Hydrochloride IP 1000 mg | |
| (as extaned release form) | |
| Tenengliptin Hydrobromide Hydrate IP | |
| eq. to Teneligliptin 20 mg | |
| Approved colour to used | |
| | |
| Pirfonidone Tablets IP | Each film coated tablet contains | |
| Pirfenidone IP 200 mg | |
| Approved colour to used | |
| | |
| Tapentadol Hydrochloride | Each film coated sustain realease tablet contains | |
| Sustain Release Tablet | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 100 mg | |
| Approved colour to used | |
| | |
| Tapentadol Hydrochloride | Each film coated tablet contains | |
| Tablet | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 100 mg | |
| Approved colour lo used | |
| | |
| Azilsartan Medoxomil Tablets | Each uncoated tablet contains: | |
| Azilsartan Kamedoxomil | |
| Eq. to Azilsartan Medoxomil 40 mg | |
| Approved colour to used | |
| | |
| Azilsartan Medoxomil Tablets | Each uncoated tablet contains: | |
| Azilsartan Kamedoxomil | |
| Eq. to Azilsartan Medoxomil 80 mg | |
| Approved colour to used | |
| | |
| Tadalafil Tablets | Each film coated tablel contains | |
| Tadalafil IP 2.5 mg | |
| Approved colour to used | |
| | |
| Tadalafil Tablets | Each film coated tablel contains | |
| Tadalafil IP 5 mg | |
| Approved colour to used | |
| | |
| Tadalafil Tablets | Each film coated tablel contains | |
| Tadalafil IP 10 mg | |
| Approved colour to used | |
| | |
| Tadalafil Orally Tablets | Each orally disintegrating tablet contains : | |
| Disintegrating Tablets | Tadalafil IP 20 mg | |
| Approved colour lo used | |
| | |
| Udenafil Tablets 100 mg | Each film coated tablet contains : | |
| Udenafil IP 100 mg | |
| Approved colour to used | |
| | |
| Udenafil Tablets 200 mg | Each film coated tablet contains : | |
| Udenafil IP 200 mg | |
| Approved colour to used | |
| | |
| Phenobarbitone Tablets IP 30 mg | Each uncoated tablet contains : | |
| Phenobarbitone IP 30 mg | |
| Approved colour to used | |
| | |
| Phenobarbitone Tablets IP 60 mg | Each uncoated tablet contains : | |
| Phenobarbitone IP 60 mg | |
| Approved colour to used | |
| | |
| Tramadol Hydrochloride | Each sustained release tablet contains | |
| Sustained Release Tablet | Tramadol Hydrochloride IP 100 mg | |
| Approved colour to used | |
| | |
| Ascorbic Acid & Cholecalciferol | Each uncoated chewable tablet contains : | |
| with Zinc Tablets | Ascorbic acid IP 40 mg | |
| Cholecalciferol (Vitamin D3) IP 400 IU | |
| Zinc Sulphate Monohydrate IP | |
| eq. to elemental Zinc 10 mg | |
| Approved colour to be used | |
| | |
| Ascorbic Acid & Cholecalciferol | Each uncoated chewable tablet contains : | |
| Tablets | Ascorbic acid IP 20 mg | |
| Cholecalciferol (Vitamin D3) IP 200 IU | |
| Approved colour to be used | |
| | |
| Ascorbic Acid & Cholecalciferol | Each uncoated chewable tablet contains : | |
| Tablets | Ascorbic acid IP 40 mg | |
| Cholecalciferol (Vitamin D3) IP 400 IU | |
| Approved colour to be used | |
| | |
| Ascorbic Acid | Each uncoated chewable tablet contains : | |
| Tablets | Ascorbic acid IP 50 mg | |
| Approved colour to be used | |
| | |
| Cholecalciferol Chewable Tablets | Each uncoated chewable tablet contains : | |
| Cholecalciferol (Vitamin D3) IP 600 IU | |
| Approved colour to be used | |
| | |
| Cholecalciferol Chewable Tablets | Each uncoated chewable tablet contains : | |
| Cholecalciferol (Vitamin D3) IP 400 IU | |
| Approved colour to be used | |
| | |
| Vitamin A Chewable Tablets | Each uncoated chewable tablet contains : | |
| Vitamin A IP 1000 IU | |
| Approved colour to be used | |
| | |
| Vitamin A Chewable Tablets | Each uncoated chewable tablet contains : | |
| Vitamin A IP 5000 IU | |
| Approved colour to be used | |
| | |
| Vitamin A Chewable Tablets | Each uncoated chewable tablet contains : | |
| Vitamin A IP 50000 IU | |
| Approved colour to be used | |
| | |
| Vitamin A & Vitamin D | Each uncoated chewable tablet contains : | |
| Chewable Tablets | Vitamin A IP 1000 IU | |
| Vitamin D3 IP 400 IU | |
| Approved colour to be used | |
| | |
| Vitamin A & Vitamin D | Each uncoated chewable tablet contains : | |
| Chewable Tablets | Vitamin A IP 10000 IU | |
| Vitamin D3 IP 1000 IU | |
| Approved colour to be used | |
| | |
| Clarithromycin | Each film coated tablet contains : | |
| Tablets IP | Clarithromycin IP 250 mg | |
| Approved colour to used | |
| | |
| Clarithromycin | Each film coated tablet contains : | |
| Tablets IP | Clarithromycin IP 500 mg | |
| Approved colour to used | |
| | |
| Dexamethasone | Each uncoated tablet contains : | |
| tablets | Dexamethasone IP 4 mg | |
| | |
| Dexamethasone | Each uncoated tablet contains : | |
| tablets | Dexamethasone IP 8 mg | |
| | |
| Alprazolam Tablets IP 0.25 mg | Each uncoated tablet contains : | |
| Alprazolam IP 0.25 mg | |
| Approved colour to be used | |
| | |
| Alprazolam Tablets IP 0.5 mg | Each uncoated tablet contains : | |
| Alprazolam IP 0.5 mg | |
| Approved colour to be used | |
| | |
| Chlordiazepoxide Tablets IP | Each film coated tablet contains : | |
| Chlordiazepoxide IP 5 mg | |
| Approved colour to be used | |
| | |
| Diazepam Tablets IP | Each uncoated tablet contains : | |
| Diazepam IP 5 mg | |
| | |
| Ephedrine Hydrochloride Tablets IP | Each uncoated tablet contains : | |
| Ephedrine Hydrochloride IP 15 mg | |
| | |
| Nitrazepam Tablets IP | Each uncoated tablet contains : | |
| Nitrazepam IP 10 mg | |
| | |
| Alprazolam (PR) Tablets IP | Each uncoated prolonged-release tablet contains : | |
| Alprazolam IP 0.5 mg | |
| Approved colour to be used | |
| | |
| Chlordiazepoxide & Trifluoperazine | Each film coated tablet contains : | |
| Tablets | Chlordiazepoxide IP 10 mg | |
| Trifluoperazine Hydrochloride IP | |
| eq. to Trifluoperazine 1 mg | |
| Approved colour to be used | |
| | |
| Triplodine Hcl & | Each uncoated tablet contains | |
| Pseudoephedrine Hcl Tablets | Pseudoephedrine Hydrochloride IP 60 mg | |
| Triplodine Hydrochloride IP 2.5 mg | |
| Approved colour to be used | |
| | |
| Voriconazole | Each film coated tablets contains : | |
| Tablets IP | Voriconazole IP 50 mg | |
| Approved colour to used | |
| | |
| Voriconazole | Each film coated tablets contains : | |
| Tablets IP | Voriconazole IP 200 mg | |
| Approved colour to used | |
| | |
| Diphenoxylate Hydrochloride | Each uncoated tablet contains : | |
| & Atropine Tablets IP | Diphenoxylate Hydrochloride IP 2.50 mg | |
| Atropine Sulphate IP 0.0250 mg | |
| Approved colour to used | |
| | |
| Paracetamol, | Each uncoated tablet contains : | |
| Phenylephrine, Caffeine & | Paracetamol IP 500 mg | |
| Diphenhydramine Tablets | Caffeine (Anhydrous) IP 30 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Diphenhydramine Hydrochloride IP 25 mg | |
| Approved colour to used | |
| | |
| Doxolyline & | Each film / uncoated tablet contains : | |
| Montelukast Tablets | Doxofyline IP 400 mg | |
| Montelukast Sodium IP | |
| eq. to Montelukast 10 mg | |
| Approved colour to used | |
| | |
| Povidone – lodine Soution IP | Contains : | |
| Povidone – lodine IP 7.5 % W/V | |
| Permitted Color Used | |
| | |
| Povidone – lodine | Contains : | |
| Germicide Gargle 2% w/v | Povidone – lodine IP 2 % W/V | |
| (Available lodine 0.2% w/v) | |
| Permitted Color Used | |
| | |
| Ascorbic Acid & Cholecalciferol | Each uncoated chewable tablet contains : | |
| with Zinc Tablets | Ascorbic acid IP 500 mg | |
| Cholecalciferol (Vitamin D3) IP 400 IU | |
| Zinc Sulphate Monohydrate IP | |
| eq. to elemental Zinc 5 mg | |
| Approved colour to be used | |
| | |
| Ascorbic Acid & Cholecalciferol | Each uncoated chewable tablet contains : | |
| with Zinc Tablets | Ascorbic acid IP 1000 mg | |
| Cholecalciferol (Vitamin D3) IP 1000 IU | |
| Zinc Sulphate Monohydrate IP | |
| eq. to elemental Zinc 10 mg | |
| Approved colour to be used | |
| | |
| Cholecalciferol Chewable Tablets | Each uncoated chewable tablet contains : | |
| Cholecalciferol (Vitamin D3) IP 60000 IU | |
| Approved colour to be used | |
| | |
| Azithromycin Tablets | Each filmcoated tablet contains : | |
| Azithromycin (As Di hydratel) IP | |
| Eq. to Anhydrous Azithromycin 100 mg | |
| Approved colour to be used | |
| | |
| Hydroxychloroquine Tablets IP | Each film coated tablet contains : | |
| Hydroxychloroquine Sulphate IP 100 mg | |
| Approved colour to be use | |
| | |
| Hydroxychloroquine Tablets IP | Each film coated tablet contains : | |
| Hydroxychloroquine Sulphate IP 200 mg | |
| Approved colour to be use | |
| | |
| Hydroxychloroquine Tablets IP | Each film coated tablet contains : | |
| Hydroxychloroquine Sulphate IP 300 mg | |
| Approved colour to be use | |
| | |
| Hydroxychloroquine Tablets IP | Each film coated tablet contains : | |
| Hydroxychloroquine Sulphate IP 400 mg | |
| Approved colour to be use | |
| | |
| Chloroquine Tablets IP | Each film coated tablet contains : | |
| Chloroquine Sulphate IP 100 mg | |
| Approved colour to be use | |
| | |
| Chloroquine Tablets IP | Each film coated tablet contains : | |
| Chloroquine Sulphate IP 500 mg | |
| Approved colour to be use | |
| | |
| Ascorbic Acid & Sodium Ascorbate | Each uncoated chewable tablet contains : | |
| with Zinc Tablets | Ascorbic Acid IP 100 mg | |
| Sodium Ascorbate IP 450 mg | |
| Eq. to Ascorbic Acid 400 mg | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 50 mg | |
| Approved colour to be used | |
| | |
| Ascorbic Add & Sodium Ascorbate | Each uncoated chewable tablet contains : | |
| with Zinc Tablets | Ascorbic Acid IP 100 mg | |
| Sodium Ascorbate IP 450 mg | |
| Eq. to Ascorbic Acid 400 mg | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 20 mg | |
| Approved colour to be used | |
| | |
| Vitamin C & Zinc Tablets | Each uncoated chewable tablet contains : | |
| Vitamin C IP 1000 mg | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 20 mg | |
| Approved colour to be used | |
| | |
| Vitamin C & Zinc Tablets | Each uncoated chewable tablet contains : | |
| Vitamin C IP 1000 mg | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 50 mg | |
| Approved colour to be used | |
| | |
| Vitamin C & Zinc Tablets | Each uncoated chewable tablet contains : | |
| Vitamin C IP 500 mg | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 20 mg | |
| Approved colour to be used | |
| | |
| Vitamin C & Zinc Tablets | Each uncoated chewable tablet contains : | |
| Vitamin C IP 500 mg | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 50 mg | |
| Approved colour to be used | |
| | |
| Doxycyline Dispersible Tablets IP | Each uncoated dispersible tablet contains : | |
| Doxycycline Hyclate IP | |
| eq. to Doxycycline 100 mg | |
| Approved colour to be used | |
| | |
| Ivermectin Tablets USP | Each uncoated tablet contains | |
| Ivermectin IP 12 mg | |
| Approved colour to be used | |
| | |
| Zinc Sulphate Dispersible Tablets IP | Each uncoated dispersible tablet contains: | |
| Zinc Sulphate Monohydrate IP | |
| eq. to elemental Zinc 10 mg | |
| Approved colour to be used | |
| | |
| Zinc Sulphate Dispersible Tablets IP | Each uncoated dispersible tablet contains: | |
| Zinc Sulphate Monohydrate IP | |
| eq. to elemental Zinc 20 mg | |
| Approved colour to be used | |
| | |
| Zinc Sulphate Tablets | Each uncoated tablet contains : | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 10 mg | |
| Approved colour to be used | |
| | |
| Zinc Sulphate Tablets | Each uncoated tablet contains : | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 20 mg | |
| Approved colour to be used | |
| | |
| Zinc Sulphate Tablets | Each uncoated tablet contains : | |
| Zinc Sulphate IP | |
| eq. to elemental Zinc 50 mg | |
| Approved colour to be used | |
| | |
| Zinc Acetate Tablets | Each uncoated tablet contains: | |
| Zinc Acetate IP | |
| eq. to elemental Zinc 20 mg | |
| Approved colour to be used | |
| | |
| Zinc Acetate Tablets | Each uncoated tablet contains: | |
| Zinc Acetate IP | |
| eq. to elemental Zinc 50 mg | |
| Approved colour to be used | |
| | |
| Povidone lodine solution IP | Contains : | |
| Povidone-lodine IP 5 % w/v | |
| Permitted Color Used | |
| | |
| Sildenafil Citrate | Each film coated tablet contains : | |
| Tablets IP | Sildenafil Citrate IP | |
| Equivalent to Sildenafil 25 mg | |
| Permitted Color Used | |
| | |
| Sucralfate | Each uncoated tablet contains | |
| Tablet IP | Sucralfate IP 1000 mg | |
| | |
| Betahistine | Each uncoated tablet contains | |
| Hydrochloride Tablets IP | Betahistine Hydrochloride IP 8 mg | |
| | |
| Diclofenac Sodium | Each gastro-resistant tablet contains : | |
| Gastro-Resistant Tablets IP | Diclofenac Sodium IP 25 mg | |
| Permitted Color Used | |
| | |
| Diclofenac Sodium | Each gastro-resistant tablet contains : | |
| Gastro-Resistant Tablets IP | Diclofenac Sodium IP 100 mg | |
| Permitted Color Used | |
| | |
| Diclofenac Sodium & | Each uncoated tablet contains : | |
| Paracetamol Tablets | Diclofenac Sodium IP 25 mg | |
| Paracetamol IP 250 mg | |
| | |
| Diclofenac Sodium & | Each uncoated tablet contains : | |
| Paracetamol Tablets | Diclofenac Sodium IP 25 mg | |
| Paracetamol IP 325 mg | |
| | |
| Aceclofenac Sustained Release | Each sustained release tablet contains : | |
| Tablets | Aceclofenac IP 200 mg | |
| Permitted Color Used | |
| | |
| Teneligliptin Tablets 20 mg. | Each film coated tablets contains : | |
| Teneligliptin Hydromide Hydrate | |
| eq. to Teneligliptin 20 mg | |
| Permitted Color Used | |
| | |
| Metformin Tablets IP | Each uncoated tablet contains | |
| Metformin Hydrochloride IP 250 mg | |
| | |
| Nortriptyline Tablets IP | Each film coated tablet contains : | |
| Nortriptyline IP 10 mg | |
| Permitted Color Used | |
| | |
| Nortriptyline Tablets IP | Each film coated tablet contains : | |
| Nortriptyline IP 25 mg | |
| Permitted Color Used | |
| | |
| Olmesartan Medoxomil | Each film coated tablet contains : | |
| Tablets IP | Olmesartan Medoxomil IP 20 mg | |
| Permitted Color Used | |
| | |
| Paracetamol, Phenylephrine, Caffeine | Each uncoated tablet contains : | |
| & Diphenhydramine Tablets | Paracetamol IP 325 mg | |
| Caffeine (Anhydrous) IP 30 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Diphenhydramine Hydrochloride IP 25 mg | |
| Permitted Color Used | |
| | |
| Cetirizine Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Cetirizine Hydrochloride IP 10 mg | |
| Permitted Color Used | |
| | |
| Metformin & Glibenclamide | Each film coated tablet contains | |
| Pioglitazone Tablets | Metformin Hydrochloride IP 500 mg | |
| Glibenclamide IP 5 mg | |
| Pioglitazone IP 15 mg | |
| Permitted Color Used | |
| | |
| Metformin & Gliclazide with | Each uncoated tablet contains | |
| Pioglitazone Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 40 mg | |
| Pioglitazone IP 15 mg | |
| Permitted Color Used | |
| | |
| Metformin & Gliclazide with | Each uncoated tablet contains | |
| Pioglitazone Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 80 mg | |
| Pioglitazone IP 15 mg | |
| Permitted Color Used | |
| | |
| Metformin (SR) & Voglibose | Each uncoated tablet contains | |
| Tablets | Metformin Hydrochloride (SR) IP 500 mg | |
| Voglibose IP 0.20 mg | |
| Permitted Color Used | |
| | |
| Tapentadol Tablets | Each film coated tablets contains : | |
| Tapentadol Hydrochloride IP 75 mg | |
| Permitted Color Used | |
| | |
| Tapentadol Tablets | Each film coated tablets contains : | |
| Tapentadol Hydrochloride IP 50 mg | |
| Permitted Color Used | |
| | |
| Iron & Folic Acid | Each film coated tablet contains: | |
| Tablets IP | Ferrous Sulphate IP | |
| Eq. to elemental Iron 100 mg | |
| Folic Acid IP 1.5 mg | |
| Permitted Color Used | |
| | |
| Calcium & Vitamin D 3 | Each uncoated tablet contains: | |
| Tablets IP | Calcium Carbonate | |
| eq. to Elemental Calcium 250 mg | |
| Vitamin D 3 IP 200 IU | |
| Excipients q.s. | |
| Permitted Color Used | |
| | |
| Calcium & Vitamin D 3 | Each uncoated tablet contains: | |
| Tablets IP | Calcium Carbonate | |
| eq. to Elemental Calcium 500 mg | |
| Vitamin D 3 IP 200 IU | |
| Excipients q.s. | |
| Permitted Color Used | |
| | |
| Mecobalamine, Foilc Acid, | Each film coated tablet contains: | |
| Riboflavin, Pyridoxine, Naicinamide | Mecobalamine IP 1000 mcg | |
| Calcium Panthothenate Tablets | Foilc Acid, IP 1 mg | |
| (For Therapeutic Use) | Riboflavin IP 10 mg | |
| Pyridoxine Hydrochloride IP 3 mg | |
| Naicinamide IP 45 mg | |
| Calcium Panthothenate IP 50 mg | |
| Excipients q.s. | |
| Permitted Color Used | |
| | |
| Vitamin K 2-7, Calcium Citrate, | Each film coated tablet contains: | |
| Calcitriol, Zinc Sulphate, | Vitamin K 2-7 50 mcg | |
| With Folic Acid Tablets | Calcium Citrate Maleate | |
| eq. to Elemental Calcium 250 mg | |
| Calcitriol IP 0.25 mcg | |
| Zinc Sulphate IP 7.5 mg | |
| Folic Acid IP 100 mcg | |
| Excipients q.s. | |
| Permitted Color Used | |
| | |
| Vitamin A Acetate, Vitamin D 3 | Each film coated tablet contains : | |
| Thiamine, Riboflavin, | Vitamin A Acetate IP 750 mcg | |
| Naicinamide Tablets | Vitamin D 3 IP 200 IU | |
| (For Prophylactic Use ) | Thiamine Monanitrate IP 0.5 mg | |
| Riboflavin IP 0.5 mg | |
| Naicinamide IP 5 mg | |
| Excipients q.s. | |
| Permitted Color Used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated sustain release tablet contains | |
| Tablets | Metformin HCI IP 850 mg | |
| | |
| Metformin Hydrochloride | Each uncoated tablet contains | |
| Tablets IP | Metformin HCI IP 850 mg | |
| | |
| Metformin (SR) & Glimepiride | Each uncoated sustain release tablet contains | |
| Tablets | Metformin HCl (as sustain release) IP 1000 mg | |
| Glimepiride IP 1 mg | |
| Colour : Erythrosine /Tartrazine / Sunset yellow / Titanium Dioxide IP | |
| | |
| Metformin (SR) & Glimepiride | Each uncoated sustain release tablet contains | |
| Tablets | Metformin HCl (as sustain release) IP 1000 mg | |
| Glimepiride IP 2 mg | |
| Colour : Erythrosine /Tartrazine / Sunset yellow / Titanium Dioxide IP | |
| | |
| Paracetamol | Each uncoated tablet contains | |
| Phenylephrine Hydrochloride & | Paracetamol IP 250 mg | |
| Chlorpheniramine Maleate | Phenylephrine Hydrochloride IP 5 mg | |
| Tablets | Chlorpheniramine Maleate IP 2 mg | |
| Colour : Erythrosine /Tartrazine / Sunset yellow / Titanium Dioxide IP | |
| | |
| Acyclovir Tablets IP | Each uncoated tablet contains | |
| Acyclovir IP 200 mg | |
| | |
| Acyclovir Tablets IP | Each uncoated tablet contains | |
| Acyclovir IP 400 mg | |
| | |
| Chlorthalidone Tablets | Each uncoated tablet contains | |
| Chlorthalidone IP 6.25 mg | |
| | |
| Chlorthalidone Tablets | Each uncoated tablet contains | |
| Chlorthalidone IP 12.50 mg | |
| | |
| Deltiazem Hydrochloride | Each uncoated tablet contains | |
| Tablets | Deltiazem Hydrochloride IP 30.00 mg | |
| | |
| Levetiracetam Tablets IP | Each uncoated tablet contains | |
| Levetiracetam 250 mg | |
| | |
| Levetiracetam Tablets IP | Each uncoated tablet contains | |
| Levetiracetam 500 mg | |
| | |
| Levetiracetam Tablets IP | Each uncoated tablet contains | |
| Levetiracetam 750 mg | |
| | |
| Artesunate Tablets | Each uncoated tablet contains | |
| Artesunate IP 100 mg | |
| | |
| Glicazide Extended Release | Each uncoated extend release tablet contains | |
| Tablets | Glicazide IP 30 mg | |
| | |
| Metoloprol Succinate with | Each uncoated tablet contains : | |
| Amlodipine Tablets IP | Metoloprol Succinate IP 23.7 mg | |
| Amlodipine Besiylate IP | |
| Eq. to Amlodipine 5 mg | |
| | |
| Meloloprol Succinate & Amlodipine | Each uncoated tablet contains : | |
| Tablets IP | Metoloprol Succinate IP 47.5 mg | |
| Amlodipine Besiylate IP | |
| Eq. to Amlodipine 5 mg | |
| | |
| Rosuvastatin & Fenofibrate | Each film coated tablet contains: | |
| Tablets IP | Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 10 mg | |
| Fenofibrale IP 160 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| | |
| Isosorbide Mononitrate Tablets IP | Each uncoated tablet contains | |
| Isosorbide Mononitrate IP 10 mg | |
| | |
| Isosorbide Mononitrate Tablets IP | Each uncoated tablet contains | |
| Isosorbide Mononitrate IP 20 mg | |
| | |
| Isosorbide Mononitrate Tablets IP | Each uncoated tablet contains | |
| Isosorbide Mononitrate IP 30 mg | |
| | |
| Glicazide Tablets IP | Each uncoated tablet contains | |
| Glicazide IP 80 mg | |
| | |
| Glibenclamide Tablets IP | Each uncoated tablet contains | |
| Glibenclamide IP 5 mg | |
| | |
| Glyceryl Trinitrate Tablets IP | Each uncoated tablet contains | |
| Glyceryl Trinitrate IP 500 mcg | |
| | |
| Nifedipine Prolonged-release | Each prolonged-release tablet contains | |
| Tablets IP | Nifedipin IP 20 mg | |
| | |
| Spironolactone Tablets IP | Each uncoated tablet contains | |
| Spironolactone IP 25 mg | |
| | |
| Spironolactone Tablets IP | Each uncoated tablet contains | |
| Spironolactone IP 50 mg | |
| | |
| Spironolactone Tablets IP | Each uncoated tablet contains | |
| Spironolactone IP 100 mg | |
| | |
| Enalapril Maleate Tablets IP | Each uncoated tablet contains: | |
| Enalapril Maleate IP 2.5 mg | |
| | |
| Enalapril Maleate Tablets IP | Each uncoated tablet contains: | |
| Enalapril Maleate IP 5 mg | |
| | |
| Enalapril Maleate Tablets IP | Each uncoated tablet contains: | |
| Enalapril Maleate IP 10 mg | |
| | |
| Enalapril Maleate Tablets IP | Each uncoated tablet contains: | |
| Enalapril Maleate IP 20 mg | |
| | |
| Lisinopril Tablets IP | Each uncoated tablet contains : | |
| Lisinopril IP 5 mg | |
| | |
| Captopril Tablets IP | Each film coated tablet contains: | |
| Captopril IP 25 mg | |
| | |
| Amiodarone Hydrochloride Tablets | Each uncoated tablet contains : | |
| Amiodarone Hydrochloride IP 100 mg | |
| | |
| Pioglitazone Tablets IP | Each uncoated tablet contains | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 7.5 mg | |
| | |
| Pioglitazone Tablets IP | Each uncoated tablet contains | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| | |
| Pioglitazone Tablets IP | Each uncoated tablet contains | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 30 mg | |
| | |
| Carvedilol Tablets IP | Each uncoated tablet contains | |
| Carvedilol IP 3.125 mg | |
| | |
| Carvedilol Tablets IP | Each uncoated tablet contains | |
| Carvedilol IP 6.25 mg | |
| | |
| Carvedilol Tablets IP | Each uncoated tablet contains | |
| Carvedilol IP 12.5 mg | |
| | |
| Sitagliptin and Metformin Hydrochloride | Each film coated tablet contains | |
| Tablets | Sitagliptin (As Phosphate) IP 50 mg | |
| Metformin Hydrochloride IP 500 mg | |
| Colur: Titanium Dioxide | |
| | |
| Sitagliptin and Metformin Hydrochloride | Each film coated tablet contains | |
| Tablets | Sitagliptin IP 50 mg | |
| Metformin Hydrochloride IP 1000 mg | |
| Colur: Titanium Dioxide | |
| | |
| Sitagliptin and Metformin Hydrochloride | Each film coated tablet contains | |
| Tablets | Sitagliptin IP 50 mg | |
| Metformin Hydrochloride IP 850 mg | |
| Colur: Titanium Dioxide | |
| | |
| Voglibose and Metformin Hydrochloride (SR) | Each uncoated tablet contains | |
| Tablet | Voglibose 0.3 mg | |
| Metformin Hydrochloride IP 500 mg | |
| (As Sustain Release) | |
| | |
| Vildagliptin and Metformin Hydrochloride | Each uncoated tablet contains | |
| Tablets | Vildagliptin 50 mg | |
| Metformin Hydrochloride IP 500 mg | |
| | |
| Vildagliptin and Metformin Hydrochloride | Each uncoated tablet contains | |
| Tablets | Vildagliptin 50 mg | |
| Metformin Hydrochloride IP 850 mg | |
| | |
| Vildagliptin and Metformin Hydrochloride | Each uncoated tablet contains | |
| Tablets | Vildagliptin 50 mg | |
| Metformin Hydrochloride IP 1000 mg | |
| | |
| Sitagliptin Tablets IP | Each film coated tablet contains | |
| Sitagliptin (As Phosphate IP 25 mg | |
| Colur: Titanium Dioxide | |
| | |
| Sitagliptin Tablets IP | Each film coated tablet contains | |
| Sitagliptin (As Phosphate IP 50 mg | |
| Colur: Titanium Dioxide | |
| | |
| Sitagliptin Tablets IP | Each film coated tablet contains | |
| Sitagliptin (As Phosphate IP 100 mg | |
| Colur: Titanium Dioxide | |
| | |
| Ursodeoxycholic Acid (SR) | Each sustain release coated tablet contains | |
| Tablets IP | Ursodeoxycholic Acid IP 450 mg | |
| | |
| Levothyroxine Sodium | Each uncoated tablet contains | |
| Tablets IP | Levothyroxine Sodium IP | |
| eq.to Thyroxine Sodium 175 mcg | |
| | |
| Levothyroxine Sodium | Each uncoated tablet contains | |
| Tablets IP | Levothyroxine Sodium IP | |
| eq.to Thyroxine Sodium 350 mcg | |
| | |
| Levothyroxine Sodium | Each uncoated tablet contains | |
| Tablets IP | Levothyroxine Sodium IP | |
| eq.to Thyroxine Sodium 700 mcg | |
| | |
| Citicoline Tablets IP | Each uncoated tablet contains | |
| Citicoline Sodium IP 500 mg | |
| | |
| Citicoline & Piracetam | Each uncoated tablet contains | |
| Tablets | Citicoline IP 500 mg | |
| Piracetam IP 800 mg | |
| | |
| Flunarizine Dihydrochloride | Each uncoated tablet contains | |
| Tablets IP | Flunarizine Dihydrochloride IP 10 mg | |
| | |
| Duloxetine Gastro- resistant | Each entric coated tablet contains | |
| Tablets IP | Duloxetine Hydrochloride IP 30 mg | |
| | |
| Duloxetine Gastro- resistant | Each entric coated tablet contains | |
| Tablets IP | Duloxetine Hydrochloride IP 40 mg | |
| | |
| Escitalopram Tablets IP | Each uncoated tablet contains | |
| Escitalopram Oxalate 10 mg | |
| | |
| Escitalopram Tablets IP | Each uncoated tablet contains | |
| Escitalopram Oxalate 20 mg | |
| | |
| Hydrochlorothiazide Tablets IP | Each uncoated tablet contains : | |
| Hydrochlorothiazide IP 12.5 mg | |
| | |
| Hydrochlorothiazide Tablets IP | Each uncoated tablet contains : | |
| Hydrochlorothiazide IP 25 mg | |
| | |
| Olmesartan Medoxomil & | Each uncoated tablet contains : | |
| Hydrochlorothiazide Tablets | Olmesartan Medoxomil IP 40 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| | |
| Olmesartan Medoxomil & | Each uncoated tablet contains : | |
| Hydrochlorothiazide With | Olmesartan Medoxomil IP 40 mg | |
| Amlodipine Tablets | Hydrochlorothiazide IP 12.5 mg | |
| Amlodipine Besiylate IP | |
| Eq. to Amlodipine 5 mg | |
| | |
| Metoloprol Succinate with | Each uncoated tablet contains : | |
| Amlodipine Tablets | Metoloprol Succinate IP 50 mg | |
| Amlodipine Besiylate IP | |
| Eq. to Amlodipine 5 mg | |
| | |
| Olmesartan Medoxomil, | Each uncoated tablet contains | |
| Chlorothiazide Tablets | Olmesartan Medoxomil IP 20 mg | |
| Chlorothiazide IP 12.5 mg | |
| | |
| Olmesartan Medoxomil, | Each uncoated tablet contains | |
| Chlorothiazide Tablets | Olmesartan Medoxomil IP 40 mg | |
| Chlorothiazide IP 12.5 mg | |
| | |
| Nitroglycerin | Each uncoated CR tablet contains : | |
| Controlled Release Tablets IP | Diluted Nitroglycerin IP | |
| eq. to Nitroglycerin 2.6 mg | |
| Colour: Sunset yellow FCF | |
| | |
| Nitroglycerin | Each uncoated CR tablet contains : | |
| Controlled Release Tablets IP | Diluted Nitroglycerin IP | |
| eq. to Nitroglycerin 6.4 mg | |
| Colour: Sunset yellow FCF | |
| | |
| Atorvastatin & Clopidogrel | Each filmcoated tablet contains: | |
| Tablets | Atorvastatin Calcium IP | |
| eq. to Atorvastatin 10 mg | |
| Clopidogrel Bisulphate BP | |
| Eq. to Clopidogrel 75 mg | |
| | |
| Atorvastatin & Clopidogrel | Each filmcoated tablet contains: | |
| Tablets | Atorvastatin Calcium IP | |
| eq. to Atorvastatin 20 mg | |
| Clopidogrel Bisulphate BP | |
| Eq. to Clopidogrel 75 mg | |
| | |
| Rosuvastatin & Fenofibrate | Each filmcoated tablet contains : | |
| Tablets | Rosuvastatin Calcium IP 10 mg | |
| eq. to Rosuvastatin | |
| Clopidogrel Bisulphate BP | |
| Eq. to Clopidogrel 75 mg | |
| | |
| Rosuvastatin & Clopidogrel | Each filmcoated tablet contains : | |
| Tablets | Rosuvastatin Calcium IP 20 mg | |
| eq. to Rosuvastatin | |
| Clopidogrel Bisulphate BP | |
| Eq. to Clopidogrel 75 mg | |
| | |
| Atorvastatin & | Each uncoated tablet contains: | |
| Metformin Hydrochloride (ER) | Atorvastatin Calcium IP | |
| Tablets | Eq. to Atorvastatin 10 mg | |
| Metformin HCI IP 500 mg | |
| As extand release | |
| | |
| Pioglitazone & | Each uncoated tablet contains | |
| Metformin Hydrochloride (ER) | Pioglitazone Hydrochloride IP 15 mg | |
| Tablets | Eq. to Pioglitazone | |
| Metformin HCI IP 500 mg | |
| As extand release | |
| | |
| Pioglitazone & | Each uncoated tablet contains | |
| Metformin Hydrochloride (ER) | Pioglitazone Hydrochloride IP 30 mg | |
| Tablets | Eq. to Pioglitazone | |
| Metformin HCI IP 500 mg | |
| As extand release | |
| | |
| Pioglitazone & | Each uncoated tablet contains | |
| Metformin Hydrochloride (ER) | Pioglitazone Hydrochloride IP | |
| Tablets | Eq. to Pioglitazone 15 mg | |
| Metformin HCI IP 1000 mg | |
| As extand release | |
| | |
| Ploglitazone & | Each uncoated tablet contains | |
| Metformin Hydrochloride (ER) | Ploglitazone Hydrochloride IP | |
| Tablets | Eq. to Ploglitazone 30 mg | |
| Metformin HCI IP 1000 mg | |
| As extand release | |
| | |
| Ploglitazone & | Each uncoated tablet contains | |
| Glimepride Tablets | Ploglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Glimepride IP 1 mg | |
| | |
| Ploglitazone & | Each uncoated tablet contains | |
| Glimepride Tablets | Ploglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Glimepride IP 2 mg | |
| | |
| Pioglitazone & | Each uncoated tablet contains | |
| Metformin Hydrochloride , | Pioglitazone Hydrochloride IP | |
| Glimepride Tablets | Eq. to Ploglitazone 15 mg | |
| Metformin HCI IP 500 mg | |
| Glimepride IP 1 mg | |
| | |
| Pioglitazone & | Each uncoated tablet contains | |
| Metformin Hydrochloride , | Pioglitazone Hydrochloride IP | |
| Glimepride Tablets | Eq. to Ploglitazone 15 mg | |
| Metformin HCI IP 500 mg | |
| Glimepride IP 2 mg | |
| | |
| Sodium Valproate Tablets IP | Each uncoated tablet contains | |
| Sodium Valproate IP 100 mg | |
| | |
| Sodium Valproate Tablets IP | Each uncoated tablet contains | |
| Sodium Valproate IP 200 mg | |
| | |
| Sodium Valproate Tablets IP | Each uncoated tablet contains | |
| Sodium Valproate IP 300 mg | |
| | |
| Sodium Valproate Tablets IP | Each uncoated tablet contains | |
| Sodium Valproate IP 500 mg | |
| | |
| Clomipramine Hydrochloride | Each uncoated tablet contains | |
| Tablets IP | Clomipramine Hydrochloric IP 50 mg | |
| | |
| Paracetamol & | Each uncoated tablet contains : | |
| Chlorzoxazone Tablets | Paracetamol IP 325 mg | |
| Chlorzoxazone USP 250 mg | |
| | |
| Diltiazem (SR) Tablets | Each sustain release tablet contains | |
| Diltiazem IP 90 mg | |
| | |
| Acarbose Tablets IP | Each uncoated tablet contains : | |
| Acarbose IP 25 mg | |
| | |
| Acarbose Tablets IP | Each uncoated tablet contains : | |
| Acarbose IP 50 mg | |
| | |
| Aceclofenac, Paracetamol & | Each film coated tablet contains | |
| Thiocolchicoside Tablets | Aceclofenac IP 100 mg | |
| Paracetamol IP 325 mg | |
| Thiocolchicoside 4 mg | |
| Colour:Sunset yellow or Apple Green / Titanium Dioxide IP | |
| | |
| Aceclofenac & Tizanidine | Each sustain release tablet contains | |
| Tablets | Aceclofenac IP 100 mg | |
| Tizanidine Hydrochloride 2 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| or Titanium Dioxide IP / Sunset Yellow | |
| | |
| Amlodipine Besiylate | Each uncoated tablet contains : | |
| Tablets | Amlodipine Besiylate BP | |
| Eq. to Amlodipine 2.5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Amlodipine Besiylate | Each uncoated tablet contains : | |
| Tablets | Amlodipine Besiylate BP | |
| Eq. to Amlodipine 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Amlodipine Besiylate | Each uncoated tablet contains : | |
| Tablets | Amlodipine Besiylate BP | |
| Eq. to Amlodipine 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Atorvastatin Tablets IP | Each filmcoated tablet contains : | |
| Atorvastatin Calcium IP | |
| eq. to Atorvastatin 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Atorvastatin Tablets IP | Each filmcoated tablet contains : | |
| Atorvastatin Calcium IP | |
| eq. to Atorvastatin 30 mg | |
| Colour: Erythrosine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Atorvastatin Tablets IP | Each filmcoated tablet contains : | |
| Atorvastatin Calcium IP | |
| eq. to Atorvastatin 40 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Titanium Dioxide IP | |
| | |
| Atorvastatin Tablets IP | Each film coated tablet contains : | |
| Atorvastatin Calcium IP | |
| eq. to Atorvastatin 80 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Atorvastatin & Ezetimibe | Each film coated tablet contains : | |
| Tablets | Atorvastatin Calcium IP | |
| eq. to Atorvastatin 10 mg | |
| Ezetimibe IP 10 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Atorvastatin & Fenofibrate | Each filmcoated tablet contains : | |
| Tablets | Atorvastatin Calcium IP | |
| eq. to Atorvastatin 10 mg | |
| Fenofibrate IP 160 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Bromhexine Hydrochloride | Each uncoated tablet contains | |
| Tablets IP | Bromhexine Hydrochloride IP 4 mg | |
| Colour : Erythrosine /Sunset Yellow /Quinoline Yellow | |
| | |
| Cilnidipine & Telmisartan | Each film coated tablet contains : | |
| Tablets | Cilnidipine IP 10 mg | |
| Telmisartan IP 40 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Cinnarizine Tablets IP | Each film coated tablet contains | |
| Cinnarizine Hydrochloride IP 25 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| | |
| Clindamycin Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Clindamycin Hydrochloride IP | |
| Eq. to Clindamycin 150 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Clindamycin Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Clindamycin Hydrochloride IP | |
| Eq. to Clindamycin 300 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Clopidogrel Bisulphate | Each film coated tablet contains : | |
| Tablets IP | Clopidogrel Bisulphate BP | |
| Eq. to Clopidogrel 75 mg | |
| Colour: Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Dexchlorphenramine Maleate | Each uncoated tablet contains | |
| Tablets IP | Dexchlorphenramine Maleate IP 2 mg | |
| Colour : Tartrazine / Sunset Yellow / Ponceau 4R | |
| | |
| Diclofenac Potassium & Thiocolchicoside | Each film coated tablet contains | |
| Tablets | Diclofenac Potassium IP 50 mg | |
| Thiocolchicoside 4 mg | |
| Colour: Brilliant Blue / Erythrosine (Tartrazine/ | |
| Sunset yellow or Apple Green / Titanium Dioxide IP | |
| | |
| Diclofenac Potassium & Thiocolchicoside | Each film coated tablet contains | |
| Tablets | Diclofenac Potassium IP 50 mg | |
| Thiocolchicoside 8 mg | |
| Colour: Erythrosine (Tartrazine/ | |
| Sunset yellow / Titanium Dioxide IP | |
| | |
| Disulfiram Tablets IP | Each uncoated tablet contains | |
| Disulfiram IP 250 mg | |
| | |
| Disulfiram Tablets IP | Each uncoated tablet contains | |
| Disulfiram IP 500 mg | |
| | |
| Duloxetine Tablets IP | Each uncoated tablet contains | |
| Duloxetine Hydrochloride IP 20 mg | |
| | |
| Etizolam Tablets | Each uncoated tablet contains | |
| Etizolam I? 0.25 mg | |
| Colour: Brilliant Blue /Tartrazine / | |
| Sunset yellow or Apple Green | |
| | |
| Etizolam Tablets | Each uncoated tablet contains | |
| Etizolam I? 0.50 mg | |
| Colour: Brilliant Blue /Tartrazine / | |
| Sunset yellow or Apple Green | |
| | |
| Etizolam Tablets | Each uncoated tablet contains | |
| Etizolam IP 1 mg | |
| Colour: Erythrosine /Tartrazine / | |
| Sunset yellow / Titanium Dioxide IP | |
| | |
| Etizolam & Escitalopram | Each uncoated tablet contains | |
| Tablets | Etizolam IP 0.50 mg | |
| Escitalopram 10 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| or Titanium Dioxide IP | |
| | |
| Etoricoxib & Thiocolchicoside | Each film coated tablet contains | |
| Tablets IP | Etoricoxib IP 60 mg | |
| Thiocolchicoside 4 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine / | |
| Sunset yellow / Titanium Dioxide IP | |
| | |
| Etoricoxib & Thiocolchicoside | Each film coated tablet contains | |
| Tablets IP | Etoricoxib IP 90 mg | |
| Thiocolchicoside 4 mg | |
| Colour: Brilliant Blue / Erythrosine Tartrazine/ | |
| Sunset yellow or Apple Green / Titanium Dioxide IP | |
| | |
| Febuxostat Tablets IP | Each filmcoated tablet contains : | |
| Febuxostat IP 80 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Fexofenadine Tablets IP | Each film / uncoated tablet contains : | |
| Fexofenadine Hydrochloride IP 120 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Fexofenadine Tablets IP | Each film / uncoated tablet contains : | |
| Fexofenadine Hydrochloride IP 180 mg | |
| Colour: Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Flunarizine Dihydrochloride, Domperidone | Each uncoated tablet contains | |
| Paracetamol Tablets | Flunarizine Dihydrochloride IP 5 mg | |
| Domperidone IP 10 mg | |
| Paracetamol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| or Titanium Dioxide IP / Ferric Oxide Yellow | |
| | |
| Flupentixol Dihydrochloride | Each film coated tablet contains | |
| Tablets | Flupentixol Dihydrochloride BP | |
| eq. to Flupentixol 0.5 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| or Titanium Dioxide IP / Ferric Oxide Yellow | |
| | |
| Fluoxetine Hydrochloride | Each film coated tablet contains | |
| Tablets | Fluoxetine Hydrochloride BP | |
| eq. to Fluoxetine 20 mg | |
| Colour: Brilliant Blue / Erythrosine Tartrazine | |
| or Titanium Dioxide IP / Ferric Oxide Yellow | |
| | |
| Gabapentin Tablets IP | Each uncoated tablet contains | |
| Gabapentin IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Glimepride Tablets IP | Each uncoated tablet contains | |
| Glimepride IP 1 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Glimepride Tablets IP | Each uncoated tablet contains | |
| Glimepride IP 2 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Glimepride Tablets IP | Each uncoated tablet contains | |
| Glimepride IP 3 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Glimepride Tablets IP | Each uncoated tablet contains | |
| Glimepride IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Ketoconazole Tablets IP | Each uncoated tablet contains | |
| Ketoconazole IP 200 mg | |
| | |
| Ketoprofen & Thiocolchicoside | Each uncoated tablet contains | |
| Tablets | Ketoprofen 50 mg | |
| Thiocolchicoside 4 mg | |
| | |
| Levocetirizine, Montelukast | Each uncoated tablet contains | |
| & Ambroxol Tablets | Levocetirizine Hydrochloride IP 5 mg | |
| Montelukast Sodium IP | |
| eq. to Montelukast 10 mg | |
| Ambroxol Hydrochloride IP 75 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine | |
| | |
| Levocetirizine Hydrochloride | Each uncoated tablet contains | |
| Phenylephrine Hydrochloride & | Levocetirizine Hydrochloride IP 5 mg | |
| Paracetamol Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Paracetamol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| or Titanium Dioxide IP/Ferric Oxide Yellow | |
| | |
| Linezolide Tablets | Each film coated tablet contains | |
| Linezolide IP 600 mg | |
| | |
| Lornoxicam & Thiocolchicoside | Each film coated tablet contains : | |
| Tablets | Lornoxicam IP 4 mg | |
| Thiocolchicoside 4 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Lornoxicam & Thiocolchicoside | Each film coated tablet contains : | |
| Tablets | Lornoxicam IP 8 mg | |
| Thiocolchicoside 4 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Losartan Tablets | Each film coated tablet contains : | |
| Losartan Potassium IP 25 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Losartan Tablets | Each film coated tablet contains : | |
| Losartan Potassium IP 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Losartan & Hydrochlorothiazide | Each film coated tablet contains : | |
| Tablets | Losartan Potassium IP 50 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated sustain release tablet contains | |
| Tablets | Metformin HCI IP 500 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine / | |
| Sunset yellow or Apple Green / Titanium Dioxide IP | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated sustain release tablet contains | |
| Tablets | Metformin HCI IP 1000 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine / | |
| Sunset yellow or Apple Green / Titanium Dioxide IP | |
| | |
| Metformin Hydrochloride | Each uncoated tablet contains | |
| Tablets | Metformin HCI IP 1000 mg | |
| Colour: Brilliant Blue / Erythrosine Tartrazine / | |
| Sunset yellow or Apple Green / Titanium Dioxide IP | |
| Mirtazipine Tablets | Each uncoated tablet contains | |
| Mirtazipine IP 15 mg | |
| Colour: Tartrazine / Sunset Yellow | |
| | |
| Mirtazipine Tablets | Each uncoated tablet contains | |
| Mirtazipine IP 30 mg | |
| Colour: Tartrazine / Sunset Yellow | |
| | |
| Moxifloxacin Tablets | Each film coated tablet contains | |
| Moxifloxacin Hydrochloride IP | |
| eq. to Moxifloxacin 400 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine / | |
| Sunset yellow or Apple Green / Titanium Dioxide IP | |
| | |
| Olmesartan Medoxomil | Each film coated tablet contains : | |
| Tablets IP | Olmesartan Medoxomil IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Olmesartan Medoxomil | Each film coated tablet contains : | |
| Tablets IP | Olmesartan Medoxomil IP 40 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Piracetam Tablets | Each uncoated tablet contains | |
| Piracetam IP 800 mg | |
| | |
| Propranolol Hydrochloride | Each uncoated tablet contains | |
| Tablets | Propranolol Hydrochloride IP 10 mg | |
| | |
| Propranolol Hydrochloride | Each uncoated tablet contains | |
| Tablets | Propranolol Hydrochloride IP 20 mg | |
| | |
| Propranolol Hydrochloride & | Each uncoated tablet contains | |
| Etizolam Tablets | Propranolol Hydrochloride IP 10 mg | |
| Etizolam 0.25 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine | |
| or Titanium Dioxide IP | |
| | |
| Prulifloxacin Tablets | Each film coated tablet contains | |
| Prulifloxacin Hydrochloride IP | |
| eq. to Prulifloxacin 600 mg | |
| | |
| Ramipril Tablets IP | Each filmcoated tablet contains : | |
| Ramipril IP 2.5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Ramipril Tablets IP | Each filmcoated tablet contains : | |
| Ramipril IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Ramipril Tablets IP | Each filmcoated tablet contains : | |
| Ramipril IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Ramipril With | Each filmcoated tablet contains : | |
| Hydrochlorothiazide Tablets | Ramipril IP 2.5 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP/ | |
| Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Risperidone Tablets IP | Each uncoated tablet contains : | |
| Risperidone IP 2 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Rosuvastatin Tablets IP | Each film coated tablet contains : | |
| Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Rosuvastatin Tablets IP | Each film coated tablet contains : | |
| Rosuvastatin Calcium IP | |
| eq. lo Rosuvastatin 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Rosuvastatin Tablets IP | Each film coated tablet contains : | |
| Rosuvastatin Calcium IP | |
| eq. lo Rosuvastatin 40 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Rosuvastatin & Clopidogrel | Each film coated tablet contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 40 mg | |
| Clopidogrel Bisulphate BP | |
| Eq. to Clopidogrel 75 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Telmisartan Tablets IP | Each uncoated tablet contains : | |
| Telmisartan IP 80 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Telmisartan & Hydrochlorothiazide | Each uncoated tablet contains : | |
| Tablets | Telmisartan IP 80 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Telmisartan With Amlodipine Besylate | Each uncoated tablet contains : | |
| Tablets | Telmisartan IP 40 mg | |
| Amlodipine Besylate BP | |
| Eq. to Amlodipine 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Terbinafine Hydrochloride | Each uncoated tablet contains | |
| Tablets USP | Terbenafine Hydrochloride USP 250 mg | |
| | |
| Thyroxine Sodium Tablets IP | Each uncoated tablet contains | |
| Thyroxine Sodium IP 25 mcg | |
| | |
| Thyroxine Sodium Tablets IP | Each uncoated tablet contains | |
| Thyroxine Sodium IP 50 mcg | |
| | |
| Thyroxine Sodium Tablets IP | Each uncoated tablet contains | |
| Thyroxine Sodium IP 75 mcg | |
| | |
| Thyroxine Sodium Tablets IP | Each uncoated tablet contains | |
| Thyroxine Sodium IP 100 mcg | |
| | |
| Thyroxine Sodium Tablets IP | Each uncoated tablet contains | |
| Thyroxine Sodium IP 125 mcg | |
| | |
| Tranexamic Acid Tablets | Each uncoated tablet contains | |
| Tranexamic Acid BP 500 mg | |
| | |
| Tranexamic Acid & Mefenamic Acid | Each uncoated tablet contains | |
| Tablets | Tranexamic Acid BP 500 mg | |
| Mefenamic Acid IP 250 mg | |
| | |
| Trimetazidine Hydrochloride | Each uncoated tablet contains | |
| Tablets | Trimetazidine Hydrochloride IP 20 mg | |
| | |
| Trimetazidine Hydrochloride | Each uncoated tablet contains | |
| Tablets | Trimetazidine Hydrochloride IP 35 mg | |
| | |
| Aceclofenac, Paracetamol & | Each film coated tablet contains : | |
| Tramadol Tablets | Aceclofenac IP 100 mg | |
| Paracetamol IP 325 mg | |
| Tramadol Hydrochloride IP 37.5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Calcium, Glucosamine, Methylcobalamin | Each film coated tablet contains | |
| & Methyl sulphonylmethane | Calcim Carbonate IP 250 mg | |
| Tablets | Glucosamine Sulphate Potassium Chloride USP 500 mg | |
| Manganese (Maganese Sulphate IP) 20 mg | |
| Vitamin E 4 mg | |
| Methyl sulphonyl Methane USP 250 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Diacerein, Glucosamine, | Each film coated tablet contains | |
| Methylcobalamin & Methyl sulphonyl Methane | Diacerein IP 50 mg | |
| Tablels | Glucosamine Sulphate Potassium Chloride IP 750 mg | |
| Methylcobalamin 750 mcg | |
| Methyl sulphonyl Methane USP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Gabapentin with | Each film coated tablet contains | |
| Methylcobalamin | Gabapentin IP 100 mg | |
| Tablets | Methylcobalamin 1500 mcg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Glucosamine, Methylcobalamin | Each film coated tablet contains | |
| Methyl sulphonyl Methane | Glucosamine Sulphate Potassium Chloride IP 750 mg | |
| Tablets | Methylcobalamin 750 mcg | |
| Methyl sulphonyl Methane USP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Methylcobalamin, Biotin with | Each film coated tablet contains | |
| Pyridoxine Hydrochloride | Methylcobalamin 1500 mcg | |
| Folic Acid Tablets | Biotin IP 5 mg | |
| Pyridoxine Hydrochloride IP 10 mg | |
| Folic Acid IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| IApple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Trypsin, Bromelain with | Each film coated tablet contains | |
| Rotoside Trihydrate Tablets | Trypsin IP 48 mg | |
| Bromelain 90 mg | |
| Rotoside Trihydrate USP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Diclofenac Potassium, | Each film coated tablet contains | |
| Trypsin & Bromelain | Diclofenac Potassium IP 50 mg | |
| with Rutoside Trihydrate | Trypsin IP 48 mg | |
| Tablets | Bromelain 90 mg | |
| Rutoside Trihydrate USP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Methylcobalamin, Pyridoxine | Each film coated tablet contains | |
| & Folic Acid Tablets | Methylcobalamin 500 mcg | |
| Pyridoxine Hydrochloride IP 5 mg | |
| Folic Acid IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green/Iron oxide red,Iron oxide Yellow | |
| | |
| Azithromycin | Each uncoated dispersible tablet contains : | |
| Dispersible Tablets | Azithromycin Anhydrous IP 100 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Erythromycin | Each film coated tablet contains : | |
| Tablets IP | Erythromycin Estolate | |
| Equivalent to Erythromycin Base IP 333 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/ | |
| uinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Vitamin B-Complex Tablets | Each film coated tablet contains | |
| Thiamine Mononitrate IP 2 mg | |
| Riboflavin IP 2 mg | |
| Pyridoxine Hydrochloride IP 1 mg | |
| Niacinamide IP 15 mg | |
| Calcium Pantothenate IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Calcium Citrate, | Each film coated tablet contains | |
| Calcitriol with Zinc Tablets | Calcium Citrate Malate 1000 mg | |
| Calcitriol IP 0.25 mcg | |
| Zinc Sulphate IP 7.5 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Ofloxacin With | Each flim coated tablet contains | |
| Cefixime Tablets | Ofloxacin IP 200 mg | |
| Cefixime Trihydrate IP | |
| eq. to Cefixime 200 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Cefixime | Each uncoated dispersible tablet contains | |
| Dispersible Tablets | Cefixime Trihydrate IP | |
| eq. to Cefixime 100 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine / | |
| Ponceau 4R or Titanium Dioxide IP/Sunset Yellow | |
| | |
| Cefixime | Each uncoated dispersible tablet contains | |
| Dispersible Tablets | Cefixime Trihydrate IP | |
| eq. to Cefixime 200 mg | |
| Colour: Brilliant Blue / Erythrosine /Tartrazine / | |
| Ponceau 4R or Titanium Dioxide IP/Sunset Yellow | |
| | |
| Protein , Multivitamins, | Each 30 g contains : | |
| Calcium , Iron | Protein Hydrolysate 20% 5 mg | |
| & Zinc Powder | Elemental Calcium 225 mg | |
| Elemental Phosphorus 174 mg | |
| (As Dibasic Calcium Phosphate Dihydrate IP) | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Vitamin D3 (As Cholecalciferol) IP 100 I.U. | |
| Niacinamide IP 15 mg | |
| Zinc (As Zinc Sulphate) USP 1.5 mg | |
| Iron (As Ferric Ammonium Citrate IP) | |
| Manganese (As Sulphate) USP 1.5 mcg | |
| Excipients q.s. | |
| | |
| Doxycycline | Each film coated tablet contains : | |
| Lactic Acid Bacillus | Doxycycline Hyclate IP | |
| Tablets | Equivalent to Doxycycline 100 mg | |
| Lactic Acid Bacillus 60 ms | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / | |
| Quinoline Yellow / Sunset yellow or Titanium Dioxide IP | |
| /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Multivitamins, Mutiminerals | Each 30 g contains : | |
| Calcium, Iron & Zinc Powder | Pyridoxine Hydrochloride IP 0.5 mg | |
| Cyanocobalamin IP 1mcg | |
| Vitamin D3 As Cholecalciferol) IP 100 I.U | |
| Folic Acid IP 300 mcg | |
| Naicinamide IP 15 mg | |
| Calcium ( As Dibasic Calcium Phosphate Dihydrate IP 200 mg | |
| Manganese (As Sulphate) USP 1.5 mcg | |
| Zinc (As Zinc Sulphate) USP 1.5 mg | |
| Iron (Ferric Ammonium Citrate ) IP 10 mg | |
| Magnesium Oxide IP 4 mg | |
| Cupperic Sulphate USP 2.5 mg | |
| Chromium (As Chromium Chloride) IP 25 mg | |
| Selenium Dioxide Monohydrate USP 20 mcg | |
| Potassium Chloride IP 5 mg | |
| Sodium Chloride IP 33 mg | |
| lodine ( As Potassium lodide ) IP 100 mcg | |
| Excipients q.s. | |
| | |
| Acetylsalicylic Acid Tablets IP | Each uncoated tablet contains: | |
| Approved Date : 19/04/2007 | Acetylsalicylic Acid IP 300 mg | |
| | |
| Aminophylline Tablets IP | Each uncoated tablet contains: | |
| Approved Date : 19/04/2007 | Aminophylline | |
| Eq, to Anhydrous Aminophylline IP 100 mg | |
| | |
| Bromhexine | Each uncoated tablet contains : | |
| Hydrochloride Tablets IP | Bromhexine Hydrochloride IP 8 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Chlorpromazine | Each film coated tablet contains : | |
| Hydrochloride Tablets IP | Chlorpromazine Hydrochloride IP 10 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Ciprofloxacin | Each film coated tablet contains : | |
| Hydrochloride Tablets IP 250 mg | Ciprofloxacin Hydrochloride IP | |
| Approved Date : 19/04/2007 | Eq. to Ciprofloxacin 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Ciprofloxacin | Each film coated tablet contains : | |
| Hydrochloride Tablets IP 500 mg | Ciprofloxacin Hydrochloride IP | |
| Approved Date : 19/04/2007 | Eq. to Ciprofloxacin 500 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Co-Trimoxazole Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Trimethoprim IP 80 mg | |
| Sulphamethoxazole IP 400 mg | |
| | |
| Co-Trimoxazole Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Trimethoprim IP 160 mg | |
| Sulphamethoxazole IP 800 mg | |
| | |
| Cyproheptadine Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Cyproheptadine Hydrochloride IP 4 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Diclofenac Sodium Tablets IP | Each enteric coated tablet contains : | |
| Approved Date : 19/04/2007 | Diclofenac Sodium IP 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Diethylcarbamazine Citrate | Each uncoated tablet contains : | |
| Tablets IP 100 mg | Diethylcarbamazine Citrate IP 100 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Domperidone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Domperidone IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ethambutol Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP 200 mg | Ethambutol Hydrochloride IP 200 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Ethambutol Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP 400 mg | Ethambutol Hydrochloride IP 400 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Ethambutol Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP 800 mg | Ethambutol Hydrochloride IP 800 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Famotidine Tablets IP 20 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Famotidine IP 20 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Frusemide Tablets IP 40 mg | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Frusemide IP 40 mg | |
| | |
| Furazolidone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Furazolidone IP 100 mg | |
| | |
| Ibuprofen Tablets IP 200 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Ibuprofen IP 200 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ibuprofen Tablets IP 400 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Ibuprofen IP 400 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ibuprofen Tablets IP 600 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Ibuprofen IP 600 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Loperamide Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Loperamide Hydrochloride IP 2 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Mebendazole Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Mebendazole IP 100 mg | |
| | |
| Methylergomatrine Maleate | Each uncoated tablet contains : | |
| Tablets IP | Methylergomatrine Maleate IP 0.125 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Paracetamol & Metoclopramide Hydrochloride | Each uncoated tablet contains : | |
| Tablets | Paracetamol 325mg | |
| 06.09.2024 | Metoclopramide Hydrochloride IP 10 mg | |
| Eq. to Anhydrous Metoclopramide Hydrochloride | |
| Excipients qs | |
| | |
| Metoclopramide Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Metoclopramide Hydrochloride IP 10 mg | |
| Approved Date : 19/04/2007 | Eq. to Anhydrous Metoclopramide Hydrochloride | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunsel yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Metronidazole Tablets IP 200 MG. | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Metronidazole IP 200 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Metronidazole Tablets IP 400 MG. | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Metronidazole IP 400 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Nimesulide Tablets BP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Nimesulide BP 100 mg | |
| Not to be used below 12 years of age. | | |
| | |
| Norfloxacin Tablets IP | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Norfloxacin IP 400 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Ofloxacin Tablets IP 200 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Ofloxacin IP 200 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Ofloxacin Tablets IP 400 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Ofloxacin IP 400 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Oxyphenbutazone Tablets IP | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Oxyphenbutazone IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Paracetamol Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Paracetamol IP 500 mg | |
| | |
| Paracetamol Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Paracetamol IP 650 mg | |
| | |
| Phenylbutazone Tablets IP | Each sugar coated tablet contains : | |
| Approved Date : 19/04/2007 | Phenylbutazone IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunser yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Phenylbutazone Tablets IP 07 | Each sugar coated tablet contains : | |
| Approved Date : 19/04/2007 | Phenylbutazone IP07 200 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunser yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Prochlorperazine Maleate | Each uncoated tablet contains : | |
| Tablets IP | Prochlorperazine Maleate IP 10 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Promethazine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Promethazine Hydrochloride IP 10 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red iron oxide Yellow | |
| | |
| Quiniodochlor Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Quiniodochlor IP 250 mg | |
| | |
| Ranitidine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Ranitidine Hydrochloride IP | |
| Approved Date : 19/04/2007 | Eq. to Ranitidine 150 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ranitidine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Ranitidine Hydrochloride IP | |
| Approved Date : 19/04/2007 | Eq. to Ranitidine 300 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Salbutamol Sulphate | Each uncoated tablet contains : | |
| Tablets IP 2 mg. | Salbutamol Sulphate IP | |
| Approved Date : 19/04/2007 | Eq. to Salbutamol 2 mg | |
| | |
| Salbutamol Sulphate | Each uncoated tablet contains : | |
| Tablets IP 2 mg. | Salbutamol Sulphate IP | |
| Approved Date : 19/04/2007 | Eq. to Salbutamol 4 mg | |
| | |
| Trifluoperazine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Trifluoperazine Hydrochloride IP | |
| Approved Date : 19/04/2007 | Eq. to Trifluoperazine 1 mg | |
| | |
| Atenolol Tablets IP 25 mg | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Atenolol IP 25 mg | |
| | |
| Paracetamol , Caffeine & | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate Tablets | Paracetamol IP 300 mg | |
| Approved Date : 19/04/2007 | Caffeine (Anhydrous) IP 20 mg | |
| Chlorpheniramine Maleate IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide ip /Apple Green / Iron oxide red, Iron Oxide Yelloy | |
| | |
| Paracetamol & Caffeine | Each uncoated tablet contains : | |
| Tablets | Paracetamol IP 325 mg | |
| Approved Date : 19/04/2007 | Caffeine (Anhydrous) IP 30 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| Jor Titanium Dioxide IP /Apple Green/Iron oxide red iron oxide Yellow | |
| | |
| Atenolol Tablets IP 50 mg | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Atenolol IP 50 mg | |
| | |
| Ciprofloxacin Hydrochloride & Tinidazole | Each film coated tablet contains : | |
| Tablets | Ciprofloxacin Hydrochloride IP | |
| Approved Date : 19/04/2007 | Eq. to Ciprofloxacin 500 mg | |
| Tinidazole IP 600 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red Iron oxide Yellow | |
| | |
| Chlorpheniramine Maleate | Each uncoated tablet contains : | |
| Tablets IP | Chlorpheniramine Maleate IP 4 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red, Iron Oxide Yellow | |
| | |
| Diclofenac Sodium & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Diclofenac Sodium IP 50 mg | |
| Approved Date : 19/04/2007 | Paracetamol IP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Diclofenac Sodium, Paracetamol & | Each uncoated tablet contains : | |
| Magnesium Trisilicate Tablets | Diclofenac Sodium IP 50 mg | |
| Approved Date : 19/04/2007 | Paracetamol IP 250 mg | |
| Magnesium Trisilicate IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / iron oxide red, iron oxide Yellow | |
| | |
| Etofylline & Theophylline | Each uncoated tablet contains : | |
| Tablets | Etofylline IP 85 77 mg | |
| Approved Date : 19/04/2007 | Theophylline (Anhydrous) IP 2.3 mg | |
| | |
| Levofloxacin Tablets IP 250 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Levofloxacin Hemihydrate IP | |
| Equivalent to Levofloxacin 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yelloy / Sunset yellow | |
| or Tanium Dioxide IP /Apple Green / Iron oxide red, Iron Oxide Yeller | |
| | |
| Levofloxacin Tablets IP 500 mg | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Levofloxacin Hemihydrate IP | |
| Equivalent to Levofloxacin 500 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red, Iron oxide Yellow | |
| | |
| Levocetirizine Hydrochloride | Each film coated tablet contains: | |
| Tablets IP | Levocetirizine Hydrochloride IP 5 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Survet yellow | |
| | |
| Sparfloxacin Tablets | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Sparfloxacin 200 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / tron oxide red, Iron Oxide Yellow | |
| | |
| Magnesium Trisilicate & | Each chewable tablet contains : | |
| Dried Aluminium Hydroxide | Magnesium Trisilicate IP 250 mg | |
| Chewable Tablets | Dried Aluminium Hydroxide Gel IP 120 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Furazolidone , Metronidazole & | Each uncoated tablet contains : | |
| Dicyclomine Hydrochloride Tablets | Furazolidone IP 50 mg | |
| Approved Date : 19/04/2007 | Metronidazole IP 200 mg | |
| Dicyclomine Hydrochloride IP 10 mg | |
| | |
| Pheniramine Maleate | Each uncoated tablet contains : | |
| Tablets IP 25 mg | Pheniramine Maleate IP 25 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Pantoprazole Tablets | Each enteric coated tablet contains : | |
| Approved Date : 19/04/2007 | Pantoprazole Sodium Sesquihydrate IP | |
| Eq. to Pantoprazole 40 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Pantoprazole & Domperidone | Each enteric coated tablet contains : | |
| Tablets | Pantoprazole Sodium Sesquihydrate IP | |
| Approved Date : 19/04/2007 | Eq. to Pantoprazole 40mg | |
| Domperidone IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red, iron oxide kllow | |
| | |
| Nimesulide & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Nimesulide BP 100 mg | |
| Approved Date : 19/04/2007 | Paracetamol IP 325 mg | |
| Not to be used below 12 years of age. | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow/Sunset yellow | |
| for Titanium Dioxide IP /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Nimesulide & Tizanidine Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Nimesulide BP 100 mg | |
| Approved Date : 19/04/2007 | Tizanidine Hydrochloride IP | |
| Not to be used below 12 years of age. | Eq. to Tizanidine 2 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Nimesulide, Paracetamol & | Each uncoated tablet contains : | |
| Tizanidine Hydrochloride Tablets | Nimesulide BP 100 mg | |
| Paracetamol IP 325 mg | |
| Approved Date : 19/04/2007 | Tizanidine Hydrochloride IP | |
| Not to be used below 12 years of age. | Eq. to Tizanidine 2 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide iP /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Ofloxacin Dispersible Tablets | Each dispersible tablet contains : | |
| Approved Date : 19/04/2007 | Ofloxacin IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ofloxacin & Tinidazole | Each film coated tablet contains : | |
| Tablets | Ofloxacin IP 200 mg | |
| Approved Date : 19/04/2007 | Tinidazole IP 600 mg | |
| Colour: Brilliant Blue/Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red, Iron oxide Yellow | |
| | |
| Diclofenac Sodium, Paracetamol | Each uncoated tablet contains : | |
| & Chlorzoxazone Tablets | Diclofenac Sodium IP 50 mg | |
| Paracetamol IP 325 mg | |
| Approved Date : 19/04/2007 | Chlorzoxazone USP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Paracetamol & Domperidone | Each film coated tablet contains : | |
| Tablets | Paracetamol IP 325 mg | |
| Approved Date : 19/04/2007 | Domperidone IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline ellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red, Iron Oxide Yellow | |
| | |
| Piroxicam Dispersible | Each dispersible tablet contains : | |
| Tablets | Piroxicam IP 20 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunsel yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Sulphaguanidine Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Sulphaguanidine IP66 500 mg | |
| | |
| Sildenafil Citrate | Each film coated tablet contains : | |
| Tablets IP 50 mg | Sildenafil Citrate IP | |
| Approved Date : 19/04/2007 | Equivalent to Sildenafil 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide ip /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Sildenafil Citrate | Each film coated tablet contains : | |
| Tablets IP 100 mg | Sildenafil Citrate IP | |
| Approved Date : 19/04/2007 | Equivalent to Sildenafil 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide ip /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Salbutamol Sulphate & | Each uncoated tablet contains : | |
| Bromhexine Hydrochloride Tablets | Salbutamol Sulphate IP | |
| Approved Date : 19/04/2007 | Equivalent to Salbutamol 2 mg | |
| Bromhexine Hydrochloride IP 8 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron Oxide Yellow | |
| | |
| Salbutamol Sulphate & | Each uncoated tablet contains : | |
| Bromhexine Hydrochloride Tablets | Salbutamol Sulphate IP | |
| Approved Date : 19/04/2007 | Equivalent Salbutamol 2 mg | |
| Bromhexine Hydrochloride IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Cetirizine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Cetirizine Hydrochloride IP 10 mg | |
| Approved Date : 19/04/2007 | Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Cetirizine Hydrochloride With | Each film coated tablet contains : | |
| Ambroxol Hydrochloride Tablets | Cetirizine Hydrochloride IP 5 mg | |
| Approved Date : 19/04/2007 | Ambroxol HCL IP 60 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Paracetamol, Nimesulide & | Each uncoated tablet contains : | |
| Chlorzoxazone Tablets | Paracetamol IP 325 mg | |
| Approved Date : 19/04/2007 | Nimesulide BP 100 mg | |
| Not to be used below 12 years of age. | Chlorzoxazone USP 375 mg | |
| Colour: Brilliant Blue / Crythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red, Iron oxide Yellow | |
| | |
| Amlodipine Besiylate & | Each uncoated tablet contains : | |
| Atenolol Tablets | Amlodipine Besiylate BP | |
| Approved Date : 11/10/2007 | Eq. to Amlodipine 5 mg | |
| Atenolol IP 50 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunsel yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Propranolol Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Propranolol Hydrochloride IP 40 mg | |
| Approved Date : 11/10/2007 | Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green /tron oxide red, Iron Oxide Yellow | |
| | |
| Analgin Tablets IP | Each uncoated tablet contains : | |
| Approved Date: 05/09/2008 | Analgin IP 500 mg | |
| | |
| Chloroquine Phosphate | Each film coated tablet contains : | |
| Tablets IP | Chloroquine Phosphate IP 250 mg | |
| Approved Date : 05/09/2008 | Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or Titanium Dioxide IP /Apple Green / | |
| Iron oxide red iron oxide Yellow | |
| | |
| Diclofenac Sodium Tablets IP | Each film coated tablet contains : | |
| Approved Date: 05/09/2008 | Diclofenac Sodium IP 50 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Diethylcarbamazine Citrate | Each uncoated tablet contains : | |
| Tablets IP 50 mg | Diethylcarbamazine Citrate IP 50 mg | |
| Approved Date : 05/09/2008 | | |
| | |
| Calcium Lactate Tablets IP | Each uncoated tablet contains : | |
| Approved Date: 05/09/2008 | Calcium Lactate IP 300 mg | |
| | |
| Ibuprofen & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Ibuprofen IP 200 mg | |
| Approved Date: 05/09/2008 | Paracetamol IP 325 mg | |
| | |
| Diclofenac Sodium Tablets IP | Each uncoated tablet contains : | |
| Approved Date: 05/09/2008 | Diclofenac Sodium IP 50 mg | |
| | |
| METRONIDAZOLE & | Each uncoated tablet contains : | |
| FURAZOLIDONE Tablets | Metronidazole IP 200 mg | |
| Approved Date: 05/09/2008 | Furazolidone IP 100 mg | |
| | |
| Mefenamic Acid & Dicyclomine Hydrochloride | Each uncoated tablet contains : | |
| Tablets | Mefenamic Acid IP 250 mg | |
| Approved Date : 05/09/2008 | Dicyclomine Hydrochloride IP 10 mg | |
| | |
| Norfloxacin & Tinidazole | Each uncoated tablet contains : | |
| (With Betacyclodextrin) Tablets | Norfloxacin IP 400 mg | |
| Approved Date: 05/09/2008 | Tinidazole IP 600 mg | |
| ( With Betacyclodextrin) | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Propyphenazone, Paracetamol | Each uncoated tablet contains : | |
| With Caffeine Tablets | Propyphenazone IP 150 mg | |
| Approved Date : 05/09/2008 | Paracetamol IP 250 mg | |
| Caffeine (Anhydrous) IP 50 mg | |
| | |
| Aceclofenac Tablets | Each film coated tablet contains : | |
| Approved Date: 05/09/2008 | Aceclofenac IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline | |
| Yellow/Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron Oxide red Iron oxide Yellow | |
| | |
| Prochlorperazine Maleate Tablets IP | Each uncoated tablet contains : | |
| Approved Date: 05/12/2008 | Prochlorperazine Maleate IP 5 mg | |
| | |
| Magnesium Hydroxide, | Each uncoated chewable tablet contains : | |
| Dried Aluminium Hydroxide With | Magnesium Hydroxide IP 250 mg | |
| Simethicone Chewable Tablets | Dried Aluminium Hydroxide Gel IP 250 mg | |
| Approved Date: 05/12/2008 | Simethicone IP 25 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green/Iron oxide red, Iron Oxide Yollow | |
| | |
| Dextromethorphan , Guaiphenesin & | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate With | Dextromethorphan Hbr IP 10 mg | |
| Bromhexine Hydrochloride Tablets | Guaiphenesin IP 100 mg | |
| Approved Date: 05/12/2008 | Chlorpheniramine Maleate IP 2 mg | |
| Bromhexine Hydrochloride IP 8 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Terbutaline Sulphate & | Each uncoated tablet contains : | |
| Bromhexine Hydrochloride Tablets | Terbutaline Sulphate IP 2.50 mg | |
| Approved Date : 22/12/2008 | Bromhexine Hydrochloride IP 16 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Nimesulide & | Each uncoated tablet contains : | |
| Dicyclomine Hydrochloride Tablets | Nimesulide IP 100 mg | |
| Approved Date : 22/12/2008 | Dicyclomine Hydrochloride IP 10 mg | |
| Not to be used below 12 years of age. | Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Dicyclomine Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Dicyclomine Hydrochloride IP 20 mg | |
| Approved Date : 26/05/2009 | Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Domperidone Dispersible Tablets IP | Each dispersible tablet contains : | |
| Approved Date : 26/05/2009 | Domperidone IP 10 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Ofloxacin & Ornidazole Tablets | Each film coated tablet contains : | |
| Approved Date : 26/05/2009 | Ofloxacin IP 200 mg | |
| Ornidazole IP 500 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Terbutaline Sulphate With | Each uncoated tablet contains : | |
| Bromhexine Hydrochloride Tablets | Terbutaline Sulphate IP 1.25 mg | |
| Approved Date : 26/05/2009 | Bromhexine Hydrochloride IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow/Sunset | |
| yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Metformin Hydrochloride Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 26/05/2009 | Metformin Hydrochloride IP 500 mg | |
| | |
| Metformin Hydrochloride | Each uncoated tablet contains : | |
| With Gliclazide Tablets | Metformin Hydrochloride IP 500 mg | |
| Approved Date : 26/05/2009 | Gliclazide BP 80 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Norfloxacin With | Each film coated tablet contains : | |
| Betacyclodextrin Tablets | Norfloxacin IP 400 mg | |
| Approved Date : 01/07/2009 | Betacyclodextrin USP 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Norfloxacin , Tinidazole With | Each film coated tablet contains : | |
| Betacyclodextrin Tablets | Norfloxacin IP 400 mg | |
| Approved Date : 01/07/2009 | Tinidazole IP 600 mg | |
| Betacyclodextrin USP 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Co-Trimoxazole Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 01/07/2009 | Trimethoprim IP 40 mg | |
| Sulphamethoxazole IP 200 mg | |
| | |
| Ibuprofen & Paracetamol Tablets | Each uncoated tablet contains : | |
| Approved Date : 04/08/2009 | Ibuprofen IP 400 mg | |
| Paracetamol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Paracetamol, Caffeine & | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate Tablets | Paracetamol IP 325 mg | |
| Approved Date : 11/12/2009 | Caffeine (Anhydrous) IP 10 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Dicyclomine Hydrochloride | Each uncoated tablet contains : | |
| & Paracetamol Tablets | Dicyclomine Hydrochloride IP 10 mg | |
| Approved Date : 11/12/2009 | Paracetamol IP 325 mg | |
| | |
| Phenolphthaleine, Senna Powder & | Each uncoated tablet contains : | |
| Myrobalan With Lactose Tablets | Phenolphthaleine IP 85 IP 129.60 mg | |
| Approved Date : 11/12/2009 | Senna Powder IP 66 IP 16.20 mg | |
| Myrobalan Powder IP 66 IP 16.20 mg | |
| Lactose IP qs. | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green/Iron oxide red,Iron oxide Yellow | |
| | |
| Ranitidine Hydrochloride, | Each film coated tablet contains : | |
| Dicyclomine Hydrochloride & | Ranitidine Hydrochloride IP | |
| Simethicone Tablets | Eq. to Ranitidine 150 mg | |
| Approved Date : 11/12/2009 | Dicyclomine Hydrochloride IP 10 mg | |
| 06.09.2024 | Simethicone IP 20 mg | |
| Excipients qs | |
| Approved colour to be used | |
| | |
| Ranitidine Hydrochloride, | Each film coated tablet contains : | |
| Domperidone & | Ranitidine Hydrochloride IP | |
| Simethicone Tablets | Eq. to Ranitidine 150 mg | |
| Approved Date : 11/12/2009 | Domperidone IP 10 mg | |
| Simethicone IP 20 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Aceclofenac Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 25/03/2010 | Aceclofenac IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Famotidine Tablets IP 40 mg | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Famotidine IP 40 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Bisacodyl Tablets IP | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Bisacodyl IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Tinidazole Tablets IP 300 mg | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Tinidazole IP 300 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Tinidazole Tablets IP 600 mg | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Tinidazole IP 600 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Mefenamic Acid Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 25/03/2010 | Mefenamic Acid IP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Albendazole Chewable Tablets IP | Each uncoated chewable tablet contains : | |
| Approved Date : 25/03/2010 | Albendazole IP 400 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Tramadol Hydrochloride Tablets | Each uncoated tablet contains : | |
| Approved Date : 25/03/2010 | Tramadol Hydrochloride IP 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / tron oxide red,Iron oxide Yellow | |
| | |
| Esomeprazole Tablets IP | Each enteric-coated tablet contains :- | |
| Approved Date : 25/03/2010 | Esomeprazole magnesium trihydrate IP | |
| Eq. to Esomeprazole 40 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / | |
| Sunset yellow or | |
| Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Paracetamol Tablets IP 300 mg | Each uncoated tablet contains : | |
| Approved Date : 25/03/2010 | Paracetamol IP 300 mg | |
| | |
| Paracetamol Dispersible Tablets | Each uncoated dispersible tablet contains : | |
| Approved Date : 25/03/2010 | Paracetamol BP 125 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ibuprofen & Paracetamol | Each uncoated dispersible tablet contains | |
| Dispersible Tablets | Ibuprofen IP 100 mg | |
| Approved Date: 25/03/2010 | Paracetamol IP 125 mg | |
| Colour: Brilliant Blue / Erythrosine/ Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP IApple Green / Iran oxide red,Iron oxide Yellow | |
| | |
| Doxofylline Tablets IP | Each uncoated tablet contains: | |
| Approved Date: 25/03/2010 | Doxofylline IP 400 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartraz ine /Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide P /Apple Green / Iron oxide red,lron oxide Yellow | |
| | |
| Rabeprazole Sodium Tablets IP | Each enteric-coated tablet contains | |
| Approved Date: 25/03/2010 | Rabeprazole Sodium IP 20 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP IApple Green / Iron oxide red, ron oxide Yellow | |
| | |
| Rabeprazole Sodium & | Each enteric-coated tablet contains: | |
| Domperidone Tablets IP | Rabeprazole Sodium IP 20 mg | |
| Approved Date : 25/03/2010 | Domperidone IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine/ Tartraz ine/ Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP IApple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Olmesartan Medoxomil Tablets IP | Each film coated tablet contains: | |
| Approved Date : 25/03/2010 | Olmesartan Medoxomil IP 20 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| | |
| Olmesartan Medoxomil & | Each film coated tablet contains: | |
| Hydrochlorothiazide Tablets | Olmesartan Medoxomil IP 20 mg | |
| Approved Date: 25/03/2010 | Hydrochlorothiazide IP 12.5 mg | |
| Colour: Brilliant Blue/ Erythrosine/ Tartraz ine / Quinoline Yellow/ Sunset yelow | |
| or Titanium Dioxide IP IApple Green /Iron oxide red,Iron oxide Yellow | |
| | |
| Etoricoxib Tablets IP 90 mg | Each film coated tablet contains | |
| Approved Date: 25/03/2010 | Etoricoxib IP 90 mg | |
| Colour: Brilliant Blue / Erythrosine/ Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Bisacodyl Tablets IP | Each enteric-coated tablet contains | |
| Approved Date: 25/03/2010 | Bisacodyl IP 5 mg | |
| Colour: Brilliant Blue l Erythrosine / Tartraz ine /Quinoline Yellow/ Sunset yellow | |
| or Titaniuin Dioxide IP IApple Green / Iron oxide red,Iron oxide Yeld | |
| | |
| Etoricoxib Tablets IP 120 mg | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Etoricoxib IP 120 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red dron oxide Yellow | |
| | |
| Magnesium Trisilicate | Each uncoated chewable tablet contains : | |
| Chewable Tablets | Magnesium Trisilicate IP 250 mg | |
| Approved Date : 25/03/2010 | Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Ranitidine Hydrochloride & | Each film coated tablet contains : | |
| Domperidone Tablets | Ranitidine Hydrochloride IP | |
| Approved Date : 13/10/2010 | Eq. to Ranitidine 150 mg | |
| Domperidone IP 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red Iron oxide Yellow | |
| | |
| Aceclofenac , Paracetamol & | Each uncoated tablet contains : | |
| Chlorzoxazone Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 13/10/2010 | Paracetamol IP 325 mg | |
| Chlorzoxazone USP 250 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine I Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Misoprostol Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 13/10/2010 | Misoprostol IP 200 mcg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide P /Apple Green/Iron oxide red Iron oxide Yellow | |
| | |
| Nimesulide Dispersible Tablets | Each uncoated dispersible tablet contains : | |
| Approved Date : 15/01/2011 | Nimesulide BP 100 mg | |
| Not to be used below 12 years of age. | | |
| | |
| Levocetirizine With | Each film coated tablet contains : | |
| Montelukast Tablets | Levocetirizine Hydrochloride IP 5 mg | |
| Approved Date : 15/10/2011 | Montelukast Sodium IP | |
| Eq. to Montelukast 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Paracetamol & | Each sugar-coated tablet contains : | |
| Diclofenac Potassium Tablets | Paracetamol IP 250 mg | |
| Approved Date: 15/10/2011 | Diclofenac Potassium IP 50 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Paracetamol & | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride Tablets | Paracetamol IP 325 mg | |
| Approved Date : 15/10/2011 | Phenylephrine Hydrochloride IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green /tron oxide red,Iron oxide Yellow | |
| | |
| Ivermectin Tablets | Each uncoated tablet contains : | |
| Approved Date : 14/10/2011 | Ivermectin IP 6 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / tron oxide red iron oxide Yellow | |
| | |
| Diclofenac Potassium , Paracetamol | Each uncoated tablet contains : | |
| With Chlorzoxazone Tablets | Diclofenac Potassium IP 50 Mg | |
| Approved Date : 22/12/2012 | Paracetamol IP 325 mg | |
| Chlorzoxazone USP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide ip /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Terbutaline Sulphate , Guaiphensin & | Each uncoated tablet contains : | |
| Bromhexine Hydrochloride Tablets | Terbutaline Sulphate IP 1.25 mg | |
| Approved Date : 27/06/2013 | Guaiphensin IP 50 mg | |
| Bromhexine Hydrochloride IP 4 mg | |
| Colour: Brilliant Blue/Erytheosine / Tartrazine/Quinoline Yellow / Sunsel yellow | |
| or Thanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Diclofenac Sodium & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Diclofenac Sodium IP 50 mg | |
| Approved Date : 27/06/2013 | Paracetamol IP 325 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Diclofenac Sodium, Paracetamol With | Each uncoated tablet contains : | |
| Magnesium Trisilicate Tablets | Diclofenac Sodium IP 50 mg | |
| Approved Date : 27/06/2013 | Paracetamol IP 325 mg | |
| Magnesium Trisilicate IP 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Aceclofenac & Paracetamol Tablets | Each film coated tablet contains : | |
| Approved Date : 27/06/2013 | Aceclofenac IP 100 mg | |
| Paracetamol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ondansetron Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Ondansetron Hydrochloride IP | |
| Approved Date : 27/06/2013 | eq. to Ondansetron 4 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Ondansetron Orally | Each orally disintegrating tablets contains : | |
| Disintegrating Tablets IP | Ondansetron Hydrochloride IP | |
| Approved Date: 27/06/2013 | eq. to Ondansetron 4 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Cetirizine Hydrochloride, | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride, | Cetirizine Hydrochloride IP 5 mg | |
| Paracetmol Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date: 08/01/2014 | Paracetmol IP 325 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Cetirizine Hydrochloride, | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride, | Cetirizine Hydrochloride IP 10 mg | |
| Paracetmol With CaffeineTablets | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date: 08/01/2014 | Paracetmol IP 325 mg | |
| Caffeine (Anhydrous) IP 20 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Paracetamol & Chlorpheniramine Maleate | Each uncoated tablet contains : | |
| Tablets | Paracetamol IP 325 mg | |
| Approved Date: 08/01/2014 | Chlorpheniramine Maleate IP 2 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Diclofenac Sodium & Paracetamol | Each sugar coated tablet contains : | |
| Tablets | Diclofenac Sodium IP 50 mg | |
| Approved Date: 08/01/2014 | Paracetamol IP 325 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Paracetamol & Diclofenac Potassium | Each uncoated tablet contains : | |
| Tablets | Paracetamol IP 325 mg | |
| Approved Date: 08/01/2014 | Diclofenac Potassium IP 50 mg | |
| Colour: Brilliant Blue/Erythrosine/Tartrazine/Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Drotaverine Hydrochloride & | Each film coated tablet contains : | |
| Mefenamic Acid Tablets | Drotaverine Hydrochloride IP 80 mg | |
| Approved Date : 08/01/2014 | Mefenamic Acid IP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Dicyclomine Hydrochloride & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Dicyclomine Hydrochloride IP 20 mg | |
| Approved Date : 08/01/2014 | Paracetamol IP 325 mg | |
| | |
| Dicyclomine Hydrochloride & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Dicyclomine Hydrochloride IP 10 mg | |
| Approved Date : 08/01/2014 | Paracetamol IP 250 mg | |
| | |
| Mefenamic Acid & Paracetamol | Each uncoated tablet contains : | |
| Tablets | Mefenamic Acid IP 250 mg | |
| Approved Date : 08/01/2014 | Paracetamol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red, Iron Oxide Yellow | |
| | |
| Levocetirizine Hydrochloride, | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride, | Levocetirizine Hydrochloride IP 5 mg | |
| Ambroxol Hdrochloride With | Phenylephrine Hydrochloride IP 5 mg | |
| Paracetmol Tablets | Ambroxol Hdrochloride IP 30 mg | |
| Approved Date : 08/01/2014 | Paracetmol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Levocetirizine Hydrochloride With | Each film coated tablet contains : | |
| Ambroxol Hdrochloride Tablets | Levocetirizine Hydrochloride IP 5 mg | |
| Approved Date: 08/01/2014 | Ambroxol Hdrochloride IP 60 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Nimesulide | Each orally disintegrating tablet contains : | |
| Orally Disintegrating Tablets | Nimesulide BP 100 mg | |
| Approved Date : 08/01/2014 | Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / Sunset yellow | |
| Not to be used below 12 years of age. | or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Norfloxacin & Ornidazole Tablets | Each film coated tablet contains : | |
| Approved Date : 08/01/2014 | Norfloxacin IP 400 mg | |
| Ornidazole IP 500 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Paracetmol , Chlorpheniramine Maleate | Each uncoated tablet contains: | |
| Caffeine Tablets | Paracetmol IP 325 mg | |
| Chlorpheniramine Maleate IP 4 mg | |
| Approved Date : 00/01/2014 | Caffeine (Anhydrous) IP 20 mg | |
| Colour Brillow Blue/Frythrosine/Tartrazine/Quinoline Yellow/Suret yellow | |
| Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Paracetmol , | Each uncoated tablet contains: | |
| Phenylephrine Hydrochloride With | Paracetmol IP 325 mg | |
| Chlorpheniramine Maleate Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date: 01/01/2014 | Chlorpheniramine Maleate IP 4 mg | |
| Colour Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunsel yellow | |
| or Titanium Dioxide ip /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Paracetmol , | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride With | Paracetmol IP 325 mg | |
| Chlorpheniramine Maleate With Caffeine | Phenylephrine Hydrochloride IP 5 mg | |
| Tablets | Chlorpheniramine Maleate IP 2 mg | |
| Approved Date : 08/01/2014 | Caffeine (Anhydrous) IP 30 mg | |
| Colour: Brilliant Blue/Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Tramadol Hydrochloride & | Each film coated tablet contains : | |
| Paracetmol Tablets | Tramadol Hydrochloride IP 37.5 mg | |
| Approved Date : 08/01/2014 | Paracetmol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunset yellow or | |
| Titanium Dioxide ir /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Tramadol Hydrochloride & | Each film coated tablet contains : | |
| Paracetmol Tablets | Tramadol Hydrochloride IP 50 mg | |
| Approved Date : 08/01/2014 | Paracetmol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide ir /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Pyrazinamide Tablets | Each uncoated tablet contains : | |
| Approved Date : 17/04/2014 | Pyrazinamide IP 750 mg | |
| | |
| Aceclofenac & Thiocochicoside | Each film coated tablet contains : | |
| Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 28/06/2014 | Thiocochicoside IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yelley | |
| or Titanium Dioxide ip /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Dapoxetine Tablets | Each film coated tablet contains : | |
| Approved Date:17/04/2014 | Dapoxetine Hydrochloride IP | |
| eq. to Dapoxetine 60 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Aceclofenac & | Each film coated tablet contains : | |
| Thiocochicoside Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 28/06/2014 | Thiocochicoside IP 8 mg | |
| Colour: Brilliant Blue / Crythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Dapoxetine Tablets | Each film coated tablet contains : | |
| Approved Date : 28/06/2014 | Dapoxetine Hydrochloride IP | |
| eq. to Dapoxetine 30 mg | |
| Colour: Brilliant Blue/Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Domperidone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 28/06/2014 | Domperidone Maleate IP | |
| eq.to Domperidone 10 mg | |
| Colour: Brilliant Blue/ Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Etoricoxib & THIOCOLCHICOSIDE | Each film coated tablet contains : | |
| Tablets | Etoricoxib IP 60 mg | |
| Approved Date : 28/06/2014 | Thiocochicoside IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, iron oxide Yellow | |
| | |
| Fluconazole Tablets IP 150 mg | Each uncoated tablet contains : | |
| Approved Date : 28/06/2014 | Fluconazole IP 150 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Levocetirizine With | Each uncoated dispersible tablet contains : | |
| Dispersible Tablets | Levocetirizine Hydrochloride IP 2.5 mg | |
| Approved Date : 28/06/2014 | Montelukast Sodium IP | |
| eq. to Montelukast 4 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Senset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Lornoxicam & Paracetmol Tablets | Each film coated tablet contains : | |
| Approved Date : 28/06/2014 | Lornoxicam IP 8 mg | |
| Paracetmol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Sildenafil Citrate | Each orally disintegrating tablet contains : | |
| Orally Disintegrating Tablets | Sildenafil Citrate IP | |
| Approved Date : 28/06/2014 | Equivalent to Sildenafil 100 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / | |
| Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Bromhexine, Guaiphenesin | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate, | Bromhexine Hcl IP 8 mg | |
| Paracetamol & Phenylephrine Hydrochloride | Guaiphenesin IP 50 mg | |
| Tablets | Chlorpheniramine Maleate IP 4 mg | |
| Approved Date : 21/11/2014 | Paracetamol IP 325 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red,Iron oxide Yellow | |
| | |
| Cetirizine Hydrochloride | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride With Paracetmol | Cetirizine Hydrochloride IP 5 mg | |
| Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Approved Date : 21/11/2014 | Paracetmol IP 325 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Etamsylate Tablets 250 mg | Each uncoated tablet contains : | |
| Approved Date : 21/11/2014 | Etamsylate BP 250 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Etamsylate Tablets 250 mg | Each uncoated tablet contains : | |
| Approved Date : 21/11/2014 | Etamsylate BP 500 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Fexofenadine & Montelukast | Each film / uncoated tablet contains : | |
| Tablets | Fexofenadine Hydrochloride IP 120 mg | |
| Approved Date : 21/11/2014 | Montelukast Sodium IP | |
| eq. to Montelukast 10 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow/ Runsel yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellon | |
| | |
| Nimesulide, Cetirizine Hydrochloride With | Each uncoated tablet contains : | |
| Phenylephrine Hydrochloride | Nimesulide IP 100 mg | |
| Tablets | Cetirizine Hydrochloride IP 5 mg | |
| Approved Date : 21/11/2014 | Phenylephrine Hydrochloride IP 5 mg | |
| Not to be used below 12 years of age. | Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide ip /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Diclofenac Sodium, | Each uncoated tablet contains : | |
| Magnesium Trisilicate , | Diclofenac Sodium IP 50 mg | |
| Paracetamol With Chlorpheniramine Maleate | Magnesium Trisilicate IP 100 mg | |
| Tablets | Paracetamol IP 325 mg | |
| Approved Date : 21/11/2014 | Chlorpheniramine Maleate IP 4 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Febuxostate Tablets | Each filmcoated tablet contains : | |
| Approved Date : 20/07/2016 | Febuxostate IP 40 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron Oxide red,Iron oxide Yellow | |
| | |
| Rifampicin & Isoniazid | Each filmcoated tablet contains : | |
| Tablets | Rifampicin IP 450 mg | |
| Approved Date : 20/07/2016 | Isoniazid IP 300 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow/Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Metformin (SR), Glimepride Tablets | Each uncoated tablet contains | |
| Approved Date : 20/07/2016 | Metformin Hydrochloride IP 500 mg | |
| (As sustained release form) | |
| Glimepride IP 2 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Metformin (SR), Glimepride Tablets | Each uncoated tablet contains | |
| Approved Date : 20/07/2016 | Metformin Hydrochloride (As sustained rel IP 500 mg | |
| (As sustained release form) | |
| Glimepride IP 1 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Atorvastatin Tablets IP | Each film coated tablet contains : | |
| Approved Date : 20/07/2016 | Atorvastatin Calcium IP | |
| eq. to Atorvastatin 20 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Telmisartan Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 20/07/2016 | Telmisartan IP 40 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Rosuvastatin Tablets IP | Each film coated tablet contains : | |
| Approved Date : 20/07/2016 | Rosuvastatin Calcium IP | |
| eq. to Rosuvastatin 20 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine/Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Tadalafil Tablets USP | Each film coated tablet contains : | |
| Approved Date : 20/07/2016 | Tadalafil Citrate IP | |
| Equivalent to Tadalafil 20 mg | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron Oxide yellow | |
| | |
| Tadalafil With Dapoxetine Tablets | Each film coated tablet contains : | |
| Approved Date : 20/07/2016 | Tadalafil Citrate IP | |
| Equivalent to Tadalafil 20 mg | |
| Dapoxetine Hydrochloride IP | |
| eq. to Dapoxetine 30 mg | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Nimesulide Tablets | Each uncoated tablet contains | |
| Approved Date : 19/04/2007 | Nimesulide BP 200 mg | |
| | |
| Gatifloxacin Tablets | Each film coated tablet contains | |
| Approved Date : 19/04/2007 | Gatifloxacin 400 mg | |
| Approved colour to used | |
| | |
| Terbutaline Sulphate & Bromhexine Hcl | Each uncoated tablet contains | |
| Tablets | Terbutaline Sulphate IP 2.5 mg | |
| Approved Date:05/12/2008 | Bromhexine Hydrochloride IP 8 mg | |
| Approved colour to be used | |
| | |
| Metformin Hydrochloride | Each uncoated tablet contains: | |
| With Gliclazide Tablets | Metformin Hydrochloride IP 500 mg | |
| Approved Date : 26/05/2009 | Gliclazide BP 80 mg | |
| Approved colour to be used | |
| | |
| Aceclofenac & Paracetamol | Each uncoated tablet contains: | |
| Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 13/10/2010 | Paracetamol IP 325 mg | |
| Approved Color to be use in Tablet | |
| | |
| Pantoprazole & Domperidone | Each enteric coated tablet contains: | |
| Tablets | Pantoprazole Sodium Sesquihydrate IP | |
| Approved Date : 15/01/2011 | Eq. lo Pantoprazole 20 mg | |
| Domperidone IP 10 mg | |
| Approved colour to used | |
| | |
| Phenylephrine Hydrochloride & | Each uncoated tablet contains | |
| Chlorpheniramine Maleate Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Approved Date : 15/10/2011 | Chlorpheniramine Maleate IP 4 mg | |
| Approved Color to be use in Tablet | |
| | |
| Paracetamol , Phenylephrine Hcl & | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate , | Paracetamol IP 325 mg | |
| Caffeine Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date : 27/03/2012 | Chlorpheniramine Maleate IP 4 mg | |
| Caffeine (Anhydrous) IP 20 mg | |
| Approved colour to be used | |
| | |
| Norfloxacin , Tinidazole With | Each film coated tablet contains : | |
| Betadex Tablets | Norfloxacin IP 400 mg | |
| Approved Date:27/03/2012 | Tinidazole IP 600 mg | |
| Betadex (Anhydrous) USP 10 mg | |
| Approved colour to used | |
| | |
| Mefenamic Acid & Dicyclomine Hydrocloride | Each uncoated tablet contains | |
| Tablets | Mefenamic Acid IP 250 mg | |
| Approved Date : 27/03/2012 | Dicyclomine Hydrochloride IP 20 mg | |
| | |
| Albendazole Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Albendazole IP 3000 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Ciprofloxacin Hydrocloride Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Ciprofloxacin HCL IP | |
| Approved Date : 19/04/2007 | Equivalent to Ciprofloxacin 1500 mg | |
| | |
| Sulpdimidine Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Sulpdimidine IP 5000 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Trimethoprim & | Each uncoated bolus contains | |
| Sulphamethoxazole Bolus | Trimethoprim IP 400 mg | |
| For Veterinary Use | Sulphamethoxazole IP 2000 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Paracetamol , Nimesulide | Each uncoated bolus contains | |
| & Chlorzoxazone Bolus | Paracetamol IP 1500 mg | |
| For Veterinary Use | Nimesulide BP 400 mg | |
| Approved Date : 19/04/2007 | Chlorzoxazone USP 1000 mg | |
| Colour : Quinoline Yellow | |
| | |
| Ivermectin Tablets | Each uncoated tablet contains | |
| Approved Date : 19/10/2011 | Ivermectin IP 10 mg | |
| Colour : Erythrosine | |
| | |
| Ivermectin Tablets | Each uncoated tablet contains | |
| For Veterinary Use | Ivermectin IP 100 mg | |
| Approved Date : 19/10/2011 | Colour : Sunset Yellow | |
| | |
| Ketoprofen & Paracetamol Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Ketoprofen USP 1500 mg | |
| Approved Date : 19/10/2011 | Paracetamol IP 1500 Mg | |
| | |
| Oxfendazole E Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Oxfendazole IP 2200 mg | |
| Approved Date : 19/10/2011 | Colour: Sunset Yellow FCF | |
| | |
| Oxfendazole Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Oxfendazole IP 150 mg | |
| Approved Date : 19/10/2011 | Colour : Sunset Yellow FCF | |
| | |
| Ascorbic Acid Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Ascorbic Acid IP 100 mg | |
| Excipients q.s. | |
| | |
| Betamethasone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Betamethasone IP 0.50 mg | |
| Excipients q.s. | |
| | |
| Betamethasone Sodium Phosphate | Each uncoated tablet contains : | |
| Tablets IP | Betamethasone Sodium Phosphate IP | |
| Approved Date : 19/04/2007 | Equivalent to Betamethasone 0.50 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Dexamethasone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Dexamethasone IP 0.50 mg | |
| Excipients q.s. | |
| | |
| Erythromycin Stearate | Each uncoated tablet contains : | |
| Tablets IP | Erythromycin Stearate | |
| Approved Date : 19/04/2007 | Equivalent to Erythromycin IP 250 mg | |
| Excipients q.s. | |
| | |
| Folic Acid Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Folic Acid IP 100 mcg | |
| Excipients q.s. | |
| | |
| Griseofulvin Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Griseofulvin IP 125 mg | |
| Excipients q.s. | |
| | |
| Griseofulvin Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Griseofulvin IP 250 mg | |
| Excipients q.s. | |
| | |
| Prednisolone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Prednisolone IP 5 mg | |
| Excipients q.s. | |
| | |
| Prednisolone Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Prednisolone IP 10 mg | |
| Excipients q.s. | |
| | |
| Yeast Tablets B.P.C | Each uncoated tablet contains | |
| Approved Date : 19/04/2007 | Dried Yeast Powder BPC 300 mg | |
| Excipients q.s. | |
| | |
| Erythromycin | Each uncoated tablet contains: | |
| Tablets IP 250 mg. | Erythromycin Estolate | |
| Approved Date : 19/04/2007 | Equivalent to Erythromycin Base IP 250 mg | |
| Excipients q.s. | |
| | |
| Cyanocobalamin Tablets IP | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Cyanocobalamin IP 10 mcg | |
| Excipients q.s. | |
| Colour – Tartrazine & Sunset Yellow FCF. | |
| | |
| Doxycycline Tablets IP | Each film coated tablet contains : | |
| Approved Date : 19/04/2007 | Doxycycline Hyclate LP | |
| Equivalent to Doxycycline 100 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Fluconazole Tablets IP 150 mg. | Each uncoated tablet contains : | |
| Approved Date : 19/04/2007 | Fluconazole USP 150 mg | |
| Excipients q.s. | |
| | |
| Nimesulide & Serratiopeptidase | Each film coated tablet contains : | |
| Tablets | Nimesulide BP 100 mg | |
| Not to be used below 12 years of age | Serratiopeptidase IP 10 mg | |
| Approved Date : 19/04/2007 | (20,000 Uints of Serratiopeptidase As Enteric Coated) | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Methylprednisolone | Each uncoated tablet contains : | |
| Tablets IP 4 mg. | Methylprednisolone IP 4 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Methylprednisolone | Each uncoated tablet contains : | |
| Tablets IP 8 mg. | Methylprednisolone IP 8 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Methylprednisolone | Each uncoated tablet contains : | |
| Tablets IP 16 mg. | Methylprednisolone IP 16 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine/Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Diclofenac Potassium | Each film coated tablet contains : | |
| & Serratiopeptidase Tablets | Diclofenac Potassium IP 50 mg | |
| Approved Date : 19/04/2007 | Serratiopeptidase (As Enteric Coated) IP 10 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red,Iron oxid IP | |
| | |
| Fungal Diastase, Papain , | Each film coated tablet contains : | |
| Simethicone & Niacinamide | Fungal Diastase (1:800) IP 50 mg | |
| With Thiamine Mononitrate , | Papain IP 40 mg | |
| Rivoflavin Tablets | Simethicone IP 50 mg | |
| For Therapeutic Use | Niacinamide 25 mg | |
| Approved Date : 19/04/2007 | Thiamine Mononitrate IP 2.5 mg | |
| Vitamin B2 IP 2.5 mg | |
| Excipients q.s. | |
| Colour – Black Oxide of Iron | |
| | |
| Serratiopeptidase Tablets | Each enteric coated tablet contains : | |
| Approved Date : 19/04/2007 | Serratiopeptidase (20,000 Serratiopeptidase Units) IP 10 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Pyridoxine Hydrochloride | Each uncoated tablet contains : | |
| Tablets IP | Pyridoxine Hydrochloride IP 10 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Azithromycin | Each film coated tablet contains : | |
| Tablets IP 250 mg. | Azithromycin Anhydrous IP 250 mg | |
| Approved Date : 19/04/2007 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| THIAMINE (Mono), Riboflavin | Each film coated tablet contains : | |
| With Cyanocobalamin Tablets | Thiamine Mononitrate IP 1 mg | |
| Riboflavin IP 1 mg | |
| For Prophylactic Use | Cyanocobalamin IP 1 mcg | |
| Approved Date: 05/09/2008 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red, Iron oxide Yellow | |
| | |
| Calcium With Vitamin D3 Tablets | Each uncoated chewable tablet contains : | |
| Approved Date: 05/09/2008 | Tribasic Calcium Phosphate IP 380 mg | |
| Vitamin D3 IP 400 IU | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red iron oxide Yellow | |
| | |
| Thiamine (Mono), Riboflavin | Each film coated tablet contains : | |
| Pyridoxine Hydrochloride | Thiamine Mononitrate IP 10 mg | |
| Cyanocobalamin , Naicinamide With | Riboflavin IP 10 mg | |
| Calcium Panthothenate Tablets | Pyridoxine Hydrochloride IP 3 mg | |
| For Therapeutic Use | Cyanocobalamin IP 15 mcg | |
| Approved Date: 05/09/2008 | Naicinamide IP 45 mg | |
| Calcium Panthothenate IP 50 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Calcium Carbonate With | Each film coated tablet contains : | |
| Vitamin D 3 Tablets | 1.25 gm. Of Calcium Carbonate from an Organic | |
| Approved Date: 05/09/2008 | Source (Osystershell) eq. to Elemental Calcium 500 mg | |
| Vitamin D 3 IP 250 IU | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Folic Acid Tablets IP | Each uncoated tablet contains : | |
| Approved Date: 05/09/2008 | Folic Acid IP 5 mg | |
| Excipients q.s. | |
| | |
| Vitamin B-Complex Tablets | Each film coated tablet contains : | |
| For Prophylactic Use | Vitamin B1 IP 2 mg | |
| Approved Date: 05/09/2008 | Vitamin B2 IP 2 mg | |
| Vitamin B6 IP 0.50 mg | |
| Naicinamide IP 25 mg | |
| Calcium Panthothenate IP 1 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Erythromycin Estolate | Each uncoated tablet contains : | |
| Tablets IP 500 mg. | Erythromycin Estolate | |
| Approved Date: 05/12/2008 | Eq. to Erythromycin Base IP 500 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Norfloxacin With | Each film coated tablet contains : | |
| Lactic Acid Bacillus Tablets | Norfloxacin IP 400 mg | |
| Approved Date: 05/12/2008 | Lactic Acid Bacillus 90 ms. | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red,Iron oxide Yellow | |
| | |
| Thiamine (Mono), Riboflavine | Each film coated tablet contains : | |
| Pyridoxine Hydrochloride, | Vitamin B 1 Mononitrate IP 2 mg | |
| Cynocobalamin, Naicinamide | Vitamin B 2 IP 2 mg | |
| Calcium Panthothenate Tablets | Vitamin B6 IP 1 mg | |
| For Prophylactic Use | Vitamin B 12 IP 1 mcg | |
| Approved Date : 26/05/2009 | Naicinamide IP 15 mg | |
| Calcium Panthothenate IP 5 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Chloramphenicol Tablets | Each sugar coated tablet contains : | |
| Approved Date : 25/03/2010 | Chloramphenicol IP 250 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red, Iror oxide Yellow | |
| | |
| Roxithromycin Tablets IP | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Roxithromycin IP 150 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Fungal Diastase, Papain With | Each film coated tablet contains : | |
| Activated Charcoal Tablets | Fungal Diastase (1:800) IP 50 mg | |
| Approved Date : 25/03/2010 | Papain IP 40 mg | |
| Activated Charcoal IP 75 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Erythromycin Stearate Tablets IP | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Erythromycin Stearate IP | |
| Eq. to Erythromycin 500 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Erythromycin Estolate Tablets IP | Each film coated tablet contains : | |
| Approved Date : 25/03/2010 | Erythromycin Estolate | |
| Equivalent to Erythromycin Base IP 500 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red,Iron oxide Yellow | |
| | |
| Vitamin C Chewable Tablets IP | Each uncoated chewable tablet contains : | |
| Approved Date : 25/03/2010 | Vitamin C IP 100 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Riboflavin Tablets IP | Each uncoated tablet contains : | |
| For Therapeutic Use | Riboflavin IP 10 mg | |
| Approved Date : 25/03/2010 | Excipients q.s. | |
| | |
| Thiamine (Mono), Riboflavine | Each film coated tablet contains : | |
| Pyridoxine Hydrochloride | Thiamine Monoitrate IP 4.5 mg | |
| Cyanocobalamin , Naicinamide | Riboflavine IP 5 mg | |
| With Folic Acid & | Nicotinamide IP 45 mg | |
| Calcium Panthothenate Tablets | Pyridoxine Hydrochloride IP 1.5 mg | |
| For Therapeutic Use | Calcium Pantothenate IP 5 mg | |
| Approved Date: 13/10/2010 | Cyanocobalamin IP 5 mcg | |
| Folic Acid IP 1 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Thiamine (Mono), Riboflavine | Each film coated tablet contains : | |
| Pyridoxine Hydrochloride | Thiamine Monoitrate IP 1 mg | |
| Cyanocobalamin , Naicinamide | Riboflavine IP 1 mg | |
| With Folic Acid & | Pyridoxine Hydrochloride IP 0.5 mg | |
| Calcium Panthothenate Tablets | Cyanocobalamin IP 0.5 mcg | |
| For Prophylactic Use | Naicinamide IP 5 mg | |
| Approved Date : 27/06/2013 | Folic Acid IP 0.3 mg | |
| Calcium Panthothenate IP 2 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Aceclofenac , Paracetamol | Each film coated tablet contains : | |
| & Serratiopeptidas Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 08/01/2014 | Paracetamol IP 325 mg | |
| Serratiopeptidase (An enteric coated) IP 10 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Aceclofenac , Paracetamol | Each film coated tablet contains : | |
| & Serratiopeptidas Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 08/01/2014 | Paracetamol IP 325 mg | |
| Serratiopeptidase (An enteric coated) IP 15 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Aceclofenac & | Each film coated tablet contains : | |
| Serratiopeptidase Tablets | Aceclofenac IP 100 mg | |
| Approved Date : 08/01/2014 | Serratiopeptidase IP 10 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red Iron oxide Yellow | |
| | |
| Vitamin C Chewable Tablets IP | Each uncoated chewable tablet contains : | |
| Approved Date : 08/01/2014 | Ascorbic Acid IP 500 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Diclofenac Potasium , Paracetamol | Each film coated tablet contains : | |
| & Serratiopeptidase Tablets | Diclofenac Potasium IP 50 mg | |
| Approved Date : 08/01/2014 | Paracetamol IP 325 mg | |
| Serratiopeptidase ( An enteric coated) IP 10 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Roxithromycin | Each ucoated dispersible tablet contains : | |
| Dispersible Tablets IP | Roxithromycin IP 50 mg | |
| Approved Date : 28/06/2014 | Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green/Iron oxide red,Iron oxide Yellow | |
| | |
| Protine, Calcium, Multivitamins, | Each 30 g contains : | |
| DHA, Iron & Zinc Powder | Protine (Whey Protine 20% ) 5 g | |
| Approved Date : 21/11/2014 | DHA 10 % 25 mg | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Vitamin D3 (As Cholecalciferol) IP 100 IU | |
| Folic Acid IP 300 mcg | |
| Naicinamide IP 15 mg | |
| Calcium (As Dibasic Calcium Phosphate Dihydrate) IP 200 mg | |
| Manganese (As Sulphate) USP 1.5 mcg | |
| Zinc ( As Zinc Sulphate) USP 1.5 mg | |
| Iron (Ferric Ammonium Citrate ) IP 10 mg | |
| Magnesium Oxide IP 4 mg | |
| Cupperic Sulphate USP 2.5 mg | |
| Chromium (As Chromium Chloride) IP 25 mg | |
| Selenium Dioxide Monohydrate USP 20 mcg | |
| Potassium Chloride IP 5 mg | |
| Sodium Chloride IP 33 mg | |
| lodine (As Potassium lodide) IP 100 mcg | |
| Excipients q.s. | |
| | |
| Protine With Multivitamins, | Each 30 g contains : | |
| Multiminerals &Lycoene Powder | Protine (Whey Protine 20% ) 5 g | |
| Approved Date : 21/11/2014 | Calcium Phosphorous ( Derived from IP 225 mg | |
| Dibasic Calcium Phosphate Dihydrate) 174 mg | |
| Lycoene 6 % USP 2000 mcg | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Vitamin D3 (As Cholecalciferol) IP 100 IU | |
| Folic Acid IP 0.3 mg | |
| Naicinamide IP 15 mg | |
| Manganese (As Sulphate) USP 1.5 mcg | |
| Zinc (As Zinc Sulphate) USP 5 mg | |
| Iron (Ferric Ammonium Citrate ) IP 7.5 mg | |
| Magnesium Oxide IP 4 mg | |
| Cupperic Sulphate USP 2.5 mg | |
| Chromium (As Chromium Chloride) IP 25 mg | |
| Selenium Dioxide Monohydrate USP 20 mcg | |
| Potassium Chloride IP 5 mg | |
| Sodium Chloride IP 33 mg | |
| lodine (As Potassium lodide) IP 100 mcg | |
| Excipients q.s. | |
| | |
| Multivitamins, Multiminerals | Each film coated tablet contains : | |
| With Ginseng Tablets | Vitamin A IP 250 mcg | |
| Approved Date : 21/11/2014 | Vitamin B 1 Mononitrate IP 1 mg | |
| Vitamin B 2 IP 1.5 mg | |
| Vitamin B3 IP 10 mg | |
| Vitamin B6 IP 1 mg | |
| Vitamin B 12 IP 1 mcg | |
| Vitamin D3 (As Cholecalciferol) IP 5 IU | |
| Vitamin E IP 1.25 mg | |
| Folic Acid IP 0.15 mg | |
| Biotin 30 mcg | |
| Zinc ( As Zinc Sulphate) USP 15 mg | |
| lodine (As Potassium lodide) IP 0.15 mg | |
| Carbonyl Iron 30 mg | |
| Maganesium Sulphate IP 100 mg | |
| Manganese USP 2.5 mg | |
| Copper USP 2 mg | |
| Calcium IP 250 mg | |
| Phosphorous 125 mg | |
| Potassium 40 mg | |
| Chloride IP 36.3 mg | |
| Selenium USP 30 mcg | |
| Nickel IP 5 mcg | |
| Silicon USP 2 mg | |
| Vanadium IP 10 mcg | |
| Boron IP 150 mcg | |
| Chromium 25 mcg | |
| Tin 10 mcg | |
| Ginseng extract powder 21.25 mg | |
| Excipients q.s. | |
| | |
| Deflazacort Tablets | Each uncoated tablet contains : | |
| Approved Date : 20/07/2016 | Deflazacort IP 6 mg | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Diclofenac Potassium & | Each enteric coated tablet contains : | |
| Trypsin Chymotrypsin Tablets | Diclofenac Potassium BP 50 mg | |
| Approved Date : 20/07/2016 | 5000 Armour units of enzymatic activity | |
| (Supplied by a purified concentrate which | |
| specific Trypsin & Chymotrypsin IP activity | |
| in a ratio of approximate 6:1 ) | |
| Excipients q.s. | |
| Colour: Brilliant Blue / Erythrosine / Tartrazine / Quinoline Yellow / Sunset yellow | |
| or Titanium Dioxide IP /Apple Green / Iron oxide red, Iron oxide Yellow | |
| | |
| Ofloxacin With | Each film coated tablet contains : | |
| Lactic Acid Bacillus Tablets | Ofloxacin IP 200 mg | |
| Approved Date : 19/04/2007 | Lactic Acid Bacillus IP 60 ml s.p. | |
| Approved Color to be use in Tablet | |
| | |
| Prednisolone Tablets IP | Each uncoated tablet contains | |
| Approved Date : 26/05/2009 | Prednisolone IP 20 mg | |
| | |
| Thiamine (Mono), Riboflavine , | Each film coated tablet contains : | |
| Nicotinamide & Pyridoxine Hcl, | Thiamine Monoitrate IP 5 mg | |
| Calcium Pantothenate, | Riboflavine IP 5 mg | |
| With Cyanocobalamin | Nicotinamide IP 50 mg | |
| Foilc Acid Tablets | Pyridoxine Hydrochloride IP 1.5 mg | |
| For Therapeutic Use | Calcium Pantothenate IP 10 mg | |
| Approved Date : 11/12/2009 | Cyanocobalamin IP 5 mcg | |
| Foilc Acid IP 1000 mcg | |
| Approved Color to be use in Tablet | |
| | |
| Azithromycin | Each film coated tablet contains : | |
| Tablets IP 500 mg. | Azithromycin Anhydrous IP 500 mg | |
| Approved Date : 28/06/2014 | Excipients q.s. | |
| Approved Color to be use in Tablet | |
| | |
| Thiamine (Mono), Riboflavine , | Each film coated tablet contains : | |
| Nicotinamide & Pyridoxine Hcl, | Thiamine Monoitrate IP 10 mg | |
| Calcium Pantothenate, | Riboflavine IP 5 mg | |
| With Cyanocobalamin | Nicotinamide IP 100 mg | |
| Tablets | Pyridoxine Hydrochloride IP 3 mg | |
| For Therapeutic Use | Calcium Pantothenate IP 50 mg | |
| Approved Date : 27/03/2012 | Cyanocobalamin IP 15 mcg | |
| Excipients q.s. | |
| Approved Color to be use in Tablet | |
| | |
| Antioxident, Multivitamins, | Each film coated tablet contains : | |
| With Multiminerals Tablets | Vitamin A Acetate IP 5000 IU | |
| For Therapeutic Use | Folic Acid IP 1 mg | |
| Approved Date : 27/03/2012 | Vitamin E Acetate IP 25 mg | |
| Thiamine Monoitrate IP 10 mg | |
| Riboflavine IP 10 mg | |
| Pyridoxine Hydrochloride IP 3 mg | |
| Nicotinamide IP 50 mg | |
| Cyanocobalamin IP 5 mcg | |
| Calcium Pantothenate IP 12.5 mg | |
| Vitamin C IP 100 mg | |
| Zinc Sulphate IP | |
| Eq. to. Elemental Zinc 15 mg | |
| Copper Sulphate IP | |
| Eq. to. Elemental Copper 1.6 mg | |
| Manganese Gluconate USP 1.4 mg | |
| Selenium Selenite USP | |
| Eq. to Selenium 60 mcg | |
| Approved Color used in Tablet | |
| | |
| Diclofenac Potasium, | Each film coated tablet contains : | |
| Paracetamol & | Diclofenac Potasium IP 50 mg | |
| Serratiopeptidase Tablets | Paracetamol IP 250 mg | |
| Approved Date : 21/11/2014 | Serratiopeptidase ( An enteric coated) IP 10 mg | |
| Excipients q.s. | |
| Approved Color to be use in Tablet | |
| | |
| Lycopene, Protine, | Each 100 g contains : | |
| Amino Acids With Multivitamins | Lycopene 6% USP 6000 mcg | |
| Multiminerals Powder | Protine (Whey Protine 20% ) 40 g | |
| Approved Date : 21/11/2014 | Carbohydrate 60 g | |
| Fat (Less than ) 2 g | |
| Glutamic Acid 10 mg | |
| Vitamin A 3000 IU | |
| Vitamin D3 (As Cholecalciferol) 300 IU | |
| Thiamine Monoitrate IP 3 mg | |
| Riboflavine IP 3 mg | |
| Pyridoxine Hydrochloride IP 2 mg | |
| Methylocabalamine IP 50 mcg | |
| Vitamin C IP 50 mg | |
| Vitamin E IP 5 mg | |
| Folic Acid IP 1 mg | |
| Calcium Pantothenate IP 3 mg | |
| Naicinamide IP 30 mg | |
| Calcium 1000 mg | |
| Phosphorous 425 mg | |
| Magnesium Sulphate IP 12 mg | |
| Manganese (As Sulphate) USP 50 mcg | |
| Zinc (As Zinc Sulphate) USP 10.0mg | |
| Carbonyl Iron IP 20 mg | |
| Magnesium Oxide IP 4 mg | |
| Copper 2.5 mg | |
| Chromium (As Sulphate) IP 75 mcg | |
| Selenium Dioxide Monohydrate USP 60 mcg | |
| lodine ( As Potassium lodide ) IP 0.1 mg | |
| Excipients q.s. | |
| | |
| Oxytetracycline Bolus | Each uncoated bolus contains | |
| For Veterinary Use | Oxytetracycline Hcl IP 500 mg | |
| Approved Date : 19/04/2007 | | |
| | |
| Methylcobalmine, | Each hard gelatin capsule contains | |
| Alpha Lipoic Acid, Biotin | Methylcobalmine IP 1500 mcg | |
| & Folic Acid, Pyridoxine Hcl, | Alpha Lipoic Acid 200 mg | |
| Vitamin D3 | Biotin IP 200 mcg | |
| Tablets | Folic Acid IP 1500 mcg | |
| For Prophylactic Use | Pyridoxine HCl IP 3 mg | |
| Vitamin D3 IP 1000 IU | |
| | |
| Gliclazide and Rosiglitazone with | Each uncoated tablet contains : | |
| Metformin HCl Tablets | Gliclazide IP 40 mg | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Metformin HCl IP 500 mg | |
| Approved colour to used | |
| | |
| Gliclazide and Rosiglitazone with | Each uncoated tablet contains : | |
| Metformin HCl Tablets | Gliclazide IP 80 mg | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 2 mg | |
| Metformin HCl IP 500 mg | |
| Approved colour to used | |
| | |
| Rosiglitazone and Metformin HCl | Each uncoated tablet contains : | |
| Tablets | Metformin HCl IP 500 mg | |
| Rosiglitazone Maleate | |
| Eq. to Rosiglitazone 1 mg | |
| Approved colour to used | |
| | |
| Gliclazide, Metformin HCl and | Each uncoated tablet contains | |
| Pioglitzone Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 80 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Bilastine & Montelukast Tablets | Each film coated tablet contains : | |
| Blistine 20 mg | |
| Montelukast Sodium IP | |
| eq. to Montelukast 10 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Citicoline Sodium Tablets IP | Each film coated tablet contains : | |
| Citicoline Sodium IP | |
| Eq. to Citicoline 500 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Citicoline Sodium and Piracetam | Each film coated tablet contains : | |
| Tablets | Citicoline Sodium IP | |
| Eq. to Citicoline 500 mg | |
| Piracetam IP 800 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Citicoline Sodium and Piracetam | Each film coated tablet contains : | |
| Tablets | Citicoline Sodium IP | |
| Eq. to Citicoline 500 mg | |
| Piracetam IP 400 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Piracetam Tablets | Each film coated tablet contains : | |
| Piracetam IP 800 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Tapentadol Hydrochloride and | Each uncoated tablet contains | |
| Carisoprodol Tablets | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 125 mg | |
| Carisoprodol IP 100 mg | |
| Excipients q.s. | |
| | |
| Acetylcysteine 600 mg | Each Effervescent tablet contains : | |
| Effervescent Tablets | Acetylcysteine BP 600 mg | |
| Excipients q.s. | |
| | |
| | |
| Acetylcysteine and Ambroxol HCl | Each film coated tablet contains : | |
| Tablets | Acetylcysteine BP 200 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Acetylcysteine and Ambroxol HCl | Each film coated tablet contains : | |
| Tablets | Acetylcysteine BP 300 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Tolperisone Hydrochloride | Each Sustained Release tablet contains : | |
| Sustained Release Tablets | Tolperisone Hydrochloride JP 450 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Paracetamol, Guaiphenesin | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate, | Paracetamol IP 450 mg | |
| Phenylephrine Hydrochloride and | Guaiphenesin IP 50 mg | |
| Bromhexine HCl Tablets | Chlorpheniramine Maleate IP 4 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Bromhexine Hydrochloride IP 4 mg | |
| Approved colour to used | |
| | |
| Hydroxyzine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Hydroxyzine Hydrochloride IP 25 mg | |
| Approved colour to used | |
| | |
| Hydroxyzine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Hydroxyzine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Duloxetine Gastro-Resistant Tablets IP | Each enteric coated tablet contains : | |
| Duloxetine Hydrochloride IP | |
| Eq. to Duloxetine 20 mg | |
| Approved color to be use | |
| | |
| Duloxetine Gastro-Resistant Tablets IP | Each enteric coated tablet contains : | |
| Duloxetine Hydrochloride IP | |
| Eq. to Duloxetine 30 mg | |
| Approved color to be use | |
| | |
| Duloxetine Gastro-Resistant Tablets IP | Each enteric coated tablet contains : | |
| Duloxetine Hydrochloride IP | |
| Eq. to Duloxetine 40 mg | |
| Approved color to be use | |
| | |
| Escitalopram Tablets IP | Each uncoated tablet contains : | |
| Escitalopram Oxalate IP | |
| Eq. to Escitalopram 10 mg | |
| Approved colour to used | |
| | |
| Escitalopram Tablets IP | Each uncoated tablet contains : | |
| Escitalopram Oxalate IP | |
| Eq. to Escitalopram 20 mg | |
| Approved colour to used | |
| | |
| Ramipril Tablets IP | Each uncoated tablets contains : | |
| Ramipril IP 5 mg | |
| | |
| Etizolam & Escitalopram Tablets | Each uncoated tablets contains | |
| Etizolam IP 0.5 mg | |
| Escitalopram Oxalate IP | |
| Eq. to Escitalopram 10 mg | |
| Approved color to be use | |
| | |
| Prulifloxacin Tablets | Each film coated tablets contains: | |
| Prulifloxacin HCl 600 mg | |
| Approved color to be use | |
| | |
| Terbinafine Hydrochloride Tablets IP | Each uncoated tablet contains : | |
| Terbinafine Hydrochloride IP | |
| Eq. to Terbinafine 250 mg | |
| Approved colour to used | |
| | |
| Tinidazole Tablets IP 500 mg | Each film coated tablet contains : | |
| Tinidazole IP 500 mg | |
| Approved colour to used | |
| | |
| Apixaban Tablets | Each film coated tablet contains : | |
| Apixaban 2.5 mg | |
| Approved colour to used | |
| | |
| Apixaban Tablets | Each film coated tablet contains : | |
| Apixaban 5 mg | |
| Approved colour to used | |
| | |
| Warfarin Sodium Tablets IP 3 mg | Each uncoated tablet contains : | |
| Warfarin Sodium IP 3 mg | |
| Approved colour to used | |
| | |
| Warfarin Sodium Tablets IP 5 mg | Each uncoated tablet contains : | |
| Warfarin Sodium IP 5 mg | |
| Approved colour to used | |
| | |
| Warfarin Sodium Tablets IP 10 mg | Each uncoated tablet contains : | |
| Warfarin Sodium IP 10 mg | |
| Approved colour to used | |
| | |
| Ticagrelor Tablets IP 90 mg | Each film coated tablet contains : | |
| Ticagrelor IP 90 mg | |
| Approved colour to used | |
| | |
| Prasugrel Tablets IP 5 mg | Each film coated tablet contains : | |
| Prasugrel Hydrochloride IP | |
| Eq. to Prasugrel 5 mg | |
| Approved colour to used | |
| | |
| Prasugrel Tablets IP 10 mg | Each film coated tablet contains : | |
| Prasugrel Hydrochloride IP | |
| Eq. to Prasugrel 10 mg | |
| Approved colour to used | |
| | |
| Nicoumalone Tablets IP 1 mg | Each uncoated tablet contains : | |
| Nicoumalone IP 1 mg | |
| Approved colour to used | |
| | |
| Nicoumalone Tablets IP 2 mg | Each uncoated tablet contains : | |
| Nicoumalone IP 2 mg | |
| Approved colour to used | |
| | |
| Nicoumalone Tablets IP 3 mg | Each uncoated tablet contains : | |
| Nicoumalone IP 3 mg | |
| Approved colour to used | |
| | |
| Nicoumalone Tablets IP 4 mg | Each uncoated tablet contains : | |
| Nicoumalone IP 4 mg | |
| Approved colour to used | |
| | |
| Roflumilast Tablets 500 mcg | Each uncoated tablet contains : | |
| Roflumilast IP 500 mcg | |
| | |
| Tadalafil With Dapoxetine Tablets | Each film coated tablet contains : | |
| Tadalafil IP 10 mg | |
| Dapoxetine Hydrochloride IP | |
| eq. to Dapoxetine 30 mg | |
| Approved colour to used | |
| | |
| Glipizide Tablets IP 5 mg | Each uncoated tablet contains : | |
| Glipizide IP 5 mg | |
| | |
| Glipizide Tablets 10 mg | Each uncoated tablet contains : | |
| Glipizide IP 10 mg | |
| | |
| Dapagliflozin Tablets 10 mg | Each film coated tablet contains : | |
| Dipagliflozin IP 10 mg | |
| Approved colour to used | |
| | |
| Doxofylline Tablets 200 mg | Each uncoated tablet contains : | |
| Doxofylline IP 200 mg | |
| Approved colour to be use | |
| | |
| Doxofylline and Ambroxol HCl | Each uncoated tablet contains : | |
| Tablets | Doxofylline IP 400 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Approved colour to be use | |
| | |
| Doxofylline and Acebrophylline | Each uncoated tablet contains : | |
| Tablets | Doxofylline IP 400 mg | |
| Acebrophylline IP 100 mg | |
| Approved colour to be use | |
| | |
| Tramadol HCl Tablets | Each film coated tablet contains : | |
| Tramadol Hydrochloride IP 100 mg | |
| Approved colour to used | |
| | |
| Aceclofenac and Paraceamol Tablets | Each film coated tablet contains : | |
| Aceclofenac IP 50 mg | |
| Paracetamol IP 250 mg | |
| Approved colour to used | |
| | |
| Diacerein with Glucosamine Tablets | Each film coated tablet contains : | |
| Diacerein IP 50 mg | |
| Glucosamine Sulphate Potassium Chloride USP 500 mg | |
| Approved colour to be use | |
| | |
| Diacerein with Glucosamine Tablets | Each film coated tablet contains : | |
| Diacerein IP 50 mg | |
| Glucosamine Sulphate Potassium Chloride USP 750 mg | |
| Approved colour to be use | |
| | |
| Acebrophylline Sustained Release | Each uncoated Sustained Release tablet contains : | |
| Tablets 200 mg | Acebrophylline 200 mg | |
| Approved colour to be use | |
| | |
| Tolperisone Hydrochloride | Each film coated tablet contains : | |
| Tablets 50 mg | Tolperisone Hydrochloride JP 50 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Tolperisone Hydrochloride | Each film coated tablet contains : | |
| Tablets 100 mg | Tolperisone Hydrochloride JP 100 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Tolperisone Hydrochloride | Each film coated tablet contains : | |
| Tablets 150 mg | Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Drotaverine Tablets IP | Each film coated tablet contains : | |
| Drotaverine Hydrochloride IP 40 mg | |
| Approved coloured used | |
| | |
| Oxcarbazepine Tablets IP 150 mg | Each film coated tablet contains : | |
| Oxcarbazepine IP 150 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Oxcarbazepine Tablets IP 300 mg | Each film coated tablet contains : | |
| Oxcarbazepine IP 300 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Oxcarbazepine Tablets IP 450 mg | Each film coated tablet contains : | |
| Oxcarbazepine IP 450 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Oxcarbazepine Tablets IP 600 mg | Each film coated tablet contains : | |
| Oxcarbazepine IP 600 mg | |
| Excipients q.s | |
| Approved colour to used | |
| | |
| Paroxetine Tablets IP 10 mg | Each film coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| eq. to Paroxetine 10 mg | |
| Approved colour to used | |
| | |
| Paroxetine Tablets IP 20 mg | Each film coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| eq. to Paroxetine 20 mg | |
| Approved colour to used | |
| | |
| Paroxetine Tablets IP 30 mg | Each film coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| eq. to Paroxetine 30 mg | |
| Approved colour to used | |
| | |
| Amiloride Hydrochloride and | Each uncoated tablet contains : | |
| Hydrochlorothiazide Tablets IP | Amiloride Hydrochloride IP | |
| Eq. to Anhydrous Amiloride Hydrochloride 2.5 mg | |
| Hydrochlorothiazide 25 mg | |
| Approved colour to used | |
| | |
| Amiloride Hydrochloride and | Each uncoated tablet contains : | |
| Hydrochlorothiazide Tablets IP | Amiloride Hydrochloride IP | |
| Eq. to Anhydrous Amiloride Hydrochloride 5 mg | |
| Hydrochlorothiazide IP 50 mg | |
| Approved colour to used | |
| | |
| Amiloride Hydrochloride Tablets IP | Each uncoated tablet contains : | |
| Amiloride Hydrochloride IP | |
| Eq. to Anhydrous Amiloride Hydrochloride 5 mg | |
| Approved colour to used | |
| | |
| Isoniazid Tablets IP 300 mg | Each filmcoated tablet contains : | |
| Isoniazid IP 300 mg | |
| Approved colour to used | |
| | |
| Isoniazid Tablets IP 100 mg | Each filmcoated tablet contains : | |
| Isoniazid IP 100 mg | |
| Approved colour to used | |
| | |
| Isoniazid Tablets IP 50 mg | Each filmcoated tablet contains : | |
| Isoniazid IP 50 mg | |
| Approved colour to used | |
| | |
| Amodiaquine Hydrochloride Tablets IP | Each uncoated tablet contains : | |
| Amodiaquine Hydrochloride IP | |
| Eq. to Amodiaquine 200 mg | |
| Approved colour to used | |
| | |
| Diiodohydroxyquinoline | Each uncoated tablet contains : | |
| Tablets IP 300 mg | Diiodohydroxyquinoline IP 300 mg | |
| Approved colour to used | |
| | |
| Diiodohydroxyquinoline | Each uncoated tablet contains : | |
| Tablets IP 600 mg | Diiodohydroxyquinoline IP 600 mg | |
| Approved colour to used | |
| | |
| Diloxanide Furoate Tablets IP 500 mg | Each uncoated tablet contains : | |
| Diloxanide Furoate IP 500 mg | |
| Approved colour to used | |
| | |
| Diloxanide Furoate and Tinidazole | Each uncoated tablet contains : | |
| Tablets | Diloxanide Furoate IP 150 mg | |
| Tinidazole IP 250 mg | |
| Approved colour to used | |
| | |
| Diloxanide Furoate and Metronidazole | Each uncoated tablet contains : | |
| Tablets | Diloxanide Furoate IP 500 mg | |
| Metronidazole IP 400 mg | |
| Approved colour to used | |
| | |
| Irbesartan Tablets IP 150 mg | Each uncoated tablet contains : | |
| Irbesartan IP 150 mg | |
| Approved colour to used | |
| | |
| Irbesartan Tablets IP 300 mg | Each uncoated tablet contains : | |
| Irbesartan IP 300 mg | |
| Approved colour to used | |
| | |
| Irbesartan and Hydrochlorothiazide | Each uncoated tablet contains : | |
| Tablets IP | Irbesartan IP 150 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Approved colour to used | |
| | |
| Irbesartan and Hydrochlorothiazide | Each uncoated tablet contains : | |
| Tablets IP | Irbesartan IP 300 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Approved colour to used | |
| | |
| Irbesartan Tablets 75 mg | Each uncoated tablet contains : | |
| Irbesartan IP 75 mg | |
| Approved colour to used | |
| | |
| Imipramine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP 25 mg | Imipramine Hydrochloride IP 25 mg | |
| Approved colour to used | |
| | |
| Imipramine Hydrochloride | Each film coated tablet contains : | |
| Tablets IP 10 mg | Imipramine Hydrochloride IP 10 mg | |
| Approved colour to used | |
| | |
| Meloxicam Tablets | Each uncoated tablet contains : | |
| Meloxicam IP 7.5 mg | |
| Approved colour to used | |
| | |
| Meloxicam Tablets | Each uncoated tablet contains : | |
| Meloxicam IP 15 mg | |
| Approved colour to used | |
| | |
| Glibenclamide and Metformin HCl | Each uncoated tablet contains : | |
| Tablets IP | Glibenclamide IP 5 mg | |
| Metformin HCl IP 500 mg | |
| Approved colour used | |
| | |
| Glibenclamide and Metformin HCl | Each uncoated tablet contains : | |
| Tablets IP | Glibenclamide IP 2.5 mg | |
| Metformin HCl IP 400 mg | |
| Approved colour used | |
| | |
| Glibenclamide and Metformin HCl | Each uncoated tablet contains : | |
| Sustained Release Tablets | Glibenclamide IP 5 mg | |
| Metformin HCl (As Sustained Release) IP 500 mg | |
| Approved colour used | |
| | |
| Glibenclamide and Metformin HCl | Each uncoated tablet contains : | |
| Sustained Release Tablets | Glibenclamide IP 2.5 mg | |
| Metformin HCl (As Sustained Release) IP 500 mg | |
| Approved colour used | |
| | |
| Levocetirizine Hydrochloride Tablets | Each film coated tablet contains : | |
| Levocetirizine Hydrochloride IP 10 mg | |
| Approved colour used | |
| | |
| Piroxicam Tablets IP | Each uncoated tablet contains : | |
| Piroxicam IP 20 mg | |
| Approved colour to used | |
| | |
| Sulpiride Tablets IP 100 mg | Each uncoated tablet contains : | |
| Sulpiride IP 100 mg | |
| Approved colour to used | |
| | |
| Sulpiride Tablets IP 200 mg | Each uncoated tablet contains : | |
| Sulpiride IP 200 mg | |
| Approved colour to used | |
| | |
| Sulpiride Tablets IP 400 mg | Each uncoated tablet contains : | |
| Sulpiride IP 400 mg | |
| Approved colour to used | |
| | |
| Levosulpiride Sustained Released | Each uncoated Sustained Released tablet contains : | |
| Tablets | Levosulpiride 75 mg | |
| | |
| Levosulpiride Sustained Released | Each uncoated Sustained Released tablet contains : | |
| Tablets | Levosulpiride 150 mg | |
| | |
| Levosulpiride Sustained Released | Each uncoated Sustained Released tablet contains : | |
| Tablets | Levosulpiride 200 mg | |
| | |
| Paracetamol, Phenylephrine HCl and | Each uncoated tablet contains : | |
| Chlorpheniramine Maleate Tablets | Paracetamol IP 325 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Approved colour to used | |
| | |
| Levocetirizine Hydrochloride and | Each uncoated dispersible tablet contains : | |
| Montelukast dispersible Tablets | Levocetirizine Hydrochloride IP 2.5 mg | |
| Montelukast Sodium IP | |
| Eq. to Montelukast 5 mg | |
| Approved colour used | |
| | |
| Levocetirizine Hydrochloride and | Each uncoated tablet contains : | |
| Montelukast Tablets | Levocetirizine Hydrochloride IP 2.5 mg | |
| Montelukast Sodium IP | |
| Eq. to Montelikast 5 mg | |
| Approved colour used | |
| | |
| Doxofylline Sustained Released and | Each uncoated Sustained Released tablet contains : | |
| Montelukast Tablets | Doxofylline IP 400 mg | |
| Montelukast Sodium IP | |
| Eq. to Montelukast 10 mg | |
| Approved colour to be use | |
| | |
| Doxofylline Sustained Released and | Each uncoated Sustained Released tablet contains : | |
| Montelukast Tablets | Doxofylline IP 800 mg | |
| Montelukst Sodium IP | |
| Eq. to Montelukast 10 mg | |
| Approved colour to be use | |
| | |
| Warfarin Sodium Tablets IP 1 mg | Each uncoated tablet contains : | |
| Warfarin Sodium IP 1 mg | |
| Approved colour to used | |
| | |
| Warfarin Sodium Tablets 4 mg | Each uncoated tablet contains : | |
| Warfarin Sodium IP 4 mg | |
| Approved colour to used | |
| | |
| Nicorandil Tablets IP 10 mg | Each uncoated tablet contains : | |
| Nicorandil IP 10 mg | |
| Approved colour to used | |
| | |
| Nicorandil Tablets IP 20 mg | Each uncoated tablet contains : | |
| Nicorandil IP 20 mg | |
| Approved colour to used | |
| | |
| Apixaban Tablets 2.5 mg | Each film coated tablet contains : | |
| Apixaban IP 2.5 mg | |
| Approved colour to used | |
| | |
| Apixaban Tablets 5 mg | Each film coated tablet contains : | |
| Apixaban IP 5 mg | |
| Approved colour to used | |
| | |
| Paroxetine Hydrochloride Tablets | Each film coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| Eq. to Paroxetine 40 mg | |
| Approved colour to be use | |
| | |
| Paroxetine Prolonged Release Tablets | Each Enteric coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| Eq. to Paroxetine 12.5 mg | |
| Approved colour to be use | |
| | |
| Paroxetine Prolonged Release Tablets | Each Enteric coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| Eq. to Paroxetine 25 mg | |
| Approved colour to be use | |
| | |
| Paroxetine Prolonged Release Tablets | Each Enteric coated tablet contains : | |
| Paroxetine Hydrochloride IP | |
| Eq. to Paroxetine 37.5 mg | |
| Approved colour to be use | |
| | |
| Pregabalin Sustained Release Tablets | Each uncoated tablet contains : | |
| Pregabaline IP 75 mg | |
| Approved colour to be use q.s | |
| | |
| Pregabalin Sustained Release Tablets | Each uncoated tablet contains : | |
| Pregabaline IP 150 mg | |
| Approved colour to be use | |
| | |
| Pregabalin Sustained Release Tablets | Each uncoated tablet contains : | |
| Pregabaline IP 300 mg | |
| Approved colour to be use | |
| | |
| Albendazole and Ivermectin | Each uncoated tablet contains : | |
| Tablets | Albendazole IP 400 mg | |
| lvermectin IP 6 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HCl (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| (As sustained release) | |
| Glimepiride IP 3 mg | |
| Voglibose IP 0.3 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HCl (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Glimepiride IP 3 mg | |
| Voglibose IP .03 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HCl (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Glimepiride IP 2 mg | |
| Voglibose IP 0.2 mg | |
| Approved coloured used | |
| | |
| Glimepiride, Metformin HCl (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Glimepiride IP 1 mg | |
| Voglibose IP 0.2 mg | |
| Approved coloured used | |
| | |
| Etizolam Mouth Dissoving Tablets | Each uncoated tablets contains | |
| Etizolam IP 0.25 mg | |
| Approved color to be use | |
| | |
| Etizolam Mouth Dissoving Tablets | Each uncoated tablets contains | |
| Etizolam IP 0.5 mg | |
| Approved color to be use | |
| | |
| Etizolam Mouth Dissoving Tablets | Each uncoated tablets contains | |
| Etizolam IP 1 mg | |
| Approved color to be use | |
| | |
| Glimepiride and Metformin HCl | Each uncoated tablet contains | |
| Tablets | Metformin Hydrochloride IP 500 mg | |
| Glimepiride IP 1 mg | |
| Approved coloured used | |
| | |
| Glimepiride and Metformin HCl | Each uncoated tablet contains | |
| Tablets | Metformin Hydrochloride IP 500 mg | |
| Glimepiride IP 2 mg | |
| Approved coloured used | |
| | |
| Dextromethorphan Hbr, | Each uncoated tablet contains | |
| Guaiphenesin & Ambroxol Hcl | Dextromethorphan Hbr IP 10 mg | |
| Chlorpheniramine Maleate Tablet | Guaiphenesin IP 100 mg | |
| Ambroxol Hydrochloride IP 8 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| | |
| Riboflavin, Folic Acid, Niacinamide | Each uncoated tablet contains : | |
| and Lactic acid Bacillus Tablets | Riboflavin IP 10 mg | |
| Foilc Acid IP 1.5 mg | |
| For Therapeutic Use | Niacinamide IP 100 mg | |
| Lactic acid Bacillus 60 mil.spo | |
| Approved colour to be use | |
| | |
| Methylcobalamin, Pregabaline & | Each film coated tablet contains : | |
| Nortriptyline Tablets | Methylcobalamin IP 1500 mcg | |
| Pregabaline IP 75 mg | |
| For Therapeutic Use | Nortriptyline HCl IP | |
| Eq. to Nortriptyline 10 mg | |
| Approved colour to be use q.s. | |
| | |
| Doxycycline and Bromhexine HCl | Each film coated tablet contains : | |
| Tablets | Doxycycline Hydrochloride IP | |
| Equivalent to Doxycycline 100 mg | |
| Bromhexine HCl IP 8 mg | |
| Approved colour to be use | |
| | |
| Methylcobalamin and Gabapentine | Each film coated tablet contains : | |
| Tablets | Methylcobalamin IP 500 mcg | |
| Gabapentine IP 300 mg | |
| Approved colour to be use q.s. | |
| | |
| Methylcobalamin, Glutamic Acid | Each film coated tablet contains : | |
| and Folic Acid Tablets | Methylcobalamin IP 1500 mcg | |
| Glutamic Acid IP 100 mg | |
| For Therapeutic Use | Folic acid IP 1 mg | |
| Approved colour to be use q.s. | |
| | |
| Doxycycline and Ambroxol Tablets | Each film coated tablet contains : | |
| Doxycycline Hydrochloride IP | |
| Equivalent to Doxycycline 100 mg | |
| Ambroxol Hydrochloride IP 7.5 mg | |
| Approved colour to be use | |
| | |
| Lactic acid Bacillus tablet | Each uncoated tablet contains : | |
| Lactic acid Bacillus 60 mil. spo. | |
| Approved colour to be use | |
| | |
| Lactic acid Bacillus tablet | Each uncoated tablet contains : | |
| Lactic acid Bacillus 120 mil. spo. | |
| Approved colour to be use | |
| | |
| Etodolac and Thiocolchicoside | Each film coated tablets conlains | |
| Tablels | Etodolac IP 300 mg | |
| Thiocolchicoside IP 8 mg | |
| Approved color to be use | |
| | |
| Fexofenadine and Montelukast | Each uncoated chewable tablet contains: | |
| Chewable Tablets | Fexofenadine Hydrochloride IP 120 mg | |
| Montelukast Sodium IP | |
| eq. to Montelukast 10 mg | |
| Approved color to be use | |
| | |
| Diclofenac Sodium (SR) and | Each uncoated tablet contains | |
| With Tramadol Tablets | Diclofenac Sodium IP 75 mg | |
| (As Sustained release) | |
| Tramadol Hydrochloride IP 50 mg | |
| Approved color to be use | |
| | |
| Olmesartan Medoxomil | Each uncoated tablet contains | |
| Hydrochlorothiazide with | Olmesartan Medoxomil IP 40 mg | |
| Amlodipine Tablets | Hydrochlorothiazide IP 25 mg | |
| Amlodipine Besiylate IP | |
| Eq.to Amlodipine 10 mg | |
| | |
| Olmesartan Medoxomil | Each uncoated tablet contains: | |
| Hydrochlorothiazide with | Olmesartan Medoxomil IP 20 mg | |
| Amlodipine Tablets | Hydrochlorothiazide IP 12.5 mg | |
| Amlodipine Besiylate IP | |
| Eq. to Amlodipine 5 mg | |
| | |
| Olmesartan Medoxomil | Each uncoated tablet contains: | |
| Hydrochlorothiazide with | Olmesartan Medoxomil IP 5 mg | |
| Amlodipine Tablets | Hydrochlorothiazide IP 12.5 mg | |
| Amlodipine Besiylate IP | |
| Eq. to Amlodipine 2. 5 mg | |
| | |
| Lansoprazole Orally | Each orally disintegrating tablet contains | |
| Disintegrating Tablets | Lansoprazole IP 15 mg | |
| Approved coloured used | |
| | |
| Sucralfate Tablets | Each uncoated tablet contains : | |
| Sucralfate IP 500 mg | |
| Approved colour to used | |
| | |
| Tolperisone Hydrochloride and | Each film coated tablet contains: | |
| Diclofenac sodium Tablets | Tolperisone Hydrochloride JP 150 mg | |
| Diclofenac Sodium IP 50 mg | |
| Excipients q . s. | |
| Approved colour to used | |
| | |
| Telmisartan, Amlodioine and | Each uncoated tablet contains: | |
| Hydrochlorothiazide Tablets | Telmisartan IP 20 mg | |
| Amlodipine Besylate IP | |
| Eq. to Amlodipine 2.5 mg | |
| Hydrochlorothiazide IP 6.25 mg | |
| | |
| Telmisartan With | Each uncoated bilayered tablet contains: | |
| Hydrochlorothiazide Tablets IP | Telmisartan IP 80 mg | |
| Hydrochlorothiazide IP 25 mg | |
| Excipients q . s. | |
| Approved colour to used | |
| | |
| Telmisartan With | Each uncoated bilayered tablet contains: | |
| Hydrochlorothiazide Tablets IP | Telmisartan IP 80 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Excipients q . s. | |
| Approved colour to used | |
| | |
| Artemether With Lumefantrine | Each uncoated tablet contains: | |
| Tablets | Artemether IP 20 mg | |
| Lumefantrine 120 mg | |
| Excipients q . s. | |
| | |
| Tolperisone Hydrochloride and | Each sustained released tablet contains: | |
| Diclofenac sodium Tablets | Tolperisone Hydrochloride JP 450 mg | |
| Diclofenac Sodium IP 100 mg | |
| Excipients q . s. | |
| Approved colour to used | |
| | |
| Mefenamic Acid, Paracetamol | Each uncoated tablet contains: | |
| and Dicyclomine Tablets | Mefenamic Acid IP 250 mg | |
| Paracetamol IP 325 mg | |
| Dicyclomine Hydrochloride IP 10 mg | |
| Approved colour to be used | |
| | |
| Montelukast sodium and | Each film coated tablet contains: | |
| Hydroxyzine Tablets | Montelukast Sodium IP | |
| eq. to Montelukast 10 mg | |
| Hydroxyzine Hydrochloride IP 25 mg | |
| Approved colour to be used | |
| | |
| Sildenafil Chewable | Each uncoated chewable tablet contains : | |
| Tablets | Sildenafil Citrate IP | |
| Eq. to Sildenfil 100 mg | |
| Approved colour to be used | |
| | |
| Tapentadol Hydrochloride | Each film coated tablet contains | |
| and Carisoprodol Tablets | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 100 mg | |
| Carisoprodol IP 350 mg | |
| Approved color to be use | |
| | |
| Olmesartan Medoxomil | Each uncoated tablet contains: | |
| Hydrochlorothiazide with | Olmesartan Medoxomil IP 40 mg | |
| Amlodipine Tablets | Hydrochlorothiazide IP 25 mg | |
| Approved Date: 26/03/2018 | Amlodipine Besiylate IP | |
| Eq. to Amlodipine 5 mg | |
| Each uncoated tablet contains: | |
| | |
| Artemether With Lumefantrine | Each uncoated tablet contains: | |
| Tablets | Artemether IP 60 mg | |
| Lumefantrine 360 mg | |
| Excipients q.s. | |
| | |
| Drotaverine and Aceclofenac | Each film coated tablet contains: | |
| Tablets | Drotaverine Hydrochloride IP 80 mg | |
| Aceclofenac IP 100 mg | |
| Approved coloured used | |
| | |
| Clonazepam and Escitalopram | Each uncoated tablet contains : | |
| Tablet IP | Clonazepam IP 0.50 mg | |
| Escitalopram Oxelate IP | |
| Eq. to Escitalopram 10 mg | |
| Excipients q.s. | |
| | |
| Calcium Carbonate and Vitamin D3 | Each film coated tablet contains: | |
| Tablets | Calcium Carbonate IP 1250 mg | |
| Eq. to Elemental Calcium 500 mg | |
| Vitamin D3 IP 500 IU | |
| Excipients q.s. | |
| Approved colour use | |
| | |
| Calcium Carbonate, | Each film coated tablet contains: | |
| Calcitriol, Zinc Sulphate, | Calcium Carbonate IP 1250 mg | |
| Methylcobalamin | Calcitriol IP 0.25 mcg | |
| and Magnesium Tablets | Zinc sulphate IP 7.5 mg | |
| Methylcobalamin IP 1500 mcg | |
| Magnesium IP 50 mg | |
| Excipients q.s. | |
| Approved colour use | |
| | |
| Rivaroxaban Tablets | Each film coated tablet contains : | |
| Rivaroxaban 10 mg | |
| Approved colour to used | |
| | |
| Rivaroxaban Tablets | Each film coated tablet contains : | |
| Rivaroxaban 20 mg | |
| Approved colour to used | |
| | |
| Rivaroxaban Tablets | Each film coated tablet contains : | |
| Rivaroxaban 15 mg | |
| Approved colour to used | |
| | |
| Bilastine Tablets | Each uncoated tablet contains: | |
| Bilastine 40 mg | |
| Approved colour to used | |
| | |
| Ranolazine Sustained Release | Each uncoated Sustained Release tablet contains | |
| Tablets | Ranolazine 750 mg | |
| Excipients q.s. | |
| | |
| Ranolazine Sustained Release | Each uncoated Sustained Release tablet contains | |
| Tablets | Ranolazine 500 mg | |
| Excipients q.s. | |
| | |
| Ranolazine Sustained Release | Each uncoated Sustained Release tablet contains | |
| Tablets | Ranolazine 1000 mg | |
| Excipients q.s. | |
| | |
| Itopride Hydrochloride Tablets IP | Each film coated tablet contains: | |
| Itopride Hydrochloride IP 50mg | |
| Approved colour use | |
| | |
| Cilnidipine Tablets IP 5 mg | Each film coated tablets contains: | |
| Cilnidipine IP 5 mg | |
| Approved colour use | |
| | |
| Cilnidipine Tablets IP 10 mg | Each film coated tablets contains: | |
| Cilnidipine IP 10 mg | |
| Approved colour use | |
| | |
| Cilnidipine Tablets IP 20 mg | Each film coated tablets contains : | |
| Cilnidipine IP 20 mg | |
| Approved colour to be used | |
| | |
| Flupirtine Maleate & Paracetamol | Each Uncoated bilayered coated tablets contains: | |
| Tablets | Flupirtine Maleate 100 mg | |
| Paracetamol IP 325 mg | |
| Excipients q.s. | |
| | |
| Flupentixol and Melitracen | Each film coated tablets contains: | |
| Tablets | Flupentixol Hydrochloride BP | |
| Eq. to Flupentixol 0.5 mg | |
| Melitracen Hydrochloride | |
| Eq. to Melitracen 10 mg | |
| Approved colour to be used | |
| | |
| Clidinium Bromide and | Each film coated tablet contains: | |
| Chlordiazepoxide Tablets | Clidinium Bromide USP 2.5 mg | |
| Chlordiazepoxide IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Clonazepam Mouth Dissoving | Each orally disintegrating tablets contains | |
| Tablets | Clonazepam IP 0.5 mg | |
| Approved color to be use | |
| | |
| Clonazepam Mouth Dissoving | Each orally disintegrating tablets contains | |
| Tablets | Clonazepam IP 0.25 mg | |
| Approved color to be use | |
| | |
| Clonazepam Tablets IP | Each uncoated tablet contains : | |
| Clonazepam IP 0.25 mg | |
| Excipients q.s. | |
| | |
| Clobazam Tablets IP | Each uncoated tablet contains : | |
| Clonazepam IP 5 mg | |
| Excipients q.s. | |
| | |
| Clobazam Tablets IP | Each uncoated tablet contains : | |
| Clonazepam IP 10 mg | |
| Excipients q.s. | |
| | |
| Clobazam Tablets IP | Each uncoated tablet contains : | |
| Clonazepam IP 20 mg | |
| Excipients q.s. | |
| | |
| Rifaximin Dispersible Tablets | Each uncoated dispersible tablets contains | |
| Rafaximin BP 200 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Levofloxacin Tablets IP 750 mg | Each film coated tablet contains : | |
| Levofloxacin Hemihydrate IP | |
| Equivalent to Levofloxacin 750 mg | |
| Approved colour to be used | |
| | |
| Betahistine Hydrochloride Tablets | Each uncoated tablet contains : | |
| Betahistine Hydrochloride IP 16 mg | |
| | |
| Betahistine Hydrochloride Tablets | Each uncoated tablet contains : | |
| Betahistine Hydrochloride IP 24 mg | |
| | |
| Atomoxetine Tablets 10 mg | Each film coated tablet contains: | |
| Atomoxetine Hydrochloride IP | |
| Equivalent to Atomoxetine 10 mg | |
| Approved colour to be used | |
| | |
| Ondansetron Hydrochloride | Each uncoated tablet contains: | |
| Tablets IP | Ondansetron Hydrochloride IP | |
| eq. to Ondansetron 8 mg | |
| Approved colour to be used | |
| | |
| Ondansetron Orally Disintegrating | Each orally disintegrating tablet contains: | |
| Tablets IP | Ondansetron Hydrochloride IP | |
| eq. to Ondansetron 8 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Gastro-resistant | Each Enteric coated tablet contains: | |
| Divalproex sodium IP | |
| Eq. to Valproic acid 125 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Gastro-resistant | Each Enteric coated tablet contains: | |
| Divalproex sodium IP | |
| Eq. to Valproic acid 250 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Gastro-resistant | Each Enteric coated tablet contains: | |
| Divalproex sodium IP | |
| Eq. to Valproic acid 500 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Extended-release | Each film coated Extende-release tablet contains: | |
| Tablets IP | Divalproex sodium IP | |
| Eq. to Valproic acid 125 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Extended-release | Each film coated Extende-release tablet contains: | |
| Tablets IP | Divalproex sodium IP | |
| Eq. to Valproic acid 250 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Extended-release | Each film coated Extende-release tablet contains: | |
| Tablets IP | Divalproex sodium IP | |
| Eq. to Valproic acid 500 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Extended-release | Each film coated Extende-release tablet contains: | |
| Tablets IP | Divalproex sodium IP | |
| Eq. to Valproic acid 750 mg | |
| Approved colour to be used | |
| | |
| Divalproex Sodium Extended-release | Each film coated Extende-release tablet contains: | |
| Tablets IP | Divalproex sodium IP | |
| Eq. to Valproic acid 1000 mg | |
| Approved colour to be used | |
| | |
| Lamotrigine Dispersible Tablets IP | Each uncoated dispersible tablet contains: | |
| Lamotrigine IP 25 mg | |
| Approved colour to be used | |
| | |
| Lamotrigine Dispersible Tablets IP | Each uncoated dispersible tablet contains: | |
| Lamotrigine IP 50 mg | |
| Approved colour to be used | |
| | |
| Lamotrigine Dispersible Tablets IP | Each uncoated dispersible tablet contains: | |
| Lamotrigine IP 100 mg | |
| Approved colour to be used | |
| | |
| Lamotrigine Sustained-release | Each uncoated sustained release tablet contains: | |
| Tablets IP | Lamotrigine IP 50 mg | |
| Approved colour to be used | |
| | |
| Lamotrigine Sustained-release | Each uncoated sustained release tablet contains: | |
| Tablets IP | Lamotrigine IP 100 mg | |
| Approved colour to be used | |
| | |
| Lamotrigine Sustained-release | Each uncoated sustained release tablet contains: | |
| Tablets IP | Lamotrigine IP 200 mg | |
| Approved colour to be used | |
| | |
| Modafinil Tablets IP | Each uncoated tablet contains : | |
| Modafinil IP 100 mg | |
| Approved colour to be used | |
| | |
| Modafinil Tablets IP | Each uncoated tablet contains : | |
| Modafinil IP 200 mg | |
| Approved colour to be used | |
| | |
| Oxcarbazepine Extended Release | Each film coated extended release tablet contains: | |
| Tablets | Oxcarbazepine IP 300 mg | |
| Approved colour to be used | |
| | |
| Oxcarbazepine Extended Release | Each film coated extended release tablet contains: | |
| Tablets | Oxcarbazepine IP 600 mg | |
| Approved colour to be used | |
| | |
| Topiramate Tablets IP | Each film coated tablet contains: | |
| Topiramate IP 25 mg | |
| Approved colour to be used | |
| | |
| Topiramate Tablets IP | Each film coated tablet contains: | |
| Topiramate IP 50 mg | |
| Approved colour to be used | |
| | |
| Topiramate Tablets IP | Each film coated tablet contains: | |
| Topiramate IP 100 mg | |
| Approved colour to be used | |
| | |
| Topiramate Tablets IP | Each film coated tablet contains: | |
| Topiramate IP 200 mg | |
| Approved colour to be used | |
| | |
| Topiramate Tablets IP | Each film coated tablet contains: | |
| Topiramate IP 300 mg | |
| Approved colour to be used | |
| | |
| Topiramate Tablets IP | Each film coated tablet contains: | |
| Topiramate IP 400 mg | |
| Approved colour to be used | |
| | |
| Citalopram Tablets IP | Each uncoated tablet contains: | |
| Citalopram Hydrobromide IP | |
| Eq. to Citalopram 10 mg | |
| Approved colour to be used | |
| | |
| Citalopram Tablets IP | Each uncoated tablet contains: | |
| Citalopram Hydrobromide IP | |
| Eq. to Citalopram 20 mg | |
| Approved colour to be used | |
| | |
| Citalopram Tablets IP | Each uncoated tablet contains: | |
| Citalopram Hydrobromide IP | |
| Eq. to Citalopram 40 mg | |
| Approved colour to be used | |
| | |
| Clonazepam and Paroxetine | Each uncoated bilayer tablet contains: | |
| Tablets | Clonazepam IP 0.25mg | |
| Paroxetine Hydrochloride IP | |
| Eq. to Paroxetine 12.5 mg | |
| Excipients q.s | |
| | |
| Mebeverine Hydrochloride and | Each uncoated tablet contains : | |
| Chlordiazepoxide Tablets | Mebeverine Hydrochloride IP 135 mg | |
| Chlordiazepoxide IP 5 mg | |
| Excipients q.s | |
| Approved colour to be used | |
| | |
| Naproxen Sodium & Domperidone | Each film coated tablet contains: | |
| Tablets | Naproxen Sodium IP 500 mg | |
| Domperidone Maleate IP | |
| Eq. to Domperidone 10 mg | |
| Approved colour to be used | |
| | |
| Sertraline Tablets IP | Each film coated tablet contains : | |
| Sertraline Hydrochloride IP | |
| Eq. to Paroxetine 25 mg | |
| Excipients q.s | |
| | |
| Sertraline Tablets IP | Each film coated tablet contains : | |
| Sertraline Hydrochloride IP | |
| Eq. to Paroxetine 50 mg | |
| Excipients q.s | |
| | |
| Sertraline Tablets IP | Each uncoated tablet contains : | |
| Sertraline Hydrochloride IP | |
| Eq. to Paroxetine 100 mg | |
| Excipients q.s | |
| | |
| Venlafaxine Prolonged-release | Each uncoated Prolonged-release tablet contains : | |
| Tablets IP | VenlafaxineHydrochloride IP | |
| Eq. to Venlafaxine 25 mg | |
| Excipients q.s | |
| | |
| Venlafaxine Prolonged-release | Each uncoated Prolonged-release tablet contains : | |
| Tablets IP | VenlafaxineHydrochloride IP | |
| Eq. to Venlafaxine 37.5 mg | |
| Excipients q.s | |
| | |
| Venlafaxine Prolonged-release | Each uncoated Prolonged-release tablet contains : | |
| Tablets IP | VenlafaxineHydrochloride IP | |
| Eq. to Venlafaxine 75 mg | |
| Excipients q.s | |
| | |
| Venlafaxine Prolonged-release | Each uncoated Prolonged-release tablet contains : | |
| Tablets IP | VenlafaxineHydrochloride IP | |
| Eq. to Venlafaxine 150 mg | |
| Excipients q.s | |
| | |
| Calcium Carbonate, Vitamin D3, | Each film coated tablet contains: | |
| Methylcobalamin, L-Methylfolate | Calcium Carbonate IP 1250 mg | |
| Calium & Pyridoxal-5-Phosphate | Eq. to Elemental Calcium 500 mg | |
| Tablets | Vitamin D3 IP 2000 IU | |
| Methylcobalamin IP 1500 mcg | |
| L-Methylfolate Calcium 1 mg | |
| Pyridoxal-5-Phosphate 20 mg | |
| Excipients q.s | |
| Approved colour use | |
| | |
| Vitamin K2-7, Calcium Carbonate, | Each film coated tablet contains : | |
| Calcitriol, Zinc Sulphate, | Vitamin K 2-7 45 mcg | |
| L-Methyl Folate, Methylcobalamin | Calcium Carbonate IP 1250 mg | |
| and Magnesium Tablets | Calcitriol IP 0.25 mcg | |
| Zinc sulphate IP 7.5 mg | |
| L-Methyl Folate 800 mcg | |
| Methylcobalamin IP 1500 mcg | |
| Magnesium IP 50 mg | |
| Excipients q.s | |
| Approved colour use | |
| | |
| Folic Acid Tablets IP | Each uncoated tablet contains: | |
| Folic Acid IP 1 mg | |
| Excipients q.s | |
| | |
| Folic Acid Tablets IP | Each uncoated tablet contains: | |
| Folic Acid IP 10 mg | |
| Excipients q.s | |
| | |
| Folic Acid Tablets | Each uncoated tablet contains: | |
| Folic Acid IP 2 mg | |
| Excipients q.s | |
| | |
| Folic Acid Tablets | Each uncoated tablet contains: | |
| Folic Acid IP 3 mg | |
| Excipients q.s | |
| | |
| Ferrous Sulphate Tablets IP | Each film coated tablet contains : | |
| Dried Ferrous Sulphate IP 200 mg | |
| Eq. to Ferrous Iron 60 mg | |
| Approved colour use | |
| | |
| Buprenorphine Hydrochloride & | Each uncoated sublingual tablet contains | |
| Naloxone Sublingual Tablets IP | Buprenorphine Hydrochloride IP | |
| For De-addiction ceters only | Eq. to Buprenorphine 0.4 mg | |
| Naloxone Hydrochloride IP | |
| Eq. to Naloxone 0.1 mg | |
| Approved colour to be use | |
| | |
| Buprenorphine Hydrochloride & | Each uncoated sublingual tablet contains | |
| Naloxone Sublingual Tablets IP | Buprenorphine Hydrochloride IP | |
| For De-addiction ceters only | Eq. to Buprenorphine 2 mg | |
| Naloxone Hydrochloride IP | |
| Eq. to Naloxone 0.5 mg | |
| Approved colour to be use | |
| | |
| Buprenorphine Hydrochloride & | Each uncoated sublingul tablet contains: | |
| Sublingual Tablets IP | Buprenorphine Hydrochloride IP | |
| For De-addiction ceters only | Eq. to Buprenorphine 200 ug | |
| Approved colour to be use | |
| | |
| Buprenorphine Hydrochloride & | Each uncoated sublingul tablet contains: | |
| Sublingual Tablets IP | Buprenorphine Hydrochloride IP | |
| For De-addiction ceters only | Eq. to Buprenorphine 400 ug | |
| Approved colour to be use | |
| | |
| Buprenorphine Hydrochloride & | Each uncoated tablet contains : | |
| Naloxone Tablets | Buprenorphine Hydrochloride IP | |
| For De-addiction ceters only | Eq. to Buprenorphine 2 mg | |
| Naloxone Hydrochloride IP | |
| Eq. to Naloxone 0.4 mg | |
| Approved colour to be use | |
| | |
| Buprenorphine Hydrochloride & | Each uncoated tablet contains : | |
| Naloxone Tablets | Buprenorphine Hydrochloride IP | |
| For De-addiction ceters only | Eq. to Buprenorphine 0.5 mg | |
| Naloxone Hydrochloride IP | |
| Eq. to Naloxone 0.1 mg | |
| Approved colour to be use | |
| | |
| Naltrexone Hydrochloride | Each uncoated tablets contains: | |
| Tablets IP 50 mg | Naltrexone Hydrochloride IP 50 mg | |
| For De-addiction ceters only | Approved colour to be use | |
| | |
| Quetiapine Fumarate Tablets IP | Each film coated tablet contains: | |
| Quetiapine Fumarate IP 25 mg | |
| Eq. to Quetiapine | |
| Approved colour to used | |
| | |
| Quetiapine Fumarate Tablets IP | Each film coated tablet contains: | |
| Quetiapine Fumarate IP 50 mg | |
| Eq. to Quetiapine | |
| Approved colour to used | |
| | |
| Quetiapine Fumarate Tablets IP | Each film coated tablet contains: | |
| Quetiapine Fumarate IP 100 mg | |
| Eq. to Quetiapine | |
| Approved colour to used | |
| | |
| Quetiapine Fumarate Tablets IP | Each film coated tablet contains: | |
| Quetiapine Fumarate IP 200 mg | |
| Eq. to Quetiapine | |
| Approved colour to used | |
| | |
| Quetiapine Fumarate Tablets IP | Each film coated tablet contains: | |
| Quetiapine Fumarate IP 300 mg | |
| Eq. to Quetiapine | |
| Approved colour to used | |
| | |
| Quetiapine Sustained release | Each film coated Sustained released tablet contains: | |
| Tablets | Quetiapine Fumarate IP | |
| Eq. to Quetiapine 50 mg | |
| Approved colour to be used | |
| | |
| Quetiapine Sustained release | Each film coated Sustained released tablet contains: | |
| Tablets | Quetiapine Fumarate IP | |
| Eq. to Quetiapine 200 mg | |
| Approved colour to be used | |
| | |
| Quetiapine Sustained release | Each film coated Sustained released tablet contains: | |
| Tablets | Quetiapine Fumarate IP | |
| Eq. to Quetiapine 300 mg | |
| Approved colour to be used | |
| | |
| Quetiapine Sustained release | Each film coated Sustained released tablet contains: | |
| Tablets | Quetiapine Fumarate IP | |
| Eq. to Quetiapine 400 mg | |
| Approved colour to be used | |
| | |
| Cinitapride Tablets | Each uncoated tablet contains : | |
| Cinitapride Hydrogen Tartrate | |
| Eq. to Cinitapride 1 mg | |
| Approved colour to be used | |
| | |
| Cinitapride Tablets | Each uncoated tablet contains : | |
| Cinitapride Hydrogen Tartrate | |
| Eq. to Cinitapride 3 mg | |
| Approved colour to be used | |
| | |
| Losartan Potassium Tablets | Each film coated tablets contains | |
| Losartan Potassium IP 100 mg | |
| Approved colour to be use | |
| | |
| Losartan Potassium & Atenolol | Each uncoated tablet contains : | |
| Tablets | Losartan Potassium IP 50 mg | |
| Atenolol IP 5 mg | |
| Approved color to be use | |
| | |
| Rosuvastatin and Fenofibrate | Each film coated tablet contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Fenofibrate IP 160 mg | |
| Approved colour to be use | |
| | |
| Nebivolol Hcl Tablets IP | Each uncoated tablet contains : | |
| Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 5 mg | |
| Approved colour to be use | |
| | |
| Nebivolol Hcl Tablets IP | Each uncoated tablet contains : | |
| Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 10 mg | |
| Approved colour to be use | |
| | |
| Nebivolol Hydrochloride and | Each uncoated tablet contains : | |
| Hydrochlorothiazide Tablets | Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 5 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Approved colour to used | |
| | |
| Indapamide (Sustained Release) and | Each uncoated bilayered tablet contains : | |
| Nebivolol Hydrochloride Tablets | Indapamide IP 1.5 mg | |
| (As sustained release) | |
| Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 2.5 mg | |
| Approved colour to used | |
| | |
| Indapamide (Sustained Release) and | Each uncoated bilayered tablet contains : | |
| Nebivolol Hydrochloride Tablets | Indapamide IP 1.5 mg | |
| (As sustained release) | |
| Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 5 mg | |
| Approved colour to be used | |
| | |
| Amlodipine and Nebivolol | Each uncoated tablet contains : | |
| Tablets IP | Amlodipine Besylate IP | |
| Eq. to Amlodipine 5 mg | |
| Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 5 mg | |
| Approved colour to be used | |
| | |
| Nebivolol and Telmisartan | Each film coated tablets contains | |
| Tablets | Nebivolol Hydrochloride IP | |
| Eq. to Nebivolol 5 mg | |
| Telmisartan IP 40 mg | |
| Approved color to be use | |
| | |
| Amitriptyline Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Amitriptyline Hydrochloride IP 10 mg | |
| Approved colour to be used | |
| | |
| Amitriptyline Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Amitriptyline Hydrochloride IP 25 mg | |
| Approved colour to be used | |
| | |
| Amitriptyline Hydrochloride | Each film coated tablet contains : | |
| Tablets IP | Amitriptyline Hydrochloride IP 50 mg | |
| Approved colour to be used | |
| | |
| Amitriptyline Hydrochloride | Each film coated tablet contains : | |
| Tablets | Amitriptyline Hydrochloride IP 75 mg | |
| Approved colour to be used | |
| | |
| Valsartan Tablets IP | Each film coated tablet contains : | |
| Valsartan IP 40 mg | |
| Approved colour to be used | |
| | |
| Valsartan Tablets IP | Each film coated tablet contains : | |
| Valsartan IP 80 mg | |
| Approved colour to be used | |
| | |
| Valsartan Tablets IP | Each film coated tablet contains : | |
| Valsartan IP 160 mg | |
| Approved colour to used | |
| | |
| Valsartan Tablets IP | Each film coated tablet contains : | |
| Valsartan IP 320 mg | |
| Approved colour to used | |
| | |
| Amisulpride (Sustained Release) | Each uncoated sustained released tablet contains: | |
| Tablets | Amisulpride IP 200 mg | |
| Approved colour to used | |
| | |
| Amisulpride (Sustained Release) | Each uncoated sustained released tablet contains: | |
| Tablets | Amisulpride IP 400 mg | |
| Approved colour to used | |
| | |
| Amisulpride Tablets IP | Each uncoated tablet contains : | |
| Amisulpride IP 50 mg | |
| Approved colour to used | |
| | |
| Amisulpride Tablets IP | Each uncoated tablet contains : | |
| Amisulpride IP 100 mg | |
| Approved colour to used | |
| | |
| Amisulpride Tablets IP | Each uncoated tablet contains : | |
| Amisulpride IP 200 mg | |
| Approved colour to used | |
| | |
| Amisulpride Tablets IP | Each uncoated tablet contains : | |
| Amisulpride IP 400 mg | |
| Approved colour to used | |
| | |
| Aripiprazole Tablets IP | Each uncoated tablet contains : | |
| Aripiprazole IP 5 mg | |
| Approved colour to used | |
| | |
| Aripiprazole Tablets IP | Each uncoated tablet contains : | |
| Aripiprazole IP 10 mg | |
| Approved colour to used | |
| | |
| Aripiprazole Tablets IP | Each uncoated tablet contains : | |
| Aripiprazole IP 15 mg | |
| Approved colour to used | |
| | |
| Aripiprazole Tablets IP | Each uncoated tablet contains : | |
| Aripiprazole IP 20 mg | |
| Approved colour to used | |
| | |
| Aripiprazole Tablets IP | Each uncoated tablet contains : | |
| Aripiprazole IP 30 mg | |
| Approved colour to used | |
| | |
| Haloperidol Tablets | Each uncoated tablet contains : | |
| Haloperidol IP 0.5 mg | |
| Approved colour to used | |
| | |
| Haloperidol Tablets IP | Each uncoated tablet contains : | |
| Haloperidol IP 1.5 mg | |
| Approved colour to used | |
| | |
| Haloperidol Tablets IP | Each uncoated tablet contains : | |
| Haloperidol IP 5 mg | |
| Approved colour to used | |
| | |
| Haloperidol Tablets IP | Each uncoated tablet contains : | |
| Haloperidol IP 10 mg | |
| Approved colour to used | |
| | |
| Lurasidone Hydrochloride Tablets | Each film coated tablet contains : | |
| Lurasidone Hydrochloride 40 mg | |
| Approved colour to used | |
| | |
| Lurasidone Hydrochloride Tablets | Each film coated tablet contains : | |
| Lurasidone Hydrochloride 80 mg | |
| Approved colour to used | |
| | |
| Risperidone Tablets IP | Each uncoated tablets contains | |
| Risperidone IP 0.5 mg | |
| Approved color to be use | |
| | |
| Risperidone Tablets IP | Each uncoated tablets contains | |
| Risperidone IP 1 mg | |
| Approved color to be use | |
| | |
| Risperidone Tablets IP | Each uncoated tablets contains | |
| Risperidone IP 3 mg | |
| Approved color to be use | |
| | |
| Risperidone Tablets IP | Each uncoated tablets contains | |
| Risperidone IP 4 mg | |
| Approved color to be use | |
| | |
| Risperidone and Trihexyphenidyl | Each uncoated tablet contains : | |
| Tablets | Risperidone IP 2 mg | |
| Trihexyphenidyl Hydrochloride IP 2 mg | |
| Approved colour to be used | |
| | |
| Risperidone and Trihexyphenidyl | Each uncoated tablet contains : | |
| Tablets | Risperidone IP 4 mg | |
| Trihexyphenidyl Hydrochloride IP 2 mg | |
| Approved colour to be used | |
| | |
| Olanzapine Tablets IP | Each film coated tablet contains: | |
| Olanzapine IP 2.5 mg | |
| Approved colour to used | |
| | |
| Olanzapine Tablets IP | Each film coated tablet contains: | |
| Olanzapine IP 5 mg | |
| Approved colour to used | |
| | |
| Olanzapine Tablets IP | Each film coated tablet contains: | |
| Olanzapine IP 7.5 mg | |
| Approved colour to used | |
| | |
| Olanzapine Tablets IP | Each film coated tablet contains: | |
| Olanzapine IP 10 mg | |
| Approved colour to used | |
| | |
| Olanzapine Tablets | Each film coated tablet contains: | |
| Olanzapine IP 15 mg | |
| Approved colour to used | |
| | |
| Procyclidine Tablets IP | Each uncoated tablet contains: | |
| Procyclidine Hydrochloride IP 2.5 mg | |
| Approved colour to used | |
| | |
| Procyclidine Tablets IP | Each uncoated tablet contains: | |
| Procyclidine Hydrochloride IP 5 mg | |
| Approved colour to used | |
| | |
| Desvenlafaxine Extended Release | Each uncoated Extended Release tablet contains: | |
| Tablets | Desvenlafaxine Succinate IP | |
| Eq. to Desvenlafaxine 50 mg | |
| Approved colour to used | |
| | |
| Desvenlafaxine Extended Release | Each uncoated Extended Release tablet contains: | |
| Tablets | Desvenlafaxine Succinate IP | |
| Eq. to Desvenlafaxine 100 mg | |
| Approved colour to used | |
| | |
| Ramosetron Hydrochloride Tablets | Each uncoated tablet contains: | |
| Ramosetron Hydrochloride 2.5 mcg | |
| Approved colour to used | |
| | |
| Ramosetron Hydrochloride Tablets | Each uncoated tablet contains: | |
| Ramosetron Hydrochloride 5 mcg | |
| Approved colour to used | |
| | |
| Ramosetron Hydrochloride Tablets | Each uncoated tablet contains: | |
| Ramosetron Hydrochloride 0.1 mg | |
| Approved colour to used | |
| | |
| Fluvoxamine Maleate Tablets IP | Each film coated tablet contains: | |
| Fluvoxamine Maleate IP 50 mg | |
| Approved colour to used | |
| | |
| Fluvoxamine Maleate Tablets IP | Each film coated tablet contains: | |
| Fluvoxamine Maleate IP 100 mg | |
| Approved colour to used | |
| | |
| Dextromethorphan HBr, | Each uncoated tablet contains: | |
| Chlorpheniramine Maleate, | Dextromethorphan HBr IP 10 mg | |
| Phenylephrine, Ambroxol HCl, | Chlorpheniramine Maleate IP 2 mg | |
| Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Approved color to be use | |
| | |
| Propranolol HCl and Flunarizine | Each uncoated tablet contains : | |
| Tablets | Propranolol HCI IP 40 mg | |
| Flunarizine Dihydrochloride IP | |
| Eq. to Flunarizine 5 mg | |
| Approved colour to be used | |
| | |
| Telmisartan, Hydrochlorothiazide and | Each film coated tablets contains | |
| Amlodipine Tablets | Telmisartan IP 40 mg | |
| Hydrochlorothiazide IP 12.5 mg | |
| Amlodipine Besylate IP | |
| Eq.to Amlodipine 5 mg | |
| Approved colour to be used | |
| | |
| Telmisartan, Chlorthalidone and | Each film coated tablet contains | |
| Metoprolol Tablets | Telmisartan IP 40 mg | |
| Chlorthalidone IP 12.5 mg | |
| Metoprolol Succinate IP 23.75 mg | |
| Eq.to Metoprolol Tartrate 25 mg | |
| Approved colour to be used | |
| | |
| Telmisartan, Chlorthalidone and | Each film coated tablet contains | |
| Metoprolol (ER) Tablets | Telmisartan IP 40 mg | |
| Chlorthalidone IP 12.5 mg | |
| Metoprolol Succinate IP 47.5 mg | |
| Eq.to Metoprolol Tartrate 50 mg | |
| Approved colour to be used | |
| | |
| Propranolol HCl and Flunarizine | Each uncoated tablet contains : | |
| Tablets | Propranolol HCI IP 40 mg | |
| Flunarizine Dlhydrochloride IP | |
| Eq. to Flunarizine 5 mg | |
| Approved colour to used | |
| | |
| Gabapentin and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Gabapentin IP 300 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Approved coloured used | |
| | |
| Paracetamol & Tolperisone | Each film coated tablet contains : | |
| Tablets | Paracetamol IP 500 mg | |
| 06.09.2024 | Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol & Tolperisone | Each film coated tablet contains : | |
| Tablets | Paracetamol IP 325 mg | |
| 06.09.2024 | Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Diclofenac Sodium & Tolperisone | Each film coated tablet contains : | |
| Tablets | Diclofenac Sodium IP 50 mg | |
| Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Diclofenac Potassium & Tolperisone | Each film coated tablet contains : | |
| Tablets | Diclofenac Potassium IP 50 mg | |
| Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Diclofenac Sodium (SR) & Tolperisone | Each film coated tablet contains : | |
| Tablets | Diclofenac Sodium IP 100 mg | |
| Tolperisone Hydrochloride JP 450 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tolperisone Tablets | Each film coated tablet contains : | |
| Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tolperisone Sustained Release | Each Sustained Release tablet contains : | |
| Tablets | Tolperisone Hydrochloride JP 450 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tolperisone Sustained Release | Each Sustained Release tablet contains : | |
| Tablets | Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tolperisone Sustained Release | Each Prolonged Release tablet contains : | |
| Tablets | Tolperisone Hydrochloride JP 450 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Ferrous Fumarate, Folic Acid and | Each film coated tablets contains | |
| Zinc Tablets | Ferrous Fumarate IP 152 mg | |
| Eq. to Elemental Iron 49.5 mg | |
| Folic Acod IP 750 mcg | |
| Zinc Sulphate Monohydrate IP 61.8 mg | |
| Eq. to Elemental Zinc 22.5 mg | |
| Approved color to be use | |
| | |
| Calcium Citrate Maleate, Calcitriol , | Each film coated tablet contains: | |
| Methylcobalamin with Zinc | Calcium Citrate Maleate | |
| & Folic acid Tablets | Eq. to Elemental Calcium 250 mg | |
| Calcitriol IP 0.5 mcg | |
| Methylcobalamin IP 1500 mcg | |
| For Therapeutic Use | Zinc Sulphate Mononitrate IP | |
| Eq. to Elemental Zinc 15 mg | |
| Folic Acid IP 1 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| L-Ornithine – L-Aspartate, Silymarin | Each film coated tablet contains: | |
| with Mutil-Vitamins Tablets | L-Ornithine – L-Aspartate 250 mg | |
| Silymarin 140 mg | |
| Calcium D Pantothenate IP 10 mg | |
| Thiamine Mononitrate IP 5 mg | |
| Riboflavine IP 5 mg | |
| Pyridoxine Hydrochloride IP 3 mg | |
| Methylcobalamin IP 20 mcg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Calcium Citrate Maleate, | Each film coated tablet contains: | |
| Vitamin D3 and | Calcium Citrate Maleate 500 mg | |
| Folic acid Tablets | Vitamin D3 IP 200 IU | |
| Folic acid IP 5 mg | |
| Approved colour to be use q.s. | |
| | |
| Ethinylestradiol Tablets IP | Each uncoated tablet contains : | |
| Ethinylestradiol IP 10 ug | |
| Excipients q.s. | |
| | |
| Ethinylestradiol Tablets IP | Each uncoated tablet contains : | |
| Ethinylestradiol IP 20 ug | |
| Excipients q.s. | |
| | |
| Ethinylestradiol Tablets IP | Each uncoated tablet contains : | |
| Ethinylestradiol IP 50 ug | |
| Excipients q.s. | |
| | |
| Cyproterone Acetate and | Each uncoated tablets contains | |
| Ethinylestradiol Tablets | Cyproterone Acetate IP 2 mg | |
| Ethinylestradiol IP 0.035 mg | |
| Approved colour to be used | |
| | |
| Drospirenone and | Each uncoated tablets contains | |
| Ethinylestradiol Tablets | Drospirenone IP 3 mg | |
| Ethinylestradiol IP 0.035 mg | |
| Approved colour to be used | |
| | |
| Drospirenone and | Each uncoated tablets contains | |
| Ethinylestradiol Tablets IP | Drospirenone IP 3 mg | |
| Ethinylestradiol IP 0.03 mg | |
| Approved colour to be used | |
| | |
| Drospirenone and | Each uncoated tablets contains | |
| Ethinylestradiol Tablets IP | Drospirenone IP 3 mg | |
| Ethinylestradiol IP 0.02 mg | |
| Approved colour to be used | |
| | |
| Spiramycin Tablets | Each film coated tablets contains | |
| Spiramycin IP 8000000 IU | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Nimesulide, Paracetamol and | Each film coated tablet contains : | |
| Serratiopeptidase Tablets | Nimesulide BP 100 mg | |
| Paracetamol IP 325 mg | |
| Serratiopeptidase(As enteric coat IP 15 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Doxylamine, Pyridoxine HCI | Each enteric coated tablet contains : | |
| and Folic Acid Tablets | Doxylamine Succinate BP 10 mg | |
| Pyridoxine Hydrochloride IP 10 mg | |
| Folic acid IP 2.5 mg | |
| Approved colour to be use | |
| | |
| Ferrous Sulphate, | Each Sugar coated tablet contains : | |
| and Folic Acid Tablets | Dried Ferrous Sulphate IP 200 mg | |
| Eq. to Elemental Iron 60 mg | |
| Folic acid IP 1 mg | |
| Approved colour to be use | |
| | |
| Myo-Inositol and | Each film coated tablet contains | |
| Metformin HCI Tablets | Myo-lnositol IP 600 mg | |
| Metformin Hydrochloride IP 250 mg | |
| Approved colour to be use | |
| | |
| Myo-Inositol and | Each uncoated bilayer tablet contains | |
| Metformin HCI (SR) Tablets | Myo-Inositol IP 600 mg | |
| Metformin Hydrochloride IP 250 mg | |
| (As sustained release form) | |
| Approved colour to be used | |
| | |
| Tofacitinib Tablets | Each film coated tablet contains | |
| Tofacitinb Citrate | |
| Eq. to Tofacitinib 5 mg | |
| Approved colour to be used | |
| | |
| Propranolol Sustained | Each uncoated sustained release tablet contains : | |
| Release Tabiets 20 mg | Propranolol Hydrochloride IP 20 mg | |
| Approved colour to be used | |
| | |
| Propranolol Sustained | Each uncoated sustained release tablet contains : | |
| Release Tabiets 80 mg | Propranolol Hydrochloride IP 80 mg | |
| Approved colour to be used | |
| | |
| Propranolol Sustained | Each uncoated sustained release tablet contains : | |
| Release Tabiets 160 mg | Propranolol Hydrochloride IP 160 mg | |
| Approved colour to be used | |
| | |
| Escitalopram and Etizolam | Each uncoated tablets contains | |
| Tablets | Escitalopram Exalate IP | |
| Eq. to Escitalopram 5 mg | |
| Etizolam IP 0.5 mg | |
| Approved colour to be used | |
| | |
| Empagliflozin Tablets | Each film coated tablet contains | |
| Empagliflozin 10 mg | |
| Approved colour to be used | |
| | |
| Empagliflozin Tablets | Each film coated tablet contains | |
| Empagliflozin 25 mg | |
| Approved colour to be used | |
| | |
| Tramadol | Each film coated tablet contains : | |
| Hydrochloride Tablets | Tramadol Hydrochloride IP 100 mg | |
| Approved colour to be used | |
| | |
| Dextromethorphan HBr, | Each uncoated tablet contains : | |
| Cetirizine Hydrochioride, | Dextromethorphan Hydrobromi IP 10 mg | |
| Phenylephrine HCl and | Cetirizine Hydrochloride IP 5 mg | |
| Ambroxol HCL Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Ambroxol Hydrochloride IP 15 mg | |
| Approved colour to be used | |
| | |
| Glimepiride, Metformin HCI (SR) | Each uncoated bilayered tablet contains | |
| and Voglibose Tablets | Metformin Hydrochloride IP 1000 mg | |
| (As sustained release) | |
| Glimepiride IP 3 mg | |
| Voglibose IP 0.2 mg | |
| Approved colour to be used | |
| | |
| Vardenafil & Dapoxetine HCI | Each film coated tablet contains : | |
| Tablets | Vardenafil Hydrochloride | |
| Eq. to Vardenafil 20 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 60 mg | |
| Approved colour to be used | |
| | |
| Avanafil and Dapoxetine HCI | Each film coated tablet contains : | |
| Tablets | Avanafil 50 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 30 mg | |
| Approved colour to be used | |
| | |
| Avanafil and Dapoxetine HCI | Each film coated tablet contains : | |
| Tablets | Avanafil 100 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 60 mg | |
| Approved colour to be used | |
| | |
| Avanafil and Dapoxetine HCI | Each film coated tablet contains : | |
| Tablets | Avanafil 200 mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 60 mg | |
| Approved colour to be used | |
| | |
| Metformin HCI (SR) | Each uncoated bilayered tablet contains | |
| Gliclazide (SR) & Pioglitazone | Metformin Hydrochloride IP 1000 mg | |
| Tablets | (As sustained release) | |
| Gliclazide (As sustained release) IP 30 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Approved colour to be used | |
| | |
| Aceclofenac, Paracetarmol, | Each flim coated tablet contains : | |
| Cetirizine HCI, | Aceclofenac IP 100 mg | |
| Phenylephrine HCI | Paracetamol IP 325 mg | |
| & Caffeine Tablets | Cetirizine HCI IP 10 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Caffeine (Anhydrous) IP 25 mg | |
| Approved colour to be used | |
| | |
| Aceclofenac, Paracetamol, | Each flim coated tablet contains : | |
| Cetirizine HCI, | Aceclofenac IP 100 mg | |
| Phenylephrine HCl Tablets | Paracetamol IP 325 mg | |
| Cetirizine HCI IP 10 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Approved colour to be used | |
| | |
| Lithium Carbonate | Each uncoated Prolonged released tablet contains | |
| Prolonged-release | Lithium Carbonate IP 300 mg | |
| Tablets IP 300 mg | (As Prolonged release) | |
| | |
| Lithium Carbonate | Each uncoated Prolonged released tablet contains | |
| Prolonged-release | Lithium Carbonate IP 400 mg | |
| Tablets IP 400 mg | (As Prolonged release) | |
| | |
| Lithium Carbonate | Each uncoated Prolonged released tablet contains | |
| Prolonged-release | Lithium Carbonate IP 450 mg | |
| Tablets IP 450 mg | (As Prolonged release) | |
| Excipients q.s. | |
| Lithium Carbonate | Each uncoated tablet contains | |
| Tablets IP 300 mg | Lithium Carbonate IP 300 mg | |
| | |
| Tramadol Hydrochloride & | Each Film coated sustained release tablet contains: | |
| Paracetmol Sustained Release Tablet | Tramadol Hydrochloride IP 37.5 mg | |
| Paracetmol IP 325 mg | |
| Approved colour to be used | |
| | |
| Aceclofenac & Trypsin | Each enteric coated tablet contains : | |
| Chymotrypsin Tablets | Aceclofenac IP 100 mg | |
| 5000 Armour units of enzymatic activity | |
| (Supplied by a purified concentrate which | |
| specific Trypsin & Chymotrypsin IP activity | |
| in a ratio of approximate six to one) | |
| Approved colour to be used | |
| | |
| Aceclofenac, Paracetamol & | Each enteric coated tablet contains : | |
| Trypsin Chymotrypsin Tablets | Aceclofenac IP 100 mg | |
| Paracetmol IP 325 mg | |
| 5000 Armour units of enzymatic activity | |
| (Supplied by a purified concentrate which | |
| specific Trypsin & Chymotrypsin IP activity | |
| in a ratio of approximate six to one) | |
| Approved colour to be used | |
| | |
| Mycophenolate Mofetil | Each film coated tablets contains | |
| Tablets IP 250 mg | Mycophenolate Mofetil IP 250 mg | |
| Approved colour to be used | |
| | |
| Mycophenolate Mofetil | Each film coated tablets contains | |
| Tablets IP 360 mg | Mycophenolate Mofetil IP 360 mg | |
| Approved colour to be used | |
| | |
| Mycophenolate Mofetil | Each film coated tablets contains | |
| Tablets IP 500 mg | Mycophenolate Mofetil IP 500 mg | |
| Approved colour to be used | |
| | |
| Mycophenolate Mofetil | Each film coated tablets contains | |
| Tablets IP 750 mg | Mycophenolate Mofetil IP 750 mg | |
| Approved colour to be used | |
| | |
| Cyproterone Acetate | Each uncoated tablets contains | |
| Tablets IP | Cyproterone Acetate IP 50 mg | |
| Approved colour to be used | |
| | |
| Clenbuterol Hydrochioride | Each uncoated tabiets contains | |
| Tablets | Clenbuterol Hydrochloride BP 0.02 mg | |
| Approved colour to be used | |
| | |
| Trimetazidine Hydrochlorde | Each uncoated tablets contains | |
| Tablets IP 20 mg | Trimetazidine Hydrochlorde IP 20 mg | |
| | |
| Trimetazidine Hydrochlorde | Each modified release film coated tablet contains : | |
| Modified release tablets | Trimetazidine Hydrochlorde IP 35 mg | |
| Approved colour to be used | |
| | |
| Allopurinol | Each uncoated tablets contains | |
| Tablets IP 100 mg | Allopurinol IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Allopurinol | Each uncoated tablets contains | |
| Tablets IP 300 mg | Allopurinol IP 300 mg | |
| Approved colour to be used | |
| | |
| Racecadotril Dispersible Tablets | Each uncoated dispersible tablet contains : | |
| Racecadotril IP 10 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Racecadotril Dispersible Tablets | Each uncoated dispersible tablet contains : | |
| Racecadotril IP 30 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Alprazolam Sustained Released | Each uncoated sustained released tablet contains : | |
| Tablets | Alprazolam (Sustained Released) IP 1.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Alprazolam Sustained Released and | Each uncoated bilayered tablet contains : | |
| Sertraline Tablets | Alprazolam (Sustained Released) IP 0.25 mg | |
| Sertraline Hydrochloride IP | |
| Eq. to Sertraline 50 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Mebeverine Hydrochloride and | Each film coated tablet contains: | |
| Chlordiazepoxide Tablets | Mebeverine Hydrochloride IP 135 mg | |
| Chlordiazepoxide IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Dutasteride Tablets | Each film coated tablet contains : | |
| Dutasteride IP 0.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Dutasteride & Tamsulosin | Each film coated tablet contains: | |
| Hydrochloride Tablets | Dutasteride IP 0.5 mg | |
| Tamsulosin hydrochloride IP 0.4 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Dutasteride & Tamsulosin | Each film coated tablet contains: | |
| Hydrochloride (MR) Tablets | Dutasteride IP 0.5 mg | |
| Tamsulosin hydrochloride IP 0.4 mg | |
| (As Modified Release) | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tamsulosin | Each film coated tablet contains: | |
| Hydrochloride (MR) Tablets | Tamsulosin hydrochloride IP 0.4 mg | |
| (As Modified Release) | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tamsulosin | Each film coated tablet contains: | |
| Hydrochloride Tablets | Tamsulosin hydrochloride IP 0.4 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Dutasteride & Alfuzocin | Each film coated tablet contains: | |
| Hydrochloride (ER) Tablets | Dutasteride IP 0.5 mg | |
| Alfuzocin Hydrochloride IP 10.0 mg | |
| (As Modified Release) | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Mecobalamin, Pyridoxine HCI | Each film coated tablet contains: | |
| Alpha Lipoic Acid and | Mecobalamin IP 0.5 mg | |
| Benfotiamine Tablets | Pyridoxine Hydrochloride IP 50 mg | |
| Benfotiamine 100 mg | |
| Alpha Lipoic Acid IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Mecobalamin, Pyridoxine and | Each film coated tablet contains : | |
| Nicotinamide Tablets | Mecobalamin IP 750 mcg | |
| Pyridoxine Hydrochloride IP 1.5 mg | |
| Nicotinamide IP 45 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Amitriptyline and | Each film coated tablet contains : | |
| Methylcobalamin Tablets | Amitriptyline Hydrochloride IP 5 mg | |
| Methylcobalamin IP 1500 mcg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Trypsin, Bromelain, Papain and | Each film coated tablet contains : | |
| Rotoside Trihydrate Tablets | Trypsin BP 96 mg | |
| Bromelain 180 mg | |
| Rotoside Trihydrate BP 200 mg | |
| Papain IP 120 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Calcium, Vitamin D3, | Each film coated tablet contains : | |
| Mecobalamin and | Calcium Carbonate IP 1250 mg | |
| L-Methylfolate Calcium With | Eq. to Elemental Calcium 500 mg | |
| Pyridoxal-5-Phosphate Tablets | Vitamin D3 IP 2000 IU | |
| Mecobalamin IP 1500 mcg | |
| L-Methylfolate Calcium 1 mg | |
| Pyridoxal-5-Phosphate IP 20 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Rececadotril Tablets | Each uncoated tablet contains : | |
| Rececadotril IP 100 mg | |
| Excipients q.s. | |
| | |
| Cinnarizine & Dimenhydrinate | Each uncoated tablet contains : | |
| Tablets | Cinnarizine IP 20 mg | |
| Dimenhydrinate BP 40 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Griseofulvin & Cetirizine | Each uncoated tablet contains : | |
| Hydrochloride Tablets | Griseofulvin IP 250 mg | |
| Cetirizine Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Levocetirizine Hydrochloride | Each uncoated tablet contains | |
| Phenylephrine Hydrochloride & | Levocetirizine Hydrochloride IP 5 mg | |
| Paracetamol Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Paracetamol IP 500 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Diclofenac Sodium, Paracetamol, | Each uncoated tablet contains : | |
| Chlorphenramine Maleate | Diclofenac Sodium IP 50 mg | |
| Tablets | Paracetamol IP 325 mg | |
| Chlorphenramine Maleate IP 4 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Aceclofenac (SR) &, Pregabalin (SR) | Each uncoated biylayered tablet contains : | |
| Tablets | Aceclofenac (As sustained release) IP 200 mg | |
| Pregabalin (As sustained release) IP 75 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Aceclofenac, Paracetamol, | Each film coated tablet contains | |
| Tolperisone Hydrochloride | Aceclofenac IP 100 mg | |
| Tablets | Paracetamol IP 325 mg | |
| Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Mefenamic acid and Tizanidine | Each unCoated tablet contains : | |
| Tablets | Mefenamic acid IP 500 mg | |
| Tizanidine Hydrochloride IP | |
| Equivalent to Tizanidine 6 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Aceclofenac and Tizanidine | Each film coated tablet contains : | |
| Tablets | Aceclofenac IP 100 mg | |
| Tizanidine Hydrochloride IP | |
| Equivalent to Tizanidine 2 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Cefdinir dispersible Tablets 125 mg | Each dispersible uncoated tablet contains | |
| Cefdinir IP 125 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Cefdinir Tablets 300 mg | Each film coated tablet contains : | |
| Cefdinir IP 300 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Cinnarizine and Domperidone | Each uncoated tablets contains | |
| Tablets | Cinnarizine IP 20 mg | |
| Domperidone IP 15 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Udenafil & Dapoxetine Hcl | Each film coated tablet contains : | |
| Tab?ets | Udenafil IP 100 Mg | |
| Dapoxetine Hydrochloride IP | |
| Eq. to Dapoxetine 60 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Diclofenac Potassium, Paracetamol, | Each uncoated tablet contains : | |
| Cetirizine Hydrochloride and | Diclofenac Potassium IP 50 mg | |
| Magnesium Trisilicate Tablets | Paracetamol IP 325 mg | |
| Cetirizine Hydrochloride IP 5 mg | |
| Magnesium Trisilicate IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Artemether With Lumefantrine | Each uncoated tablet contains: | |
| Tablets | Artemether IP 40 mg | |
| Lumefantrine IP 240 mg | |
| Excipients q.s. | |
| | |
| Artemether With Lumefantrine | Each uncoated tablet contains: | |
| Tablets | Artemether IP 80 mg | |
| Lumefantrine IP 480 mg | |
| Excipients q.s. | |
| | |
| Cinnarizine Tablets | Each uncoated tablets contains | |
| Cinnarizine IP 15 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tizanidine Tablets IP | Each uncoated tablet contains: | |
| Tizanidine Hydrochloride IP | |
| Equivalent to Tizanidine 2 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Tizanidine Tablets IP | Each uncoated tablet contains: | |
| Tizanidine Hydrochloride IP | |
| Equivalent to Tizanidine 4 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Tizanidine Tablets IP | Each uncoated tablet contains: | |
| Tizanidine Hydrochloride IP 6 mg | |
| Equivalent to Tizanidine | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Benidipine Hydrochloride Tablets | Each film coated tablet contains | |
| Benidipine Hydrochloride JP 4 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Benidipine Hydrochloride Tablets | Each film coated tablet contains | |
| Benidipine Hydrochloride JP 8 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Repaglinide and Voglibose Tablets | Each uncoated tablet contains | |
| Repaglinide IP 0.5 mg | |
| Voglibose IP 0.2 mg | |
| Excipients q.s. | |
| | |
| Repaglinide and Voglibose Tablets | Each uncoated tablet contains | |
| Repaglinide IP 1 mg | |
| Voglibose IP 0.2 mg | |
| Excipients q.s. | |
| | |
| Repaglinide and Voglibose Tablets | Each uncoated tablet contains | |
| Repaglinide IP 0.5 mg | |
| Voglibose IP 0.3 mg | |
| Excipients q.s. | |
| | |
| Repaglinide and Voglibose Tablets | Each uncoated tablet contains | |
| Repaglinide IP 1 mg | |
| Voglibose IP 0.3 mg | |
| Excipients q.s. | |
| | |
| Metformin Hydrochloride & | Each uncoated bilayered-tablet contains | |
| Repaglinide Tablets | Metformin Hydrochloride IP 500 mg | |
| Repaglinide IP 2 mg | |
| Excipients q.s. | |
| Approved coloured used | |
| | |
| Nicoumalone Tablets IP | Each uncoated tablet corntains | |
| Nicoumalone IP 0.5 mg | |
| Excipients q.s. | |
| | |
| Nicoumalone Tablets IP | Each uncoated tablet corntains | |
| Nicoumalone IP 5 mg | |
| Excipients q.s. | |
| | |
| Nicoumalone Tablets IP | Each uncoated tablet corntains | |
| Nicoumalone IP 6 mg | |
| Excipients q.s. | |
| | |
| Diacerein, Glucosamine, | Each film coated tablet contains | |
| Methylsulphonyl Methane | Diacerein IP 50 mg | |
| Tablels | Glucosamine Sulphate Potassium IP 750 mg | |
| Methyl sulphonyl Methane USP 250 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Haloperidol Tablet IP | Each uncoated tablet contains | |
| Haloperidol IP 0.5 mg | |
| Excipients q.s. | |
| | |
| Haloperidol Tablet IP | Each uncoated tablet contains | |
| Haloperidol IP 1 mg | |
| Excipients q.s. | |
| | |
| Haloperidol Tablet IP | Each uncoated tablet contains | |
| Haloperidol IP 1.5 mg | |
| Excipients q.s. | |
| | |
| Haloperidol Tablet IP | Each uncoated tablet contains | |
| Haloperidol IP 2 mg | |
| Excipients q.s. | |
| | |
| Haloperidol Tablet IP | Each uncoated tablet contains | |
| Haloperidol IP 5 mg | |
| Excipients q.s. | |
| | |
| Haloperidol Tablet IP | Each uncoated tablet contains | |
| Haloperidol IP 10 mg | |
| Excipients q.s. | |
| | |
| Diclofenac Potassium, Paracetamol | Each uncoated tablet contains : | |
| and Magnesium Trisilicate | Diclofenac Potassium IP 50 mg | |
| Tablets | Paracetarmol IP 325 mg | |
| Magnesium Trisilicate IP 100 mg | |
| Approved colour to be used | |
| | |
| Sartraline Tablets IP | Each film coated tablet contains : | |
| Sartraline Hydrochloride IP | |
| Eg. to Sartraline 25 mg | |
| Approved colour to be used | |
| | |
| Sartraline Tablets IP | Each film coated tablet contains : | |
| Sartraline Hydrochloride IP | |
| Eg. to Sartraline 50 mg | |
| Approved colour to be used | |
| | |
| Sartraline Tablets IP | Each film coated tablet contains : | |
| Sartraline Hydrochloride IP | |
| Eg. to Sartraline 100 mg | |
| Approved colour to be used | |
| | |
| Sumatriptan & Naproxen | Each film coated tablet contains : | |
| Tablets | Sumatriptan IP 85 mg | |
| Naproxen IP 500 mg | |
| Approved colour to be used | |
| | |
| Sumatriptan & Naproxen | Each film coated tablet contains : | |
| Tablets | Sumatriptan IP 50 mg | |
| Naproxen IP 275 mg | |
| Approved colour to be used | |
| | |
| Armodafinil Tablets | Each uncoated tablet contains : | |
| Armodafinil IP 50 mg | |
| Approved colour to be used | |
| | |
| Armodafinil Tablets | Each uncoated tablet contains : | |
| Armodafinil IP 150 mg | |
| Approved colour to be used | |
| | |
| Armodafinil Tablets | Each uncoated tablet contains : | |
| Armodafinil IP 250 mg | |
| Approved colour to be used | |
| | |
| Zopiclone Tablets IP | Each film coated tablet contains : | |
| Zopiclone IP 3.75 mg | |
| Approved colour to be used | |
| | |
| Zopiclone Tablets IP | Each film coated tablet contains : | |
| Zopiclone IP 7.5 mg | |
| Approved colour to be used | |
| | |
| Zopiclone Tablets IP | Each film coated tablet contains : | |
| Zopiclone IP 10 mg | |
| Approved colour to be used | |
| | |
| Carisoprodol Tablets IP | Each uncoated tablet contains: | |
| Carisoprodol IP 350 mg | |
| Approved colour to be used | |
| | |
| Carisoprodol Tablets IP | Each uncoated tablet contains: | |
| Carisoprodol IP 500 mg | |
| Approved colour to be used | |
| | |
| Eszopiclone Tablets | Each film coated tablet contains : | |
| Eszopiclone IP 1 mg | |
| Approved colour to be used | |
| | |
| Eszopiclone Tablets | Each film coated tablet contains : | |
| Eszopiclone IP 2 mg | |
| Approved colour to be used | |
| | |
| Eszopiclone Tablets | Each film coated tablet contains : | |
| Eszopiclone IP 3 mg | |
| Approved colour to be used | |
| | |
| Pantoprazole Dual-release | Each Dual-release gastro-resistant tablet contains : | |
| gastro-resistant Tablets | Pantoprazole Sodium IP 80 mg | |
| Eq.to Pantoprazole | |
| Approved colour to be used | |
| | |
| Diazepam Tablets IP | Each uncoated tablet contains: | |
| Diazepam IP 10 mg | |
| Approved colour to used | |
| | |
| Dihydrocodeine Tablets | Each uncoated tablet contains : | |
| Dihydrocodeine IP 30 mg | |
| Approved colour to used | |
| | |
| Codeine Phosphate | Each uncoated tablet contains : | |
| Tablets IP | Codeine Phosphate IP 10 mg | |
| Approved colour to used | |
| | |
| Codeine Phosphate | Each uncoated tablet contains : | |
| Tablets IP | Codeine Phosphate IP 30 mg | |
| Approved colour to used | |
| | |
| Codeine Phosphate | Each uncoated tablet contains : | |
| Tablets IP | Codeine Phosphate IP 60 mg | |
| Approved colour to used | |
| | |
| Clonazepam and Escitalopram | Each film coated tablet contains : | |
| Tablets | Clonazepam IP 0.5 mg | |
| Escitalopram Oxelate IP | |
| Eq. to Escitalopram 10 mg | |
| Excipients q.s. | |
| | |
| Clonazepam and Escitalopram | Each film coated tablet contains : | |
| Tablets | Clonazepam IP 0.5 mg | |
| Escitalopram Oxelate IP | |
| Eq. to Escitalopram 5 mg | |
| Excipients q.s. | |
| | |
| Etizolam Tablets | Each film coated tablets contains | |
| Etizolam IP 0.25 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Etizolam Tablets IP | Each film coated tablets contains | |
| Etizolam IP 0.5 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Phenylephrine Hydrochloride & | Each uncoated tablet çontains: | |
| Chlorpheniramine Maleate | Phenylephrine Hydrochloride IP 5 mg | |
| Tablets | Chlorpheniramine Maleate IP 4 mg | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Metformin, Gliclazide and | Each uncoated tablet contains : | |
| Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 80 mg | |
| Voglibose IP 0.2 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Metformin, Gliclazide and | Each uncoated tablet contains : | |
| Voglibose Tablets | Metformin Hydrochloride IP 500 mg | |
| Gliclazide IP 80 mg | |
| Voglibose IP 0.3 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Lacosamide Tablets | Each film coated tablet contains : | |
| Lacosamide 50 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Lacosamide Tablets | Each film coated tablet contains : | |
| Lacosamide 100 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Lacosamide Tablets | Each film coated tablet contains : | |
| Lacosamide 150 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Lacosamide Tablets | Each film coated tablet contains : | |
| Lacosamide 200 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Moxonidine Tablets | Each film coated tablet contains : | |
| Moxonidine BP 0.2 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Moxonidine Tablets | Each film coated tablet contains : | |
| Moxonidine BP 0.3 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Moxonidine Tablets | Each film coated tablet contains : | |
| Moxonidine BP 0.4 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Torsemide and Amiloride Tablets | Each uncoated tablet contains : | |
| Torsemide IP 10 mg | |
| Amiloride Hydrochloride IP | |
| Eq. to Anhydrous Amiloride Hcl 5 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Torsemide and Spironolactone | Each uncoated tablet contains : | |
| Tabiets | Torsemide IP 10 mg | |
| Spironolactone IP 25 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Torsemide and Spironolactone | Each uncoated tablet contains : | |
| Tabiets | Torsemide IP 10 mg | |
| Spironolactone IP 50 mg | |
| Excipients q.s. | |
| Approved colour used | |
| | |
| Cilnidipine and Telmisartan | Each uncoated bilayered tablet contains | |
| Metoprolol Succinate SR Tablets | Cilnidipine IP 10 mg | |
| Telmisartan IP 40 mg | |
| MetoprololSuccinate IP 23.75 mg | |
| Eq.to Metoprolol Tartrate 25 mg | |
| (As sustained release) | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Cilnidipine and Telmisartan | Each uncoated bilayered tablet contains | |
| Metoprolol Succinate SR Tablets | Cilnidipine IP 10 mg | |
| Telmisartan IP 40 mg | |
| Metoproioi Succinate IP 47.5 mg | |
| Eq.to Metoprolol Tartrate 50 mg | |
| (As sustained release) | |
| Excipients q.s. | |
| Approved color to be use | |
| | |
| Ascorbic Acid with Zinc Tablets | Each uncoated chewable tablet contains : | |
| Ascorbic Acid IP 500 mg | |
| Zinc Sulphate IP | |
| Eq. to elemental Zinc 5 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Ascorbic Acid & Sodium Ascorbate | Each uncoated chewable tablet contains: | |
| with Zinc Tablets | Ascorbic Acid IP 100 mg | |
| Sodium Ascorbate IP 450 mg | |
| Eq. to Ascorbic acid 400 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Ascorbic Acid & Sodium Ascorbate | Each uncoated chewable tablet contains: | |
| with Zinc Tablets | Ascorbic Acid IP 100 mg | |
| Sodium Ascorbate IP 450 mg | |
| Eq. to Ascorbic acid 400 mg | |
| Zinc Citrate IP | |
| Eq. to elemental Zinc 5 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Ascorbic Acid & Sodium Ascorbate | Each uncoated chewable tablet contains: | |
| with Zinc Tablets | Ascorbic Acid IP 100 mg | |
| Sodium Ascorbate IP 450 mg | |
| Eq. to Ascorbic acid 400 mg | |
| Zinc Sulphate | |
| Eq. to elemental Zinc 5 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Vitamin D3, Calcium, | Each film coated chewable tablet contains : | |
| L-Methylfolate & Boron with | Vitamin D3 IP 1000 IU | |
| Methylcobalamin Tablets | Caclium Citrate Maleate IP 1180 mg | |
| Eq. to Calcium 250 mg | |
| L-Methylfolate 468 mg | |
| Boron 1.5 mg | |
| Methylcobalamin IP 1500 mcg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Gabapentin and Methylcobalamin | Each film coated tablet contains : | |
| Tablets | Gabapentin IP 100 mg | |
| Methylcobalamin IP 500 mcg | |
| Approved colour to be use q.s. | |
| | |
| Calciumn and Vitamin D3 Tablets | Each film coated tablet contains : | |
| Calcium Carbonate IP 1500 mg | |
| Eq. to Calcium 600 mg | |
| Vitammin D3 IP 200 IU | |
| Approved colour to be use q.s. | |
| | |
| Calcium Carbonate Tablets | Each film coated tablet contains : | |
| Calcium Carbonate IP 1500 mg | |
| Eq. to Calcium 600 mg | |
| Approved colour to be use q.s. | |
| | |
| Silymarin, L-Onithine L-Aspartate, | Each film coated tablet contains : | |
| Pancreatin, Lecithin, Pyridoxine and | Silymarin 140 mg | |
| Folic acid Tablets | L-Onithine L-Aspartate 150 mg | |
| Pancreatin IP 100 mg | |
| Lecithin 125 mg | |
| Pyridoxine Hcl IP 2 mg | |
| Folic acid IP 1.5 mcg | |
| Approved colour to be use | |
| | |
| Diosmin Tablets | Each film coated lablet contains : | |
| Diosmin (Micronised) BP 150 mg | |
| Approved colour to be use q.s. | |
| | |
| Diosmin Tablets | Each film coated lablet contains : | |
| Diosmin (Micronised) BP 300 mg | |
| Approved colour to be use q.s. | |
| | |
| Norethisterone Acetate | Each film coated controlled released tablet contains : | |
| Controlled released Tablets | Norethisterone Acetate BP 10 mg | |
| Approved colour to be use | |
| | |
| Norethisterone Tablets IP | Each uncoated tablet contains : | |
| Norethisterone IP 5 mg | |
| Excipients q.s. | |
| | |
| Methylcobalamin & Pregabaline | Each film coated tablet contains : | |
| Tablets | Methylcobalamin IP 750 mcg | |
| Pregabaline IP 75 mg | |
| Approved colour to be use | |
| | |
| Sacubitril and Valsartan | Each film coated tablets contains | |
| Tablets | Sacubutril 24 mg | |
| Valsartan IP 26 mg | |
| Approved colour to be used | |
| | |
| Sacubitril and Valsartan | Each film coated tablets contains | |
| Tablets | Sacubutril 49 mg | |
| Valsartan IP 51 mg | |
| Approved colour to be used | |
| | |
| Sacubutril and Valsartan | Each film coated tablets contains | |
| Tablets | Sacubutril 97 mg | |
| Valsartan IP 103 mg | |
| Approved colour to be used | |
| | |
| Diltiazem Sustained Release | Each film coated Sustained Release tablet contains | |
| Tablets | Diltiazem Hydrochloride IP 90 mg | |
| Approved colour to be used | |
| | |
| Diltiazem Sustained Release | Each film coated Sustained Release tablet contains | |
| Tablets | Diltiazem Hydrochloride IP 120 mg | |
| Approved colour to be used | |
| | |
| Glibenclamide, Pioglitazone | Each uncoated tablet contains : | |
| and Metformin HCI Tablets | Glibenclamide IP 5 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Metformin Hydrochloride IP 500 mg | |
| Approved colour to be used | |
| | |
| Dydrogesterone Tablets IP 10mg | Each film coated tablet conains: | |
| Dydrogesterone IP 10 mg | |
| Approved colour to be used | |
| | |
| Rosuvastatin and Aspirin | Each film coated tablet contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Aspirin IP 75 mg | |
| Approved colour to be used | |
| | |
| Rosuvastatin and Aspirin | Each film coated tablet contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 10 mg | |
| Aspirin IP 75 mg | |
| Approved colour to be used | |
| | |
| Nicorandil Tablets 5 mg | Each uncoated tablet contains : | |
| Nicorandil IP 5 mg | |
| Approved colour to used | |
| | |
| Nicorandil Prolonged Release | Each uncoated Prolonged-release tablet contains : | |
| Tablets IP 10 mg | Nicorandil IP 10 mg | |
| Excipient q.s | |
| | |
| Nicorandil Prolonged Release | Each uncoated Prolonged-release tablet contains : | |
| Tablets IP 20 mg | Nicorandil IP 20 mg | |
| Excipient q.s | |
| | |
| Trimetazidine Tablets IP 20mg | Each film coated tablet contains : | |
| Trimetazidine Hydrochloride IP 20 mg | |
| Approved colour to be used | |
| | |
| Trimetazidine HCL (SR) Tablets | Each modified release film coated tablet contains : | |
| Trimetazidine Hydrochloride IP 35 mg | |
| Approved colour to be used | |
| | |
| Trimetazidine Tablets | Each uncoated tablet contains : | |
| Trimetazidine Hydrochloride IP 3 mg | |
| Approved colour to be used | |
| | |
| Trimetazidine HCI (SR) Tablets | Each Sustained release film coated tablet contains : | |
| Trimetazidine Hydrochloride IP 60 mg | |
| Approved colour to be used | |
| | |
| Gabapentin and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Gabapentin IP 100 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Approved colour to be used | |
| | |
| Levodopa Tablets IP | Each uncoated tablet contains : | |
| Levodopa IP 250 mg | |
| Excipients | |
| | |
| Levodopa Tablets IP | Each uncoated tablet contains : | |
| Levodopa IP 500 mg | |
| Excipients | |
| | |
| Levodopa and Carbidopa | Each uncoated tablet contains: | |
| Tablets IP | Levodopa IP 100 mg | |
| Carbidopa IP | |
| Eq. to Anhydrous Carbidopa 10 mg | |
| Excipients q.s. | |
| | |
| Levodopa and Carbidopa | Each uncoated tablet contains: | |
| Tablets IP | Levodopa IP 100 mg | |
| Carbidopa IP | |
| Eq. to Anhydrous Carbidopa 25 mg | |
| Excipients q.s. | |
| | |
| Levodopa and Carbidopa | Each uncoated tablet contains: | |
| Tablets IP | Levodopa IP 250 mg | |
| Carbidopa IP | |
| Eq. to Anhydrous Carbidopa 25 mg | |
| Excipients q.s. | |
| | |
| Levetiracetam (PR) | Each uncoated tablet contains : | |
| Tablets IP | Levetiractam IP 500 mg | |
| (Prolonged released) | |
| Excipients q.s. | |
| | |
| Pregabaline and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Pregabaline IP 75 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Pregabaline and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Pregabaline IP 50 mg | |
| 25.03.2022 | Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Pregabaline and Nortriptyline | Each film coated tablet contains: | |
| Tablets | Pregabaline IP 37.5 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Tramadol Hydrochloride & | Each film coated tablet contains | |
| Aceclofenac Tablets | Aceclofenac IP 100 mg | |
| Tramadol Hydrochloride IP 50 mg | |
| Excipients q.s. | |
| | |
| Cetirizine Hydrochloride & | Each film coated tablet contains : | |
| Phenylephrine Hydrochloride | Cetirizine Hydrochloride IP 5 mg | |
| Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Cetirizine Hydrochloride & | Each film coated tablet contains : | |
| Phenylephrine Hydrochloride | Cetirizine Hydrochloride IP 10 mg | |
| Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Levetiracetam Tablets IP | Each uncoated tablet contains : | |
| Levetiractam IP 1000 mg | |
| Excipients q.s. | |
| | |
| Levetiracetam Tablets IP | Each film coated tablet contains : | |
| Levetiractam IP 500 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| Parácetamol, Phenylephrine, | Each uncoated tablet contains: | |
| Cetirizine HCI Tablets | Paracetamol IP 500 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Cetirizine Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| | |
| Parácetamol, Phenylephrine, | Each uncoated tablet contains: | |
| Cetirizine HCI Tablets | Paracetamol IP 500 mg | |
| Phenylephrine Hydrochloride IP 10 mg | |
| Cetirizine Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| | |
| Clozapine Tablets IP | Each uncoated tablet contains : | |
| Clozapine IP 25 mg | |
| Excipients q.s. | |
| | |
| Clozapine Tablets IP | Each uncoated tablet contains : | |
| Clozapine IP 50 mg | |
| Excipients q.s. | |
| | |
| Clozapine Tablets IP | Each uncoated tablet contains : | |
| Clozapine IP 100 mg | |
| Excipients q.s. | |
| | |
| Cyclobenzaprine Hydrochloride | Each uncoated tablet contains: | |
| Tablets IP | Cyclobenzaprine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| | |
| Cyclobenzaprine Hydrochloride | Each uncoated tablet contains: | |
| Tablets IP | Cyclobenzaprine Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| | |
| Cyclobenzaprine Hydrochloride | Each film coated sustained release bilayered tablet contains | |
| & Aceclofenac Tablets | Cyclobenzaprine Hydrochloride IP 15 mg | |
| Aceclofenac IP 200 mg | |
| Excipients q.s. | |
| | |
| Piroxicam and | Each uncoated tablet contains : | |
| Paracetamol Tablets | Piroxicam IP 20 mg | |
| Paracetamol IP 500 mg | |
| Excipients q.s. | |
| | |
| Piroxicam and | Each uncoated tablet contains : | |
| Paracetamol Tablets | Piroxicam IP 20 mg | |
| Paracetamol IP 325 mg | |
| Excipients q.s. | |
| | |
| Doxofylline SR and | Each uncoated tablet contains | |
| Acebrophylline Tablets | Doxofylline (Sustained released) IP 400 mg | |
| Acebrophylline IP 100 mg | |
| Excipients q.s. | |
| | |
| Paracetamol, Caffeine, | Each uncoated tablet contains | |
| Phenylephrine HCL, and | Paracetamol IP 500 mg | |
| Chlorpheniramine Maleate | Caffeine (Anhydrous) IP 30 mg | |
| Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Chlorpheniramine maleate IP 4 mg | |
| Excipients q.s. | |
| | |
| Acebrophyline (SR), | Each film coated tablet contains: | |
| Montelukast sodium and | Acebrophylline (Sustained released) 200 mg | |
| Desloratidine Tablets | Montelukast sodium IP | |
| Eq. to Montelukast 10 mg | |
| Desloratidine 5 mg | |
| Excipients q.s. | |
| Approved colour to be use | |
| | |
| SILDENAFIL CITRATE | Each orally disintegrating tablet contains : | |
| ORALLY DISINTEGRATING TABLETS | Sildenafil Citrate IP | |
| Approved Date : 28/06/2014 | Equivalent to Sildenafil 25 mg | |
| 06.09.2024 | Excipients q.s. | |
| Approved colour to be used | |
| | |
| SILDENAFIL CITRATE | Each orally disintegrating tablet contains : | |
| ORALLY DISINTEGRATING TABLETS | Sildenafil Citrate IP | |
| Approved Date : 28/06/2014 | Equivalent to Sildenafil 50 mg | |
| 06.09.2024 | Excipients q.s. | |
| Approved colour to be used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayered tablet contains : | |
| and Dapagliflozin tablets | Metformin Hydrochloride IP 500 mg | |
| 06.09.2024 | (As sustained release) | |
| Dapagliflozin propanediol Monohydrate | |
| Equivalent to Dapagliflozin IP 10 mg | |
| Approved colour to be used | |
| | |
| Metformin Hydrochloride (SR) | Each uncoated bilayered tablet contains : | |
| and Dapagliflozin tablets | Metformin Hydrochloride IP 1000 mg | |
| 06.09.2024 | (As sustained release) | |
| Dapagliflozin propanediol Monohydrate | |
| Equivalent to Dapagliflozin IP 10 mg | |
| Approved colour to be used | |
| | |
| Linagliptin Tablets | Each uncoated tablet contains | |
| Linagliptin IP 400 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Lornoxicam Tablets IP 8mg | Each film coated tablet contains: | |
| Lornoxicam 8mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Ferrous Ascorbate & Folic Acid Tablets | Each film coated tablet contains: | |
| Ferrous Ascorbate IP 100mg | |
| Eq. to elemental Iron | |
| Folic Acid IP 1.5mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Praziquantel Tablets IP 600mg | Each film coated tablets contains : | |
| Praziquantel IP 600 mg | |
| Approved colour to be used | |
| | |
| Levamisole Hydrochloride Tablets IP | Each uncoated tablets contains | |
| Levamisole Hydrochloride IP | |
| Eq. to Levamisole 50 mg | |
| Approved colour to be used | |
| | |
| Levamisole Hydrochloride Tablets IP | Each uncoated tablets contains | |
| Levamisole Hydrochloride IP | |
| Eq. to Levamisole 150 mg | |
| Approved colour to be used | |
| | |
| Levamisole Hydrochloride & | Each film coated tablets contains : | |
| Albendazole Tablets | Levamisole Hydrochloride IP | |
| Eq. to Levamisole 50 mg | |
| Albendazole IP 400 mg | |
| Approved colour to be used | |
| | |
| Ethionamide Tablets IP | Each film coated tablets contains : | |
| Ethionamide IP 125 mg | |
| Approved colour to be used | |
| | |
| Ethionamide Tablets IP | Each film coated tablets contains : | |
| Ethionamide IP 250 mg | |
| Approved colour to be used | |
| | |
| Ranitidine Hydrochloride, Dicyclomine | Each film coated tablets contains : | |
| Hydrochloride & Simethicone Tablets | Ranitidine Hydrochloride IP | |
| Eq. to Ranitidine 150 mg | |
| Dicyclomine Hydrochloride IP 10 mg | |
| Simethicone IP 20 mg | |
| | |
| Letrozole Tablets IP | Each film coated tablets contains : | |
| Letrozole IP 2.5 mg | |
| Approved colour to be used | |
| | |
| Brivaracetam Tablets IP 50mg | Each film coated tablets contains : | |
| Brivaracetam IP 50 mg | |
| Approved colour to be used | |
| | |
| Brivaracetam Tablets IP 75mg | Each film coated tablets contains : | |
| Brivaracetam IP 75 mg | |
| Approved colour to be used | |
| | |
| Brivaracetam Tablets IP 100mg | Each film coated tablets contains : | |
| Brivaracetam IP 100 mg | |
| Approved colour to be used | |
| | |
| Ramosetron Hydrochloride Tablets | Each uncoated tablets contains | |
| Ramosetron Hydrochloride 100 mcg | |
| Approved colour to be used | |
| | |
| Cynocobalamin Tablets IP | Each uncoated tablets contains | |
| Cynocobalamin IP 1500 mcg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Methylcobalamin, Pyridoxine Hydrochloride,Vit D3 | Each uncoated mouth dissolving tablets contains | |
| and Folic Acid Tablets | Methylcobalamin IP 1500 mcg | |
| Pyridoxine Hydrochloride IP 3 mg | |
| Vitamin d3 IP 1000 IU | |
| Folic Acid IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Pantoprazole Sodium Gastro-Resistant Tablets IP | Each enteric coated tablet contains : | |
| 20 mg | Pantoprazole Sodium IP | |
| Eq. to Pantoprazole 20 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol, Phenylephrine,Caffeine and | Each uncoated bilayered tablets contains | |
| Diphenhydramine Tablets | Paracetamol IP 500 mg | |
| Caffeine (Anhydrous) IP 30 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Diphenhydramine Hydrochloride IP 25 mg | |
| Approved colour to be used | |
| | |
| Diclofenac Sodium Prolonged release | Each sustained release film coated tablets contains : | |
| Tablets IP 75 mg | Diclofenac Sodium IP 75 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Diclofenac Sodium | Each film coated tablets contains : | |
| Tablets IP 75 mg | Diclofenac Sodium IP 75 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol, Phenylephrine Hydrochloride, | Each uncoated tablets contains | |
| Chlorpheniramine Maleate Tablets | Paracetamol IP 325 mg | |
| Phenylephrine Hydrochloride IP 10 mg | |
| Chlorpheniramine Maleate IP 4 mg | |
| Approved colour to be used | |
| | |
| Diclofenac Sodium Prolonged Release Tablets IP | Each film coated prolonged release tablets contains : | |
| 100 mg | Diclofenac Sodium IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Benedipine Hydrochloride & Telmisartan | Each film coated bilayered tablets contains | |
| Tablets | Benedipine Hydrochloride 4 mg | |
| Telmisartan IP 40 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Linagliptin Tablets | Each uncoated tablet contains | |
| Linagliptin IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol, Phenylephrine HCL & | Each Uncoated tablet contains: | |
| Chlorpheniramine Maleate Tablets | Paracetamol IP 500 mg | |
| Phenylephrine Hydrochloride IP 10 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Meclizine HCL (SR) with Folic Acid | Each film coated Sustain release tablets contains | |
| Tablets | Meclizine Hydrochloride IP 50 mg | |
| Eq. to Meclizine | |
| (On form -28) | (As sustain release) | |
| Folic acid IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Etizolam & Propranolol Hydrochloride | Each Uncoated tablet contains: | |
| Tablets | Etizolam 0.25 mg | |
| Propranolol Hydrochloride IP 20 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Thiamine Hydrochloride | Each film coated tablets contains : | |
| Tablets | Thiamine Hydrochloride IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Lactic acid basillus, Vitamin B12 and | Each Uncoated Dispersible tablet contains: | |
| Folic acid Dispersible Tablets | Lactic acid basillus 120 mill. Spore | |
| Vitamin B 12 IP 5 mcg | |
| Folic acid IP 1500 mcg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Ascorbic acid, Menadione, Dibasic Calcium | Each film coated tablets contains : | |
| Phophate , Cholecalciferol and Rutin | Ascorbic acid IP 50 mg | |
| Tablets | Menadione Sodium Bisulphate 20 mg | |
| Dibasic Calcium Phosphate IP 150 g | |
| Cholecalciferol (Vitamin D3) IP 300 I.U | |
| Rutin U.S.S.R.P 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Mecobalamin & Epalrestat | Each Uncoated tablet contains: | |
| Tablets | Mecobalamin IP 500 mcg | |
| Epalrestat 50 mg | |
| Approved colour to be used | |
| | |
| Ebastine & Phenylephrine | Each film coated tablets contains : | |
| Tablets | Ebastine IP 10 mg | |
| Phenylephrine Hydrochloride IP 10 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Isotretinoin Tablets | Each Uncoated tablet contains: | |
| Isotretinoin IP 10 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Isotretinoin Tablets | Each Uncoated tablet contains: | |
| Isotretinoin IP 20 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol & Caffeine | Each Uncoated tablet contains: | |
| Tablets | Paracetamol IP 325 mg | |
| Caffeine (Anhydros) IP 10 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Vonoprazan Tablets | Each film coated tablets contains : | |
| Vonoprazan Fumarate | |
| Eq. to Vonoprazan 20 mg | |
| Approved colour to be used | |
| | |
| Mefenamic Acid Dispersible | Each Uncoated Dispersible tablet contains: | |
| Tablets | Mefenamic Acid IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol, Phenylephrine Hydrochloride | Each Uncoated tablet contains: | |
| & Chlorpheniramine Maleate | Paracetamol IP 500 mg | |
| Tablets | Phenylephrine Hydrochloride IP 5 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Paracetamol , Phenylephrine Hydrochloride | Each Uncoated tablet contains: | |
| & Chlorpheniramine Maleate | Paracetamol IP 500 mg | |
| Tablets | Phenylephrine Hydrochloride IP 10 mg | |
| Chlorpheniramine Maleate IP 4 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Tapentadol Hydrochloride | Each film coated sualain realease tablet contains | |
| Sustain Release Tablets | Tapentadol Hydrochloride IP | |
| Eq. to Tapentadol 50 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Tramadol Hydrochloride & | Each uncoated bilayered tablet contains : | |
| Paracetamol Tablets | Tramadol Hydrochloride IP 37.5 mg | |
| Paracetamol IP 325 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Activated Charcoal & Simethicone | Each film coated tablets contains : | |
| Tablets | Activated Charcoal IP 250 mg | |
| Simethicone IP 80 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| Activated Charcoal & Simethicone | Each Dual coated tablets contains : | |
| Tablets | Outer layer (Sugar Coated for Gastric release) | |
| Simethicone IP 80 mg | |
| Inner layer (Enteric Coated for Intestinal release) | |
| Activated Charcoal IP 250 mg | |
| Excipients q.s. | |
| Approved colour to used | |
| | |
| | |
| Pentoxifylline Extended release | Each film coated Extended release tablets contains : | |
| Tablets IP 400 mg | pentoxifylline IP 400 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Cabergoline Tablets IP 0.5 mg | Each Uncoated tablet contains: | |
| Cabergoline IP 0.5 mg | |
| Excipients q.s. | |
| | |
| | |
| Cabergoline Tablets IP 1 mg | Each Uncoated tablet contains: | |
| Cabergoline IP 1 mg | |
| Excipients q.s. | |
| | |
| | |
| Tetrabenazine Tablets 25 mg | Each Uncoated tablet contains: | |
| Tetrabenazine 25 mg | |
| Excipients q.s. | |
| | |
| | |
| Dimenhydrinate TabletsBP 50 mg | Each Uncoated tablet contains: | |
| Dimenhydrinate BP 50 mg | |
| Excipients q.s. | |
| | |
| | |
| Desloratadine Tablets 5 mg | Each film coated tablets contains : | |
| Desloratadine BP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Rosuvastatin and Teneligliptin | Each film coated tablets contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Teneligliptin Hydrobromide hydrat IP | |
| Eq. to Teneligliptin 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Rosuvastatin and Teneligliptin | Each film coated tablets contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Teneligliptin Hydrobromide hydrat IP | |
| Eq. to Teneligliptin 10 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Rosuvastatin and Teneligliptin | Each film coated tablets contains : | |
| Tablets | Rosuvastatin Calcium IP | |
| Eq. to Rosuvastatin 20 mg | |
| Teneligliptin Hydrobromide hydrat IP | |
| Eq. to Teneligliptin 20 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Ranolazine Extend Release | Each film coated Sustained release tablets contains : | |
| Tablets | Ranolazine 500 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Ranolazine Sustained Release | Each film coated Extended release tablets contains : | |
| Tablets | Ranolazine 500 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Ketorolac Tromethamine | Each Uncoated tablet contains: | |
| Tablets IP 10 mg | Ketorolac Tromethamine IP 10 mg | |
| Excipients q.s. | |
| | |
| | |
| Teneligliptin and Pioglitazone Hydrochloride | Each film coated tablets contains : | |
| Tablets | Teneligliptin Hydrobromide Hydrate IP | |
| Eq. to Teneligliptin 20 mg | |
| Pioglitazone Hydrochloride IP | |
| Eq. to Pioglitazone 15 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Hydrocortisone Tablets USP 5 mg | Each Uncoated tablet contains: | |
| Hydrocortisone IP 5 mg | |
| | |
| | |
| Hydrocortisone Tablets USP 10 mg | Each Uncoated tablet contains: | |
| Hydrocortisone IP 10 mg | |
| | |
| | |
| Hydrocortisone Tablets USP 20 mg | Each Uncoated tablet contains: | |
| Hydrocortisone IP 20 mg | |
| | |
| | |
| Midodrine Hydrochloride | Each film coated tablets contains : | |
| Tablets USP 2.5 mg | Midodrine Hydrochloride USP 2.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Midodrine Hydrochloride | Each film coated tablets contains : | |
| Tablets USP 5 mg | Midodrine Hydrochloride USP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Fenofibrate Tablets IP 160 mg | Each film coated tablets contains : | |
| Fenofibrate IP 160 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Fenofibrate Tablets IP 200 mg | Each film coated tablets contains : | |
| Fenofibrate IP 200 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Primaquine Tablets IP 15 mg | Each film coated tablets contains : | |
| Primaquine Phosphate IP 26 mg | |
| Eq. to Primaquine 15mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Trihexyphenidyl Hydrochloride | Each Uncoated tablet contains: | |
| Tablets IP 2 mg | Trihexyphenidyl Hydrochloride IP 2 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Trihexyphenidyl Hydrochloride | Each Uncoated tablet contains: | |
| Tablets IP 5 mg | Trihexyphenidyl Hydrochloride IP 5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Trihexyphenidyl Hydrochloride Dispersible | Each Uncoated dispersible tablet contains: | |
| Tablets IP 2 mg | Trihexyphenidyl Hydrochloride IP 2 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Magnesium Hydroxide, Dried Aluminium | Each Uncoated chewable tablet contains: | |
| Hydroxide With Simethicone ( Actvated Dimethicone) | Magnesium Hydroxide IP 250 mg | |
| Chewable Tablets | Dried Aluminium Hydroxide Gel IP 250 mg | |
| Simethicone (Activated Dimethicone) IP 50 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Desvenlafexine Extened Release | Each Uncoated bilayered tablet contains: | |
| and clonazepam Tablets | Desvenlafexine Succinate USP | |
| Eq. to Desvenlafexine 50 mg | |
| (As extened release form) | |
| Clonazepam IP 0.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Gabapentin and Nortriptyline | Each film coated tablets contains : | |
| Tablets | Gabapentin IP 200 mg | |
| Nortriptyline Hydrochloride IP | |
| Eq. to Nortriptyline 10 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Phenylbutazone Tablets IP | Each film coated tablets contains : | |
| Phenylbutazone IP07 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Phenylbutazone Tablets IP | Each film coated tablets contains : | |
| Phenylbutazone IP07 200 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Primaquine Tablets IP 7.5 mg | Each film coated tablets contains : | |
| Primaquine Phosphate IP 13 mg | |
| Eq. to Primaquine 7.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Sodium Valproate and Valproic Acid | Each film coated controlled release tablets contains : | |
| Controlled release Tablets | Sodium Valproate IP 133.5 mg | |
| Valproic Acid IP 58 mg | |
| ( Both together corresponds to sodium Valproate IP 200 mg ) | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Etodolac and Tolperisone Hydrochloride | Each film coated tablets contains : | |
| Tablets | Etodolac IP 400 mg | |
| Tolperisone Hydrochloride JP 150 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Glimepiride Tablets IP 0.5 mg | Each film coated tablets contains : | |
| Glimepiride IP 0.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Metformin Hydrochloride Prolonged release | Each Uncoated bilayered tablet contains: | |
| and glimepiride Tablets | Metformin Hydrochloride IP 1000 mg | |
| ( As prolonged release form | |
| Glimepiride IP 0.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Tofisopam Tablets 50 mg | Each uncoated / film coated tablets contains : | |
| Tofisopam JP 50 mg | |
| Excipients q.s. | |
| | |
| | |
| Tofisopam Tablets 100 mg | Each uncoated / film coated tablets contains : | |
| Tofisopam JP 100 mg | |
| Excipients q.s. | |
| | |
| | |
| Flavoxate Hydrochloride 100 mg | Each film coated tablets contains : | |
| Flavoxate Hydrochloride IP 100 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| | |
| Hydralazine Hydrochloride | Each uncoated tablets contains : | |
| Tablets 25 mg | Hydralazine Hydrochloride BP 25 mg | |
| Approved colour to be used | |
| | |
| | |
| Hydralazine Hydrochloride | Each uncoated tablets contains : | |
| Tablets 50 mg | Hydralazine Hydrochloride BP 50 mg | |
| Approved colour to be used | |
| | |
| | |
| Isosorbibe Dinitrate and Hydralazine | Each film coated tablets contains : | |
| Hydrochloride Tablets | Diluted Isosorbibe Dinitrate IP | |
| Eq. to Isosorbibedrinate 20 mg | |
| Hydralazine Hydrochloride IP 37.5 mg | |
| Excipients q.s. | |
| Approved colour to be used | |
| | |
| Pheniramine Maleate | Each 5 ml Contains : | |
| Syrups | Pheniramine Maleate IP 15 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Pheniramine Maleate | Each 5 ml Contains : | |
| Syrups | Pheniramine Maleate IP 30 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Lactulose Oral Solution USP | Each 15 ml. contains : | |
| Lactulose Concentrate USP | |
| eq. to Lactulose 10 g | |
| Approved colour used in flavoured syrupy base | |
| | |
| Phenobarbitone Syrup | Each 5 ml Contains : | |
| Phenobarbitone Sodium IP | |
| Eq. to Phenobarbitone 20 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Mefenamic Acid & | Each 5 ml. contains: | |
| Paracetamol Suspension | Mefenamic Acid IP 100 mg | |
| Paracetamol IP 250 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Multivitamin Drops | Each ml contains : | |
| For paediatric use | Thiamine Mononitrate IP 1 mg | |
| For infants less then 1 year | Riboflavine IP 1.5 mg | |
| Pyridoxine HCL IP 1.5 mg | |
| Cyanocobalamin IP 3 mcg | |
| Nicotinamide IP 15 mg | |
| Cholecalciferol (Vitamin D3) IP 400 IU | |
| Zinc Sulphate Monohydrate IP | |
| Eq. to elemantel Zinc 2.50 mg | |
| Vitamin A (As Palmetate) IP 2000 IU | |
| Omega 3 30 mg | |
| Selenium Dioxide IP 15 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Multivitamin Syrups | Each 5 ml contains : | |
| For Prophylatic use | Thiamine Mononitrate IP 2 mg | |
| Riboflavine IP 2 mg | |
| Pyridoxine HCL IP 1.0 mg | |
| Cyanocobalamin IP 3 mcg | |
| Nicotinamide IP 25 mg | |
| Cholecalciferol (Vitamin D3) IP 400 IU | |
| Zinc Sulphate Monohydrate IP | |
| Eq. to elemantel Zinc IP 5 mg | |
| Vitamin A (As Palmetate) IP 3000 IU | |
| Selenium Dioxide IP 25 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Vitamin A Drops | Each ml contains : | |
| For paediatric use | Vitamin A (As Palmetate) IP 1500 IU | |
| Approved colour used in flavoured syrupy base | |
| | |
| Vitamin A Drops | Each ml contains : | |
| For paediatric use | Vitamin A (As Palmetate) IP 2500 IU | |
| Approved colour used in flavoured syrupy base | |
| | |
| Cholecalciferol Syrup | Each 5 ml Contains : | |
| For Therapeutic Use | Cholecalciferol (Vitamin D3) IP 1000 IU | |
| Approved colour used in flavoured syrupy base | |
| | |
| Prednisolone Syrup USP | Each 5 ml Contains : | |
| Prednisolone IP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Clarithromycin | Each 5 ml Contains: | |
| Oral Suspension | Clarithromycin IP 125 mg | |
| For pediatric Use | Approved colour used in flavoured syrupy base | |
| | |
| Clarithromycin | Each 5 ml Contains: | |
| Oral Suspension | Clarithromycin IP 250 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Posaconazole | Each ml contains : | |
| Oral Suspension | Posaconazole 40 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Voriconazole | Each ml contains : | |
| Oral powder for solution | Voriconazole IP 40 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Multivitamin With | Each 5 ml contains : | |
| Cyproheptadine Syrup | Thiamine Mononitrate IP 1 mg | |
| Pyridoxine HCL IP 1.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Nicotinamide IP 15 mg | |
| D-Panthenol IP 5 mg | |
| Zinc Sulphate Monohydrate IP | |
| Eq. to elemantel Zinc 1.82 mg | |
| Cyproheptadine Hydrochloride IP 2 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Simethicone, Dill Oil | Each ml contains : | |
| with Fennel Oil Drops | Simethicone IP 40 mg | |
| For Paediatric Use | Dill Seed Oil IP 0.005 ml | |
| Fennel Oil IP 0.0007 ml | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| Iron, Folic acid and | Each 5 ml contains : | |
| Cyanocobalamin Syrup | Ferric Amonium Citrate IP 110 mg | |
| 17.11.2021 | Eq. to Elemental Iron 22.5 mg | |
| Folic acid IP 1.5 mg | |
| Cyanocobalamin IP 15 mcg | |
| Sorbitol solution (70%) Non crystalling q.s. | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Multivitamin, Mineral with | Each 15 ml contains : | |
| Lycopene Syrup | Lycopene 10% 1000 mcg | |
| For Prophylactic Use | Niacitamide IP 25 mg | |
| Pyridoxine HCl IP 1.5 mg | |
| Cyanocobalamin IP 1 mg | |
| Folic acid IP 100 mcg | |
| Selenium (As sodium seleneate) 35 mcg | |
| Zinc (As Zinc Glucotate) BP 3 mg | |
| lodine (As Potassium lodide) IP 100 mcg | |
| Copper (As Copper Sulphate) BP 500 mcg | |
| Biotine BP 100 mcg | |
| Magnesium Gluconate BP 100 mcg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Iron (III) Polymaltose, Folic acid | Each 15 ml contains : | |
| Syrup | Iron (III) Hydroxide Polymaltose | |
| For Therapeutic Use | Complex Eq. to Elemental Iron 50 mg | |
| Folic acid IP 0.5 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Sucralfate and Oxetacaine | Each 5 ml contains : | |
| Suspension | Sucralfate IP 500 mg | |
| Oxetacaine BP 10 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Dextromethorphan HBr and | Each 5 ml contains : | |
| Chlorpheniramine Syrup | Dextromethorphan HBr IP 10 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Nitazoxanide Suspension | Each 5 ml contains : | |
| Nitazoxanide 100 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Dicyclomine Hydrochloride | Each 5 ml contains : | |
| Suspension | Dicyclomine Hydrochloride IP 10 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Dried Aluminium Hydroxide, | Each 10 ml contains : | |
| Magnesium Hydroxide and | Aluminuum Hydroxide Past | |
| Simethicone Syrup | Eq. to Dried Aluminium Hydroxide IP 250 mg | |
| Magnesium Hydroxide | |
| Eq. to Magnesium Hydroxide IP 250 mg | |
| Simethicone IP 50 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Ursodeoxycholic Acid | Each 5 ml contains : | |
| Oral Suspension | Ursodeoxycholic Acid IP 125 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Ursodeoxycholic Acid | Each 5 ml contains : | |
| Oral Suspension | Ursodeoxycholic Acid IP 250 mg | |
| Approved coloured use in a flavoured syrup base | |
| Bilastine Oral Solution | Each ml contains : | |
| Bilastine 2.5 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Dicyclomine Hydrochloride and | Each 5 ml contains : | |
| Simethicone Suspension | Dicyclomine Hydrochloride IP 10 mg | |
| Simethicone IP 40 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Magaldrate, Oxetacaine and | Each 5 ml contains : | |
| Simethicone Suspension | Magaldrate IP 480 mg | |
| Oxetacaine BP 10 mg | |
| Simethicone IP 20 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Dried Aluminium Hydroxide, | Each 5 ml contains : | |
| Magnesium Hydroxide and | Aluminuum Hydroxide 0.291 gm | |
| Oxetacaine Syrup | (Added as Aluminium Hydroxide paste | |
| Eq. to 0.380 gm Dried Aluminium Hydroxide IP) | |
| Magnesium Hydroxide IP 98 mg | |
| (Added as Magnesium Hydroxide paste) | |
| Oxetacaine BP 10 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Paracetamol and | Each 5 ml contains : | |
| Domperidone Suspension | Paracetamol IP 250 mg | |
| Domperidone IP 5 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Domperidone Suspension | Each 5 ml contains : | |
| Domperidone IP 5 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Dextromethorphan HBr, Phenylephrine Hcl, | Each 5 ml contains : | |
| Chlorpheniramine Maleate Syrups | Dextromethorphan HBr IP 15 mg | |
| Phenylephrine Hydrochloride IP 5 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Approved coloured use in a flavoured syrup base | |
| | |
| Mecobalamine, Alfacacidol, Riboflavin, | Each 5 ml contains : | |
| Thiamine, Pyridoxine, Nicotinamide, | Mecobalamine IP 1 mcg | |
| Calcium D pantothenate & Zinc Syrup | Alfacalcidol IP 0.25 mcg | |
| For Prophylactic Use | Thiamine mononitrate IP 1 mg | |
| Riboflavin IP 1.1 mg | |
| Pyridoxine hydrochloride IP 0.80 mg | |
| Nicotinamide IP 15 mg | |
| Calcium D Pantothenate IP 3 mg | |
| Zinc sulphate monohydrate IP | |
| Eq. to elemntal Zinc 1.82 mg | |
| Approved coloured used in flavoured syrupy base | |
| | |
| Pyridoxine, Nicotinamide, | Each 5 ml contains : | |
| Mecobalamine, L-Lysine Syrup | Pyridoxine hydrochloride IP 0.75 mcg | |
| For Prophylactic Use | Nicotinamide IP 15 mg | |
| Mecobalamine IP 2 mg | |
| L-Lysine Hydrochloride IP 37.5 mg | |
| Sorbitol Solution (70%) IP q.s | |
| (Non Crystallizing) | |
| Approved coloured used in flavoured syrupy base | |
| | |
| Mefenaimic Acid Suspension | Each 5 ml contains : | |
| Mefenamic acid IP 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol, Phenylephrine Hcl, | Each 5 ml contains : | |
| Chlorpheniramine Maleate and | Paracetamol IP 125 mg | |
| Sodium Citrate Suspension | Chlorpheniramine Maleate IP 1 mg | |
| Phenylephrine Hcl IP 5 mg | |
| Sodium Citrate IP 60 mg | |
| Menthol qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol, Phenylephrine Hcl, | Each 5 ml contains : | |
| Chlorpheniramine Maleate and | Paracetamol IP 250 mg | |
| Sodium Citrate Suspension | Chlorpheniramine Maleate IP 2 mg | |
| Phenylephrine Hcl IP 5 mg | |
| Sodium Citrate IP 60 mg | |
| Menthol qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| Diphenhydramine Hcl, Terpine Hydrate | Each 5 ml contains : | |
| Ammonium chloride, Sodium Citrate | Diphenyhydramine Hcl IP 12.5 mg | |
| Suspension | Terpine Hydrate IP 7.5 mg | |
| Ammonium Chloride IP 125 mg | |
| Sodium Citrate IP 55 mg | |
| Mentheol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| Ambroxol Hcl, Guaiphenesin, | Each 5 ml contains : | |
| Phenylephrine Hcl and | Ambroxol Hcl IP 15 mg | |
| Chlorpheniramine Maleate | Guaiphenesin IP 50 mg | |
| Suspension | Phenylephrine Hcl IP 2.5 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Mentheol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| Magaldrate, Oxetacaine and | Each 5 ml contains | |
| Activated Dimethicone Suspension | Magaldrate IP 540 mg | |
| Oxetacaine BP 10 mg | |
| Activated Dimethicone IP 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Sodium Plcosulphate | Each 5 ml contains | |
| Oral Solution BP | Sodium Picosulphate BP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Dried Aluminium Hydroxide | Each 10 ml contains | |
| Magnesium Hydroxide with | Dried Aluminium Hydroxide Gel IP 250 mg | |
| Activated Dimethicone | Magnesium Hydroxide IP 250 mg | |
| Suspension | Activated Dimethicone IP 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Magaldrate with Simethicone | Each 5 ml contains: | |
| Suspension | Magaldrate IP 480 mg | |
| Simethicone IP 20 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Dried Aluminium Hydroxide, | Each 5 ml contains: | |
| Magnesium Hydroxide, | Dried Aluminium Hydroxide Gel IP 291 mg | |
| Oxetacaine Suspension | Magnesium Hydroxide IP 98 mg | |
| Oxetacaine IP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Magaldrate, Alginic Acid and | Each 5 ml contains: | |
| Activated Dimethicone | Magaldrate IP 540 mg | |
| Suspension | Alginic Acid IP 50 mg | |
| Activated Dimethicone IP 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Disodium Hydrogen Citrate | Each 5 ml contains | |
| Syrup | Disodium Hydrogen citrate BP 1.53 gm | |
| Approved colour used in flavoured syrupy base | |
| | |
| Sucralfate Suspension | Each 5 ml contains : | |
| Sucralfate IP 500 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Fexofenadine and | Each 5 ml contains : | |
| Montelukast Suspension | Fexofenadine IP 60 mg | |
| Montelukast Sodium IP | |
| eq. to Montelukast 4 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Ofloxacin & Metronidazole | Each 5 ml contains : | |
| Oral Suspension | Ofloxacin IP 100 mg | |
| Metronidazole Benzoate IP | |
| Equivalent to Metronidazole 200 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Terbutaline Sulphate, | Each 5 ml contains : | |
| Ambroxol Hydrochloride | Terbutaline Sulphate IP 0.63 mg | |
| Guaiphenesin Syrup | Ambroxol Hydrochloride IP 10 mg | |
| Guaiphenesin IP 25 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levosalbutamol Sulphate, | Each 5 ml contains : | |
| Ambroxol Hydrochloride | Levosalbutamol Sulphate IP | |
| Guaiphenesin Syrup | Eq. to Levosalbutamol 0.5 mg | |
| Ambroxol Hydrochloride IP 15 mg | |
| Guaiphenesin IP 25 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Hydroxyzine Hydrochloride | Each 5 ml contains : | |
| Oral Suspension IP | Hydroxyzine Hydrochloride IP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Terbutaline Sulphate, | Each 5 ml contains : | |
| Acebrophylline with | Terbutaline Sulphate IP 1.25 mg | |
| Guaiphenesin Syrup | Acebrophylline IP 50 mg | |
| Guaiphenesin IP 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Racecadotril | Each 5 ml contains : | |
| Suspension | Racecadotril IP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol, Phenylephrine Hcl, | Each ml contains : | |
| Chlorpheniramine Maleate Drops | Paracetamol IP 125 mg | |
| Chlorpheniramine Maleate IP 1 mg | |
| Phenylephrine Hcl IP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Artemether & Lumefantrine Suspension | Each 5 ml Reconstituted Suspension contains : | |
| Artemether IP 40 mg | |
| Lumefantrine 240 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levocetirizine Hcl & Ambroxol Hcl | Each 5 ml contains : | |
| Syrup | Levocetirizine HCl IP 5 mg | |
| Ambroxol Hcl IP 30 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levosalbutamol Sulphate, | Each 5 ml. contains | |
| Ambroxol Hydrochloride & | Levosalbutamol Sulphate | |
| Guaiphenesin Syrup | eq. to Levosalbutamol IP 1 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Guaiphenesin IP 50 mg | |
| Colour: Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| Paracetamol | Each ml. contains | |
| Oral Suspension IP | Paracetamol IP 100 mg | |
| For paediatric use | Colour: Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| Levosalbutamol Sulphate, | Each 5 ml. contains | |
| Ambroxol Hydrochloride & | Levosalbutamol Sulphate | |
| Guaiphenesin Syrup | eq. to Levosalbutamol IP 1 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Guaiphenesin IP 50 mg | |
| Colour: Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| Fexofenadine & | Each 5 ml. contains | |
| Montelukast Suspension | Fexofenadine Hydrochloride IP 30 mg | |
| For paediatric use | Montelukast Sodium IP | |
| Jeq. to Montelukast 4 mg | |
| Colour : Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| Fexofenadine Suspension | Each 5 ml. contains | |
| For paediatric use | Fexofenadine Hydrochloride IP 30 mg. | |
| Colour: Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| in flavoured syrupy base | |
| | |
| Calcium With Cholecalciferol, | Each 5 ml. contains | |
| Suspension | Calcium Carbonate IP | |
| For Therapeutic use | eq. to Calcium 250 mg | |
| Cholecalciferol IP 125 IU | |
| Colour : Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| Zinc Sulphate Syrup | Each 5 ml. contains | |
| Zinc Sulphate IP | |
| eq. to Zinc 10 mg | |
| Colour : Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| Zinc Sulphate Syrup | Each 5 ml. contains | |
| For paediatric use | Zinc Sulphate IP | |
| eq. to Zinc 5 mg | |
| Colour : Erythrosine / Tartrazine / Sunset Yellow | |
| Ponceau-4R or Carmosine | |
| In flavoured syrupy base | |
| | |
| CHLOROQUINE SYRUP IP | Each 5 ml contains : | |
| Approved Date : 19/04/2007 | Chloroquine Phosphate IP | |
| Equivalent to Chloroquine 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| CO-TRIMOXAZOLE | Each 5 ml contains : | |
| SUSPENSION IP | Trimethoprim IP 40 mg | |
| For paediatric use | Sulphamethoxazole IP 200 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| CYPROHEPTADINE | Each 5 ml contains : | |
| HYDROCHLORIDE SYRUP IP | Cyproheptadine Hydrochloride IP 2 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| FURAZOLIDONE | Each 5 ml contains : | |
| SUSPENSION IP | Furazalidone IP 25 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| METOCLOPRAMIDE | Each 5 ml contains : | |
| HYDROCHLORIDE SYRUP IP | Metoclopramide Hydrochloride | |
| Approved Date : 19/04/2007 | Eq.to Anhydrous Metoclopramide Hydrochloride IP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| METRONIDAZOLE BENZOATE | Each 5 ml contains : | |
| SUSPENSION IP | Metronidazole Benzoate IP | |
| Approved Date : 19/04/2007 | Equivalent to Metronidazole 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PARACETAMOL SYRUP IP | Each 5 ml contains : | |
| Approved Date : 19/04/2007 | Paracetamol IP 125 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| | |
| PIPERAZINE CITRATE SYRUP IP | Each 5 ml contains : | |
| Approved Date : 19/04/2007 | Piperazine Citrate IP | |
| For paediatric use | Equivalent to Piperazine Hydrate 750 mg | |
| Approved colour used in flavoured syrupy base | |
| PROMETHAZINE | Each 5 ml contains : | |
| HYDROCHLORIDE SYRUP IP | Promethazine Hydrochloride IP 5 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| DISODIUM HYDROGEN | Each 5 ml contains : | |
| CITRATE SYRUP IP | Disodium Hydrogen citrate BP 1.4 gm | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| ALBENDAZOLE | Each ml contains : | |
| SUSPENSION IP | Albendazole IP 25 mg | |
| For veterinary use | Approved colour used in flavoured syrupy base | |
| Approved Date : 19/04/2007 | | |
| | |
| ALBENDAZOLE | Each 5 ml contains : | |
| SUSPENSION IP | Albendazole IP 200 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 19/04/2007 | | |
| | |
| SALBUTAMOL | Each 5 ml contains : | |
| SULPHATE SYRUP IP | Salbutamol Sulphate IP | |
| Approved Date : 19/04/2007 | Equivalent to Salbutamol 2 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PARACETAMOL | Each 5 ml contains : | |
| SUSPENSION IP | Paracetamol IP 125 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 19/04/2007 | | |
| | |
| CYPROHEPTADINE HYDROCHLORIDE | Each ml contains : | |
| & TRICHOLINE CITRATE DROPS | Cyproheptadine Hydrochloride IP 1.50 mg | |
| For paediatric use | Tricholine Citrate 55 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| CYPROHEPTADINE HYDROCHLORIDE, | Each 5 ml contains : | |
| TRICHOLINE CITRATE WITH | Cyproheptadine Hydrochloride IP 2 mg | |
| SORBITOL 70% SYRUP | Tricholine citrate 275 mg | |
| Approved Date : 19/04/2007 | Sorbitol Soluion (Non crystallizing 70%) 3.575 gm | |
| Approved colour used in flavoured syrupy base | |
| | |
| NORFLOXACIN WITH | Each 5 ml contains : | |
| METRONIDAZOLE ORAL SUSPENSION | Norfloxacin IP 100 mg | |
| For paediatric use | Metronidazole Benzoate IP | |
| Approved Date : 19/04/2007 | Equivalent to Metronidazole 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| IBUPROFEN & PARACETAMOL | Each 5 ml contains : | |
| ORAL SUSPENSION IP | Ibuprofen IP 100 mg | |
| For paediatric use | Paracetamol IP 125 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| DOMPERIDONE | Each ml contains : | |
| ORAL SUSPENSION IP | Domperidone IP 1 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 19/04/2007 | | |
| | |
| OFLOXACIN | Each 5 ml contains : | |
| ORAL SUSPENSION IP | Ofloxacin IP 50 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 19/04/2007 | | |
| | |
| OFLOXACIN & METRONIDAZOLE | Each 5 ml contains : | |
| ORAL SUSPENSION | Ofloxacin IP 50 mg | |
| For paediatric use | Metronidazole Benzoate IP | |
| Approved Date : 19/04/2007 | Equivalent to Metronidazole 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| DIPHENHYDRAMINE HYDROCHLORIDE, | Each 5 ml contains : | |
| AMMONIUM CHLORIDE, | Diphenhydramine Hydrochloride IP 14.08 mg | |
| SODIUM CITRATE, MENTHOL SYRUP | Ammonium chloride IP 1.38 mg | |
| Sodium citrate IP 57.03 mg | |
| Approved Date : 19/04/2007 | Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| MAGALDRATE WITH ACTIVATED | Each 5 ml contains : | |
| DIMETHICONE SUSPENSION | Magaldrate IP 450 mg | |
| Approved Date : 19/04/2007 | Activated Dimethicone IP 20 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| SALBUTAMOL SULPHATE, | Each 10 ml contains : | |
| BROMHEXINE HYDROCHLORIDE, | Salbutamol Sulphate IP | |
| GUAIPHENESIN WITH | Equivalent to Salbutamol 2 mg | |
| MENTHOL SYRUP | Bromhexine Hydrochloride IP 4 mg | |
| Approved Date : 19/04/2007 | Guaiphenesin IP 100 mg | |
| Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| CHLORPHENRAMINE MALEATE, | Each 5 ml contains : | |
| AMMONIUM CHLORIDE, | Chlorpheniramine Maleate IP 2 mg | |
| SODIUM CITRATE WITH | Ammonium chloride IP 100 mg | |
| MENTHOL SYRUP | Sodium Citrate IP 50 mg | |
| Approved Date : 19/04/2007 | Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| TERBUTALINE SULPHATE, | Each 10 ml contains : | |
| BROMHEXINE HYDROCHLORIDE, | Terbutaline Sulphate IP 2.5 mg | |
| GUAIPHENESIN WITH | Bromhexine Hydrochloride IP 8 mg | |
| MENTHOL SYRUP | Guaiphenesin IP 100 mg | |
| Approved Date : 19/04/2007 | Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| CETIRIZINE | Each 5 ml contains : | |
| HYDROCHLORIDE SYRUP IP | Cetirizine Hydrochloride IP 5 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 19/04/2007 | | |
| | |
| PARACETAMOL & PROMETHAZINE | Each 5 ml contains : | |
| HYDROCHLORIDE SUSPENSION | Paracetamol IP 125 mg | |
| For paediatric use | Promethazine Hydrochloride IP 5 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| CYPROHEPTADINE HYDROCHLORIDE, | Each 5 ml contains : | |
| TRICHOLINE CITRATE WITH | Cyproheptadine Hydrochloride IP 2 mg | |
| SORBITOL 70% SYRUP | Tricholine citrate IP 275 mg | |
| Approved Date : 11/10/2007 | Sorbitol Soluion (Non crysatallizing 70%) IP 2 gm | |
| Approved colour used in flavoured syrupy base | |
| | |
| DICYCLOMINE HYDROCHLORIDE & | Each ml contains : | |
| ACTIVATED DIMETHICONE SUSPENSION | Dicyclomine Hydrochloride IP 10 mg | |
| For paediatric use | Activated Dimethicone IP 40 mg | |
| Approved Date : 05/09/2008 | Approved colour used in flavoured syrupy base | |
| | |
| ONDANSETRON | Each 5 ml contains : | |
| ORAL SOLUTION IP | Ondansetron Hydrochloride IP | |
| For paediatric use | Eq. to Ondansetron 2 mg | |
| Approved Date: 05/09/2008 | Approved colour used in flavoured syrupy base | |
| | |
| DEXTROMETHORPHAN HBr, | Each 5 ml contains : | |
| BROMHEXINE HYDROCHLORIDE, | Dextromethorphan Hydrobomide IP 5 mg | |
| CHLORPHENRAMINE MALEATE, | Bromhexine Hydrochloride IP 4 mg | |
| GUAIPHENESIN | Chlorpheniramine Maleate IP 2 mg | |
| WITH MENTHOL SYRUP | Guaiphenesin IP 50 mg | |
| Approved Date : 05/09/2008 | Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| CYPROHEPTADINE HYDROCHLORIDE, | Each 5 ml contains : | |
| TRICHOLINE CITRATE SYRUP | Cyproheptadine HCl IP 2 mg | |
| Approved Date : 05/09/2008 | Tricholine Citrate 275 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| IBUPROFEN & PARACETAMOL | Each 5 ml contains : | |
| ORAL SUSPENSION IP | Ibuprofen IP 100 mg | |
| For paediatric use | Paracetamol IP 162.5 mg | |
| Approved Date: 05/09/2008 | Approved colour used in flavoured syrupy base | |
| | |
| NORFLOXACIN & | Each 5 ml contains : | |
| METRONIDAZOLE | Norfloxacin IP 100 mg | |
| ORAL SUSPENSION | Metronidazole Benzoate IP | |
| For paediatric use | Equivalent to Metronidazole 120 mg | |
| Approved Date : 05/09/2008 | Approved colour used in flavoured syrupy base | |
| | |
| FURAZOLIDONE & | Each 5 ml contains : | |
| METRONIDAZOLE | Furazalidone IP 30 mg | |
| ORAL SUSPENSION | Metronidazole Benzoate IP | |
| For paediatric use | Equivalent to Metronidazole IP 100 mg | |
| Approved Date : 05/09/2008 | Approved colour used in flavoured syrupy base | |
| | |
| DEXTROMETHORPHAN HBr , | Each 5 ml contains : | |
| PHENYLEPHRINE HYDROCHLORIDE, | Dextromethorphan Hydrobomide IP 10 mg | |
| CHLORPHENRAMINE MALEATE SYRUP | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date: 05/12/2008 | Chlorpheniramine Maleate IP 2 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PHENYLEPHERINE HYDROCHLORIDE, | Each 5 ml contains : | |
| CHLORPHENRAMINE MALEATE SYRUP | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date: 05/12/2008 | Chlorpheniramine Maleate IP 2 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| | |
| OFLOXACIN WITH | Each 5 ml contains : | |
| ORNIDAZOLE ORAL SUSPENSION | Ofloxacin IP 50 mg | |
| For paediatric use | Ornidazole IP 125 mg | |
| Approved Date : 26/05/2009 | Approved colour used in flavoured syrupy base | |
| | |
| NORFLOXACIN, METRONIDAZOLE & | Each 5 ml contains : | |
| FURAZOLIDONE ORAL SUSPENSION | Norfloxacin IP 100 mg | |
| For paediatric use | Metronidazole Benzoate IP | |
| Approved Date : 26/05/2009 | Equivalent to Metronidazole 100 mg | |
| Furazolidone IP 20 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| LIQUOR BISMUTH, | Each 5 ml contains : | |
| AMMONIUM CHLORIDE | Liquor Bismuth | |
| BELLADONNA DRY EXTRACT, | Ammonium Citrate BP 2.50 ml | |
| THYMOL & MENTHOL SYRUP | (Equivalent to Bi2 O3 140 mg) | |
| Approved Date : 01/07/2009 | Belladonna Dry Extract IP 9 mg | |
| Thymol IP 0.15 mg | |
| Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| LEVOCETIRIZINE | Each 5 ml contains : | |
| HYDROCHLORIDE SYRUP IP | Levocetirizine Hydrochloride IP 2.5 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 01/07/2009 | | |
| | |
| CIPROFLOXACIN & | Each 5 ml contains : | |
| TINIDAZOLE SUSPENSION | Ciprofloxacin Hydrochloride IP | |
| For paediatric use | Eq. to Ciprofloxacin 125 mg | |
| Approved Date : 01/07/2009 | Tinidazole IP 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| THEOPHYLLINE & | Each 5 ml contains : | |
| ETOFYLLINE SYRUPS | Theophylline IP 14 mg | |
| Approved Date : 25/03/2010 | Etofylline IP 46.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| SALBUTAMOL SULPHATE, | Each 5 ml contains : | |
| BROMHEXINE | Salbutamol Sulphate IP | |
| HYDROCHLORIDE SYRUP | Equivalent to Salbutamol 2 mg | |
| Approved Date : 25/03/2010 | Bromhexine Hydrochloride IP 4 mg | |
| Menthol IP qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| POTASSIUM CITRATE & | Each 5 ml contains : | |
| MAGNESIUM CITRATE SYRUP | Potassium Citrate IP 1100 mg | |
| Approved Date : 25/03/2010 | Magnesium Citrate USP 375 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| DICYCLOMINE HYDROCHLORIDE | Each 5 ml contains : | |
| PARACETAMOL SUSPENSION | Dicyclomine Hydrochloride IP 5 mg | |
| For paediatric use | Paracetamol IP 125 mg | |
| Approved Date : 13/10/2010 | Approved colour used in flavoured syrupy base | |
| | |
| CETIRIZINE HYDROCHLORIDE, | Each 5 ml contains : | |
| PHENYLEPHERINE HYDROCHLORIDE, | Cetirizine Hydrochloride IP 2.5 mg | |
| PARACETAMOL SUSPENSION | Paracetamol IP 125 mg | |
| For paediatric use | Phenylephrine Hydrochloride IP 2.5 mg | |
| Approved Date : 13/06/2011 | Approved colour used in flavoured syrupy base | |
| | |
| MAGALDRATE WITH | Each 5 ml contains : | |
| ACTIVATED DIMETHICONE | Magaldrate IP 400 mg | |
| SUSPENSION | Activated Dimethicone IP 52.5 mg | |
| Approved Date : 15/10/2011 | Approved colour used in flavoured syrupy base | |
| | |
| PHENYLEPHRINE HYDROCHLORIDE, | Each 5 ml contains : | |
| CHLORPHENRAMINE MALEATE SYRUP | Phenylephrine Hydrochloride IP 2.5 mg | |
| For paediatric use | Chlorpheniramine Maleate IP 2 mg | |
| Approved Date : 15/10/2011 | Approved colour used in flavoured syrupy base | |
| | |
| DEXTROMETHORPHAN Hbr, | Each 5 ml contains : | |
| CHLORPHENRAMINE MALEATE SYRUP | Dextromethorphan Hydrobomide IP 5 mg | |
| Approved Date : 15/10/2011 | Chlorpheniramine Maleate IP 2 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PIPERAZINE CITRATE SYRUP IP | Each 5 ml contains : | |
| For paediatric use | Piperazine Citrate IP | |
| Approved Date : 15/10/2011 | Eq. to Piperazine Hydrate 500 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| TRICHOLINE CITRATE SYRUP | Each 5 ml contains : | |
| Approved Date : 15/10/2011 | Tricholine citrate 275 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PARACETAMOL SUSPENSION IP | Each 5 ml contains : | |
| For paediatric use | Paracetamol IP 250 mg | |
| Approved Date : 15/10/2011 | Approved colour used in flavoured syrupy base | |
| | |
| DEXTROMETHORPHAN HBr | Each 10 ml contains : | |
| BROMHEXINE HYDROCHLORIDE, | Dextromethorphan Hydrobomide IP 10 mg | |
| AMMONIUM CHLORIDE SYRUP | Bromhexine Hydrochloride IP 8 mg | |
| Approved Date : 27/03/2012 | Ammonium chloride IP 100 mg | |
| Menthol qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| MEFENAMIC ACID & | Each 5 ml contains : | |
| PARACETAMOL SUSPENSION | Mefenamic Acid IP 50 mg | |
| For paediatric use | Paracetamol IP 125 mg | |
| Approved Date : 27/03/2012 | Approved colour used in flavoured syrupy base | |
| | |
| LEVOSALBUTAMOL SULPHATE, | Each 10 ml contains : | |
| BROMHEXINE HYDROCHLORIDE, | Levosalbutamol Sulphate IP | |
| GUAIPHENESIN WITH | Equivalent to Levosalbutamol 2 mg | |
| MENTHOL SYRUP | Bromhexine Hydrochloride IP 4 mg | |
| Approved Date : 27/06/2013 | Guaiphenesin IP 100 mg | |
| Menthol qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| PHENYLEPHRINE HYDROCHLORIDE, | Each 5 ml contains : | |
| PARACETAMOL, | Phenylephrine Hydrochloride IP 5 mg | |
| CHLORPHENRAMINE MALEATE SYRUP | Paracetamol IP 250 mg | |
| For paediatric use | Chlorpheniramine Maleate IP 2 mg | |
| Approved Date : 27/06/2013 | Approved colour used in flavoured syrupy base | |
| | |
| CETIRIZINE HYDROCHLORIDE, | Each 5 ml contains : | |
| PHENYLEPHRINE HYDROCHLORIDE, | Cetirizine Hydrochloride IP 2.5 mg | |
| PARACETAMOL SUSPENSION | Paracetamol IP 125 mg | |
| For paediatric use | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date : 08/01/2014 | Approved colour used in flavoured syrupy base | |
| | |
| TERBUTALINE SULPHATE, | Each 10 ml contains : | |
| AMBROXOL HYDROCHLORIDE, | Terbutaline Sulphate IP 2.5 mg | |
| GUAIPHENESIN WITH | Ambroxol Hydrochloride IP 30 mg | |
| MENTHOL SYRUP | Guaiphenesin IP 100 mg | |
| Approved Date : 08/01/2014 | Menthol qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| PHENYLEPHRINE HYDROCHLORIDE, | Each 5 ml contains : | |
| PARACETAMOL, | Phenylephrine Hydrochloride IP 5 mg | |
| CHLORPHENRAMINE | Paracetamol IP 125 mg | |
| MALEATE SYRUP | Chlorpheniramine Maleate IP 1 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 17/04/2014 | | |
| | |
| TERBUTALINE SULPHATE, | Each 5 ml contains : | |
| AMBROXOL HYDROCHLORIDE, | Terbutaline Sulphate IP 1.25 mg | |
| GUAIPHENESIN, | Ambroxol Hydrochloride IP 15 mg | |
| AMMONIUM CHLORIDE | Guaiphenesin IP 50 mg | |
| WITH MENTHOL SYRUP | Ammonium chloride IP 100 mg | |
| Approved Date : 17/04/2014 | Menthol qs | |
| Approved colour used in flavoured syrupy base | |
| | |
| MAGALDRATE WITH | Each 5 ml contains : | |
| ACTIVATED DIMETHICONE & | Magaldrate IP 400 mg | |
| OXYTHACAINE SUSPENSION | Activated Dimethicone IP 52.5 mg | |
| Approved Date : 17/04/2014 | Oxythacaine 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| DRIED ALUMINIUM HYDROXIDE | Each 5 ml contains : | |
| MAGNESIUM HYDROXIDE, | Dried Aluminium Hydroxide Gel IP 250 mg | |
| ACTIVATED DIMETHICONE | Magnesium Hydroxide IP 250 mg | |
| SUSPENSION | Activated Dimethicone IP 25 mg | |
| Approved Date : 17/04/2014 | Approved colour used in flavoured syrupy base | |
| | |
| ALBENDAZOLE & IVERMECTIN | Each 5 ml contains : | |
| SUSPENSION | Albendazole IP 200 mg | |
| For paediatric use | Ivermectin IP 1.5 mg | |
| Approved Date : 20/06/2014 | Approved colour used in flavoured syrupy base | |
| | |
| MAGALDRATE, | Each 5 ml contains : | |
| ACTIVATED DIMETHICONE | Magaldrate IP 400 mg | |
| WITH BENZOCAINE SUSPENSION | Activated Dimethicone IP 52.5 mg | |
| Approved Date : 21/11/2014 | Benzocaine IP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| TRICHOLINE CITRATE WITH | Each 10 ml contains : | |
| SORBITOL 70% SYRUP | Tricholine citrate 0.55 gm | |
| Approved Date : 21/11/2014 | Sorbitol Soluion (Non crystallizing 70%) IP 7.15 gm | |
| Approved colour used in flavoured syrupy base | |
| | |
| AMMONIUM CHLORIDE, | Each 5 ml contains : | |
| SODIUM CITRATE, | Ammonium Chloride IP 125 mg | |
| CHLORPHENRAMINE MALEATE, | Sodium Citrate IP 55 mg | |
| MENTHOL SYRUP | Chlorpheniramine Maleate IP 2.5 mg | |
| Approved Date : 21/11/2014 | Menthol IP 1 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| LEVOCETIRIZINE HYDROCHLORIDE | Each 5 ml contains : | |
| & AMBROXOL HYDROCHLORIDE | Levocetirizine Hydrochloride IP 2.5 mg | |
| SUSPENSION | Ambroxol Hydrochloride IP 15 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 21/11/2014 | | |
| | |
| LEVOCETIRIZINE HYDROCHLORIDE | Each 5 ml contains : | |
| & MONTELUKAST SUSPENSION | Levocetirizine Hydrochloride IP 2.5 mg | |
| For paediatric use | Montelukast Sodium IP | |
| Approved Date : 21/11/2014 | eq. to Montelukast 4 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| ACECLOFENAC & | Each 5 ml contains : | |
| PARACETAMOL SUSPENSION | Aceclofenac IP 50 mg | |
| For paediatric use | Paracetamol IP 125 mg | |
| Approved Date : 21/11/2014 | Approved colour used in flavoured syrupy base | |
| | |
| LEVOCETIRIZINE HYDROCHLORIDE, | Each 5 ml contains : | |
| PHENYLEPHRINE HYDROCHLORIDE, | Levocetirizine Hydrochloride IP 2.5 mg | |
| PARACETAMOL SUSPENSION | Paracetamol IP 250 mg | |
| For paediatric use | Phenylephrine Hydrochloride IP 5 mg | |
| Approved Date : 21/11/2014 | Approved colour used in flavoured syrupy base | |
| | |
| SUCRALFATE SUSPENSION | Each 5 ml contains : | |
| Approved Date : 21/11/2014 | Sucaralfate USP 1 gm | |
| Approved colour used in flavoured syrupy base | |
| | |
| SUCRALFATE & | Each 5 ml contains : | |
| BENZOCAINE SUSPENSION | Sucaralfate USP 1 gm | |
| Approved Date : 21/11/2014 | Benzocaine IP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PIPERAZINE CITRATE & | Each 5 ml contains : | |
| DIETHYL CARBAMAZINE CITRATE SYRUP | Piperazine Citrate IP | |
| For paediatric use | eq. to Piperazine Hydrate 500 mg | |
| Approved Date : 19/04/2007 | Diethyl Carbamazine Citrate IP 25 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| DEXTROMETHORPHAN HBr , | Each 5 ml contains : | |
| PHENYLEPHRINE HYDROCHLORIDE, | Dextromethorphan Hydrobromide IP 5 mg | |
| PARACETAMOL, | Phenylephrine Hydrochloride IP 5 mg | |
| CHLORPHENIRAMINE MALEATE | Paracetamol IP 125 mg | |
| SUSPENSION | Chlorpheniramine Maleate IP 1 mg | |
| Approved Date: 05/12/2008 | Approved colour used in flavoured syrupy base | |
| | |
| AMBROXOL HYDROCHLORIDE, | Each 5 ml contains : | |
| GUAIPHENESIN, | Ambroxol Hydrochloride IP 10 mg | |
| CHLORPHENIRAMINE MALEATE | Guaiphenesin IP 50 mg | |
| SYRUP | Chlorpheniramine Maleate IP 2 mg | |
| Approved Date : 15/01/2011 | Menthol q.s | |
| Approved colour used in flavoured syrupy base | |
| | |
| PHENYLEPHRINE HYDROCHLORIDE, | Each 5 ml contains : | |
| PARACETAMOL, | Phenylephrine Hydrochloride IP 2.5 mg | |
| CHLORPHENIRAMINE MALEATE | Paracetamol IP 125 mg | |
| SUSPENSION | Chlorpheniramine Maleate IP 1 mg | |
| For paediatric use | Approved colour used in flavoured syrupy base | |
| Approved Date : 27/03/2012 | | |
| | |
| DEXTROMETHORPHAN HBr , | Each 5 ml contains : | |
| AMMONIUM CHLORIDE, | Dextromethorphan Hydrobromide IP 10 mg | |
| CHLORPHENIRAMINE MALEATE | Ammonium chloride IP 60 mg | |
| GUAIPHENESIN SYRUP | Chlorpheniramine Maleate IP 2.5 mg | |
| Guaiphenesin IP 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| PARACETAMOL, AMBROXOL Hcl, | Each 5 ml contains : | |
| PHENYLEPHRINE HYDROCHLORIDE, | Paracetamol IP 125 mg | |
| CHLORPHENIRAMINE MALEATE | Ambroxol Hydrochloride IP 15 mg | |
| SUSPENSION | Phenylephrine Hydrochloride IP 5 mg | |
| For paediatric use | Chlorpheniramine Maleate IP 2 mg | |
| Approved Date : 17/04/2014 | Approved colour used in flavoured syrupy base | |
| | |
| PARACETAMOL, AMBROXOL Hcl, | Each ml contains : | |
| PHENYLEPHRINE HYDROCHLORIDE, | Paracetamol IP 100 mg | |
| CHLORPHENIRAMINE MALEATE | Ambroxol Hydrochloride IP 7.5 mg | |
| SUSPENSION | Phenylephrine Hydrochloride IP 2.5 mg | |
| For paediatric use | Chlorpheniramine Maleate IP 1 mg | |
| Approved Date : 17/04/2014 | Approved colour used in flavoured syrupy base | |
| | |
| ERYTHROMYCIN SYRUPS IP | Each 5 ml contains : | |
| For Paediatric Use | Erythromycin Estolate IP 125 mg | |
| Approved Date : 19/04/2007 | Equivalent to Erythromycin Base | |
| Approved colour used in flavoured syrupy base | |
| | |
| CALCIUM WITH VITAMIN B12 & | Each 5 ml contains : | |
| VITAMIN D3 SUSPENSION | Tribasic Calcium Phosphate | |
| For Therapeutic Use | Eq. To Elemental Calcium 82 mg | |
| Approved Date : 19/04/2007 | Vitamin B12 IP 2.50 mcg | |
| Vitamin D3(As Cholecalciferol) IP 200 I.U | |
| Approved colour used in flavoured syrupy base | |
| | |
| CHLORMPHENICOL PALMETATE | Each 5 ml contains : | |
| ORAL SUSPENSION IP | Chloramphenicol Palmetate IP | |
| For Paediatric Use | Eq. To Chloramphenicol 125 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| IRON & FOLIC ACID SYRUPS | Each 5 ml contains : | |
| For Therapeutic Use | Iron (III) Hydroxide Polymaltose Complex | |
| Approved Date : 19/04/2007 | Eq. to Elemental Iron IP 50 mg | |
| Folic Acid IP 500 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN SYRUPS | Each 5 ml contains : | |
| For Prophylactic Use | Vitamin B1 Hcl IP 1 mg | |
| Approved Date : 19/04/2007 | Vitamin B2 IP 1 mg | |
| Vitamin B12 IP 1 mcg | |
| Naicinamide IP 15 mg | |
| D-Panthenol IP 2.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| FUNGAL DIASTASE & PEPSIN SYRUPS | Each 5 ml contains : | |
| Approved Date : 19/04/2007 | Fungal Diastase(1:1200) IP 50 mg | |
| From Aspergillus Oryzae | |
| (Digest Not less than 60gms of cooked starch) | |
| Pepsin(1:3000) IP 10 mg | |
| (Digest Not less than 30gms of cogulated egg albumin) | |
| Approved colour used in flavoured syrupy base | |
| | |
| ROXITHROMYCIN SUSPENSION IP | Each 5 ml contains : | |
| For Paediatric Use | Roxithromycin BP 50 mg | |
| Approved Date : 19/04/2007 | Approved colour used in flavoured syrupy base | |
| | |
| FERROUS FUMERATE, | Each 5 ml contains : | |
| VITAMIN B12 WITH | Ferrous Fumerate IP 100 mg | |
| FOLIC ACID & ZINC SYRUPS | Eq, to Ferrous Iron IP 32.5 mg | |
| For Therapeutic Use | Vitamin B12 IP 5 mcg | |
| Approved Date : 19/04/2007 | Folic Acid IP 0.5 mg | |
| Zinc Sulphate | |
| Eq. to Zinc 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| FUNGAL DIASTASE & PEPSIN SYRUPS | Each 15 ml contains : | |
| Approved Date: 05/09/2008 | Fungal Diastase (1:1200) IP 50 mg | |
| (Digest not less than 60 gm of cooked starch) | |
| Pepsin (1:3000) IP 10 mg | |
| (Digest not less than 30 gm of coagulated ezz albumnen) | |
| Approved colour used in flavoured syrupy base | |
| | |
| FERRIC AMMONIUM CITRATE, | Each 15 ml contains : | |
| CYANOCOBALAMIN WITH | Ferric Ammonium Citrate IP 160 mg | |
| FOLIC ACID SYRUPS | (equivalent to Elemental Iron 32 mg) | |
| For Therapeutic Use | Vitamin B 12 IP 7.5 mcg | |
| Approved Date: 05/09/2008 | Folic Acid IP 1 mg | |
| 06.10.2017 | Approved Colour used in Flavoured Syrupy Base | |
| | |
| DIASTASE AND PEPSIN DROPS | Each ml contains : | |
| For Paediatric Use | Diastase (1:1200) IP 33.33 mg | |
| Approved Date : 05/09/2008 | (Digest not less than 40 gm of cooked starch) | |
| Pepsin (1:3000) IP 5 mg | |
| (Digests not less than 15gm of coagulated egg albumen) | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| BETAMETHASONE SODIUM | Each ml contains : | |
| PHOSPHATE ORAL SOLUTION IP | Betamethasone Sodium Phosphate IP | |
| For Paediatric Use | Equivalent to Betamethasone 0.5 mg | |
| Approved Date: 05/12/2008 | Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN SYRUPS | Each 5 ml contains : | |
| For Prophylactic Use | Vitamin B1 IP 1 mg | |
| Approved Date: 05/12/2008 | Vitamin B2 IP 1 mg | |
| Vitamin B6 IP 0.5 mg | |
| Vitamin B12 IP 1 mcg | |
| Naicinamide IP 15 mg | |
| D-Panthenol IP 2.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN DROPS | Each ml contains : | |
| For infants less then 1 year | Vitamin A Concentrate(Oily Form as Palmitate) IP 2500 IU | |
| Approved Date : 13/10/2010 | Vitamin D3 (As Cholecalciferol) IP 200 IU | |
| Thiamin Hcl IP 1 mg | |
| Vitamin B2 Sodium Phosphate IP | |
| Eq. to Vitamin B2 0.5 mg | |
| Naicinamide IP 5 mg | |
| Vitamin B6 HCI IP 0.5 mg | |
| D-Panthenol IP 1.5 mg | |
| Vitamin E Acetate IP 2.5 IU | |
| Approved colour used in flavoured syrupy base | |
| MULTIVITAMIN DROPS | Each ml contains : | |
| For infants less then 1 year | Vitamin A Concentrate(Oily Form as Palmitate) IP 3000 IU | |
| Approved Date : 13/10/2010 | Vitamin D3 (As Cholecalciferol) IP 400 IU | |
| Thiamin Hcl IP 1 mg | |
| Vitamin B2 Sodium Phosphate IP | |
| Eq. to Vitamin B2 1 mg | |
| Naicinamide IP 5 mg | |
| Vitamin B6 HCI IP 1 mg | |
| D-Panthenol IP 3 mg | |
| Vitamin E Acetate IP 5 I.U | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN DROPS | Each ml contains : | |
| For Paediatric Use | Vitamin A Concentrate(Oily Form as Palmil IP 4000 IU | |
| Approved Date : 13/10/2010 | Vitamin D3 (As Cholecalciferol) IP 400 IU | |
| Thiamin HCl IP 1 mg | |
| Vitamin B2 Sodium Phosphate IP 1 mg | |
| Eq. to Vitamin B2 | |
| Vitamin B6 HCI 1 mg | |
| Vitamin B12 IP 3 mcg | |
| Naicinamide IP 10 mg | |
| L-Lysine hydrochloride IP 10 mg | |
| D-Panthenol IP 3 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| LYCOPENE WITH MULTIVITAMIN & | Each 5 ml contains : | |
| MULTIMINERAL SYRUPS | Lycopene 6% USP 1000 mcg | |
| For Therapeutic Use | Zinc Sulphate Monohydrate USP 7.5 mg | |
| Approved Date : 13/10/2010 | Sodium Selenite USP | |
| eq. to Selenite 35 mcg | |
| Manganese Gluconate USP 2.75 mg | |
| Potassiu lodid IP | |
| eq. to Elemental lodine 75 mcg | |
| Copper Sulphate IP | |
| eq. to elemental Copper 1.1 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| IRON, CYANOCOBALAMIN | Each 15 ml contains | |
| wITH FOLIC ACID SYRUPS | Ferric Ammonium Citrate IP 160 mg | |
| For Therapeutic Use | (equivalent to Elemental Iron 32 mg) | |
| Approved Date: 15/10/2011 | Folic Acid IP 1500 mcg | |
| Cyanocobalamin IP 15 mcg | |
| Approved Colour used in Flavoured Syrupy Base | |
| | |
| IRON, FOLIC ACID | Each 15 ml contains: | |
| WITH ZINC SYRUPS | Iron (III) Hydroxide Polymaltose Complex | |
| For Therapeutic Use | Eq. to Elemental Iron IP 100 mg | |
| Approved Date : 15/10/2011 | Folic Acid IP 1500 mcg | |
| Zinc Sulphate IP | |
| Eq.to Elemental Zinc 10 mg | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| PROTEIN WITH MULTIVITAMIN SYRUPS | Each 15 ml contains: | |
| Approved Date: 15/10/2011 | Protein Hydrolysate (100 %) IP 500 mg | |
| For Prophylactic Use | (Elemental Nitrogen 112 mg.) | |
| L-Lysine Monohydrochloride USP 70 mg | |
| Folic Acid IP 0.5 mg | |
| Vitamin B6 IP 1.5 mg | |
| Naicinamide IP 25 mg | |
| D-Panthenol IP 5 mg | |
| Vitamin B 12 IP 1 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| IRON, FOLIC ACID, WITH | Each 15 ml contains: | |
| CYANOCOBALAMIN & ZINC SYRUPS | Elemental Iron (As Carbonyl Iron USP) 75 mg | |
| For Therapeutic Use | Folic Acid IP 1500 mcg | |
| Approved Date: 15/10/2011 | Cyanocobalamin IP 5 mcg | |
| Zinc Sulphate Monohydrate IP | |
| Elemental Zinc 20 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| IRON,MULTIVITAMIN | Each 15 ml contains: | |
| &MULTIMINERAL SYRUPS | Iron Choline Citrate IP 200 mg | |
| For Therapeutic Use | L-Lysine Hydrochloride USP 100 mg | |
| Approved Date: 27/03/2012 | Nicotinamide IP 45 mg | |
| Thiamine Mononitrate IP 5 mg | |
| Riboflavine (As Riboflavine Sodium Phosphate) IP 5 mg | |
| D Panthenol IP 5 mg | |
| Pyridoxine HCL IP 1.5 mg | |
| Zinc Sulphate Monohydrate IP 10 mg | |
| Cyanocobalamin IP 7.5 mcg | |
| Choline Dihydrogen Citrate 30 mg | |
| Glutamic Acid USP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| CALCIUM GLUCONATE, | Each 15 ml contains : | |
| VITAMIN B12 & VITAMIN D3 SYRUPS | Calcium Gluconate IP | |
| For Therapeutic Use | Eq. To Elemental Calcium 200 mg | |
| Approved Date : 27/03/2012 | Vitamin B12 IP 5 mcg | |
| Vitamin D3 (As Cholecalciferol) IP 400 IU | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN SYRUP | Each 5 ml contains : | |
| For Therapeutic Use | Thiamine Mononitrate IP 5 mg | |
| Approved Date : 27/03/2012 | Riboflavine Us Riboflavine Sodium Phosphate) IP 5 mg | |
| 06.10.2017 | Nicotinamide IP 45 mg | |
| Pyridoxine Hydrochloride IP 1.5 mg | |
| Cyanocobalamin IP 7.5 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| AZITHROMYCIN ORAL SUSPENSION IP | Each 5 ml contains : | |
| For Paediatric Use | Azithromycin IP | |
| Approved Date : 28/06/2014 | eq. to Anhydrous Azithromycin 125 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| VITAMIN A DROPS | Each ml contains : | |
| Approved Date : 28/06/2014 | Vitamin A (As Palmitate) IP 100000 IU | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN & | Each 10 ml contains : | |
| MULTIMINERAL SYRUPS | Lycopene 6% USP 2000 mcg | |
| Approved Date : 21/11/2014 | Nicotinamide IP 25 mg | |
| Pyridoxine Hydrochloride IP 1.5 mg | |
| Cyanocobalamin IP 1 mcg | |
| Sodium Selenite USP | |
| eq. to Selenite 35 mcg | |
| Zinc Gluconate USP | |
| eq.to Zinc 3 mg | |
| Manganese Gluconate | |
| eq. to Manganese 2.00 mg | |
| Potassium lodide IP | |
| eq. to Elemental lodine 100 mcg | |
| Cupric Sulphte Pentahydrate | |
| eq.to Copper USP 500 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN & MULTIMINERAL | Each 5 ml contains : | |
| SYRUP | Ferrous Gluconate IP 100 mg | |
| Approved Date : 21/11/2014 | Cyanocobalamin IP 1 mcg | |
| Folic Acid IP 0.25 mg | |
| L-Lysine Hydrochloride USP 25 mg | |
| Pyridoxine Hydrochloride IP 0.5 mg | |
| D Panthenol IP 1.25 mg | |
| Nicotinamide IP 15 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| MULTIVITAMIN & MULTIMINERAL | Each 5 ml contains : | |
| WITH L-LYSINE HYROCHLORIDE SYRUP | Pyridoxine Hydrochloride IP 0.5 mg | |
| Approved Date : 20/07/2016 | Cholecalciferol (Vitamin D3 ) IP 100 IU | |
| Nicotinamide IP 15 mg | |
| Cyanocobalamin IP 0.5 mcg | |
| Folic Acid IP 300 mcg | |
| Copper Sulphate USP 100 mcg | |
| D Panthenol IP 1.25 mg | |
| Zinc Sulphate Monohydrate IP 22.5 mg | |
| Chromium (As Chromium Chloride) IP 1 mcg | |
| Manganese Chloride IP 3 mcg | |
| L-Lysine HCL USP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| CHOLECALCIFEROL | Each ml contains : | |
| ORAL SUSPENSION (DROPS) | Cholecalciferol (Vitamin D3 ) IP 400 IU | |
| For Paediatric Use | (As stabilized) | |
| Approved Date : 20/07/2016 | Approved colour used in flavoured syrupy base | |
| | |
| DEFLAZACORT ORAL SUSPENSION | Each 5 ml contains : | |
| For Paediatric Use | Deflazcort IP 6 mg | |
| Approved Date : 20/07/2016 | Approved colour used in flavoured syrupy base | |
| | |
| PROTIN & | Each 5 ml contains : | |
| MULTIVITAMIN SYRUP | Why Protein 20% 800 mg | |
| For Prophylactic Use | Ferric Ammonium Citrate IP 160 mg | |
| Approved Date : 27/03/2012 | L-Lysine Hydrochloride USP 20 mg | |
| Cyanocobalamin IP 1 mcg | |
| Zinc Sulphate IP | |
| Eq. to Elemental Zinc 22 mg | |
| Pyridoxine Hydrochloride IP 1 mg | |
| Naicinamide IP 15 mg | |
| D-Panthenol IP 2.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| IRON, L-LYSIN HYDROCHLORIDE | Each 5 ml contains : | |
| WITH FOLIC ACID SYRUP | Iron (III) Hydroxide Polymaltose Complex | |
| For Prophylactic Use | eq. to Elemental Iron IP 50 mg | |
| Approved Date : 27/03/2012 | L-Lysine Hydrochloride USP 10 mg | |
| Cyanocobalamin IP 5 mcg | |
| Folic Acid IP 1 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| AZITHROMYCIN | Each 5 ml contains : | |
| ORAL SUSPENSION IP | Azithromycin IP | |
| For Paediatric Use | eq. to Anhydrous Azithromycin 200 mg | |
| Approved Date : 27/03/2012 | Approved colour used in flavoured syrupy base | |
| | |
| THIAMINE (MONO), RIBOFLAVINE, | Each 5 ml contains : | |
| PYRIDOXINE HCL, NICOTINAMIDE, | Thiamine Monoitrate IP 1.5 mg | |
| CYANOCOBALAMIN WITH | Riboflavine IP 1.5 mg | |
| ZINC & L-LYSIN SYRUP | Pyridoxine Hydrochloride IP 1 mg | |
| For Prophylactic Use | Nicotinamide IP 15 mg | |
| Approved Date : 27/03/2012 | Cyanocobalamin IP 1 mcg | |
| Zinc Sulphate IP | |
| eq. to Elemental Zinc 7 mg | |
| L-Lysine Hydrochloride IP 70 mg | |
| Excipients q.s | |
| Approved colour used in flavoured syrupy base | |
| | |
| AZITHROMYCIN | Each 5 ml contains : | |
| ORAL SUSPENSION IP | Azithromycin IP | |
| For Paediatric Use | eq. to Anhydrous Azithromycin 100 mg | |
| Approved Date : 28/06/2014 | Approved colour used in flavoured syrupy base | |
| | |
| Dextromethorphan HBr and | Each 5 ml contains : | |
| Chlorpheniramine Syrup | Dextromethorphan HBr IP 10 mg | |
| 29.04.2022 | Chlorpheniramine Maleate IP 4 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Dextromethorphan HBr, Cetirizine | Each 5 ml contains : | |
| Ambroxol HCl Syrup | Dextromethorphan HBr IP 10 mg | |
| Cetirizine HCl IP 5 mg | |
| Ambroxol Hydrochloride IP 15 mg | |
| Menthol q.s | |
| Approved colour used in flavoured syrupy base | |
| | |
| Sucralfate and Oxetacaine | Each 10 ml contains : | |
| Suspension | Sucralfate IP 1000 mg | |
| Oxetacaine IP 20 mg | |
| Approved coloured used in a flavoured syrup base | |
| | |
| Sucralfate and Oxetacaine | Each 5 ml contains : | |
| Suspension | Sucralfate IP 1000 mg | |
| 29.04.2022 | Oxetacaine IP 10 mg | |
| Approved coloured used in a flavoured syrup base | |
| | |
| Ranitidine Oral Solution IP | Each 5 ml contains : | |
| Ranitidine Hydrochloride IP | |
| Eq. to Ranitidine 75 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levodropropizine and | Each 5 ml contains : | |
| Chlorpheniramine Maleate Syrup | Levodropropizine IP 30 mg | |
| Chlorpheniramine Maleate IP 2 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol, | Each 5 ml contains : | |
| Cetirizine Hydrochloride | Paracetamol IP 250 mg | |
| and Phenylephrine Hydrochloride | Cetirizine HCl IP 5 mg | |
| Suspension | Phenylephrine Hydrochloride IP 5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Aceclofenac & | Each 5 ml contains : | |
| Paracetamol Suspension | Aceclofenac IP 50 mg | |
| Paracetamol IP 250 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Chlorpheniramine Maleate and | Each 5 ml contains : | |
| Codeine Phosphate Syrup | Codeine Phosphate IP 10 mg | |
| 29.04.2022 | Chlorpheniramine Maleate IP 4 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Triprolidine Hydrochloride and | Each 5 ml contains : | |
| Codeine Phosphate Syrup | Codeine Phosphate IP 10 mg | |
| Triprolidine Hydrochloride IP 1.25 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Terbutaline Sulphate, Bromhexine HCl | Each 5 ml contains : | |
| Guaiphenesin With Menthol Syrup | Terbutaline Sulphate IP 1.25 mg | |
| Bromhexine Hydrochloride IP 2 mg | |
| Guaiphenesin IP 50 mg | |
| Menthol IP q.s. | |
| Approved colour used in flavoured syrupy base | |
| | |
| Doxofylline Syrup | Each ml contains : | |
| 29.04.2022 | Doxofylline IP 20 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Fluoxetine Oral Solution | Each 5 ml contains : | |
| Fluoxetine Hydrochloride IP 20 mg | |
| Eq.to Fluxetine | |
| Approved colour used in flavoured syrupy base | |
| | |
| Dried Aluminium Hydroxide | Each 5 ml contains : | |
| Magnesium Hydroxide, Oxetacaine | Dried Aluminium Hydroxide Gel IP 300 mg | |
| Activated Dimethicone Gel | Magnesium Hydroxide IP 250 mg | |
| Activated Dimethicone IP 50 mg | |
| Oxetacaine BP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Acebrophylline Syrup | Each ml contains : | |
| 29.04.2022 | Acebrophylline 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Citicoline Sodium and Piracetam | Each 5 ml contains : | |
| Syrup | Citicoline Sodium IP | |
| Eq. to Citicoline 500 mg | |
| Piracetam IP 400 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Dextromethorphan HBr, Cetirizine | Each 5 ml contains : | |
| Phenylephrine, Ambroxol HCl, | Dextromethorphan HBr IP 15 mg | |
| Guaiphenesin & Sodium citrate | Cetirizine HCl IP 5 mg | |
| Suspension | Phenylephrine Hydrochloride IP 8 mg | |
| Ambroxol Hydrochloride IP 30 mg | |
| Guaiphenesin IP 100 mg | |
| Sodium Citrate IP 75 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol Suspension | Each 5 ml contains : | |
| Paracetamol IP 240 mg | |
| 29.04.2022 | Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol Suspension | Each 5 ml contains : | |
| Paracetamol IP 120 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol Paediatric Oral | Each ml contains : | |
| Suspension IP | Paracetamol IP 150 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Ferric Ammonium Citrate, | Each 15 ml contains : | |
| Cyanocobalamin, Folic Acid | Ferric Ammonium Citrate IP 160 mg | |
| Cupric sulphate and | (equivalent to Elemental Iron 32 mg) | |
| Manganese Sulphate Syrup | Cyanocobalamin IP 7.5 mcg | |
| Folic Acid IP 0.5 mg | |
| For Therapeutic Use | Cupric Sulphate IP 30 mcg | |
| 29.04.2022 | Manganese Sulphate IP 30 mcg | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| Ferric Ammonium Citrate, | Each 15 ml contains : | |
| Cyanocobalamin With | Ferric Ammonium Citrate IP 160 mg | |
| Folic Acid Syrup | (equivalent to Elemental Iron 32 mg) | |
| For Therapeutic Use | Cyanocobalmin IP 7.5 mcg | |
| Folic Acid IP 0.5 mg | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| Ferrous Gluconate, Folic Acid | Each 15 ml contains : | |
| Cyanocobalamin with | Ferrous Gluconate IP 129.5 mg | |
| Calcium Lactate Syrup | (equivalent to Elemental Iron 15 mg) | |
| For Therapeutic Use | Cyanocobalmin IP 1.3 mcg | |
| Folic Acid IP 0.25 mg | |
| Calcium Lactate IP 75 mg | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| Iron, Cyanocobalamin, Zinc | Each 15 ml contains : | |
| Folic Acid, and Pyridoxine Hcl | Ferric Ammonium Citrate IP 200 mg | |
| Syrup | (Equivalent to Elemental Iron 41 mg) | |
| For Therapeutic Use | Folic Acid IP 0.5 mg | |
| ( with sorbitol ) | Cyanocobalamin IP 7.5 mcg | |
| 29.04.2022 | Zinc Sulphate IP 7 mg | |
| Pyridoxine Hcl IP 1.5 mg | |
| Sorbitol solution 70 % q.s. | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| Pyridoxine Hcl, Nicotinamide, | Each 5 ml contains : | |
| Cyanocobalamin and Lysine Hcl | Pyridoxine Hydrochloride IP 0.75 mg | |
| Syrup | Nicotinamide IP 15 mg | |
| For Prophylactic Use | Cyanocobalamin IP 2 mcg | |
| Lysine Hcl USP 37.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Prednisolone Sodium Phosphate | Each 5 ml contains : | |
| Syrup | Prednisolone Sodium Phosphate IP | |
| Eq. to Prednisolone 5 mg | |
| 29.04.2022 | Approved colour used in flavoured syrupy base | |
| | |
| Calcium Carbonate and | Each 5 ml contains : | |
| Vitamin D? Syrup | Calcium Carbonate IP 625 mg | |
| For Prophylactic Use | Eq. To Elemental Calcium 250 mg | |
| Vitamin D? (As Cholecalciferol) IP 125 I.U | |
| Approved colour used in flavoured syrupy base | |
| | |
| Calcium Carbonate, Vitamin D? | Each 5 ml contains : | |
| and Zinc Sulphate Syrup | Calcium Carbonate IP 625 mg | |
| For Therapeutic Use | Eq. To Elemental Calcium IP 250 mg | |
| Vitamin D? (As Cholecalciferol) IP 400 I.U | |
| Zinc Sulphate IP 7.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Tricholine Citrate, Thiamine HCl | Each 5 ml contains : | |
| Riboflavin, Cyanocobalamin | Tricholine Citrate 250 mg | |
| With Pyridoxine HCl Syrup | Thiamine Hydrochloride IP 2.5 mg | |
| For Therapeutic Use | Riboflavin IP 2.5 mcg | |
| 29.04.2022 | Cyanocobalmin IP 5.0 mcg | |
| Pyridoxine Hydrochloride IP 0.75 mg | |
| Approved Colour used inFlavoured Syrupy Base | |
| | |
| Oral Rehydration Salts Solution | Each 200 ml. contains | |
| Sodium Chloride IP 0.52 g | |
| Dextrose Monohydrate IP 2.97 g | |
| Potassium Chloride IP 0.30 g | |
| Sodium Citrate IP 0.58 g | |
| Approved colour in flavoured syrupy base | |
| | |
| Levofloxacin | Each 5 ml contains: | |
| Oral Solution IP | Levofloxacin Hemihydrate IP | |
| eq. to Levofloxacin 125 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Rifaximin Oral | Each 5 ml contains : | |
| Suspension | Rifaximin BP 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Xylometazoline HCI | Each 5 ml contains : | |
| Nasal Solution IP | Xylometazoline HCI IP 0.05 % w/v | |
| Benzalkonium Chloride (As preservapive) IP 0.02 % w/v | |
| Sterile aqueous base q.s. | |
| | |
| Sildenafil | Each ml contains : | |
| Oral Suspension | Sildenafil Citrate IP | |
| Eq. to Sildenfil 10 mg | |
| Approved colour used in flavoured syrupy q.s. | |
| | |
| Sildenafil | Each ml contains : | |
| Oral Suspension | Sildenafil Citrate IP | |
| Eq. to Sildenfil 5 mg | |
| Approved colour used in flavoured syrupy q.s. | |
| | |
| Ondansetron Oral | Each 5 ml contains: | |
| Solution IP | Ondansetron Hydrochloride IP | |
| For paediatric use | Eq. to Ondansetron 4 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Magaldrate and Simethicone | Each 5 ml contains: | |
| Oral Suspension IP | Magaldrate IP 400 mg | |
| Simethicone IP 60 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Magaldrate, Simethicone and | Each 5 ml contains : | |
| Oxetacaine Suspension | Magaldrate IP 540 mg | |
| Simethicone IP 20 mg | |
| Oxetacaine BP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Terbutaline Sulphate, | Each ml contains : | |
| Ambroxol Hydrochloride | Terbutaline Sulphate IP 0.25 mg | |
| Guaiphenesin Drops | Ambroxol Hydrochloride IP 7.5 mg | |
| Guaiphenesin IP 12.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levosalbutamol Sulphate, | Each ml contains : | |
| Ambroxol Hydrochloride | Levosalbutamol Sulphate IP | |
| Guaiphenesin Drops | eq. to Levosalbutamol 0.25 mg | |
| Ambroxol Hydrochloride IP 7.5 mg | |
| Guaiphenesin IP 12.5 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levosalbutamol Sulphate, | Each 5 ml contains : | |
| Ambroxol Hydrochloride | Levosalbutamol Sulphate IP | |
| Guaiphenesin Syrup | eq. to Levosalbutamol 1 mg | |
| Ambroxol Hydrochloride IP 15 mg | |
| Guaiphenesin IP 50 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Paracetamol, Phenylephrine Hcl, | Each 5 ml contains : | |
| Chlorpheniramine Maleate, | Paracetamol IP 125 mg | |
| Menthol Suspension | Chlorpheniramine Maleate IP 2 mg | |
| Phenylephrine Hcl IP 2.5 mg | |
| Menthol IP | |
| Approved colour used in flavoured syrupy base | |
| | |
| Multi-Vitamin, Multi-Mineral | Each 5 ml contains : | |
| with Lycopene & Methylcobalamin | Methylcobalamin IP 500 mcg | |
| Syrups | Lycopene 6% USP 1500 mcg | |
| L-Lysine Hydrochloride 60 mg | |
| Vitamin A (As Palmetate) IP 5000 IU | |
| Vitamin E IP 15 IU | |
| Vitamin D3 IP 400 IU | |
| Thiamine Mononitrate IP 5 mg | |
| Riboflavine (As Sodium Phosphate) IP 5 mg | |
| Sodium Selenite USP | |
| eq. to Selenite 20 mcg | |
| Zinc Gluconate USP | |
| eq.to Zinc 2 mg | |
| Mangnesium Chloride IP 2 mg | |
| Potassium lodide IP | |
| eq. to Elemental lodine 100 mcg | |
| Chromium Chloride IP 16 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Mycophenolate Mofetil | Each ml contains : | |
| Suspension | Mycophenolate Mofetil IP 200 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Linezolid Oral Suspension | Each 5 ml contains: | |
| Paediatric used | Linezolid IP 100 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Diphenhydramine Hydrochloride | Each 5 ml contains : | |
| Ammonium Chloride | Diphenhydramine Hydrochloride IP 12.5 mg | |
| Sodium Citrate Syrup | Ammonium Chloride IP 80 mg | |
| Sodium Citrate IP 50 mg | |
| Menthol IP q.s | |
| Approved colour used in flavoured syrupy base | |
| | |
| Triclofos Oral Solution IP | Each 5 ml contains: | |
| 02.09.2023 | Triclofos Sodium IP 500 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Cefdinir Oral Solution IP | Each 5 ml of Reconstituted Suspension contains : | |
| 02.09.2023 | Cefdinir IP 125 mg | |
| Flavoured syrupy base | |
| | |
| Activated Dimethicone | Each 5 ml contains: | |
| & Domperidone | Activated Dimethicone IP 40 mg | |
| With Dicyclomine Suspension | Domperidone Maleate IP | |
| For Paediatric Use | Eq. to Domperidone 5 mg | |
| 02.09.2023 | Dicyclomine Hydrochloride IP 10 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Diphenhydramine Hydrochloride | Each 5 ml contains : | |
| Ammonium chloride | Diphenhydramine Hydrochloride IP 15 mg | |
| Sodium citrate, Menthol Syrup | Ammonium chloride IP 125 mg | |
| Sodium citrate IP 60 mg | |
| Menthol IP q.s. | |
| Approved colour used in flavoured syrupy base | |
| | |
| Oseltamivir Phosphate Oral | Each ml of Reconstituted Suspension contains : | |
| Suspension IP | Oseltamivir Phosphate IP | |
| Eq. to Oseltamivi 15 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Oseltamivir Phosphate Oral | Each ml of Reconstituted Suspension contains : | |
| Suspension IP | Oseltamivir Phosphate IP | |
| Eq. to Oseltamivi 12 mg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Sodium Alginate. Sodium bicarbonate and | Each 5 ml contains : | |
| Calcium Carbonate Suspension | Sodium Alginate IP 250 mg | |
| Sodium bicarbonate IP 133.5 mg | |
| Calcium carbonate IP 80 mg | |
| Excipients q.s. | |
| Approved colour used in flavoured syrupy base | |
| | |
| Levocetirizine Hcl & Ambroxol Hcl | Each 5 ml contains : | |
| Syrup | Levocetirizine HCl IP 2.5 mg | |
| Ambroxol Hcl IP 30 mg | |
| For Paediatric Use | Approved colour used in flavoured syrupy base | |
| | |
| Multi-Vitamin, Multi-Mineral | Each 5 ml contains : | |
| with Lycopene & Methylcobalamin | Methylcobalamin IP 500 mcg | |
| Syrups | Lycopene 6% USP 1500 mcg | |
| L-Lysine Hydrochloride 60 mg | |
| Vitamin A (As Palmetate) IP 5000 IU | |
| Vitamin E IP 15 IU | |
| Thiamine Mononitrate IP 5 mg | |
| Riboflavine (As Sodium Phosphate) IP 5 mg | |
| Sodium Selenite USP | |
| eq. to Selenite 20 mcg | |
| Zinc Gluconate USP | |
| eq.to Zinc 2 mg | |
| Mangnesium Chloride IP 2 mg | |
| Potassium lodide IP | |
| eq. to Elemental lodine 100 mcg | |
| Chromium Chloride IP 16 mcg | |
| Approved colour used in flavoured syrupy base | |
| | |
| Dried Aluminium Hydroxide | Each 5 ml contains : | |
| Magnesium Hydroxide, Oxetacaine | Dried Aluminium Hydroxide Gel IP 300 mg | |
| Activated Dimethicone Gel | Magnesium Hydroxide IP 150 mg | |
| Activated Dimethicone IP 125 mg | |
| Oxetacaine BP 10 mg | |
| Excipients q.s. | |
| Approved colour used in flavoured syrupy base | |
| | |
| OMEPRAZOLE EC PELLETS 7.50 % w/w | Each 1 gm enteric coated pellets contains | |
| Omeprazole 75 mg | |
| Approved colour to be use | |
| | |
| OMEPRAZOLE EC PELLETS 8.50 % w/w | Each 1 gm enteric coated pellets contains | |
| Omeprazole 85 mg | |
| Approved colour to be use | |
| | |
| OMEPRAZOLE EC PELLETS 10.00 % w/w | Each 1 gm enteric coated pellets contains | |
| Omeprazole 100 mg | |
| Approved colour to be use | |
| | |
| OMEPRAZOLE EC PELLETS 12.5 % w/w | Each 1 gm enteric coated pellets contains | |
| Omeprazole 125 mg | |
| Approved colour to be use | |
| | |
| OMEPRAZOLE EC PELLETS 25.0 % w/w | Each 1 gm enteric coated pellets contains | |
| Omeprazole 250 mg | |
| Approved colour to be use | |
| | |
| LANSOPRAZOLE EC PELLETS 8.5 % w/w | Each 1 gm enteric coated pellets contains | |
| Lansoprazole 85 mg | |
| Approved colour to be use | |
| | |
| LANSOPRAZOLE EC PELLETS 9.25 % W/W | Each 1 gm enteric coated pellets contains | |
| Lansoprazole 92.5 mg | |
| Approved colour to be use | |
| | |
| LANSOPRAZOLE EC PELLETS 10.0 % W/W | Each 1 gm enteric coated pellets contains | |
| Lansoprazole 100mg | |
| Approved colour to be use | |
| | |
| LANSOPRAZOLE EC PELLETS 11.20 % W/W | Each 1 gm enteric coated pellets contains | |
| Lansoprazole 112mg | |
| Approved colour to be use | |
| | |
| RABEPRAZOLE SODIUM EC PELLETS 8.50% W/W | Each 1 gm enteric coated pellets contains | |
| Rabeprazole Sodium 85mg | |
| Approved colour to be use | |
| | |
| RABEPRAZOLE SODIUM EC PELLETS 11.2 % W/W | Each 1 gm enteric coated pellets contains | |
| Rabeprazole Sodium 112mg | |
| Approved colour to be use | |
| | |
| RABEPRAZOLE SODIUM EC PELLETS 15.0 % W/W | Each 1 gm enteric coated pellets contains | |
| Rabeprazole Sodium 150mg | |
| Approved colour to be use | |
| | |
| PANTOPRAZOLE SODIUM EC PELLETS 8.50 % W/W | Each 1 gm enteric coated pellets contains | |
| Pantoprazole sodium 85 mg | |
| Approved colour to be use | |
| | |
| PANTOPRAZOLE SODIUM EC PELLETS 15.0 % W/W | Each 1 gm enteric coated pellets contains | |
| Pantoprazole sodium 150 mg | |
| Approved colour to be use | |
| | |
| PANTOPRAZOLE SODIUM EC PELLETS 20.0 % W/W | Each 1 gm enteric coated pellets contains | |
| Pantoprazole sodium 200 mg | |
| Approved colour to be use | |
| | |
| PANTOPRAZOLE SODIUM EC PELLETS 22.50% W/W | Each 1 gm enteric coated pellets contains | |
| Pantoprazole sodium 225 mg | |
| Approved colour to be use | |
| | |
| | |
| Itraconazole IR Pellets 20.00 % W/W | Each 1 gm coated pellets contains | |
| Itraconazole 200 mg | |
| Approved colour to be use | |
| | |
| | |
| Itraconazole IR Pellets 22.00 % W/W | Each 1 gm coated pellets contains | |
| Itraconazole 220 mg | |
| Approved colour to be use | |
| | |
| | |
| Itraconazole IR Pellets 35.00 % w/w | Each 1 gm coated pellets contains | |
| Itraconazole 350 mg | |
| Approved colour to be use | |
| | |
| | |
| Domeperdone SR Pellets 10.00% w/w | Each 1 gm of Sustain Release pellets contains | |
| Domperidone 100 mg | |
| Release Profile 1st hour -Between 15%-40% | |
| 4th hour -Between 30%-60% | |
| 8th hour -Between 55%-85% | |
| 12th hour -NLT-70% | |
| | |
| Domeperdone SR Pellets 20.00% w/w | Each 1 gm of Sustain Release pellets contains | |
| Domperidone 200 mg | |
| Release Profile 1st hour -Between 15%-40% | |
| 4th hour -Between 30%-60% | |
| 8th hour -Between 55%-85% | |
| 12th hour -NLT-70% | |
| | |
| Domeperdone SR Pellets 30.00% w/w | Each 1 gm of Sustain Release pellets contains | |
| Domperidone 300 mg | |
| Release Profile 1st hour -Between 15%-40% | |
| 4th hour -Between 30%-60% | |
| 8th hour -Between 55%-85% | |
| 12th hour -NLT-70% | |
| | |
| Domeperdone SR Pellets 40.00% w/w | Each 1 gm of Sustain Release pellets contains | |
| Domperidone 400mg | |
| Release Profile 1st hour -Between 15%-40% | |
| 4th hour -Between 30%-60% | |
| 8th hour -Between 55%-85% | |
| 12th hour -NLT-70% | |
| | |
| Blended Pellets or Carbonyl Iron Immediate Release, Zinc Sulphate | | |
| Monohydrate Sustained Release, And Folic Acid Immediate Release | | |
| Each 435 mg of Blended pellets contains | | |
| Carbonyl Iron | IHS | 50 mg |
| Zinc sulphate mono hydrate | IP | 61.8 mg |
| Folic Acid | IP | 0.5 mg |
| Colour: Approved colour | | |
| | |
| Blended Pellets or Carbonyl Iron Immediate Release, Zinc Sulphate | | |
| Monohydrate Sustained Release, Vitamin C Immediate Release, | | |
| Vitamin B12 Immediate Release And Folic Acid Immediate Release | | |
| Each 600 mg of Blended pellets contains | | |
| Carbonyl Iron | IHS | 100 mg |
| Zinc sulphate mono hydrate | IP | 61.8 mg |
| Vitamin C | IP | 75 mg |
| Vitamin B12 | IP | 15 mcg |
| Folic Acid | IP | 1.5 mg |
| Colour : Approved colour | | |
| | |
| Blended Pellets Of Dried Ferrous Sulphate Sustained Release Zinc | | |
| Sulphate Monohydrate Sustained Release And Folic Acid Immediate | | |
| Release | | |
| Each 460 mg of Blended pellets contains | | |
| Dried Ferrous Sulpahte | IP | 150 mg |
| Zinc sulphate mono hydrate | IP | 61.8 mg |
| Folic Acid | IP | 0.5 mg |
| Colour : Approved colour | | |
| | |
| Blended Pellets Of Dried Ferrous Sulphate Sustained Release And | | |
| Folic Acid Immediate Release | | |
| Each 340 mg of Blended pellets contains | | |
| Dried Ferrous Sulpahte | IP | 50 mg |
| Folic Acid | IP | 0.5 mg |
| Colour : Approved colour | | |
